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Abstract 
Increased ERα expression correlates with increased breast cancer risk, suggesting that the ER and 
estrogens play a role in cancer initiation and progression.  Nonetheless, a clear understanding of the 
involvement of the ER in breast epithelium formation, carcinogenesis and cancer progression is lacking.  
In addition to this, the role of other estrogen-responsive receptors, such GPER-1 remains unknown. 
The mammary gland is comprised of milk ducts terminating in secretory units termed acini.  These are 
comprised of a layer of epithelial cells surrounding a hollow lumen.  These cells are in turn surrounded 
by a layer of myoepithelial cells attached to an underlying basement membrane.  3D cultures of 
immortalised breast cells recapitulate many of the features of acini in vivo, such as spherical growth-
arrested acini with a layer of epithelial cells attached to an underlying basement membrane, 
surrounding a hollow lumen.  We aimed to use 3D cultures of ERα, ERβ and GPER competent MCF-12A 
cells to assess the effects of estrogenic compounds on acini formation. 
MCF-12A cells were cultured in Matrigel with etOH (solvent control), E2, bisphenol A (BPA) or n-
propylparaben.  To assess the role of the ER or GPER-1, cells were also pre-treated with the ER and GPER 
-1 antagonists, as well as inhibitors of the MAPK and PI3K signalling cascades. Immunocytochemical 
staining using antibodies against activated caspase-3 and laminin-V was performed.  Image acquisition 
was achieved by laser confocal microscopy. 
Control acini were encapsulated by a basement membrane with central cells either cleared or 
undergoing apoptosis.  In comparison, cells treated with E2, BPA or propyparaben possessed filled 
lumen with little or no sign of apoptotic central cells and were larger and disorganised.  Co-incubation 
with ER or GPER-1 antagonists, or PI3K and MAPK inhibitors reverted some of the effects of the test 
compounds resulting in growth-arrested, spherical acini with evidence of luminal clearing. 
We have successfully established an in vitro 3D model using immortalised ER competent cells to study 
the effects of estrogens on mammary gland formation.  We have demonstrated that estrogenic 
compounds disrupt acini by inducing luminal filling and preventing growth arrest.  Moreover, these 
effects seem to be mediated by both estrogen responsive receptors ER and GPER-1. 
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CHAPTER I: Introduction: The Breast and Cancer 
1.1 Epidemiology of Breast Cancer 
Since the 1970’s, breast cancer incidence rates have been on the rise and the chance of developing 
breast cancer in the United Kingdom stands at 1 in 9, making it the most commonly diagnosed cancer in 
women (Cancer Research UK, 2009).  Despite improvements in detection and survival rates, breast 
cancer remains the most common cause of cancer-related deaths in women. 
Breast cancer incidence rates can be influenced by many epidemiological characteristics such as 
age, genetic variation, familial history, ethnicity, socio-economic status, and geographical location.  
Increasing age correlates with increased breast cancer incidence (Kelsey & Gammon, 1991), and 
approximately 80% of cases occur in women aged over fifty years of age.  The majority of cases in 
women aged 50 and over appear to coincide with the years leading up to menopause.  After the age of 
65, breast cancer incidence rates decrease and then increase again after the age of 70 (Figure 1.1). This 
dip in breast cancer incidence is known as “Clemmensen’s hook” (Clemmensen, 1948) and could 
indicate two different forms of the disease being more prevalent at different ages.  In fact, it has been 
demonstrated that the molecular characteristics of the cancers differ at each “peak” (Anderson et al, 
2002; Kravchenko et al, 2011). 
In 1988, a breast cancer screening programme was started in the UK for women between the 
ages of 50-64 and this is now being extended to women in their late 40’s up until the age of 70.  This has 
consequently led to higher incidence rates, as new cases are being detected, but has also had a positive 
effect on survival rates, as breast cancer is being diagnosed at earlier stages and treated accordingly 
(Figure 1.2). 
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Figure 1.1: Age specific breast cancer incidence rates in the UK in 2006.  Breast cancer incidence increases up until 
the ages of 65-69 and then falls, before gradually increasing again (Breast Cancer UK, 2009). 
 
Figure 1.2: Age standardised breast cancer incidence and mortality rates in Europe.  In the last 30 years, the 
incidence of breast cancer has increased and since 1989 the mortality rate of breast cancer has decreased (Cancer 
Research UK, 2009). 
A family history of breast cancer has been linked to increased breast cancer risk in cases where the 
tumour suppressor genes, BRCA1 and BRCA2 are mutated and this accounts for 10% of all breast cancer 
cases (Castilla et al, 1994).  Mutations in the BRCA1 and BRCA2 genes can result in an increase of breast 
cancer of up to 80% (van Garderen & Schalken, 2002).  Other rarer genetic mutations can also increase 
an individual’s risk of developing breast cancer, such as inherited mutations in p53 and phosphatase and 
25 
 
tensin homolog (PTEN).  Familial history, where no inherited genetic mutation has been identified, also 
appears to increase the risk of breast cancer by 2 to 3-fold. 
Caucasian women have a marginally increased risk of developing breast cancer compared to 
African women, although the mortality rate for African woman is higher.  Geographical variation of 
breast cancer incidence exists, with more cases being diagnosed in developed western countries, such 
as the UK and North America and low incidence rates in Japan, India and Africa (Figure 1.3) (Cancer 
Research UK, 2008).  However, in the countries of South America and Asia, breast cancer incidence rates 
are on the rise and it is thought to be due to the adoption of westernised lifestyles. 
 
 
Figure 1.3: Incidence and mortality rates across the globe.  The highest incident rates of breast cancer are found 
in western Europe.  Mortality rates for breast cancer are also very high in western Europe with only southern and 
western Africa having a higher breast cancer mortality rate (Cancer Research UK, 2008). 
Socio-economic variation also exists for breast cancer, although unlike many other cancers, it is the 
more affluent groups that show a higher incident rate and have a 20% increase in risk of developing the 
disease (National Cancer Intelligence network, 2008).  This variation could be due to later first 
pregnancies and decreased parity in more affluent groups, two factors associated with increased breast 
cancer risk, as will be discussed next. 
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1.2 Risk Factors 
Several risk factors, in addition to epidemiological characteristics, for developing breast cancer have 
been identified including:  exposure to ionizing radiation, previous breast disease, age at menarche, age 
at first pregnancy (Kelsey et al, 1993), parity, age at menopause onset, breast density, smoking (Band et 
al, 2002), diet, obesity, alcohol consumption, use of hormone replacement therapy (HRT) (Beral et al, 
1997), and the use of oral contraceptives (Pike et al, 1993).   
Reproductive factors, such as age at menarche, first pregnancy and menopause, appear to have 
an impact on the risk of developing breast cancer.  Early menarche can increase breast cancer incidence 
by up to 22% (Garcia-Closas et al, 2006) and breast cancer risk increases by approximately 3% a year for 
every delayed year of menopause (Collaborative Group on Hormonal Factors in Breast Cancer, 1997).  
On the other hand, age at first pregnancy and increased parity have a protective effect from breast 
cancer, with a risk reduction of 7% per pregnancy (Ma et al, 2006). 
The use of HRT and to a much lesser extent, oral contraceptives, increases the risk of breast 
cancer (Collaborative Group on Hormonal Factors in Breast Cancer, 1997), with women who use HRT 
having up to a 66% increased risk of developing the disease (Beral, 2003).  The link between oral 
contraceptive use and breast cancer remains of debate, but it has been shown that people using oral 
contraceptive have a slightly increased risk of breast cancer.  Stopping their use reduces the risk back to 
levels seen in women who have never used oral contraceptives (Collaborative Group on Hormonal 
Factors in Breast Cancer, 1996). 
In addition to reproductive and medicinal factors, various lifestyle factors can impact upon 
breast cancer risk.  Post-menopausal women who are overweight have a 10-20% increased risk, with 
increasing body mass index (BMI) correlating with increased breast cancer risk (Reeves et al, 2007).  
Increased alcohol consumption also correlates with increased breast cancer risk, with each 10g (1 unit) a 
day alcohol consumption correlating to an increased relative risk of 12% (Allen et al, 2009).  Smoking 
also increases a women’s risk by 10-20% (Luo et al, 2011).  Diet may also influence an individual’s risk of 
developing breast cancer.  People with a high fat intake have a 13% increased risk of breast cancer 
compared to people on a lower fat diet (Boyd et al, 2003).  Phytoestrogen consumption may have a 
protective effect against breast cancer in Asian populations and a reduction in breast cancer risk by 15% 
in post-menopausal women with a high phytoestrogen intake has been observed (Velentzis et al, 2009; 
Dong & Qin, 2011), however, there are also studies that show no protective influence of phytoestrogens 
(Keinan-Boker et al, 2004; Hedelin et al, 2005).   
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Many of the risk factors described above contribute to an individual’s cumulative lifetime 
exposure to the endogenous hormones, estrogens.   Estrogens are physiologically important in females, 
where they function to induce reproductive tract and secondary sexual characteristics development, as 
well as regulate menstruation and reproductive processes.  In addition to sexual differentiation, 
estrogens have an important role in the development and maintenance of bone tissue (Rickard et al, 
1999), cardiovascular protection (Chambliss et al, 2010) and are capable decreasing circulating 
cholesterol levels (Liu & Bachmann, 1998).  Paradoxically, estrogens have also been shown to have a role 
in breast cancer development and progression.  This will be discussed in this chapter, after a brief 
revision of the breast development processes and morphology. 
1.3 Breast Development 
Development of the mammary gland is a highly complex and dynamic process, where proliferation, 
apoptosis and cellular differentiation all play essential roles that culminate in the formation of a network 
of milk ducts, which will eventually function to provide milk for breast feeding. 
As the breast undergoes morphological development, lobule classification alters from type 1 to 
type 4 (Figure 1.4).  Lobules classified as type 1 are present in the immature breast prior to the onset of 
puberty and are the least differentiated.  Evolution of type 1 lobules forms type 2 lobules with increased 
differentiation and an increased number ducts.  Type 3 lobules are present during pregnancy, in 
response to hormonal stimulation or following regression of type 4 lobules, after a cessation in lactation.  
Finally, during lactation, the lobules develop into type 4 and secrete milk proteins.  Following 
menopause, regression of type 2 and type 3 lobules results in the presence of type 1 lobules, with both 
parous and nulliparous women predominately possessing type 1 lobules (Russo & Russo, 1994). 
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Figure 1.4: Lobule differentiation. During morphological development of the breast, the lobules progress from a 
Type 1 classification prior to the onset of puberty, to a Type 4 classification wherein milk is produced.  Regression 
to a Type 3 classification then occurs as lactation ceases (Red notes milk production) (adapted from Russo & Russo, 
1994). 
Breast development begins at the embryonic stage, where cellular branching builds the foundations for 
the future glands and ducts.  Between birth and the age of two, breast involution occurs resulting in a 
ductal system lacking the terminal end buds (TEBs) (Howard & Gusterson, 2000), structures comprised 
of epithelial cell layers.    
Breast development then remains dormant until the onset of puberty, a period when the cells of 
the TEBs are most proliferative.  Although the precise mechanism for breast development initiation 
remains unclear, it is believed to coincide with the activation of the hypothalamic-pituitary-gonadal and 
hypothalamic-pituitary-adrenal axis.  This activation results in a surge of follicle-stimulating hormone 
(FSH) from the pituitary, which in turn stimulates the secretion of estrogen from primordial follicles in 
the ovaries.  Estrogen is then able to circulate around the body and induce cellular proliferation, 
elongation and branching of the mammary ducts.   
During the pubertal development stage of the breast, a network of between 10 and 15 
branching ducts elongate and develop from the nipple.  These transverse through the mammary gland 
terminating in TEBs, which are specialized structures responsible for driving the growth of the ductal 
network (Anbazhagen et al, 1998).  The cells of the TEBs will eventually give rise to both the luminal and 
basal cell layers of the ducts.  It is hypothesised that within these terminal end buds are populations of 
stem cells.  These stem cells are thought to play a pivotal role in normal breast development and breast 
cancer initiation (Russo & Russo, 1996).  In addition, the terminal buds exhibit the highest proliferative 
activity, highest estrogen receptor (ER) abundance and highest carcinogen-DNA binding rate of that 
found in the breast (Russo & Russo, 2008).  Each duct is associated with a specific breast lobule and 
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these lobules are separated from one another by connective tissue, in which nerves, blood vessels and 
lymphatics are located.   
The ductal network develops further, resulting in the formation of terminal ductal lobuloalveolar 
units (TDLUs) consisting of ducts and acini.  At this stage, the lobules of the breast are of the 
classification type 1.  Following pregnancy and during lactation these structures will become the 
functional milk-secretory units (Figure 1.5) where they are of the classification type 3 and 4.   
 
 
Figure 1.5: The structure of the breast.  The breast consists of a highly branched ductal network extending from 
the nipple and terminating in TDLUs. 
Further maturation of the breast occurs during pregnancy and lactation.  During this time, TDLUs, in the 
presence of hormones, develop further until the fully mature breast is comprised of a network of milk 
ducts terminating in spherical milk-producing glands, termed acini (Russo & Russo, 1998).  Once 
offspring have been weaned, involution causes mammary epithelial cell death and the regression of the 
TDLUs.  These cells are replaced by adipose tissue and mesenchyme that function to support breast 
lobules (Russo & Russo, 1993).  The mammary gland, however, remains more differentiated than that 
present in nulliparous women (Cardiff & Wellings, 1999). 
The acini of the TDLU are highly organised structures (Figure 1.6), comprising of a basement 
membrane which encapsulates a layer of myoepithelial cells, that surrounds a layer of epithelial cells, 
which in turn surround a hollow lumen.  Surrounding the entire structure is the stroma, comprised of 
fibroblasts, immune cells, adipocytes, blood vessels, lymphatic vessels and extracellular matrix (ECM).  
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The basement membrane of acini functions to provide mechanical support and to generate signals for 
cell survival to the cell attached to it, via transmembrane receptors called integrins.  At the centre of the 
structure is a hollow lumen, the size of which is dependent on whether the acini is in a state of rest, in 
which case the lumen is small, or is secreting milk, in which case the lumen is much larger (Plachot et al, 
2009).   
 
 
Figure 1.6: In vivo structure of a TDLU.  A basement membrane encapsulates an acinus of a TDLU.  Within this 
structure is a layer of myoepithelial cells and a layer of epithelial cells, surrounding a central hollow lumen. 
The myoepithelial and epithelial cells of acini possess cell-cell contacts with neighbouring cells, via 
adhesion proteins, such as E-cadherin and β-catenin (Debnath et al, 2002), and have basal polarisation 
of α6 integrin, collagen IV and laminin V.  Collagen IV and laminin V are basement membrane 
components that are secreted by cells.  Laminin via its integrin receptor is involved in ECM attachment, 
polarization differentiation and morphogenesis in vivo (Rodriguez-Boulan & Nelson, 1989; Sorokin et al, 
1990).  Collagen IV provides structural support to the basement membrane (Pöschl et al, 2004).  Disks 
large (hDlg) and the Golgi apparatus are apically located in these polarised cells (Debnath et al, 2003) 
and function in the establishment of polarity and protein modification respectively.  Work in three-
dimensional (3D) cultures has demonstrated that acini initially form as complete spheres of cells and the 
hollow lumen is achieved and maintained through caspase-mediated apoptosis, autophagy and anoikis 
of the centrally located cells (Mills et al, 2004).  The formation of the TDLUs in vivo, occurs in a very 
similar fashion to that observed in 3D in vitro models, in that the TDLUs form initially as filled structures, 
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and then the central cells undergo apoptosis and are cleared to form a hollow lumen (Humphreys et al, 
1996; Mailleux et al, 2007).  However, the exact mechanism for this i.e. whether the outer cells receive 
pro-survival signals or are protected from death signals, remains unclear. 
1.4 Breast Cancer 
Factors like genetic aberrations and epigenetic changes can result in tumour development in which 
losses or gains of function of various proteins, collectively induces alterations in cell behaviour.  These 
alterations have been classified as “The Hallmarks of Cancer” by Hanahan and Weinberg (2000) who 
propose six criteria that are auspicious for tumour growth: enhanced proliferative potential, resistance 
to apoptosis, independent growth signal production, resistance to inhibitory signals, angiogenic 
potential and the capacity to migrate and invade surrounding tissues.  Given that the breast undergoes 
extensive morphological changes through a women’s lifetime, due to a vast array of proliferative and 
hormonal influences, events like mutations and epigenetic modifications often target the cells of the 
mammary gland. 
1.4.1 Breast Cancer Subtypes 
Breast cancers arising from mesenchymal tissues are known as sarcomas, whereas the more common 
form of cancer, carcinoma, arises from epithelial tissues.  Specifically, when the cancer is derived from 
glandular epithelial tissue, it is referred to as an adenocarcinoma.  Amongst breast malignancies, 
tumours arising in the TDLUs are the most common (Wellings et al, 1975; Petersen et al, 2003). 
Various subtypes based on the molecular profile have been identified by Perou et al (2000).  
These finding were bases on the expression of the estrogen receptor (ER), progesterone receptor (PR) or 
human epidermal growth factor receptor 2 (HER2) and whether tumours were basal-like or luminal-like.  
Luminal-like tumours tend to express the ER and genes associated with luminal and glandular cells, 
whereas basal-like tumours tended to lack ER expression and express genes more associated with 
myoepithelial cells.  Further work demonstrated that the luminal sub-type could be further 
characterized into two groups: luminal A (HER2-) and luminal B (HER-2+) (Sorlie et al, 2003).  More 
recent studies have further charterized the sub-types of breast cancer.  After determining whether a 
tumour is luminal or non-luminal and confirming the HER2 status, tumours can be further cauterized 
depending on whether they express basal markers (Figure 1.7) (Blows et al, 2010). 
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Figure 1.7: Characterization of breast cancer. Luminal-like tumours were divided into HER2- (luminal 1 which is 
roughly equilivant to luminal A) and HER2+ (luminal 2 which is actually a subset of luminal B classified tumours).  
Non-luminal-like tumours were divided into two sub-groups based on HER2 expression.  All sub-groups were then 
characterized based on the expression on basal markers such as cytokeratin 5/6 (CK5/6) and epidermal growth 
factor receptor (EGFR).  Image taken from Blows et al, 2010)  
Of these subtypes, the luminal A subtype is the most prevalent and has the best prognosis, and tumours 
of this class tend to have be smaller, well differentiated and there is less likely to be lymph node 
involvement.  Triple negative subtypes appear to present as larger tumours, be poorly differentiated and 
have the poorest prognosis (Onitilo et al, 2009). 
Luminal breast cancer subtypes tend to express higher expression levels of ERα and cytokeratins 
or HER2.  HER2 is a commonly amplified oncogene in breast cancer that is related to EGFR.  It is a 
receptor tyrosine kinase that is over-expressed in 20-30% of metastatic breast cancer samples, and in 
patients this correlates with a poorer prognosis.   
The basal-like subtype tends to express cytokeritin 5/6/14/17, p-cadherin, caveolin-1 and p53 
and frequently lacks ER, PR and HER2 (Li et al, 2002; van der Rijn et al, 2002).  This subset is usually very 
aggressive in patients and presents with a high histological grade. 
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1.4.2 Models of Breast Carcinogenesis 
As with any malignancy, tumours of the breast possess distinctive hallmarks of cancer, such as 
invasiveness, metastatic ability, and can ultimately cause death in patients.  Advances in cancer research 
over recent decades have shed light on to the causes of cancers and suggested that mutations involving 
the loss of tumour suppressor genes and overexpression of oncogenes are the foundations of cancer 
initiation and progression.  The initiation and progression of breast cancer is no different and arises as a 
result of genetic mutation accumulation, increased proliferation and disruption of tissue architecture, 
although more recently theories involving tissue organisation, epigenetic modification and aneuploidy 
have been proposed for the initiation and progression of cancer. 
The somatic mutation theory (SMT) is based on the assumption that cancer arises from DNA 
mutations within cells, which, if unrepaired, lead to either loss or gain of the affected proteins.  These 
mutations accumulate over time, affecting cellular proliferation, survival, differentiation, migration and 
apoptosis and, eventually, induce a cancer phenotype (Figure 1.8).  Two models for SMT carcinogenesis 
and progression have been hypothesised: a linear and non-linear model.  The linear model is based on 
the theory that the cell of origin of the cancer is the same, regardless of tumour subtype.  Here, 
mutations in genes involved in proliferation and survival accumulate and only then the subtype, is 
determined.  The basis for alternative the non-linear model of breast carcinogenesis is that each breast 
cancer subtype has a different cell of origin (Jeselsohn et al, 2010).  
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Figure 1.8: The progression to invasive ductal carcinoma.  The progression to an invasive ductal carcinoma from a 
normal state occurs as a consequence of over-proliferation and apoptotic suppression (adapted from Myal et al, 
2010). 
More recently, the tissue organization field theory (TOFT) has been proposed.  In this model, 
carcinogenesis occurs as a result of tissue disorganization, increased proliferation and inter-cellular 
communication.  These alterations to the microenvironment result in the loss of control of tissue 
organisation upon cellular proliferation and survival, and, as a consequence, cells are able to proliferate, 
migrate and evade apoptosis (Soto & Sonnenschein, 1991; Soto & Sonnenschein, 2011).  In this context, 
the presence of mutations is random and does not occur in every cell of the tumour. 
1.5 Estrogens 
Estrogens, such as 17β-estradiol (E2), estriol (E3) and estrone (E1), are a family of steroid hormones that 
promote proliferation of both normal and cancerous cells.  They function as the primary sex hormone in 
females and are, hence, involved in a variety of physiological processes, such as the menstrual cycle and 
breast acini development.  Estrogens are also involved in cardiovascular and nervous system function 
and the regulation of bone remodelling (Venkov et al, 1996; Sims et al, 2002; Maggi et al, 2004; Kim et 
al, 2010).  However, estrogens may also have a detrimental effect on health and have been implicated in 
breast cancer development by both experimental and epidemiological data. 
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Estrogen synthesis is regulated by follicle stimulating hormone (FSH) and luteinising hormone 
(LH), which are both secreted from the anterior pituitary gland (Figure 1.9).  Upon stimulation by these 
hormones, structures such as the ovaries, corpus luteum, placenta and adrenal cortex synthesise 
estrogen.  The majority of this synthesis occurs in the ovaries and begins with synthesis of the precursor, 
progesterone from pregnolone, a derivative of cholesterol.  The most abundantly synthesised estrogen 
is E2 although E1 and E3 are also formed.  Biologically active estrogens account for just 5% of the total 
amount of circulating estrogens.  The remainder is bound to plasma proteins, such as sex hormone 
binding globulin (SHBG) and albumin. 
 
Figure 1.9: The ovarian cycle.  E2 levels increase prior to ovulation and then decrease following the release of an 
egg from the ovaries, although a slightly higher level of E2 exists to maintain uterus lining until menstruation 
(Image from Psychology Wiki http://psychology.wikia.com/wiki/File:Estradiol.Cycle.JPG) 
Natural estrogens, such as E2 and E1, undergo metabolism and conjugation in the liver to less potent 
derivatives.  Conjugation reactions, such as glucuronidation, sulfonation and O-methylation results in 
increased water solubility, allowing the derivatives to be more easily excreted in bile or urine. 
1.5.1 Endogenous Estrogens and Breast Cancer 
Many of the risk factors associated with breast cancer contribute to an individual’s cumulative lifetime 
exposure to the endogenous hormone, estrogen and, therefore, this increased cumulative estrogen 
exposure is hypothesised to contribute to increased breast cancer risk.  Both clinical and animal studies 
have reinforced this idea. 
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Early menarche, late menopause, late age at first pregnancy, increased weight or the use of HRT 
post-menopause have all been linked to an increase in the risk of developing breast cancer (Kelsey et al, 
1993).  Breast cancer risk for those with early onset of menarche, and, hence, greater lifetime estrogen 
exposure, is 1.2-2.2 times greater than individuals with a later menarche onset (Titrus-Ernstoff et al, 
1998).  Similarly, late onset of menopause, again contributing to increased estrogen exposure, correlates 
with an increased risk of breast cancer development.  Statistically, women in which menopause onset 
occurs before 45 have half the risk of breast cancer malignancy than women where onset occurs after 
the age of 55 (Trichopoulos et al, 1972). 
Another factor believed to be responsible for higher exposure to endogenous estrogens is 
obesity. This has been demonstrated, in post-menopausal women, to also contribute towards breast 
cancer risk (Le Marchand et al, 1988), although in pre-menopausal women, obesity may provide some 
level of protection against pre-menopausal breast cancer (Verla-Tebit & Chang-Claude, 2005).  The 
increase in breast cancer risk in obese post-menopausal women could be attributed to increased 
estrogen production in adipose tissues, thus, linking increased body weight with estrogen exposure.  The 
reasoning as to why increased weight has a protective effect against breast cancer in early life remains 
unclear, although it is hypothesised that obese women with abnormal ovulatory cycles have a reduced 
estrogen exposure (Pike et al, 1993). 
Animal studies have substantiated the hypothesised link between exposure to ovarian 
hormones and breast cancer: administration of estrogens has been shown to promote mammary 
carcinogenesis, an effect that can be reversed by ovariectomy (Mackenzie, 1955) or co-administration of 
estrogen with estrogen antagonists (Dao, 1981).  Ovariectomy has also been observed to decrease the 
risk of both ER positive (Press et al, 2011) and ER negative breast cancers in women carrying BRCA1 
mutation (Rebbeck et al, 1999).  Further to in vivo studies, epidemiological studies have shown that 
breast cancer patients exhibit higher estrogen serum and urine levels in comparison to their healthy 
counterparts (Key & Pike, 1988; Toniolo et al, 1995; Dorgan et al, 1996).  A role for estrogens in the 
initiation of cancers other than that of the breast, such as the kidney and liver, has also been 
demonstrated in animal models (Li et al, 1995; reviewed in Yager, 2000). 
Interestingly, early first pregnancies in life and increased parity, which would increase estrogen 
exposure, have been found to have a protective effect against breast cancer, with parity conferring a 
25% reduction in the risk of breast cancer compared to nulliparous women (Kelsey et al, 1993; Lambe et 
al, 1996; Hinkula et al, 2001; Sivaraman & Medina, 2002; Ma et al, 2010).  This protective effect 
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however, is limited to ER positive breast cancers (Ma et al, 2006) and is not immediate.  In fact, a 
comparison of uniparous and nulliparous women has shown that uniparous women have an elevated 
breast cancer risk for approximately 10 years following delivery, with more notable increases in risk in 
women aged 30 years or over at the time of delivery (Lambe et al, 1994; Schedin, 2006). 
Many hypothesises have been put forwarded to explain this.  The protective effect of pregnancy 
may be mediated by changes in the ratios of circulating estradiol, prolactin and growth hormone 
(Henderson & Feigelson, 2000).  It has also been proposed that the hormone surge during pregnancy 
induces changes in the stem cells of the terminal end buds of the breast ducts, resulting in these cells to 
differentiate, proliferate and respond to DNA damage.  Ultimately, these modified stem cells may be 
able to repair DNA damage and metabolise carcinogens unlike their unmodified counterparts in 
nulliparous females (Russo & Russo, 1997).   Similarly, the differentiation of breast epithelial cells and 
breast morphology may render cells less susceptible to carcinogenesis (Britt et al, 2007).  Comparisons 
of breast morphology of nulliparous with women who had undergone at least one full-term pregnancy, 
have shown that pregnancy causes maturation of breast lobules, resulting in increased alveoli and a 
decrease in the percentage of proliferating cells (Russo et al, 1994; Russo & Russo, 1994; Russo et al, 
2006).  This decrease in the percentage of proliferating cells could, therefore, reduce the probability of 
mutations occurring and, consequently, of a cancerous phenotype. 
It has also been hypothesised that in utero or early postnatal hormone exposure is the 
determining factor as to whether breast epithelial cells proliferate in response to estrogen or are 
estrogen independent in terms of proliferation (Trichopoulos ,1990; Nandi et al, 1995).  This idea is 
supported by epidemiological observations which demonstrated that factors associated with increased 
estrogen, increased size of foetus, obesity and mother’s age, result in increased breast cancer risk of 
female offspring (Thompson & Janerich, 1990; Ekbom et al, 1992; Vatten et al, 2002, Park et al, 2008).  
With pre-eclampsia, a condition associated with decreased estrogen levels, the risk of female offspring 
developing breast cancer appears to be reduced (Ekbom et al, 1992).  Animal studies further support 
this theory as in rats increased estrogen exposure in utero leads to an increase in the number of TEB in 
the mammary gland (Hilakivi-Clarke et al, 1997)  and it is these structures that have been identified as 
the structures from which mammary tumours arise (Russo & Russo, 1987; Russo et al, 1990). 
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1.5.2 Exogenous Estrogens and Breast Cancer 
Exogenous estrogens, such as pharmaceutics, may also have implications for breast cancer onset.  
Exogenous estrogens are commonly administered in the form of oral contraceptives, hormone 
replacement therapy (HRT) and drugs to prevent miscarriage and, overall, their use has increased over 
recent years.   
Statistically, a third of women in the UK between the ages of 50 and 64 have used HRT to treat 
the symptoms associated with menopause since the 1990’s.  However, the dramatic effects of its use 
only became apparent when a very large epidemiological study (The Women’s Health Initiative study) in 
2002 was prematurely stopped after a correlation was observed between combined estrogen-
progesterone HRT use and an increase in breast cancer development amongst the women enrolled in 
the study (Writing Group for the Women's Health Initiative Investigators, 2002, 2003).  The study also 
showed that estrogen-only HRT decreased the risk of breast cancer, however another similar study has 
shown the opposite (Million Women Study Collaborators, 2003).  Meta-analysis conducted for HRT 
studies has shown that there is a positive correlation between estrogen-only HRT use and breast cancer 
(Greiser et al, 2005). 
Incidence rates of breast cancer according to age has been increasing in women over the age of 
40 (Figure 1.10).  Although not the only factor in breast cancer incidence, the incidence rate in age 
groups over 40 years old does correspond to the age at which HRT is administered.  This observation 
must however be treated with caution as other factors, such as breast cancer screening may play a role.  
Due to the outcomes of the Million Women and the Women’s Health Initiative studies, HRT use since 
2000 has decreased significantly.  It now remains to be seen whether this will coincide with a decrease 
in breast cancer incidence. 
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Figure 1.10: Age-specific breast cancer incidence rates in the UK.   The increase in breast cancer incidence in 40-
49 year olds corresponds to the increase in HRT use in the 1990’s (Breast Cancer UK, 2009). 
Although the link between HRT use and cancer risk is substantiated by most reports, the link between 
oral contraceptive use and breast cancer risk is less clear and still the cause of much debate.  Many 
studies have found no correlation between the two (Marchbanks et al, 2002), however, several studies 
have identified a possible risk in women who use oral contraceptives for several years at younger ages, 
prior to first pregnancy (Olsson et al, 1989), after the age of 45, (Hennekens et al, 1984) and nulliparous 
women with early onset of menarche (Stradel et al, 1988).  Other studies have found that women using 
the pill have a slight, but insignificant, increased risk of developing breast cancer and this risk returns to 
that of non-users after stopping the use of oral contraceptives (Collaborative Group Study, 1996). 
Diethylstilbestrol, (DES), a synthetic estrogen and a drug prescribed to pregnant women 
between the 1940’s and 1970’s, has been associated with breast, vagina, and cervical cancer 
development in the daughters of mothers who took it (Palmer et al, 2006).  This highlights that pre-natal 
exposure to estrogenic compounds may impact upon offspring later in life.  However given that these 
individuals are only just reaching their 50s, the true impact of DES exposure during development 
remains to be seen. Further to this, the mothers prescribed DES, have experienced a 30% higher rate of 
breast cancer incidence (Greenberg et al, 1984; Colton et al, 1993; National Cancer Institute, 1999).   
1.5.3 Xenoestrogens and Cancer 
Since World War II, a multitude of chemicals have been synthesised and incorporated into people’s daily 
lives such, as pesticides, preservatives and other industrial products.  These chemicals were intended to 
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improve living standards, however, at the time, their endocrine disrupting properties were not known.  
Following evidence linking xenoestrogen exposure and reproductive health in wildlife, the endocrine 
disrupting properties of these compounds came to light.  The impact on wildlife exposed to 
xenoestrogens, such as o,p’-dichlorodiphenyltrichloroethane (o,p’-DDT) and 
dichlorodiphenyldichloroethylene (DDE), became clear, as population declines in a variety of species 
(including alligators, bald-eagles and marine birds) were observed and reproductive disorders reported 
(Colborn et al, 1993; Guillette Jr. et al, 1995; 1996).  These observations have also been reproduced in 
controlled in vivo studies involving a variety of laboratory models, such as rat models (Fusani et al, 
2007). 
Endocrine disruptors have been defined as exogenous substances that alter functions of the 
endocrine system and, consequently, cause detrimental health effects in an organism, its progeny, or 
within populations.  Such adverse effects can include cancer, birth defects and developmental disorders.  
The commonality amongst those chemicals that disrupt the endocrine system by mimicking the action of 
estrogenic hormones (so-called xenoestrogens) is the presence of a 4-OH group on the lipophillic phenyl 
A ring with a hydrophobic moiety present at the 2-position of propane (Figure 1.11) (Kitamura et al, 
2005). 
Based on the endocrine disrupting properties of environmental chemicals, it has been 
hypothesised that an individual’s lifetime exposure to estrogens may be further increased by the 
presence of these pollutants, many of which exhibit estrogenic properties.  It has been argued that the 
increased prevalence of breast cancer in developed countries could be attributed to the increased 
presence of endocrine disrupting chemicals. 
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Figure 1.11: The chemical structures of E2 and various estrogens.  Estrogenic compounds containing a phenyl ring 
and with structurally similarity to endogenous E2 are able to elicit responses through the ER. 
As mentioned above, xenoestrogens are those endocrine disruptors (either synthetic or naturally 
occurring) that exhibit estrogen-like activities through interaction with the ER.  However, it remains 
unclear whether these endocrine disrupters are able to elicit carcinogenic effects.  Contact with 
xenoestrogens in everyday life is common, as many are found in cosmetics (parabens and phthalates) or 
in the case of butyl benzyl phthalate (BBP) and bisphenol A (BPA), food packaging.  The latter of these is 
of current interest as it leaches from food packaging, such as water bottles (Brotons et al, 1995; Le et al, 
2008) and the lining of metallic food containers (Vandenberg et al, 2007), and into food products.  
Worryingly, until recently, BPA was also present in feeding bottles and equipment for babies, and there 
are concerns over the impact this may have (Maragou et al, 2008).  It can also be absorbed through the 
skin and has been found in 95% of urinary samples in an American survey (Calafat et al, 2005). 
 In regards to its estrogenic activity, BPA has been shown to bind to the ER and induce 
proliferation in MCF-7 cells, and in in vivo studies in ovariectomized mice, BPA exposure led to increased 
uterine weight (Krishnan et al, 1993; Papaconstantinou et al, 2000).  More recent studies have focused 
on the link between xenoestrogens and carcinogenesis.  In one such study, BPA treatment of MCF-10F 
cells (a non-tumourigenic mammary epithelial cell line) resulted in increased expression in genes 
involved in DNA repair, such as BRCA1 and BRCA2.  BPA also down-regulated the expression of the pro-
apoptotic gene BIM and induced hypermethylation of various other genes involved in cancer initiation 
and progression (Fernandez et al, 2012).  Further to this, epidemiological studies have found a positive 
correlation between BPA levels in urine and the development of meningioma, a tumour associated with 
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the nervous system (Duan et al, 2012).  Phthalates (chemicals used in the manufacture of plastics with 
endocrine-disrupting properties) have also been demonstrated to exhibit properties that are involved in 
the progression of liver cancer in rats (Rusyn et al, 2006).  Overall, these studies, and many more 
besides, have shown a link between the exposure to individual estrogenic compounds, present in our 
environment, and the initiation, and progression of cancer, 
1.6 Estrogens and the Estrogen Receptor 
In approximately 70% of cases, breast cancers are ER positive and hormone dependent at some point 
during their development (Masood, 1992; Musgrove & Sutherland, 2009)).  The presence, or indeed 
absence, of the ER is used to assess the prognosis of a patient and to establish the most suitable form of 
treatment.  ER expression is a characteristic of many breast cancers, which is exploited during treatment 
with anti-estrogens such as tamoxifen and fulvestrant (also known as ICI 182,780).  Unfortunately, 25% 
of patients are unresponsive to tamoxifen (the most common form of treatment) and in addition, many 
patients develop acquired hormone independence.  For this reason, it is importance to investigate the 
development of hormone-dependent cancer of the breast, and to more thoroughly understand the 
mechanisms of action exerted by estrogens.  In doing this, we, may in the future, be able to identify new 
targets for cancer therapy, which would result in a better outcome for patients. 
Estrogenic action is mediated by the nuclear receptors ER α and β.  ERα and ERβ are encoded for 
by separate genes on different chromosomes, but do still share significant sequence homology.  ERα is 
encoded for by the ESR1 gene and ERβ by ESR2 on chromosomes 6 and 14, respectively.  They are 
composed of five domains denominated A-F (Figure 1.12).  At the N-terminal are the A and B domains, 
which together make up the transcriptional activation function (AF-1) region.  This is the region of the 
receptor that can activate transcription of target genes in the absence of bound estrogen, following its 
activation by signalling pathways in response to growth factors (Bunone et al, 1996).   This 
transcriptional activation, however, is comparatively weak to that activated when estrogen is bound to 
the receptor.  The C domain is the region of the receptor that actually binds to the estrogen response 
elements (EREs) located in target genes.  The D domain acts as a hinge connecting the C domain to the E 
domain, the latter being the region where estrogen binds to activate gene transcription.  This hinged 
domain allows the receptor to undergo conformational changes upon ligand binding. Also, it is the 
location of nuclear localization signal (NLS) that permits activated receptor entry into the nucleus.  The E 
domain, in addition to acting as a binding site for estrogen, also makes up the ligand-inducible 
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transcription activation function (AF-2) region where co-activators and co-repressor proteins can bind 
and has a dimerization interface for interaction with other ERs.  Finally at the C-terminal is the F domain 
although the function of this domain remains to be discovered. 
 
 
Figure 1.12: The structure of ERα, consisting of five domains.  Ligand binding occurs in the E domain and the C 
domain is responsible for binding of the ER to the ERE.  The A/B domain contains the AF-1 region, which is 
responsible for the transcriptional activation of estrogen-responsive genes.  The F domain contains the AF-2 region 
that allows association with co-regulatory proteins required for the activation or cessation of transcription. 
Within the structure of ERα and ERβ, the greatest sequence homology is located within the DNA-binding 
domain, where the ER proteins are 96% similar and, hence, binding to the ERE of target genes is 
identical for the two subtypes.  As the sequence homology of the other regions ranges between 30 and 
54%, association with Sp-1 or Ap-1 (factors that enable activated ER to interact with genes lacking an 
ERE) is different for ERα and ERβ and hence the transcription of some genes is exclusive to one receptor 
form and more intriguingly, the same ligand can elicit both agonistic and antagonistic effects depending 
on which ER form it binds to (reviewed in Katzenellenbogen & Katzenellenbogen, 2000).  The sequence 
homology in the ligand binding domain does not impact greatly upon the binding of estrogens and 
estrogen antagonists but does, however, have an effect on phytoestrogen binding affinities, meaning 
that these bind to ERβ in preference in relation to ERα (Kuiper et al, 1998).  Despite significant sequence 
homology between ERα and ERβ, the receptors display different tissue distribution patterns and, 
possibly, mediate different effects.  ERβ expression is also often down-regulated in cancer (Bardin et al, 
2004; Ström et al, 2004), whereas ERα expression is often increased in cancer patients (Holst et al, 
2007).   
In recent years, a membrane associated receptor for estrogen has been widely debated.  
Various groups propose differing views as to the exact location and structure of this receptor, with the 
main trains of thought eluding it to be: a membrane bound ERα (mER)  (Pappas et al, 1995; Watson et 
al, 1999; Powell et al, 2001; Zivadinovic & Watson, 2004; Kim et al, 2008), a G-protein-coupled receptor, 
G-protein coupled estrogen receptor 1 (GPER-1, formally known as GPR30) (Filardo et al, 2002; Razandi 
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et al, 2003; Kumar et al, 2007) or a cooperative signalling through a membrane associated ERα and G-
proteins (Wyckoff et al, 2001).   
A number of studies have shown that the classical ERα can reside in the plasma membrane, 
although only to a level 2-3% of that in the nucleus, and that the effects of E2 mediated by this 
membrane ER are reversed by anti-estrogens, such as ICI 182,680 (Kim et al, 1999; Razandi et al, 1999; 
Haynes et al, 2000; Russell et al, 2000).  Treatment of MCF-7 cells has been shown to result in the 
translocation of ERα to the membrane, where it resides in caveolae, small cholesterol-rich invaginations 
of the plasma membrane (Levin, 2002; Razandi et al, 2002; Figtree et al, 2003; Acconcia et al, 2004; 
Zivadinovic & Watson, 2004; Acconcia et al, 2005), or interacts through its N-terminal region with 
adapter proteins containing SH2 domains, such as Src (Pelicci et al, 1996; Song et al, 2002; Song et al, 
2004).  As ERα does not contain any hydrophobic domains capable of expanding the cell membrane, the 
receptor must be modified or associate with other proteins in order to localize at the cell membrane.  
Various mechanisms have been identified for the association of the ER with the plasma membrane, such 
as post-translational palmitoylation of ER’s ligand binding domain (Acconcia et al, 2005) and association 
of the ER with caveolin-1 (Pedram et al, 2007).  Caveolin-1 is a structural component of the caveolae and 
functions to recruit components of the signalling pathway at all levels such as receptors, G-proteins, Src 
kinases and phosphatidylinositol 3-kinases (PI3K) (Levin & Pietras, 2008).  These ER associations do not 
occur in the absence of estrogens and are disrupted by anti-estrogen treatment or small interfering RNA 
(siRNA) against ERα (Song et al, 2004).  
In addition to the classical form of the ERα, truncated forms of this receptor have been 
identified in the plasma membrane, which are capable of mediating the non-genomic effects of 
estrogens (Flouriot et al, 2000; Li et al, 2003; Wang et al, 2005; Wang et al, 2006; Kim et al, 2008).  The 
46 kDa isoform of 66 kDa ERα lacks 173 amino-acids present at the N-terminus, contains no A/B domain 
and is encoded by the ERα gene lacking exon 1A. It can also mediate non-genomic estrogenic actions in 
addition to forming heterodimers with the ER to mediate transcriptional responses (Flouriot et al, 2000; 
Denger et al, 2001).  A 36 kDa (ERα36) isoform has also been identified and this lacks both the AF-1 and 
AF-2 domains, and contains an additional 27 amino acids at the C-terminal (Wang et al, 2005; Wang et 
al, 2006; Lin et al, 2010; Shi et al, 2010; Tong et al, 2010).  The lack of AF-1 and AF-2 domains renders 
ERα36 unable to mediate transcriptional responses to estrogens, but still allows the receptor to play a 
role in mediating non-genomic responses (Chaudhri et al, 2012).   
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Conversely, many other studies have demonstrated the presence of a mER that is distinctive 
from ERα or ERβ and E2-induced non-genomic signalling has been observed in cells lacking ERα or ERβ 
expression or following treatment with ER antagonists (Gu et al, 1999; Filardo et al, 2000).  A G-protein-
coupled receptor, GPER-1 has been proposed as a mediator for these ER-independent effects of E2 and 
has been identified in the cell membrane and will be discussed later (Razandi et al, 1999; Benten et al, 
2001; Filardo et al, 2002). 
1.6.1 GPER-1  
GPER-1 is hypothesised to mediate some of the rapid non-genomic effects of estrogens.  It is a G-protein 
coupled receptor (GPCR), structurally distinct from ERα or ERβ, which spans the membrane seven times 
starting with an extracellular N-terminus and ending in an intracellular C-terminus.  G-proteins function 
in a variety of physiological roles, such as sensory perception, mood and immune system regulation, 
autonomic nervous system transmission and cell density determination.  The exact localization of GPER-
1 remains the centre of some debate, with some groups showing its localization to the plasma 
membrane (Filardo et al, 2000, Filardo et al, 2007) and others to the membranes of the endoplasmic 
reticulum (Revankar et al, 2005; Otto et al, 2008). 
Specifically, GPER-1 is part of the chemokine receptor-like 2 subfamily within the class A 
rhodopsin-like family.  It shares a 28% sequence homology with the angiotensin II 1A and interleukin 8A 
receptors (Carmeci et al, 1997).  GPER-1 has been shown to couple to G-proteins and its activation by E2 
results in adenylyl cyclase activation, consequent increases in cyclic adenosine monophosphate (cAMP) 
(Thomas et al, 2005) and activation of the PI3K signalling cascade, with consequent AKT activation.  
Additionally, SRC-like tyrosine kinase activation resulting in fibronectin matrix assembly and activation of 
metalloproteases was also observed. 
GPCRs are inactive until ligand, which may be a peptide, neurotransmitter or hormone, binding 
occurs.  This induces a conformational change at the extracellular binding site that in turn induces a 
conformational change of the loops on the cytoplasmic side of the membrane.  This increases the 
affinity of the receptor for heterotrimeric G-proteins, which, bind to the receptor forming the receptor-
G protein complex.  G-proteins are composed of Gα, Gβ and Gγ subunits and their targets are 
determined by the type of Gα subunit, although Gβγ can also elicit intracellular effects.  Gα is 
palmitoylated and Gγ has a glycosylphosphatidylinositol covalently bound to it rendering them anchored 
to the membrane.  They remain inactive with a reversibly bound guanosine diphosphate (GDP) to the α 
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subunit or lacking any guanine nucleotide association, but upon binding to the GPCR and undergoing a 
conformational change, GDP is released and guanosine triphosphate (GTP) binds to the α subunit.  Gα is 
then able to dissociate from the Gβγ dimer and bind to its effectors.  This effector is determined by the 
form of Gα activated; Gs forms activate adenylyl cyclase, Gq activates phospholipase C β (PLCβ), Gi 
inhibits adenylyl cyclase and G12/13 potentially activates Ras, Src, phospholipase D and protein kinase C.  
For E2-induced GPER-1 activation, immunoprecipitation studies have shown that the Gs form mediates 
E2 responses (Thomas et al, 2005). 
1.6.2 Modes of Action of the Estrogen Receptor: Genomic Actions 
The classical mode of estrogenic action is that mediated by nuclear ERα and ERβ.  Upon diffusion into 
the cell, estrogen binds to the ligand binding domain of the ER, inducing a conformational change in the 
receptor and, liberating it from its cytosolic chaperone, heat shock protein 90 (Hsp90) (Tanenbaum et al, 
1998).  These estrogen-induced conformational changes also expose nuclear localization signals present 
in the DNA binding domain and, so, once free from its chaperone, the ER-estrogen complex is 
transported into the nucleus, where it can form dimers with other ER-estrogen complexes (Métivier et 
al, 2002).  These dimers bind to estrogen response elements (EREs) within the promoter regions of 
target genes and induce or inhibit the transcription of these genes (Figure 1.13).  In the absence of an 
ERE, estrogen is still able to induce transcriptional activity changes of target genes via ER interactions 
with AP-1 and Sp1 (Krishnan et al, 1994; Porter et al, 1996; Paech et al, 1997; Duan et al, 1998).  These 
are transcription factors that, when bound to own their response elements, can bind to ER complexes.  
This interaction recruits further co-activator or chromatin remodelling complexes, facilitating the 
formation of the transcription initiation complex, which permits RNA polymerase II interaction with the 
DNA and hence results in transcription.  Interestingly, ERα can also be activated in the absence of 
estrogens following the phosphorylation of ser118 in the A/B domain and, thus, activating AF-1 
(Lannigan, 2003). 
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Figure 1.13: The genomic mechanism of E2 action.  E2 enters the cells and binds to the ER.  The E2-ER complex 
translocates to the nucleus, dimerises and binds to the ERE of estrogen-responsive genes to activates transcription. 
Estrogens have also been found to regulate the expression of microRNA (miRNA), small, non-coding 
sequences of RNA that block translation or promote degradation of target messenger RNA (mRNA) 
(Klinge, 2009; Wickramasinghe et al, 2009).  miRNA are short, non-coding RNA sequences that, when 
incorporated into the RNA-induced silencing complex (RISC), bind to complimentary or near-
complimentary target mRNA and prevent RNA translation or target it for degradation.  If miRNA binds to 
target mRNA imperfectly, the result is translational repression, whereas perfect or near-perfect binding 
results in mRNA degradation (Rhoades et al, 2002; Zeng et al, 2002; Doech & Sharp, 2004; Cuellar & 
McManus, 2005).  Either mechanism can have implications for proliferation, apoptosis and cell 
differentiation and, therefore, the dysregulation of miRNA expression may be involved in 
carcinogenesis. 
1.6.3 Non-Genomic Estrogenic Actions 
In recent years, studies have demonstrated that, in addition to the effects mediated by the nuclear ER, 
estrogens also induce other, short-term effects, which, occur so soon after exposure that cannot be 
attributed to the classical genomic pathway.  In this instance, estrogens are now known to act via a non-
genomic mechanisms, involving the activation of secondary messenger signalling pathways, such as 
cAMP production following adenylate cyclise activation (Aroncia et al, 1994), inositol phosphate 
production (Le Mallay et al, 1997) leading to phosphatidylinositol 3-OH kinase (PI3K) activation (Haynes 
 Cytoplasm 
 
Nucleus 
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et al, 2003; Simoncini et al, 2000), increased intracellular Ca2+(Improta-Brears et al, 1999; Migliaccio et 
al, 1996; Wozniak et al, 2005; Zhao & Brinton, 2007; Szatkowski et al, 2010; Yan et al, 2011), Src and 
mitogen-activated kinase (MAPK) activation (Migliaccio et al, 2003) and protein kinase C (PKC) activation 
(Picard et al, 2003). 
The mechanism by which E2 is able to elicit its non-genomic effects is highly complex and 
involves a variety of different estrogen-responsive receptors and cross-talk between signalling 
pathways.  It has been demonstrated that E2-ERα complexes are able to associate with Src tyrosine 
kinase and the PI3-K’s regulatory subunit (Castoria et al, 2001; Razandi et al, 2003; Simoncini et al, 
2003), which has implications for proliferation and cell survival.  On the other hand, estrogens can also 
activate the G-protein-coupled receptors, GPER-1, leading to adenylate cyclase and phosphlipase C 
stimulation and subsequent activation of protein kinases involved in MAPK signalling.  E2-activated 
membrane-associated receptors, such as mER and GPER-1, can also result in EGF receptor activation 
(reviewed in Filardo, 2002). 
Cross-talk between estrogen receptors and various signalling pathways exists and this can result 
in hormone independent ER activation.  It has been observed that the ER can become activated as a 
result of MAPK and PI3K signalling pathway activation, despite the lack of estrogen presence (Kato et al, 
1995), leading to transcription of E2-inducable genes.  Additionally, E2 can rapidly activate the PI3K and 
MAPK pathways, normally associated with growth factor receptors, such as that of epidermal growth 
factor (EGF). 
1.7 Growth Factor Signalling Pathways  
Signalling pathways are governed by the presence of receptors on cell membranes.  Different classes of 
receptors mediate different signalling pathways that have implications for cell growth, survival, 
migration, proliferation, differentiation and apoptosis.  Disruption of signalling pathways, such as 
overexpression of receptors or constitutive activation of key kinases, is implicated in many cancers, 
including that of the breast.  This can be exemplified by the overexpression of the EGF receptor, Her-2.  
Activation of this receptor by its ligands activates PI3K and MAPK signalling pathways, leading to 
increased proliferation and survival.  It has been demonstrated that estrogen action can result in the 
rapid activation of Src and Erk, key components in Akt and MAPK signalling (Wozniak et al, 2005; Tong et 
al, 2010). 
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1.7.1 PI3K/AKT Signalling 
The PI3/AKT pathway is involved in cellular growth, proliferation, cell motility and survival in normal and 
cancerous cells, however in cancer, it often becomes dysregulated (Vivanco & Sawyers, 2002).  During 
tumour formation, it is also implicated in angiogenesis and EMT as a result of increased AKT activation 
(Yao et al, 2008).  The pathway can be mediated by receptor tyrosine kinases (RTKs) and the binding of 
ligands, such as EGF. 
RTKs exist as inactive monomers in the cell membrane and contain Src-homology 2 (SH2) or 
phosophotyrosine binding (PTB) domains at their cytoplasmic ends.  Ligand binding causes receptor 
dimerization and activation.  The active dimers then undergo trans-auto phosphorylation at their 
cytoplasmic regions allowing the binding of target proteins to the SH2 or PTB domains.  The binding of 
adaptor or docking proteins to these domains link signalling proteins to the receptor or provide 
additional binding sites for signalling molecules respectively.  Transcription factors, such as STAT’s can 
bind to and become activated by RTKs, as well as signalling molecules, such as PI3K, which become 
activated by binding to RTKs phosphorylation sites.  The signals from RTKs is terminated upon receptor 
internalisation. 
PI3K is a lipid kinase comprised of a p85 regulatory subunit and a p110 catalytic subunit.  PI3K is 
responsible for the reaction that synthesises the secondary messenger, phosphatidylinositol 
triphosphate (PIP3), a membrane phospholipid, from phosphatidylinositol diphosphate (PIP2).  PIP3’s 
function is to recruit Akt to the plasma membrane so that it can be phosphorylated and, hence, 
activated (Figure 1.14).  Upon activation, Akt translocates to the nucleus and is able to phosphorylate 
and activate various targets that are involved in cell cycle progression, apoptosis and epithelial–
mesenchymal transition (EMT) pathways (Yao et al, 2008).  Many of these targets are enzymes involved 
in the modulation of the Akt pathway, such as murine double minute 2 (MDM2), E3 ligase, α6β4 integrin 
and PTEN (Tokunaga et al, 2008; reviewed in Tokunaga et al, 2010).  Ultimately, Akt pathway activation 
leads to increased cell cycle progression due to the inhibition of the cell cycle inhibitors p21 and p27 
(Zhou et al, 2001), apoptotic inhibition due to caspase-3 and pro-apoptotic factor inhibition and 
increased cell survival, as a result of p53 inhibition. 
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Figure 1.14: The PI3K/AKT signalling pathway.  Following stimulation, Grb2 and Sos are recruited to the activated 
receptor and Ras GDP is converted to Ras GTP.  PI3K is then activated and converts PIP2 to PIP3, which activates 
AKT.  AKT then functions by phosphorylating and activating or inhibiting proteins involved in proliferation and 
survival, or apoptosis, respectively. 
PTEN phosphatase removes the 3-phosphate from PIP2 and PIP3, thus rendering these secondary 
messengers inactive and, consequently, causing a cessation in PI3K signalling.  Hence, the down-stream 
targets of PI3K can negatively regulate the PI3K pathway via a feedback loop. 
The PI3K pathway has been implicated in a variety of cancers, including that of the breast (Zinda 
et al, 2001) with increased Akt activity identified in up to 40% of breast cancer samples (Tokunaga et al, 
2006).  The pathway can be activated by the HER2, which is over-expressed in ~30% of breast cancers 
and ER, which is present in ~60% of breast cancers (Dancey & Sausville, 2003). Additionally, mutations in 
PTEN, often observed in breast cancers, render it functionless resulting in hyper-activation of the 
pathway (Cantley & Neel, 1999).  Finally, gene mutations in both the regulatory p85 and catalytic p110 
subunits of PI3K have also been identified in a variety of cancers, including that of the breast and are 
present in approximately 8% of breast cancer tumours (Ma et al, 2000; Philp et al, 2001; Bachman et al, 
2004; Campbell et al, 2004; Samuels et al, 2004; Levine et al, 2005).  Regardless of the mechanism, 
dysregulation of the PI3K pathway is associated with cancer and has implications for proliferation, 
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metabolism, cellular adhesion, apoptosis, migration and arrangement of the cytoskeleton (Levine et al, 
2005; Liu et al, 2010). 
1.7.2 Mitogen Activated Protein Kinase Signalling 
The MAPK signalling pathway is involved in the regulation of apoptosis, proliferation, survival, 
differentiation and motility.  MAPK’s are serine-threonine kinases that are activated by phosphorylation 
and function to transduce extracellular signals to targets within a cell, such as enzymes, components of 
the cytoskeleton and transcription factors.  Ultimately, activation of the MAPK pathway results in 
increased cell proliferation and survival.  This pathway is often dysregulated in cancer (Hilger et al, 
2002).  The MAPK pathway can be divided into four cascades: the extracellular regulated kinase 1/2 
(ERK1/2), the c-Jun N-terminal (JNK), the p38 and the ERK 5 pathway.  The ERK1/2 cascade has proved to 
be of significant relevance for the effects of estrogens and throughout this thesis will remain the primary 
focus for investigation (Santen et al, 2002; Whyte et al, 2009). 
As with PI3K signalling, one mechanism by which MAPK signalling can be activated is via RTKs.  
Ligand binding induced activation of transmembrane receptors results in the recruitment of the SH2 
domain containing adapter protein, growth factor receptor-bound protein 2 (Grb2) to the receptor.  This 
SH2 domain is present in many proteins involved in intracellular signal transduction.  Its function is to 
allow proteins containing an SH2 domain to dock with phosphorylated tyrosine residues present on 
other proteins (Figure 1.15). 
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Figure 1.15: The activation of SH2 domains and their role in signal transduction.  The SH2 domain of a protein 
binds to the phosphorylated tyrosine residues of a receptor.  The SH3 domains of the same protein are then able 
to bind to proline-rich proteins to form a protein complex required for the downstream signal transduction events 
 
Following recruitment of Grb2, the guanine nucleotide exchange factor, son of sevenless (Sos) is then 
sequestered via the SH3 domains of Grb2.  The role of these SH3 domains is to allow proteins containing 
them to interact with other proteins which are proline-rich.  This results in the assembly of protein 
complexes, such as those involved in intracellular signal transduction (Figure 1.15).  Sos then stimulates 
the dissociation of GDP and binding of GTP to Ras, thus activating it.  This activation triggers a kinase 
cascade involving Raf, MEK, and ERK’s.  ERK then phosphorylates and activates the transcription of 
genes such as c-FOS and c-JUN.  Additionally the transcription of MKP-1 is also induced which leads to 
the dephosphorylation and deactivation of ERK, thus terminating the signal (Figure 1.16). 
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Figure 1.16: The MAPK signalling pathway ERK cascade.  Following stimulation, Grb2 and Sos are recruited to the 
activated receptor and Ras GDP is converted to Ras GTP.  A phosphorylation cascade involving Raf, Mek and Erk 
subsequently induces the induction of genes involved in proliferation and cell survival. 
E2 treatment can result in the activation of MAPK signalling and a variety of mechanisms have been 
postulated regarding how this is achieved.  The first proposed mechanism is via ER interaction at the 
membrane with components of signalling pathways.  ERα can associate with SH2 domain containing 
adapter proteins, such as Shc, in the presence of E2 and growth factor receptors resulting in formation 
of the Shc-Grb2-Sos complex and activation of the MAPK pathway (Song et al, 2002).  If ERα or SH2 are 
knocked down by siRNA, or in the case of co-incubation with ER antagonists, MAPK signalling is not 
observed (Song et al, 2004).  Secondly, estrogens are able to induce MAPK signalling via GPER-1, 
independently of the presence of ER.  As with the aforementioned mechanism involving ERα association 
with Shc, activation of GPER-1 in response to E2 results in the formation of Shc-EGF receptor complexes 
and subsequent MAPK signalling (Filardo et al, 2000).  The role of GPER-1 in mediating E2’s induction of 
MAPK signalling are further supported by the observation that increased levels of Ca2+ following 
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treatment with E2 are not prevented by co-incubation with ER antagonists, but are abolished upon co-
incubation with inhibitors of Gα (Doolan & Harvey, 2003). 
Disruption of MAPK signalling is associated with cancer and can occur at many levels within the 
pathway.  At the receptor level, receptor overexpression or mutation, such as that seen with EGFR, can 
lead to increased activation of the MAPK pathway.  In normal cells, the GTP attached to Ras is 
hydrolysed to GDP making Ras inactive, however, mutations in Ras, which occurs in 30% of all cancers, 
prevent this hydrolysis of Ras, which becomes constitutively activated and MAPK signalling becomes 
dysregulated (Cox & Der, 2002; Davies et al, 2011). 
1.7.3 Crosstalk Between Estrogen and Growth Factor Pathways 
It has been demonstrated that two of the pathways through which estrogens elicit rapid non-genomic 
effects are the PI3K and MAPK signalling cascades.  For example, E2 treatment of cells increases MAPK 
activation to approximately 20% of the level observed with EGF treatment, within 5 minutes of exposure 
and this effect lasts for an hour, before returning to normal levels, even in the continued presence of E2 
or EGF (Improta-Brears et al, 1999).  Also E2-treated MCF-7 cells have been shown to have increased Shc 
phosphorylation, an indicator that E2 is causing Shc/GRB2/Sos complex formation (Migliaccio et al, 
1996) an early event in the PI3K and MAPK signalling cascades. 
Estrogen action can also interact with growth factor signalling in a process known as cross-talk.  
Cross-talk is the interaction between different signalling pathways and results in the integration of 
various signals and the different cellular responses that they elicit.  Various classes of cross-talk have 
been identified: receptor function, signal flow, substrate availability, gene expression and cellular 
communication (Figure 1.17) (Donaldson & Calder, 2011).   Receptor function cross-talk is when a 
receptor’s ability to bind to its ligand and elicit a response in one signalling pathway is affected by 
another, such as the increase in EGF receptor expression in response to E2 (Das et al, 1994) resulting in 
increased EGF-initiated signalling pathways, or MAPK pathway-induced ER phosphorylation (Tang et al, 
2004).  The phosphorylation of the ER has implications for the receptor’s  localization, dimerization and 
transcriptional activity (Chen et al, 1999; Le Goff et al, 1994; Lee & Bai, 2002) and can also induce its 
degradation via the ubiquitin-proteasome pathway (Marsaud et al, 2003).  Signal flow cross-talk occurs 
when a component of one pathway affects the activation of a protein in another pathway.  Substrate 
availability cross-talk is when two pathways compete for the same protein, for example EGF activation 
of MAPK and E2-induced activation of MAPK.  Gene expression cross-talk concerns the activation or 
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suppression of the same target genes in conflicting ways when two pathways are activated 
simultaneously.  Cellular communication cross-talk is when the activation of one pathway results in the 
release of a ligand that activates another pathway, such as the increased release of EGF in response to 
E2 (Das et al, 1994). Estrogens can also cross-talk with insulin/insulin-like growth factor-1 (IGF-1) 
signalling pathways, resulting in increased insulin signalling (Stewart et al, 1990). 
 
 
Figure 1.17: Different types of cross-talk.  Cross-talk between estrogen (blue) and growth factor (red) signalling 
pathways may have impacts upon the availability of substrates to perform certain processes, gene transcription 
and the activation of other receptors (Adapted from Donaldson & Calder, 2011). 
1.8 Theories Surrounding Hormonal Carcinogenesis 
Hormonal carcinogenesis is the initiation of carcinogenesis or the promotion of tumour growth in 
response to hormones, such as estrogens.  The process is not fully understood although various theories 
have been proposed to explain the relationship between estrogen and cancer.  Firstly, estrogen is 
thought to stimulate proliferation of receptive cells (Holland & Roy, 1995) and, as a result of this 
increased proliferation, DNA mutations accumulate and a malignant phenotype may result (Travis & 
Key, 2003).  Indeed, increased proliferation induced by E2 in vivo, results in increased lobular size of the 
mammary gland in rats (Kovalchuk et al, 2007).  The theory of proliferation-induced hormonal 
carcinogenesis differs from the chemical or genotoxic model of carcinogenesis in that no initiating event, 
such as genetic mutations, are required. 
More recently, it has been hypothesised that estrogens and their can cause genotoxicity through 
DNA adduct formation (Cavalieri et al, 1997; Lu et al, 2007; Saeed et al, 2008).  Estrogens and their 
metabolites can also induce gene mutations (Liehr, 2001), loss of heterozygosity (Russo et al, 2002), 
single strand DNA breaks (Yared et al, 2002; Rajapakse et al, 2005) and aneuploidy (Li et al, 2004; Kabil 
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et al, 2008), thus highlighting the complexity as to the role of estrogens in carcinogenesis that is not 
entirely contemplated by the more traditional theory described previously.   
E2 is metabolised via oxidations at the C-2. C4 and C16 positions to form the active metabolites: 
2-hydroxyestradiol and 4-hydroxyestradiol.  These then undergo methylation or oxidation to form 
electrophilic semiquinones and catechol estrogen quinone.  Conjugations via O-methylation by catechol-
O-methyltransferase (COMT) results in metabolite inactivation (Figure 1.18).  If however, this 
inactivation does not occur, the active metabolites can form stable adducts with DNA resulting in DNA 
strand breaks.  They can also induce depurination, processes that increase the chance of mutations, 
which, in turn, may result in carcinogenesis (Dwivedy et al, 1992; Cavalieri et al, 1997; Chakravarti et al, 
2001; Li et al, 2004).  The failure for an organism to completely metabolise estrogens could occur for a 
variety of reasons, such as polymorphisms of the genes encoding for cytochrome P450 enzymes (CYP17 
and CYP1A1, and of COMT), all of which are key enzymes involved in estrogen metabolism (Huang et al, 
1999; Dawling et al, 2001).  Interestingly, in addition to this, estrogen and its metabolites may down-
regulate or inhibit COMT (Roy et al, 1990; Xie et al, 1999). 
 
 
Figure 1.18: The metabolism of E2.  E2 metabolism can lead to the formation of reactive metabolites that are 
capable of forming adducts with the DNA. (Adapted from Medscape 
http://www.medscape.com/viewarticle/449725_2) 
Loss of heterozygosity in parts of chromosome 11 has also been observed in E2-treated cells in vitro 
(Russo et al, 2002).  Loss of heterozygosity is the loss of the normal functioning of a gene allele in a cell 
where the second allele is already inactive.  In the context of cancer, this could result in the suppression 
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of tumour suppressor genes and, consequently, tumourigenesis.   Chromosome 11 frequently exhibits 
loss of heterozygosity in breast cancer and loss of heterozytm’sgosity at the 11q23.3 loci specifically has 
been reported in approximately 35% of breast tumour samples (Tomlinson et al, 1996), suggesting the 
presence of a tumour suppressor gene close to this locus.  In a model used by Russo and Russo (2006), 
E2-treated transformed cells were injected into severe combined immunodeficient (SCID) mice and the 
result was tumour formation.  Using this method, other genomic gains and losses in response to 
estrogen treatment both in vitro and in vivo were identified.  Most notably was the genomic gain of 
8q24.1 and deletion of chromosome 4 (Fernandez et al, 2005; Fernandez et al, 2006; Russo & Russo, 
2006). 
Estrogens can affect the expression miRNAs and abnormal miRNA expression patterns have 
been observed in breast cancer (Iorio et al, 2005; Blenkiron et al, 2007; Tavazoie et al, 2008).  In rats, 
following E2-induced mammary carcinogenesis, numerous miRNAs were up- or down-regulated 
including mi RNA’s that target E2F1 and BCL6 (Kovalchuk et al, 2007).  In MCF-7 cells, E2 treatment 
affected the regulation of multiple miRNAs involved in apoptosis, proliferation, metastasis and drug 
resistance (Miller et al, 2008; Yu et al, 2008).  Notably, E2 up-regulates the miRNA that targets the 
caspase-3 and down-regulates the miRNA that targets Cyclin D, and, thus, has implications for caspase-
mediated apoptosis and proliferation (Tsang & Kwok, 2008; Yu et al, 2008) 
Estrogens can also have an impact upon epigenetic modifications, heritable changes within 
chromatin that do not alter the DNA sequence, but do nevertheless affect gene expression due to 
chromatin remodelling (Kovalchuk et al, 2007; Mello et al, 2007; Starlard-Davenport et al, 2010).  This 
can occur by DNA methylation or histone modification.  DNA methylation occurs predominately at 
cytosine and guanine dinucleotide (CpG) rich regions of DNA, termed CpG islands.  During this process a 
methyl group is transferred to the 5’ carbon of the cytosine residue resulting in the repression of gene 
expression, due to chromatin remodelling.  Whilst hypermethylation results in transcriptional 
repression, hypomethylation has the opposite effect and promotes transcription.  Both of these 
processes dysregulate gene expression and are implicated in breast cancer and can be affected by E2 
(Kovalchuk et al, 2007).  During histone modifications, the structure of chromatin is modified to either 
promote, in the case of histone acteylation, or repress, in the case of histone deacetylation, gene 
transcription.  In any case, the result of epigenetic modifications can lead to the repression of tumour 
suppressor genes, the increased expression of oncogenes or chromosomal instability, all of which can be 
involved in the initiation and progression of cancer.  Estrogens have been implicated in modification of 
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chromatin structure through the histone acteylation or deacetylation of and histone methylation or 
demethylation of the ERα gene promoter regions (Glass et al, 1997; Garcia-Bassets et al; 2007).  The 
deregulation of the enzymes involved in these processes could therefore have a role in epigenetic 
modification-induced carcinogenesis (Mann et al, 2011). 
The impact of estrogens on epigenetic modifications can be exemplified by DES, a 
pharmaceutical estrogen, mention before in this chapter.  Daughters of mothers who took DES during 
pregnancy are more likely to develop cancer (Palmer et al, 2006).  A similar outcome was also observed 
in mice studies, where animals were shown to develop breast tumours and to present demethylated 
estrogen-responsive genes, such as lactoferrin and c-fos (Newbold et al, 1990; Li et al, 1997b).  These 
findings suggest that in utero estrogen exposure can result in a predisposition for cancer later in life. 
Further to this, E2 can disrupt the dividing of stem cells (Russo et al, 2010) or enhance stem cell 
proliferation in a paracrine fashion (Fillmore et al, 2010).  Also, increased in utero E2 exposure correlates 
with increased number of stem cells (Savarese et al, 2007), indicating that estrogens may increase the 
stem cell populations, which some hypothesise to be the origin of cancer (Sell, 2004; Martinez-Climent 
et al, 2006).  Stem cell populations within the mammary gland are able to give rise to a variety of 
different cell types and have the ability to divide asymmetrically, producing one stem cell and one cell 
which will differentiate into a ductal epithelial, alveolar epithelial or myoepithelial cell (Kordon & Smith, 
1998; Shackleton et al, 2006).  During pregnancy, this enables the stem cells to maintain a stem cell pool 
whilst populating the breast in preparation for breast feeding.  Studies have shown that 1-10% of the 
total cell population displaying markers for stem cells are able to form tumours in severe Combined 
Immunodeficiency (SCID mice), contrasted to non-stem cells being unable to elicit the same tumour 
growth (Al-Hajj et al, 2003; Ponti et al, 2005; Ginestier et al, 2007). 
Additionally, estrogens can enhance remodelling of tissues within in the body through 
interactions between the stroma and epithelium (Soto & Sonnenschein, 2010), increasing the probability 
of tissues structure becoming disorganised and, hence, initiate cancer.  Nevertheless, although the 
intracellular mechanisms involved in hormonal carcinogenesis have been widely studied, little is known 
about the effects of estrogens on the glandular structure of the breast. 
1.9 Hypothesis 
The disorganisation of tissue structures, such as the ducts of the breast, is associated with cancer 
progression and, despite advances in research, it still remains unclear if this disorganisation leads to a 
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cancerous phenotype or if it is, in fact, a result of aberrations of the genome and loss of proliferative 
control, which occur as a consequence of carcinogenesis.  The role of estrogens, which are required for 
the normal development of the breast, in this disorganisation also remains unknown.   
We propose that estrogenic chemicals, such as E2, interact with estrogen-responsive receptors 
and key signalling pathways during acini formation which, ultimately, has an impact on the development 
and architecture of breast acini.  We aim to use a 3D in vitro model (which will be explained in detail in 
Chapter III) to investigate the effects of estrogens on the morphogenesis of the mammary gland, in 
addition to the role that estrogen-responsive receptor play in this. 
1.10 Scope of the Thesis 
Much of the work published in the literature concerning 3D cultures has focused on the ER negative, 
non-tumourigenic MCF-10A cell line and has revealed mechanisms and genes involved in the formation 
and maintenance of the hollow lumen of acini.  Limited work concerning the effects of 17β-estradiol on 
acini formation using the ERα negative, but ERβ positive MCF-10F cell line has demonstrated that E2 
treatment results in cells losing their ability to form acini in collagen matrices, but suggests that this 
effect is ER-independent (Russo et al, 2002; 2003; 2009; 2010).  In order to investigate the full spectrum 
of estrogenic effects on acini formation and the potential involvement of the ERα in these processes, a 
different cell line was, therefore, required.  For that, a non-tumorigenic, ERα and ERβ positive cell line 
was selected: the MCF-12A cell line. 
In Chapter II, we sought to confirm the receptor status of the cell lines to be used to further 
study the impact of estrogens upon proliferation and apoptosis in a 3D model.  In addition to confirming 
the receptor status of MCF-12A cells, the receptor status of MCF-10A cells was investigated to confirm 
its ER negative phenotype and to ascertain whether this cell line was GPER-1 competent.  Growth curves 
were also constructed for these cell lines in the presence of E2 and receptor antagonists for both the ER 
and GPER-1 to investigate the impact of E2 upon proliferation and whether this was mediated by the ER 
or GPER-1.  Finally, the well-studied MCF-7 and MDA-MB-231 cell lines were used as comparison to 
investigate the effects of E2 upon proliferation in an ER competent and ERα negative tumourigenic cell 
line. 
In Chapter III, we proceeded to optimise an established 3D model for use with MCF-12A cells 
which has previously been used with MCF-10A cells.  After optimising the conditions required to 
successfully perform 3D culture of MCF-12A cells in reconstituted basement membrane (Matrigel), we 
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established a time-course for the morphogenesis of MCF-12A acini.  This was done so that a comparison 
was available between normal MCF-12A acini formation and acini formation following treatment with 
estrogenic test compounds. 
After establishing the normal morphogenesis of MCF-12A cells in 3D culture and selecting the 
estrogenic test compounds to perform subsequent 3D studies, a time-course for E2, BPA and n-
propylparaben was established in Chapter III.  Further to this, in Chapter IV, we decided investigate 
whether the malformations induced by the estrogenic test compounds were mediated by the ER or 
GPER-1, using antagonists for these receptors.  This work has been submitted for publication (Marchese 
& Silva, 2012). 
After the observation that both of these receptors are implicated in the estrogen-induced 
disruption of MCF-12A acini, in Chapter V, we proceeded to investigate the non-genomic effects of 
estrogens using inhibitors of the PI3K and MAPK signalling pathways. 
Treatment of 3D cultures with the estrogenic test compounds resulted in deformed acini of 
increased size and displaying filled lumen.  These effects were mediated by both the ER and GPER-1, and 
were, in part, a consequence of activation of the PI3K and MAPK pathways.  We decided then, to 
investigate how estrogens impacted upon the expression of key apoptotic factors in 3D culture.  The first 
step in doing this was to optimise the primers for future real-time polymerase chain reaction (PCR).  This 
had to be conducted in monolayer due to technical and financial constraints.  We then decided in 
Chapter VI, to investigate first, whether in monolayer culture, E2 affected the gene expression of four 
key apoptotic factors: BCL-2, BCL-XL, BAX and BAD in four mammary cell lines.  After the observation 
that in monolayer, E2 did not greatly impact upon a single apoptotic factors, but did instead affect the 
expression of multiple apoptotic factors, we calculated the Bax/Bcl-2 ratio and found that estrogenic 
treatment did appear to induce an anti-apoptotic influence.  Finally, protein analysis of the PI3K and 
MAPK were performed to investigate whether in monolayer culture, E2 was capable of inducing non-
genomic effects, which was previously noticed in 3D cultures of MCF-12A cells in Chapter V. 
In order the take the analysis of gene expression one step further, this was then conducted in 
cells isolated from 3D cultures.  Initially, whole MCF-12A acini were extracted from Matrigel to 
investigate the impact of estrogens upon apoptotic factors and CCND1 (the gene encoding cyclin D1) 
expression.  We observed that E2 does have an impact on gene expression of whole acini, in that CCND1 
expression was increased in E2-treated acini.  In Chapter VII, we developed a method by which the outer 
and inner cell populations of MCF-12A acini could be separated based on their integrin β4 expression by 
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fluorescence activated cell sorting (FACS).  This enabled us to clearly see that E2 treatment did impact 
upon gene expression in a way that would promote proliferation of both inner and outer cell 
populations, and suppress apoptosis, particularly in the case of the centrally located cell population. 
Overall, throughout this work we have two main aims.  Firstly we aim to investigate whether 
estrogens can impact upon the 3D architecture of the breast, by using a 3D in vitro model of epithelial 
cells cultured in reconstituted basement membrane.  In the possibility that estrogens, in fact, affect acini 
formation of MCF-12A cells, our second aim is to dissect the mechanisms through which estrogens act in 
3D cultures of this non-tumourigenic epithelial cell line.  It is the hope, that the work conducted in this 
study will enable us to understand the role of both the nuclear ER and transmembrane receptors (GPER-
1) in estrogen-induced malformations of acini. 
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CHAPTER II: Characterization of Immortalised Cell Lines - Confirmation 
of Receptor Status and Determination of the Effect of Estrogens on 
Proliferation in Monolayer Culture 
 
A common hallmark of cancer is the ability of cells to proliferate with unlimited potential replication, 
even in the presence of anti-proliferative signals, or absence of growth signals (Hanahan & Weinberg, 
2000).  Malignancies of the breast are no different and cancer cells have been demonstrated to have a 
higher level of proliferation in comparison to non-malignant breast cells (reviewed in Lari & Kuerer, 
2011). 
Normal mammary gland growth and differentiation requires the actions of various hormones, 
such as estrogen, and growth factors.  Paradoxically, estrogens also play a role in breast carcinogenesis.  
As discussed in Chapter I, in this study, we propose to study the actions of estrogens and the role of the 
ER in mammary gland formation (and potentially carcinogenesis) by using an in vitro 3D model that can 
recapitulate the features of the normal breast epithelium.  For that, it was essential to use a human, 
immortalised, non-tumourigenic cell line, which expressed the ER and responded to estrogens.  The cell 
line selected was the MCF-12A. 
2.1 Cell Lines of Choice 
MCF-10A and MCF-12A are two non-transformed immortalised breast cell lines.  The MCF-10A cell line 
was originally derived from a patient with fibrocystic breast disease, and upon culture, spontaneously 
became immortalised.  It is reported as being of luminal origin and is ER and HER2 negative (Soule et al, 
1990; Tait et al, 1990; Paine et al, 1992).  In addition to this, MCF-10A cells also have a stable and close 
to diploid karyotype and express wild type p53, but not oncogenic ras (Soule et al, 1990; Merlo et al, 
1995).  The MCF-10A cell line is commonly used as a control for “normal” cells in breast cancer 
investigations (Hsieh et al, 2005; Spink et al, 2006).  MCF-10A cells provide a model in which to study 
cancer progression and the role of oncogenic gene expression, as well as loss of tumour suppressor 
function (Zientek-Targosz et al, 2008).  MCF-10A cells have also been used extensively in three 
dimensional cultures to investigate the process of mammary gland development in an in vitro model 
(Muthuswamy et al, 2001; Debnath et al, 2002; Debnath et al, 2003). 
The MCF-12A cell line was also derived from a patient with fibrocystic breast disease, but is ER 
status remains controversial with conflicting studies claiming it is ER negative (Thompson et al, 2004) 
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and ER positive(Eisen & Brown, 2004; Engel et al, 2011).  The MCF-12A cell line is often used to study the 
progression of cancer and the role of oncogenic gene expression (Schedin et al, 2004).  The cell line is 
used comparatively less than MCF-10A cells as a non-tumourigenic cell line and, therefore, the impact of 
estrogens on this cell line remain unknown. 
MCF-7 cells are derived from a human adenocarcinoma of the breast and are ERα, ERβ and 
GPER-1 positive, but HER2 negative (Soule et al, 1990; Carmecci et al, 1997; Filardo et al, 2000).  MCF-7 
cells have a karyotype of 69 chromosomes (the normal human karyotype is 46).  They also express wild-
type p53 but possess mutations in CDKN2A and phosphatidylinositol 3-kinase catalytic 110-KD alpha 
(PIK3CA) (Cancer Genome Project).  MCF-7 cells also display further genetic aberrations including 
deletions, translocations, chromosomal rearrangements and chromosomal loss or amplification (Wang 
et al, 2009). 
MDA-MB-231 cells are negative for ERα (Filardo et al, 2000), GPER-1 (Carmecci et al, 1997,) but 
do, however, express ERβ and HER2 (Dotzlaw et al, 1997; Okubo et al, 2004).  They express mutant p53, 
BRAF, CDKN2A and KRAS (Cancer Genome Project; Olivier et al, 2002).  Mutations in the ras gene lead to 
constitutive PI3K signalling, whereas BRAF mutations result in increased MAPK signalling, which in turn, 
results in increased proliferation and survival.  In addition to these specific mutations, microarray 
studies have shown that MDA-MB-231 cells over-express genes commonly associated with EMT (Kao et 
al, 2009).   
The MCF-7 and MDA-MB-231 cell lines are two of the most commonly used cell lines for the 
study of breast cancer and investigations of the signalling pathways and molecular mechanisms involved 
in cancer (Tobin et al, 2001). 
Long-term in vitro culture and immortalization of cells can result in genetic and epigenetic 
changes, such as the loss of the gene locus encoding cyclin-dependent kinase inhibitor 2A (CDKN2A) and 
the prevention of telomere shortening (Li et al, 2007b).  The loss of the CDKN2A locus in particular, is 
one mechanism through which mammary epithelial cells overcome retinoblastoma (Rb)-mediated cell 
cycle regulation and lose their finite lifespan to become immortalized. (Brenner et al, 1998; Li et al, 
2007b).  Despite these aberrations, MCF-10A and MCF-2A cells are still commonly used in studies as non-
tumourigenic controls, due to their near diploid karyotype, dependence on exogenous growth factors, 
and their inability to induce tumour growth when implanted into nude mice (Soule et al, 1990; Paine et 
al, 1992).  Aberrant behaviour of MCF-10A and MCF-12A cells, such as the adoption of a spindle-like 
morphology and increased expression of actin stress fibres and focal adhesion complexes has been 
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observed in monolayer cultures (Sarrió et al, 2008) and, therefore, passage number needs to be 
carefully monitored for these cell lines, in order to avoid such changes. 
 The majority of the work in this thesis will concentrate of the MCF-12A cell line, as the primary 
aim is to characterize the effects of estrogens on 3D cultures of an ER competent non-tumourigenic cell 
line.  The remaining cell lines will be used for the purpose of comparison.  The MCF-10A cell line was 
selected as it is another example of a non-tumourigenic breast cell line, although does not express the 
ER.  The MCF-7 and MDA-MB-231 cell lines on the other hand, are both tumourigenic cell lines, with 
different ER statuses, in which a lot of work has been conducted in.  These cell lines will provide us with 
the opportunity to compare the response to estrogens in cell lines that differ according to their ER 
status, in addition to the tumourigenic state. 
2.2 ER and GPER-1 Receptor Status 
As discussed in Chapter I, estrogens interfere with the growth and maintenance of normal and breast 
cancer cells, and the majority of these effects have been shown to be mediated by the ER.  As the main 
aim of our work is to investigate the effects of estrogens in normal MCF-12A cells and the mechanisms 
involved in these effects, it is important that these cells express a fully functional ER. 
Due to conflicting reports concerning the ER status of the MCF-12A cell line (Soule et al, 1990; 
Carmecci et al, 1997; Filardo et al, 2000; Eisen & Brown, 2004; Thompson et al, 2004; Moyano et al, 
2006; Engel et al, 2011) and to confirm that the remaining cell lines possess the same ER status as those 
reported in the literature, it was necessary to confirm the ERα, ERβ and GPER-1 status of all four cell 
lines.  This was achieved by analysing both the gene and protein expressions by reverse transcription 
real-time polymerase reaction (RT-real-time PCR) and immunoblotting, respectively.  Confirmation of ER 
and GPER-1 status was performed at both the gene and protein level, as, due to post-translational 
modifications, gene expression does not always correlate with protein expression.  Although the GPER-1 
status has been characterised in the MCF-7 and MDA-MB-231 cell lines, it is unknown whether MCF-10A 
or MCF-12A cells express this estrogen-responsive receptor (Migliaccio et al, 2003; Pedram et al, 2006).  
As the majority of our work will primarily involve the MCF-12A cell line, it is necessary to know if this cell 
line expresses GPER-1, as the presence of this receptor may have implications for the responses of these 
cells to estrogens and estrogen antagonists.  Furthermore, ascertaining the GPER-1 status of the 
remaining cell lines will shed some light onto the function of GPER-1 in breast cells and whether 
estrogens are able to induce effects through this receptor. 
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2.3 Principle of Reverse Transcription (RT) Real-Time Polymerase Chain Reaction 
(PCR) 
Various techniques are available in order to conduct gene expression analysis, such as, PCR, real-time 
PCR and microarrays.  For the purposes of this thesis, we decided to conduct RT real-time to investigate 
gene expression and the impact of estrogens upon this.  Although a relatively new technique, RT real-
time PCR is well established and widely used to quantify DNA, and for the investigation of gene 
expression and gene expression regulation (Logan et al, 2009).   Real-time PCR has multiple advantages 
over standard PCR.  For example, in standard PCR, the detection of the presence of target products is 
performed at the end of the PCR reaction, by additional time-consuming steps, such as through the use 
of gel electrophoresis.  Analysis is, therefore, achieved based on the size of the amplified product.  This 
presents a potential disadvantage as different fragments of similar molecular weights cannot be 
distinguished from one another, and sample variability is common.  Real-time PCR on the other hand 
allows the simultaneous amplification, detection and quantification of target DNA sequences and this 
means that real-time PCR is more sensitive to small changes in PCR product.  Also, unlike standard PCR, 
real-time PCR allows DNA content to be quantified after each reaction cycle, rather than just following 
the completion of the reaction, as in the case of standard end point PCR.  Therefore, real-time PCR 
provides us with quantitative, rather than qualitative (as in the case of standard end point PCR) data and 
permits data analysis during the exponential phase of the reaction, which is a far more accurate point at 
which to analyse target amplification. 
Although DNA microarrays would allow for the investigation of multiple genes, the technique is 
very expensive.  Furthermore, cross hybridisation can occur with microarrays due to sequence similarity 
between genes that are closely related.  This leads to the failure to specifically detect target genes that 
instead hybridise to spots corresponding to different genes.  For the reasons discussed here: cost 
sensitivity and ease of detection and quantification, RT real-time PCR will be used to study the gene 
expression of ERα, ERβ and GPER-1, and for further experiments in later chapters. 
In terms of the reaction process itself: Briefly, during the reverse transcription step, 
complementary DNA (cDNA) is produced from mRNA, and this is then amplified using real-time PCR, 
which enables us to study small changes in gene expression.  Changes in gene expression can be 
assessed via various detection methodologies, but SYBR Green is commonly used, due to its ease of use, 
accuracy and low cost.  In terms of its mode of action, SYBR Green specifically binds to the minor groove 
of newly synthesized double-stranded DNA and thus fluorescence increases as the reaction continues to 
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synthesise new cDNA strands with each cycle (Figure 2.1). However, SYBR Green also has its 
disadvantages, such as the detection of non-specific double-stranded DNA, which may lead to false 
positives and increased background.  Other methods are available for mRNA quantification in real-time 
PCR, such as probes.  Probes consist of a primer sequence with a fluorescent and a quencher molecule 
attached.  The quencher acts to suppress the fluorescent molecule.  When the probe binds to its target 
DNA sequence, the quencher molecule is cleaved by DNA polymerase, and fluorescence is emitted.  The 
use of probes, although highly specific and with the ability to reduce background, is more expensive and 
labour intensive, relative to SYBR Green.  There are instances when the use of SYBR Green is not 
advisable.  These are in the case of multiplex quantitative PCR, in which multiple gene products can be 
amplified, detected and quantified in a single plate.  In this example, SYBR Green would bind to all the 
double stranded DNA of the separate target genes and quantification would not be possible.  In this 
specific case, other multiple fluorescent primers are used with quenchers and fluorescent molecules.  
Regardless, we will not be implementing this technique, and will instead use a plate-based 
methodology, in which a single gene target is amplified in each well.  To ensure accurate results whilst 
using SYBR Green, primers for the target sequence of a high specificity will be designed and optimised, 
and this will be discussed further in the Materials and Methods section. 
SYBR Green specifically binds to the minor groove of newly synthesized double-stranded DNA 
and thus fluorescence increases as the reaction continues to synthesise new cDNA strands with each 
cycle (Figure 2.1).   
 
67 
 
 
Figure 2.1: The principle of SYBR Green-based detection in real-time PCR.  Following denaturation, primer 
annealing and extension, SYBR Green (green circles) binds to the newly synthesised complimentary DNA strand.  
Only when complexed with double-stranded DNA, does SYBR Green absorb blue light and emit green light with a 
wavelength of 520 nm. 
Following real-time PCR, amplification, standard and melt curves are generated.  As fluorescence is 
recorded after each cycle, the exponential phase of the PCR experiment can be analysed, and this is 
important, as this is the phase where the first changes in PCR product are seen, and corresponds to the 
amount of target gene being amplified.  The more target sequence that is present initially in the sample, 
the fewer cycles it takes for the reaction to produce a detectable fluorescent signal, and hence, reach 
the exponential phase.  In respect to how changes in gene expression are detected using SYBR Green: 
SYBR Green incorporates itself into the minor grove of double-stranded DNA, and once bound is able to 
emit fluorescence upon excitation.  Unbound SYBR Green, on the other hand, cannot fluoresce.  As cycle 
number during the reaction process increases, the amount of replicated double-stranded DNA increases.  
Hence, more SYBR Green binding occurs and more fluorescence is emitted and detected.  In the next 
amplification cycle, during the denaturation process, SYBR Green is released and no longer fluoresces.  
However, it is then incorporated into the newly synthesised double-stranded DNA and the process is 
repeated again. 
Amplification curves depict cycle number (x-axis) at which the level of fluorescence (y-axis) 
crosses the cycle threshold (Ct).   This is the point at which the amplification curve crosses the baseline 
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of fluorescence.  To calculate the Ct value, the baseline, is adjusted to the point where the increase in 
PCR product, as detected by fluorescence, becomes exponential (i.e. the amount of target cDNA is 
doubled following each cycle of the reaction) (Figure 2.2).  It is important that for each primer pair, this 
is kept consistent, so that the Ct value can be determined accurately, and so that gene expression 
between samples can be compared. 
Changes in gene expression can be seen from the shift of a Ct value to the left or the right of the 
initial curve.  For instance, in the event that more target cDNA is present, the curve will shift to the left.  
This is because the Ct value will be lower, as the point at which the target sequence is detected by 
florescence occurs at earlier cycles. In the case that a sample expresses less of a target gene, the curve 
will shift to the right and a higher Ct value will be observed.  This is due to more cycles being required 
for the detection of the target cDNA to be achieved (Figure 2.2). 
 
 
Figure 2.2: A hypothetical amplification curve obtained following real-time PCR.  Cycle number is plotted against 
arbitrary fluorescence.  The threshold is shown in red and is set at the point at which fluorescence becomes 
exponential.  The cycle at which the curve crosses the threshold is known as the Ct value.  In this example the blue 
line shows the gene product of a sample.  If, under specific conditions, expression levels of the gene of interest 
increases, more gene product is present and the curve shifts to the left (green).  If, under the same conditions, 
gene expression decreases, less gene product is present and the curve shifts to the right (orange). 
As increases in fluorescence could be potentially generated by SYBR Green binding to non-target 
amplification fragments, such as primer dimers, products of mis-priming and genomic DNA, melting 
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curves are used to ensure that these increases in fluorescence are a result of increases in the target 
product.  PCR products of individual primer pairs have specific melting temperatures (Tm), which is 
determined by the base composition and length of the target sequence, hence the Tm of target product 
should match that estimated for each primer pair.  The Tm is determined by increasing the temperature 
a fraction of a degree at a time and measuring changes in fluorescence.  When the Tm is reached, the 
double stranded DNA separates and the fluorescence rapidly decreases. 
The melting curve depicts temperature (x-axis) against the relative fluorescence units over time 
(dRFU/dT) (y-axis) with peaks corresponding to PCR product Tm.  Primer dimers or miss-priming 
resulting in amplification of DNA fragments other than the gene of interest results in extra peaks, which 
are normally present to the left of the actual Tm.  This is because primer dimers and alternative 
amplification products are usually short in length and consequently have a lower Tm than the gene of 
interest.  Contamination with genomic DNA would result in increased Tm values, as genomic DNA is 
longer than cDNA (as it contains both introns and exons), and would be depicted as peaks to the right of 
the actual Tm on melting curves (Figure 2.3). 
 
 
Figure 2.3: A hypothetical of a melt curve following real-time PCR.  The rate of change in relative fluorescence 
with time (-d(RFU) / dT) is plotted against temperature.  The various peaks show the melting temperature (Tm).  
The blue peak shows the actual Tm for a sample.  Primer dimers produce peaks at lower temperatures (green), 
whereas genomic DNA contaminations produces peaks at higher temperatures (orange). 
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2.4 Assessing the Effects of Estrogens and Anti-Estrogens on Proliferation 
The effect of estrogens on the proliferation of ER-competent non-tumourigenic MCF-12A cell lines is, to 
our knowledge, not documented.  We, therefore, decided to investigate how estrogens impact upon the 
proliferation of these cells and whether this effect was mediated by the ER or GPER-1.  This will enable 
us to more thoroughly understand how these cells respond to estrogens.  In future chapters, it will also 
allow us to compare the effects of estrogens on MCF-12A cells in monolayer and 3D cultures.  
Furthermore, in order to optimise the optimal seeding density and maintenance of MCF-12A cells in 3D 
cultures, it is important to investigate whether these cells proliferate in the presence of estrogens.  
Proliferation studies will also be conducted in MCF-10A, MCF-7 and MDA-MB-231 cells for the purposes 
of comparison of the impact of estrogens in non-tumourigenic and cancer cell lines and in ER positive 
and ER negative cells. 
Estrogens have previously been shown to induce proliferation in both normal and cancerous cell 
lines, and these effects have been associated with the presence of the ER.  The ER-mediated effects 
elicited by estrogens are antagonised by ER antagonists, such as tamoxifen and ICI 182,780.  More 
recently, however, it has been reported that tamoxifen and ICI 182,780 are capable of activating 
signalling pathways in some tissues, including that of the breast (Cabot et al, 1997; Wang et al, 2006).  
This may have consequences for the responsiveness to anti-estrogen therapy, as the non-genomic 
effects of these antagonists may counteract the desired effect of abrogating estrogen responsiveness to 
suppress tumour growth. 
Tamoxifen is classed as a selective estrogen receptor modulator (SERM) and it is only capable of 
inhibiting the transcription of estrogen-inducible genes under the control of the AF-2 domain of the ER.  
The term, SERM, is applied to tamoxifen because in different tissues, the dominance of AF-1 and AF-2 
differs, and thus, tamoxifen is selectively antagonistic to tissues where AF-2-activated transcription is 
dominant.  For example, in the breast, AF-2 mediated transcription is dominant, so tamoxifen acts as an 
antagonist.  In contrast, in the uterus, AF-1 is dominant, and therefore, tamoxifen acts as an agonist.  ICI 
182,780, on the other hand, is classed as a selective estrogen receptor disrupter (SERD) and inhibits the 
activity of both AF-1 and AF-2 of the ER in addition to promoting proteasome-mediated degradation of 
the ER-ICI 182,780 complex (Giamarchi et al, 1999; Wijayaratne & McDonnell, 2001; Pearce & Jordan, 
2004).  Due to tamoxifen only blocking AF-2 activity, it can only antagonise the effects of E2 where this 
domain is dominant and thus leaves the AF-1 domain of the ER susceptible to activation.  This means 
that the use of tamoxifen may only prevent the estrogen-induced transcription of genes under the 
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control of the AF-2 domain.  Furthermore, tamoxifen is postulated to act as an agonist for the 
transcription of genes under the control of the AF-2 domain (Tzukerman et al, 1994; McDonnel et al, 
1995).  Therefore, the pure ant-estrogen, ICI 182,780 will be used for all experiments to abolish both 
functioning domains of the ER and circumvent any agonist activity towards the ER. 
2.5 Materials and Methods 
2.5.1 Test Agents and Other Chemicals 
E2 (98% pure) was obtained from Sigma (Dorset, UK) and prepared in absolute ethanol as 1 mM stock 
solutions.  Subsequent dilutions were prepared using absolute ethanol also.  ICI 182,780 was a kind gift 
from Dr. Ian White (MRC Molecular Endocrinology Group, Leicester, UK) and was prepared in absolute 
ethanol (etOH), as 1mM stocks.  Subsequent dilutions were prepared using absolute ethanol.  Dilutions 
were prepared so that the final ethanol concentration would not exceed 0.5%, to ensure that the 
solvent would have no detrimental effects upon cells (Payne et al, 2000). 
The GPER-1 agonistG-1 and GPER-1 antagonist G-15 were purchased from Sigma and prepared 
as per manufacturers instruction as 1 mM stocks in dimethyl sulfoxide (DMSO).  Subsequent dilutions 
were also prepared using DMSO.  All stock solutions and dilutions were stored in critically cleaned glass 
vials and stored in a -20oC spark free freezer. 
2.5.2 Routine Culture of Cells 
MCF-10A and MCF-12A cells (obtained from the American Type Culture Collection) were maintained in 
75 cm2 flasks (Greiner, Gloucestershire, UK) flasks in supplemented Dulbecco’s Modified Eagle Medium 
and Ham’s F-12 nutrient mixture (DMEM/F12, Invitrogen, Paisley, UK) (Table 2.1) at 37oC in the 
presence of 5% CO2.  Upon 70% confluence, cells were sub-cultured using trypsin-
ethylenediaminetetraacetic acid (trypsin-EDTA, Invitrogen, Paisley, UK). 
 Briefly, media was aspirated and the surface of the flask was washed gently with 10 ml Hanks 
balanced salt solution (HBSS).  This was aspirated and 2 ml 0.25% trypsin-ethylenediaminetetraacetic 
acid (EDTA) was added, which was then aspirated so that only a thin film covered the surface of the 
flask.  Cells were then incubated at 37oC in 5% CO2 for approximately 10 minutes until cells were 
completely detached from the flask upon gentle tapping to avoid clonal selection.  4 ml of re-suspension 
media was added and cells were re-suspended and transferred to a 15 ml conical tube.  A further 4 ml or 
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re-suspension media was added to rinse the flask and this was transferred to the conical tube.  It is 
important at this point to use re-suspension media containing 20% horse serum, as this is necessary to 
inactivate the trypsin and allow re-attachment of cells in new flasks.  Cells were centrifuged at 1000 rpm 
for 5 minutes and the re-suspension media was carefully aspirated so that only the cell pellet remained.  
The pellet was then re-suspended in 10 ml growth media and seeded into fresh 75 cm2 flasks containing 
13 ml fresh growth media at a dilution of 1:5 or 1:6.  Upon 70% confluence, this process was repeated 
for a maximum of 10 subcultures. 
Table 2.1: Media components for MCF-10A and MCF-12A media (Soule et al, 1990; Debnath et al, 2003). 
Component Growth Medium Re-Suspension Medium 
DMEM/F12 (Invitrogen, Paisley, 
UK) 
500 ml 500 ml 
Horse Serum (Invitrogen, 
Paisley, UK) 
5% 20% 
Epidermal Growth Factor  20 ng/ml 20 ng/ml 
Cholera Toxin (Sigma-Aldrich, 
Dorset, UK) 
100 ng/ml 100 ng/ml 
Insulin (Sigma-Aldrich, Dorset, 
UK) 
10 µg/ml 10 µg/ml 
Hydrocortisone (Sigma-Aldrich, 
Dorset, UK) 
0.5 µg/ml 0.5 µg/ml 
Pen/Strep (Sigma-Aldrich, 
Dorset, UK) 
5000 µg/ml 5000 µg/ml 
L-Glutamine (MCF-10A media 
only) 
109.5 mg/2.8 ml 109.5 mg/2.8 ml 
EGF (Sigma-Aldrich, Dorset, UK) was prepared as a 100 g/ml stock in 0.2 m-filtered 10 mM acetic acid with 0.1% 
bovine serum albumin (BSA, Sigma-Aldrich, Dorset, UK). 
 
MCF-7 cells were obtained from M. Dufresne (University of Windsor, Ontario, Canada).  MDA-MB-231 
cells were a kind gift from Dr. Michael Johnson (Lombardi Cancer Centre, Washington DC, USA). 
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MCF-7 and MDA-MB-231 cells were maintained in 75 cm2 flasks in supplemented MEM-α 
(Invitrogen, Paisley UK) with 5% fetal bovine serum (FBS) at 37oC in the presence of 5% CO2.  Upon 70% 
confluency, cells were sub-cultured using trypsin-EDTA.  This was achieved by aspirating the media and 
washing the surface of the flask gently with 10 ml HBSS.  This was then aspirated and 2 ml 0.25% trypsin-
EDTA was added.  Flasks were placed in an incubator at 37oC in 5% CO2 for approximately 3 minutes 
until cells were completely detached from the flask upon gentle tapping to avoid clonal selection.  Cells 
were then re-suspended in 10 ml growth media and seeded into fresh 75 cm2 flasks containing 13 ml 
growth full media at a dilution of 1:10 or 1:20.  Upon 70% confluence, this process was repeated for a 
maximum of 10 subcultures.  In a similar fashion to the previously described cell lines, MCF-7 and MDA-
MB-231 cells were regularly tested for mycoplasma infection. 
Due to batch variation amongst serum lots concerning fat and protein levels, which may impact 
upon experimental results, serum of the same batch number was used throughout and stored at -20oC 
before use. 
2.5.3 Preparation of Charcoal-Dextran Stripped (CDS) Serum 
Charcoal-dextran stripping removes the hormones in serum that would otherwise be present as free or 
protein bound, and could potentially interfere with our experimental outcomes.  This procedure was 
performed as described by Soto et al (1995), as follows: a suspension of 5% charcoal and 0.5% Dextran 
T70 (Amersham, Buckinghamshire, UK) was prepared in 500 ml ultra-high quality (UHQ) water and was 
left to mix by rolling at 10 cycles/min for 30 min at room temperature.  The suspension was then 
centrifuged for 10 min at 1000g, the supernatant removed and the serum added to the pellet.  This was 
mixed by rolling at 10 cycles/min for 1 h at room temperature.  Finally, the mixture was centrifuged at 
50,000 g for 20 min at 4oC and the CDS serum was filtered through a 0.2 µm nylon filter (Nalgene, 
Dorset, UK).  CDS serum was stored at -20oC until use. 
2.5.4 Cell Culture for Gene Expression Analysis 
80,000 cells per ml were seeded in growth media in 25 cm2 flasks and, upon 70% confluence, the media 
was aspirated and replaced with D-MEM/F12 (MCF-10A and MCF-12A) or MEM-α (MCF-7 and MDA-MB-
231) phenol-red free media (Invitrogen, Paisley, UK) containing 0.5% CDS horse serum for MCF-10A and 
MCF-12A cells or 0.5% FBS for MCF-7 and MDA-MB-231 cells.  The use of phenol red-free media ensures 
that the estrogenic properties of phenol red do not influence ER expression and levels of activation, as it 
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has been shown to act as a weak estrogen (Berthois et al, 1986).  After 24 hours, cells were treated with 
1 nM E2 (98% pure, Sigma-Aldrich, Dorset, UK) or 0.5% etOH for a further 24h.  Cells were incubated at 
37oC in 5% CO2 throughout. 
2.5.5 Selection of Suitable Reference Genes 
In order to quantify gene expression, data needs to be normalised to a reference gene to allow for inter- 
PCR variation, such as sample loading errors, RNA integrity, and the efficiency of the RT.  Commonly 
used reference genes, such as GLYCERALDEHYDES-3-PHOSPHATE (GAPDH), β-ACTIN and 
HYPOXANTHINE-GUANINE PHOSPHORIBOSYL TRANSFERASE (HPRT), are present in most cell types, as 
they are essential for cell survival.  Moreover, their expression is stable and usually unaffected by 
treatment conditions (Bustin, 2002).  In order to be a suitable reference gene, this must be unaffected 
by the treatments to which samples are exposed to, and thus prior to work on gene expression, the 
effects of E2 on the expression of the potential reference genes: GAPDH, β-ACTIN and HPRT were 
assessed in all cell types. 
2.5.6 RNA Extraction and RNA Quantification 
Following 24 h treatment, cells were trypsinized using 1 ml 0.25% Trypsin-EDTA.  The cells were re-
suspended in a total of 7 ml growth media and centrifuged at 0oC for 15 minutes.  RNA extraction was 
performed using Nucleospin RNA II (Machery-Nagel, Düren, Germany) as per manufacturer’s 
instructions. 
Following the removal of media to leave just the cell pellet, the cells were lysed by vortexing 
with the addition of 350 µl RA1 buffer and 3.5 µl β-mercaptoethanol.  The lysates were filtered at 11,000 
g for 1 minute to reduce viscosity and the binding conditions were adjusted with the addition of 350 µl 
70% ethanol to the filtrate.  This was loaded to RNA binding columns which were spun at 11,000 g for 30 
sec.  The silica membranes of the binding columns were desalted using 350 µl membrane desalting 
buffer and centrifugation at 11,000 g for 1 min.  To digest contaminating genomic DNA, samples were 
incubated with 95 µl deoxyribonuclease (DNase) reaction mixture for 15 min, at room temperature 
followed by washing and drying of the silica membrane with buffers and centrifugation at 11,000 g 3 
times.  Finally, RNA was eluted in 40 µl RNase (ribonuclease )/DNase free water at 11,000 f for 1 min 
into RNase/DNase free collection tubes. 
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RNA concentration and purity was assessed using the ND-1000 Spectrophotometer (NanoDrop, 
Thermo Scientific, Delaware, USA).  2 µl of extracted RNA was pipetted onto the pedestal of the 
instrument and absorbance was read at 230, 260 and 280 nm.  Absorbance at 260 nm measures RNA 
concentration and RNA purity is measured using the ratio of 260/280 nm absorbance with a value 
between 1.8 and 2 being a generally acceptable value.  Measuring the purity ensures that the measured 
concentration is of RNA only and not of contaminants, such as proteins, carbohydrates and phenol, or 
chemicals used in the RNA extraction process.  Values lower than the generally accepted range may give 
an indication of contaminates that absorb wavelengths of approximately 280 nm, such as those 
aforementioned.  The 260/230 nm ratio provides a second measurement of RNA purity.  Accepted 
values range between 1.8 and 2.2, however this value will be less if co-purified contaminates are 
present in the sample, such as proteins. 
2.5.7 Reverse Transcription (RT) 
2.5 µg isolated total RNA corresponding to a final concentration of 0.5 µg/µl were used for each 
reaction.  For each sample: 7 µl 5x RT buffer (Promega, Southampton, UK), 4 µl 10 mM deoxynucleotide 
triphosphates (dNTPs) mix (Stratagene, Cheshire, UK), 1 µl RNAse inhibitor (Promega, Southampton, UK) 
and 1 µl random hexamer primers (Invitrogen) were added to a volume of 20 µl comprising of 2.5 µg 
total RNA and RNAse/DNAse-free water (Promega, Southampton, UK). 
Samples were heated to 65oC for 10 minutes and cooled on ice for 2 minutes prior to 42oC 
incubation with 2 µl Reverse Transcriptase (Promega, Southampton, UK) for 90 minutes.  cDNA samples 
were stored at -80oc until use. 
2.5.8 Real-Time Polymerase Chain Reaction (Real-Time PCR) 
Primer pairs were prepared as 10 µM stocks using RNase, DNase free water, except in the case of the 
HPRT primers, which were prepared as 1 µM stocks.  All primer pairs were optimised and only those that 
yielded an amplification efficiency of > 98% were used for further work. 
For each reaction: 0.8 µl cDNA from a 1:10 stock, 10 µl SYBR Green mixture (Biorad, Herts, UK), 
forward and reverse primers at the concentrations listed in Table 2.2 and RNase, DNase free water to 
make a final volume of 20 µl was added. 
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Table 2.2: Primers used for real-time PCR.  Primers were designed based on their Genebank ascension number 
using Beacon Designer 5 (Premier Biosoft, California, USA) and purchased as high quality oligos from Eurogentec 
(Hampshire, UK). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The real-time PCR reaction was performed using the iCycler IQ real-time PCR detection system (Biorad, 
Herts, UK).   cDNA was denatured at 95oC for 3 minutes and then cooled to 55oC to allow primer binding.  
40 subsequent cycles of heating to at 95oC for 1 minute and cooling to 55oC for 1 minute were 
performed to allow denaturing of the newly produced strands, further annealing and cDNA amplification 
(Figure 2.4).  Amplification and melt curves were generated upon real-time PCR protocol completion. 
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Figure 2.4: Real-time PCR cycle protocol (iCycler, Biorad). 
cDNA  Genebank 
Ascension 
Number 
Primer 
Sense 
Primer Sequence (5’-3’) Concentration 
(nM) 
Target 
Size 
(bp) 
β-
ACTIN 
X00351 Forward TGCTATCCAGGCTGTGCTAT 300 97 
Reverse GATGGAGTTGAAGGTAGGTT 300 
GAPDH NM_002046 Forward TCTCTGCTCCTCCTGTTC 900 120 
Reverse GCCCAATACGACCAAATCC 900 
HPRT M31642 Forward CCTTGGTCAGGCAGTATAATCC 100 135 
Reverse GGGCATATCCTACAACAAACTTG 100 
ERα NM_000125 Forward GCCCTCCCTCCCTGAAC 250 146 
Reverse TCAACTACCATTTACCCTCATC 250 
ERβ AF051A27 Forward TCCTCCCAGCAGCAATCC 200 138 
 Reverse CCAGCAGCAGGTCATACAC 200 
GPER-1 BC011634 Forward GTTCCTCTCGTGCCTCTAC 200 130 
  Reverse ACCGCCAGGTTGATGAAG 200  
77 
 
2.5.9 Protein Level Confirmation 
As the presence of a gene does not always correlate with protein expression, western blots were 
performed to confirm the presence of ERα, ERβ and GPER-1. 
1 million cells per ml were seeded onto 55 mm petri dishes in growth media and maintained at 
37oC in 5% CO2.  Upon 80% confluence, the media was aspirated and replaced with phenol red-free 
media containing 0.5% CDS stripped serum for 24h at 37oC in 5% CO2.  Following 24 h incubation, 
samples were placed on ice, the media removed and the dish was rinsed twice with cold HBSS. 
Lysis buffer was prepared consisting of 2.5 ml 1 M Tris pH 6.8, 2 ml 20% sodium dodecyl sulfate 
(SDS), 4 ml glycerol and 2 ml β-mercaptoethanol.  200 µl was added to each sample and a cell scraper 
was used to dislodge the cells.  The viscous cell solution was then transferred to pre-chilled eppendorf 
tubes and the samples were boiled for 10 minutes at 95oC.  After brief centrifugation, the supernatant 
was transferred to a fresh pre-chilled eppendorf tube. 
To determine the protein concentration, the Bradford assay was conducted.  For that, standards 
were prepared using bovine serum albumin (BSA, Sigma-Aldrich, Dorset, UK) from a 2 mg/ml stock 
(Table 2.3) to prepare a calibration curve in order to quantify protein level of the samples.  For the 
samples: 500 µl water, 2 µl sample and 500 µl Bradford reagent were combined in eppendorf tubes.  
250 µl of standard and sample preparation were loaded in duplicate onto a 96 well plate and 
absorbance was read to measure protein amount.   Following quantification, 6 µl of bromophenol blue 
was added to each sample in order to facilitate loading onto acrylamide gels. 
Table 2.3: Preparation of standards to generate a calibration curve in order to quantify protein concentration in 
samples. 
Protein Concentration 
(µg/µl) 
Water Volume (µl) BSA Standard Sample 
Volume (µl) 
Bradford Reagent 
Volume (µl) 
0 500 0 500 
2 500 2 500 
4 500 4 500 
6 500 6 500 
8 500 8 500 
10 500 10 500 
 
12% SDS-acrylamide running gels (Table 2.4) were prepared and allowed to polymerize.  To prevent 
bubble formation, a layer of saturated butanol was added on top of the gel and then removed using 
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blotting paper.  A 5% SDS-acrylamide gel (Table 2.4) was loaded above this and combs inserted to create 
wells.  Upon polymerization, the combs were removed. 
 
Table 2.4: Running and stacking gel compositions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The electrophoresis tank was assembled and the wells washed thoroughly to remove all traces of 
residual acrylamide.  10 µl protein marker (Cell Signalling, Hertfordshire, UK) was added.  An equal 
amount of total protein was loaded for every sample into the wells of the prepared gels (to allow for 
comparisons between samples) and separated by SDS-PAGE for 2 h at 80 V.  The proteins were then 
transferred onto nitrocellulose membranes (Amersham, Buckinghamshire, UK) in transfer buffer 
consisting of 25 mM Tris, glycine, 0.1% SDS and 20% methanol at 40 V for 1 h. 
Unspecific binding was blocked using 5% milk in Tris buffered saline (TBS) containing 0.05% 
Tween (TBS-T) for 1 h.  The membranes were then washed twice with TBS containing 0.05% Tween for 5 
minutes and incubated overnight at 4oC with the primary antibody (antibody dilutions are presented in 
Table 2.5). 
Gel Component Volume (ml) 
12% Running Gel  Water 3.3 
 30% acrylamide mix 4 
 1.5 M Tris-buffer (pH 8.8) 2.5 
 10% SDS 0.1 
 10% ammonium persulfate 0.1 
 Tetramethylethylenediamine (TEMED) 0.004 
5% Stacking Gel Water 2.1 
 30% acrylamide mix 0.5 
 1.5 M Tris-buffer (pH 6.8) 0.38 
 10% SDS 0.03 
 10% ammonium persulfate 0.03 
 TEMED 0.003 
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Table 2.5: Primary antibodies used for western blot analysis. 
Primary Antibody Source Dilution 
ERα (Sigma-Aldrich, Dorset, UK) Rabbit 1:3000 in 5% BSA in TBS-T 
ERβ (Epitomics, Insight 
Biotechnology Ltd, Wembley, UK) 
Rabbit 1:1000 in 5% BSA in TBS-T 
GPER-1 (Abcam, Cambridge, UK) Rabbit 1:1000 in 5% BSA in TBS-T 
β-actin (Cell Signalling, 
Hertfordshire, UK) 
Mouse 1:1000 in 5% milk in TBS-T 
 
Samples were then washed twice with TBS containing 0.05% Tween for 5 minutes and incubated with 
1:2000 mouse anti-rabbit horseradish peroxidase (HRP) conjugated secondary antibody (Cell Signaling 
Technology, New England Biolabs, Hertfordshire, UK) in TBS containing 0.05% Tween and 5% milk for 1h.  
Blots were then washed three times for 5 minutes with TBS containing 0.05% Tween. 
Enhanced chemiluminescence (ECL) detection was used to visualise results in a dark room.  In 
brief, 50 µl luminol (250 mM) and 25 µl coumaric acid (90 mM) were added to 10 ml ECL buffer (100 mM 
Tris-Hcl pH 8.5) and 4 µl H2O2.  Membranes were drained, placed on a flat surface and incubated with 
ECL solution for 1 min.  The excess solution was drained and the membranes placed between two sheets 
of acetate.  Membranes were exposed onto Amersham HyperfilmTM ECL (GE Healthcare, 
Buckinghamshire, UK) in a hypercassette (GE Healthcare, Buckinghamshire, UK) for 60/30/20/10 
seconds.  The autorads were developed in 1:5 developer (Kodak, Sigma-Aldrich, Dorset, UK) rinsed in 
distilled water and fixed in 1:5 fixer and replenisher solution (Kodak, Sigma-Aldrich, Dorset, UK ) for 2 
min. 
2.5.10 Cell Proliferation Studies 
To investigate the effects of estrogens on cellular proliferation, cells were treated with 1 nM E2 alone or 
with a combination of E2 and the ER antagonist ICI 182,780.  In addition to this, cells were incubated 
with and without EGF, to investigate the necessity of this growth factor for cell growth. 
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10,000 cells per ml were seeded onto 24 well plates daily for 7 days in phenol red-free assay 
media with 0.5% CDS serum to eliminate any sources of contaminating estrogens.  Samples were treated 
with the following: phenol red-free media and 0.5% CDS serum + 0.5% etOH (Control), 20 ng/ml EGF + 
0.5% etOH, 1 nM E2 + 20 ng/ml EGF, 1 nM E2 + 100 nM ICI 182,780 + 20 ng/ml EGF, 100 nM ICI 182,780 
+ 20 ng/ml EGF.  For cells co-treated with ICI 182,780, 30 minute pre-incubation with ICI 182,780 was 
carried out prior to addition of E2. 
The sulforhodamine B (SRB) assay was used to assess cell proliferation of each cell line in 
response to various treatments, using the protocol previously described (Silva et al, 2006): After 7 days, 
the plates were placed on ice for 1 minute and the media was removed.  To each well, 100 µl 10% 
trichloroacetic acid (TCA) was added and the plates were left on ice for 20 minutes.  The plates were 
then washed 5 times in cold water and left to air dry.  100 µl 4% SRB solution was added to each well 
and the samples were left for 20 minutes.  The plates were then washed with 1% acetic acid to remove 
unbound dye and left to air dry in the dark.  The bound dye was solubilised using 200 µl 10 mM Tris-base 
(pH 10.5), the solution transferred to a 96-well plate and absorbance was read at 510 nm to quantify cell 
number. 
2.5.11 The Role of GPER-1 in Cell Proliferation 
In addition to investigating the impact of E2 on cell proliferation and the role of the ER, the role of GPER-
1 was also investigated.  G-1 was used as an agonist for GPER-1 (Albanito et al, 2007) and G-15 was used 
as a GPER-1 antagonist (Dennis et al, 2011).  G-1 and G-15 were prepared as described previously. 
Cells were seeded as described previously and treated with the following: phenol red-free media 
and 0.5% CDS serum + 0.5% etOH + 0.2% DMSO (control), 0.5% etOH, 1 nM E2, 1 nM E2 + 10 nm G-15, 1 
nM E2 + 10 nM G-15 + 100 nM ICI 182,780, 100 nM G-1 or 100 nM G-1 + 10 nM G-15.  All samples other 
than controls were also treated with 20 ng/ml EGF as we observed that this was required for growth in 
the MCF-10A and MCF-12A cell lines.  For samples treated with G-15 or ICI 182,780, a 20 minute pre-
incubation with the antagonists was performed prior to addition with E2 or G-1. 
2.5.12 Statistical Analysis of Real-Time PCR Data 
Experimental variation between samples can be controlled and real-time PCR results quantified through 
the use of a reference gene.  This allows you to see the changes of expression of target genes relative to 
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a reference gene using the relative expression software tool (REST©) (Pfaffl et al, 2002).  REST allows 
the comparison of two data sets and permits the statistical analysis of these results. 
A reference gene, that showed no changes in expression following E2 treatment, was used to 
normalise gene expression for all further experiments.  The relative expression ratio (R) of the target 
gene was calculated using the Pfaffl’s mathematical equation (Pfaffl, 2001) that uses the amplification 
efficiency (E) and threshold cycle (Ct) to determine whether a target gene’s expression is up-regulated 
or down-regulated in response to a treatment.  The model also incorporates the expression of the 
reference gene under control and test conditions (Equation 2.1). 
 
R = Etarget∆Cttarget (Meancontrol-Meantreatment) 
Ereference
∆Ct
reference
 (Mean
control
-Mean
treatment
) 
Equation 2.1: The Pfaffl equation used to determine the relative expression ratio (R), where E is amplification 
efficiency and Ct is threshold cycle (Pfaffl, 2001). 
To determine whether up- or down-regulations of ERα, ERβ or GPER-1 were statistically significant, the 
pair wise fixed reallocation randomisation test was performed (REST, Pfaffl et al, 2002).  This statistical 
test makes no assumptions concerning the distribution of data, which is necessary given the quantities 
being tested are ratios and subject to variability.  The result is the calculation of a p-value (the chance 
that a data point occurred randomly, and not as a consequence of a treatment).  This is achieved by 
repeatedly and randomly pairing the sample data for target and reference genes of control and sample 
conditions, and then calculating the expression ratios based on the mean.  A p-value of < 0.05 was 
considered statistically significant. 
2.5.13 Statistical Analysis of Proliferation Curve Data 
As we wanted to make comparisons between multiple treatments at various time points, we applied the 
2-way analysis of variance (ANOVA) test to the proliferation data using the GraphPad Prism software.  2 
way-ANOVA works by calculating the mean square for both variables (in this case, the time point and 
the various treatments), a total mean square of a group (the mean for each treatment), and a remainder 
mean square (total mean square minus both mean squares for each variable).  The F-statistic (the 
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expected level of variation in a data set) for the treatments was determined by dividing the effect mean 
square for treated samples by the remainder mean square.  Finally the p-value was calculated and a 
value of < 0.05 was considered statistically significant. 
2.6 Results 
2.6.1 Selection of A Suitable Reference Gene 
In order to select an appropriate reference gene for the experimental work, three genes, regularly used 
as references were tested for response to estrogen treatment in all cell lines.  These were GAPDH, β-
ACTIN and HPRT.  The aim of this work was to indentify one gene which, in terms of expression, was not 
altered by estrogen treatment in any of the cell lines used.  Changes in gene expression would be 
observed as shifts of the curve, following E2 treatment, to the left or to the right of the curve for that of 
solvent controls.  A shift of the curve to the left would indicate a gene up-regulation, whereas, a shift to 
the right would be indicative of a gene down-regulation, relative to solvent controls. 
GAPDH expression was down-regulated in MCF-10A cells and up-regulated in MDA-MB-231 cells 
in response to E2 treatment and was, therefore, an unsuitable candidate for use as a reference gene.   
HPRT expression was expressed at low levels in MCF-10A and MCF-12A cells and E2 treatment 
down-regulated its expression even further.  Additionally, expression was barely detectable in the MCF-
7 and MDA-MB-231 cell lines and, therefore, HPRT was also unsuitable for use as a reference gene.   
β-ACTIN was the only reference gene that was unaffected in terms of gene expression in all four 
cell lines and was selected as the reference gene for all further experiments (Figure 2.5; 2.6; 2.7; 2.8). 
 
Figure 2.5: Reference gene PCR amplification curves for MCF-10A cells.  (A) β-ACTIN (B) E2-induced down-
regulation of GAPDH (C) E2-induced down-regulation of HPRT.  Red lines are solvent control samples and blue lines 
are 1 nM E2-treated samples. 
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Figure 2.6: Reference gene PCR amplification curves for MCF-12A cells.  (A) β-ACTIN (B) GAPDH (C) E2-induced 
down-regulation of HPRT.  Red lines are solvent control samples and blue lines are 1 nM E2-treated samples. 
 
Figure 2.7: Reference gene PCR amplification curves for MCF-7 cells.  (A) β-ACTIN (B) GAPDH (C) Lack of HPRT 
expression.  Red lines are solvent control samples and blue lines are 1 nM E2-treated samples. 
 
Figure 2.8: Reference gene PCR amplification curves for MDA-MB-231 cells.  (A) β-ACTIN (B) E2-induced up-
regulation of GAPDH (C) No HPRT expression detected.  Red lines are solvent control samples and blue lines are 1 
nM E2-treated samples. 
2.6.2 Confirmation of Receptor Status at the Gene Level and the Effects of 17β-
Estradiol 
The ER status of the MCF-10A, MCF-12A, MCF-7 and MDA-MB-231 cell lines has been characterized 
previously (Soule et al, 1990; Carmecci et al, 1997; Filardo et al, 2000; Engel et al, 2011).  However, due 
to gene expression variation between cell batches, it was imperative to confirm the ERα, ERβ and GPER-
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1 status of each cell line.  First, this was achieved by detecting the corresponding genes by real-time 
PCR.  Subsequently, western blots were also used to confirm the receptor status at the protein level. 
Amplification curves for ERα, ERβ and GPER-1 are shown below for solvent controls and E2-
treated samples.  Although some E2-treated samples show deviation from the solvent control curve, at 
this point, changes in gene expression, as a result of E2, cannot be confirmed.  These could instead 
indicate that a different amount of cDNA was present in each sample.  To confirm E2-induced up and 
down-regulation of the target genes, normalisation to the reference gene will be carried out and the 
REST analysis software tool will be used, and this will be discussed later.  Nevertheless, as the levels of β-
ACTIN did not change in the samples analysed, we present here the amplification curves for the 
different receptors, previous to normalisation, as well as their melt-curves, in order to provide a visual 
account of what was observed during gene expression detection. 
As can be seen in Figure 2.9, ERα and ERβ could not be detected in MCF-10A cells.  GPER-1 was, 
however, expressed in MCF-10A cells and the amplification curve was shifted to the right upon E2 
treatment, relative to solvent controls.  This may indicate a down-regulation in GPER-1 expression in 
response to E2. 
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Figure 2.9: Real-time PCR amplification curves (left) and melt curves (right) for ERα, ERβ and GPER-1 in etOH 
controls (red) and 1 nM E2-treated (blue) in MCF-10A cells.  No ERα or ERβ was detected, and hence, no 
amplification or melt curves were generated.  GPER-1 was expressed in MCF-10A cells and E2 treatment down-
regulated its expression, as indicated by a shift of the curve to the right.  The melt curves for solvent controls and 
E2-treated samples for GPER-1 are identical and show no indications of contamination or mis-priming. 
MCF-12A cells expressed both ERα and ERβ (Figure 2.10) and E2 treatment did not seem to have a great 
effect on gene expression levels, although a slight decrease in ERα was noted upon E2 treatment.  GPER-
1 was also expressed in MCF-12A cells and 24h treatment with 1 nM E2 shifted the curve to the right, 
relative to solvent controls.  This may be indicative of a down-regulation in the expression of GPER-1 
following E2 treatment. 
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Figure 2.10: Real-time PCR amplification curves (left) and melt curves (right) for ERα, ERβ and GPER-1 in etOH 
controls (red) and 1 nM E2-treated (blue) in MCF-12A cells.  No shift of the curve was observed upon E2 
treatment for ERα or ERβ.  A slight shift to the right of the GPER-1 amplification curve was observed for E2-treated 
cells, relative to controls.  Melt curve analysis indicates that only the target product was amplified and there was 
no genomic DNA contamination, primer dimers or mis-priming. 
At the gene level, it was observed that MCF-7 cells express ERα, ERβ and GPER-1 at relatively high levels 
(Figure 2.11).  24 h treatment with 1 nM E2 led to a shift of the amplification curve of ERα and ERβ to 
the right and left, respectively.  This may mean that ERα is down-regulated and ERβ is up-regulated in 
response to E2.  GPER-1 was expressed but appeared to be unaffected by E2 treatment (Figure 2.11).  
87 
 
 
Figure 2.11: Real-time PCR amplification curves (left) and melt curves (right) for ERα, ERβ and GPER-1 in etOH 
controls (red) and 1 nM E2-treated (blue) in MCF-7 cells.  The amplification curve for ERα of E2-treated cells was 
shifted to the left relative to controls.  The curve of ERβ was shifted to the left following E2 treatment, in 
comparison to the curve for solvent controls.  The data for GPER-1 was more variable but it did not appear that E2 
affected the amplification curve for this gene.  Melt curve analysis showed no mis-priming, primer dimers or 
contamination with genomic DNA. 
MDA-MB-231 cells express ERβ and GPER-1 and upon E2 treatment, the amplification curves for these 
genes shifted to the left, relative to controls.  This may indicate an up-regulation in these genes.  ERα 
was not detected at the gene level in this cell line under control conditions.  However, after treatment 
with 1 nM E2, ERα gene expression was observed (Figure 2.12). 
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Figure 2.12: Real-time PCR amplification curves (left) and melt curves (right) for ERα, ERβ and GPER-1 in etOH 
controls (red) and 1 nM E2-treated (blue) in MDA-MB-231 cells.  ERα expression was only detected in E2-treated 
cells.  E2 treatment shifted the amplification curves of ERβ and GPER-1 to the left, relative to solvent controls, 
indicating an increase in gene expression.  Melt curve analysis shows no signs of primer-dimers, mis-priming or 
genomic DNA. 
2.6.3 Relative Expression Software Tool Analysis 
After normalisation to the reference gene and according to the REST analysis, there was no significant 
change in the expression of ERα, ERβ or GPER-1 in MCF-10A and MCF-12A cells in response to E2.  In 
MCF-7 cells, E2 decreased the gene expression of ERα and increased the expression of ERβ, but had no 
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effect on GPER expression.  As MDA-MB-231 did not express ERα under solvent control conditions, 
treatments could not be compared with controls and, therefore the data is not presented on the graph 
below.  E2 treatment, in addition to inducing the gene expression of ERα, increased the gene expression 
of ERβ and GPER-1 in the MDA-MB-231 cell line (Figure 2.13). 
 
 
Figure 2.13: Fold change in gene expression in response to 1 nM E2 of ERα, ERβ and GPER-1 for all four cell lines.  
As MDA-MB-231 cells did not express ERα under solvent control conditions, the fold change cannot be shown 
here.  EtOH controls are set to 0 (x-axis).  Error bars represent standard error of the mean (n = 6).  A P-value of 0.05 
was considered statistically significant and is indicated by an *. 
Results for real-time PCR analysis of receptor status and the impact of E2 are summarised in Table 2.6. 
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Table 1.6: Table summarising gene expression of ERα, ERβ and GPER-1 in the cell lines studied and the impact of 
E2 on gene expression 
Gene MCF-10A MCF-12-A MCF-7 MDA-MB-231 
ERα X Yes Yes-Decreased by E2 No-Expressed when 
E2-treated 
ERβ X Yes Yes-Increased by E2 Yes-Increased by E2 
GPER-1 Yes-Decreased by E2 Yes Yes Yes-Increased by E2 
 
2.6.4 Receptor Confirmation at the Protein Level 
Antibodies against ERα and ERβ were optimised.  However, problems occurred with the antibodies 
against GPER-1, due to high levels of background.  This has, thus, impacted upon the quality of the 
images obtained.  This could have been due to the quality or specificity of the GPER-1 antibody. 
At the protein level, GPER-1 was expressed in all four cell lines, even though not at very high 
levels.  ERα was expressed in MCF-12A and MCF-7 cells, but was not detectable in MCF-10A or MDA-MB-
231 cells.  ERβ was expressed in MCF-12A, MCF-7 and MDA-MB-231 cells at significant levels, but was 
not expressed in the MCF-10A cell line (Figure 2.14).   
 
Figure 2.14: Western blot image confirming receptor status of MCF-10A, MCF-12A, MCF-7 and MDA-MB-231 cell 
lines. 
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2.6.5 Cell Proliferation Studies in Response to E2 
The SRB assay was used to assess cell proliferation of each cell line in response to various treatments.  
Controls consisted of phenol red free media with 0.5% CDS-stripped serum, 0.5% etOH and had no EGF.  
All other samples were treated with 20 ng/ml EGF, as this was shown to be essential for cell 
maintenance and proliferation of the non-tumourigenic cell lines. 
MCF-10A cells did not proliferate in the absence of EGF.  In solvent controls, or upon the 
addition of E2, cell proliferation gradually increased over time, peaking after 6 days and then decreased 
again and these curves were almost superimposed on one another.  This suggests that this 
corresponded just to the normal doubling of cells (i.e. the basal level of cell proliferation without 
treatment), which is normally observed in in vitro cultures, and E2 induced no significant proliferative 
effects.  The same pattern was seen with cells treated with ICI 182,780 alone or E2 + ICI 182,780.  
However, the peak in growth at day 6 was not as great as that seen with solvent controls or E2-treated 
samples.  This suggests that in this ER negative cell line, ICI 182,780 treatment exerts a small anti-
proliferation effect (Figure 2.15). 
Statistical analysis showed that there were no significant differences between the proliferation 
data for solvent controls and samples treated with E2, E2 + ICI 182,780 or ICI 182,780. 
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Figure 2.15: MCF-10A proliferation analysis.  E2 had no impact upon proliferation.  ICI 182,780, either alone or in 
combination with E2, appears to have a small anti-proliferative effect.  Cells where no EGF was present in the assay 
media did not proliferate.  Error bars show standard error of the mean (n = 6).  Solvent controls consisted of 
phenol red free media with CDS serum + 0.5% etOH.  All samples were treated with 20 ng/ml EGF, in addition to 
the indicated treatment, unless otherwise stated. 
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EGF was also necessary for the proliferation of MCF-12A cells.  For cells treated with etOH, E2, E2 + ICI 
182,780 or ICI 182,780, proliferation increased until day 5 and then started to decrease.  For samples 
treated with ICI 182,780, however, proliferation increased until day 6 to a greater level than observed in 
other treatments.  This could be indicative of delayed proliferation or due to the increase in cell number 
compared to other treatments.  E2 treatment of the ER positive MCF-12A cell did not appear to 
stimulate proliferation (Figure 2.16). 
 Statistical analysis showed that there was no significant difference between the proliferation of 
solvent controls and cells grown in the presence of E2, E2 + ICI 182,780 or ICI 182,780. 
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Figure 2.16: MCF-12A proliferation analysis.  Only ICI 182,780 appeared to have an impact upon MCF-12A 
proliferation as shown by the increased cell number at Day 6.  Error bars show standard error of the mean (n = 6).  
Solvent controls consisted of phenol red free media with CDS serum + 0.5% etOH.  All samples were treated with 
20 ng/ml EGF in addition to the indicated treatment, unless otherwise stated. 
In ERα, ERβ, GPER-1 positive tumourigenic MCF-7 cells, cells grown in the lack of EGF, did not proliferate.  
This was unexpected, as these cells normally proliferate in the absence of EGF (Silva et al, 2001).  
However, as cells were cultured in 0.5% serum in phenol red-free media, the lack of any growth factors 
probably accounts for this.  For all samples, with the exception of those where ICI 182,780 was present, 
cells proliferated until day 7 and then cell number declined.  E2 treatment induced a slight increase in 
proliferation.  Treatment with ICI 182,780, whether alone or with E2, resulted in no cell proliferation 
(Figure 2.17). 
 Statistical analysis demonstrated that E2 did significantly increase the proliferation of MCF-7 
cells, and this was inhibited by the presence of ICI 182,780 (p = 0.002).  
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Figure 2.17: MCF-7 proliferation analysis.  Proliferation increased slightly in response to E2 was this not observed 
upon co-incubation with ICI 182,780.  Cells grown the presence of ICI 182,780 did not proliferate.  Error bars show 
standard error of the mean (n = 6).  Solvent controls consisted of phenol red free media with 0.5% CDS serum + 
etOH.  All samples contained 20 ng/ml EGF in addition to the indicated treatment, unless otherwise indicated. 
 
In ERβ, GPER-1 positive, ER negative tumourigenic MDA-MB-231 cells, cells were still able to proliferate 
in the absence of EGF.  All samples proliferated in the same fashion and to the same extent, with cell 
number increasing until day 6 and then declining.  etOH-treated samples showed increasing cell number 
at day 3 as opposed to day 4 when cell number increases in all  other treated samples were observed.  
The second difference was induced by E2 treatment, these cells had a greater cell number at day 4 
compared to cells treated with ICI 182,780, E2 + ICI 182,780 or media lacking EGF (Figure 2.18).  
However, statistical analysis showed no significant differences between samples at these, or any other 
time points. 
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Figure 2.18: MDA-MB-231 proliferation analysis.  E2, alone or in combination with ICI 182,780, did not have an 
impact upon cell proliferation.  Error bars show standard error of the mean (n = 6).  Solvent controls consisted of 
phenol red free media with 0.5% CDS serum + 0.5%.  All samples contained 20 ng/ml EGF in addition to the 
indicated treatment, unless stated otherwise. 
2.6.6 The Role of GPER-1 in Proliferation 
E2 only appeared to have an impact upon MCF-7 proliferation and co-incubation with ICI 182,780 
prevented MCF-7 proliferation.  In MCF-12A cells, ICI 182,780 appeared to impact upon proliferation, 
which may be due to it agonistic properties for GPER-1 (Filardo et al, 2002).  It was therefore decided to 
investigate whether GPER-1 could mediate any of E2’s proliferative effects using the GPER-1 antagonist, 
G-15 (Dennis et al, 2011).  It was also decided to see if GPER-1 was involved in cellular proliferation 
through the use of GPER-1 agonist, G-1 (Albanito et al, 2007). 
 In MCF-10A cells, E2, either alone or in combination with ICI 182,780 or G-15, had no impact on 
proliferation (Figure 2.19).  Therefore, these  data suggests that despite being GPER-1 positive, MCF-10A 
cells do not proliferate in response to estrogen. 
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Figure 2.19: E2 and the role of GPER-1 in the proliferation of MCF-10A cells.  Solvent controls consisted of media 
and 0.5% CDS serum + 0.5% etOH + 0.2% DMSO.  All treatments contained 20 mg/ml EGF, unless otherwise stated.  
Error bars represent standard error of the mean (n = 6). 
In MCF-10A cells G-1 did not appear to increase proliferation.  However, G-15 alone and G-15 in 
combination with G-1, did decrease proliferation compared to etOH controls (Figure 2.20).  These 
changes, however, were not statistically significant. 
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Figure 2.20: The role of GPER-1 on MCF-10A proliferation.  Solvent controls consisted of media and 0.5% CDS 
serum + 0.5% etOH + 0.2% DMSO.  All treatments contained 20 mg/ml EGF.  Error bars represent standard error of 
the mean (n = 6). 
The MCF-12A proliferation curves were similar for E2 + ICI 182,780 + G-15, E2 + ICI 182,780 and E2 + G-
15 (Figure 2.21).  There were no statistically significant differences between these growth curves. 
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Figure 2.21: E2 and the role of the GPER-1 in proliferation of MCF-12A cells.  Solvent controls consisted of media 
and 0.5% CDS serum + 0.5% etOH + 0.2% DMSO.  All treatments contained 20 mg/ml EGF, unless otherwise stated.  
Error bars represent standard error of the mean (n = 6). 
In MCF-12A cells, G-1 increased proliferation and cells continued to proliferate to day 6, as opposed to 
day 5, as observed in solvent controls.  However, this was not statistically significant.  Co-incubation of 
G-1 with G-15 decreased this effect-induced by G-1, but again, this was not statistically significant.  
(Figure 2.22).  This suggests that in ER and GPER-1 positive MCF-12A cells, GPER-1 does not play a great 
role in proliferation. 
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Figure 2.22: Involvement of the GPER-1 on MCF-12A proliferation.  Solvent controls consisted of media and 0.5% 
CDS serum + 0.5% etOH + 0.2% DMSO.  All treatments contained 20 mg/ml EGF.  Error bars represent standard 
error of the mean (n = 6). 
E2 slightly increased MCF-7 proliferation and co-incubation with G-15 appeared to reduce this at several 
time points (Figure 2.23).  When statistical analysis was performed, a significant difference between E2-
treated samples and E2 + G-15 treated samples (p = 0.02).  This suggests that the GPER-1 may play some 
role in mediating the E2-induced proliferation of E2 in MCF-7 cells.   
Combined G-15 and ICI 182,780 pre-treatment prior to E2 addition resulted in lack of 
proliferation.  As this is very similar to the data seen with ICI 182,780 either alone or in combination with 
E2 (Figure 2.23), it suggests that the reduction of the effect of the hormone was due to the presence of 
the ICI 182,780 and not G-15.  Therefore, the data also suggests that the small E2-induced increased in 
proliferation in the MCF-7 cell line is mediated by the ER and not GPER-1. 
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Figure 2.23: E2 and the role of the GPER-1 in the proliferation of MCF-7 cells.  Solvent controls consisted of media 
and 0.5% CDS serum + 0.5% etOH + 0.2% DMSO.  All treatments contained 20 mg/ml EGF, unless otherwise stated.  
Error bars represent standard error of the mean (n = 6). 
G-1 treatment of MCF-7 cells appeared to slightly decrease cell proliferation, relative to solvent controls, 
and this was considered statistically significant (p = 0.0048) (Figure 2.24).  This may mean that the 
activation of GPER-1, by G-1, has an anti-proliferative effect.  G-1 + G-15 appeared to further decrease 
MCF-7 proliferation, relative to both solvent controls and G-1 treated cells.  This was only significant 
relative to solvent controls (p = 0.0057). 
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Figure 2.24: The involvement of the GPER-1 on MCF-7 proliferation.  Solvent controls consisted of media and 
0.5% CDS serum + 0.5% etOH + 0.2% DMSO.  All treatments contained 20 mg/ml EGF.  Error bars represent 
standard error of the mean (n = 6). 
Co-incubation of G-15 or ICI 182,780 G-15 with E2 did not significantly effect upon MDA-MB-231 
proliferation (Figure 2.25).   
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Figure 2.25: E2 and the role of GPER-1 in proliferation in MDA-MB-231 cells.  Solvent controls consisted of media 
and 0.5% CDS serum + 0.5% ethanol + 0.2% DMSO.  All treatments contained 20 mg/ml EGF, unless otherwise 
stated.  Error bars represent standard error of the mean (n = 6). 
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G-1, G-1 + G-15 and G-15 had no significant impact upon MDA-MB-231 proliferation (Figure 2.26).  This 
may indicate that not only does E2 not increase proliferation in this cell line, but GPER-1, is not involved 
in MDA-MB-231 proliferation, even though it is expressed at, albeit at low levels. 
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Figure 2.26: The involvement of GPER-1 on MDA-MB-231 proliferation.  Solvent controls consisted of media and 
0.5% CDS serum + 0.5% etOH + 0.2% DMSO.  All treatments contained 20 mg/ml EGF.  Error bars represent 
standard error of the mean (n = 6). 
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2.6.7 Summary Table for Cell Proliferation Studies 
Table 2.7: Summary of proliferation analysis of cell lines in response to estrogen and ER or GPER-1 antagonists 
Treatment MCF-10A MCF-12A MCF-7 MDA-MB-231 
E2 No effect No effect Increased No effect 
E2 + ICI 182,780 No effect No effect Decreased No effect 
E2 + G-15 No effect No effect Decreased relative to 
E2-treated cells 
No effect 
G-1 No effect No effect Increased No effect 
G-1 + G-15 No effect No effect Decreased No effect 
ICI 182,790 No effect No effect Decreased No effect 
G-15 No effect No effect No effect No effect 
 
2.7 Discussion 
2.7.1 Receptor Confirmation 
The ER status of the MCF-10A, MCF-12A, MCF-7 and MDA-MB-231 cell lines at both the gene and 
protein level has been confirmed.  It is widely accepted that cells vary greatly between batches (Herold 
et al, 1994; Payne et al, 2000).  As the primary aims of the work to be conducted was to investigate the 
impacts of estrogens in ER and GPER-1 competent, MCF-12A cells, in a 3D culture model, it was first 
necessary to confirm the presence of these receptors in this cell line. 
In the cell batches tested here, MCF-10A cells were found to be negative for ERα and ERβ, whilst 
MCF-12A cells expressed both ERα and ERβ.  Both “normal” cell lines expressed measurable levels of 
GPER-1.  On the other hand, the tumourigenic MCF-7 cells were positive for all three receptors and 
MDA-MB-231 cells expressed ERβ and GPER-1, but were ERα negative, at both the protein and gene 
level.  Upon E2 treatment, however, ERα was detected at the gene level in this cell line. 
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The ERα negative phenotype observed in the MCF-10A cell line tested has previously been 
observed by other groups (Spychala et al, 2004) and, hence, this cell line can be used for further 
experiments as an example of a non-tumourigenic ER negative breast cell line. 
The ERα status of the MCF-12A cell line, however, has been reported as both positive (Eisen & 
Brown, 2004; Engel et al, 2011) and negative (Thompson et al, 2004).  The American Type Culture 
Collection (ATCC) MCF-12A cell line used in this study was proven by us to express both ERα and ERβ in 
measurable amounts, at both the gene and protein level.  The precise reason for discrepancies between 
research groups is unknown; however, it has previously been shown that the ER negative MCF-10A cell 
line can spontaneously become ER positive and the same could, therefore, be true for the MCF-12A cell 
line (Lane et al, 1999).  It is not clearly understood how this may have occurred, although other groups 
have found that ectopic expression of oncogenic Ha-ras can result in ERα expression in previously ER 
negative cell lines (Shekhar et al, 1998).  Other factors that may account for the variability in responses 
to estrogens, or indeed their ER status, can include seeding density, length of estrogen-deprivation prior 
to E2 treatment and cytogenetic changes (Payne et al, 2000).  For instance, it has been demonstrated 
that in E2-deprived MCF-7 cells, ERα is up-regulated, leading to increased responses when estrogens are 
added (Katzenellenbogen et al, 1987).  Furthermore, low seeding densities appear to increase estrogen 
responsiveness in MCF-7 cells (Payne et al, 2000). 
Although small, the decrease in ERα gene expression in response to E2 in MCF-12A cells was 
statistically significant (P < 0.05).  This decrease in ERα expression may lead to decreased estrogen 
responsiveness, and this possibly presents a negative feedback mechanism through which estrogen 
responsiveness is controlled. 
As the focus of the work described in this thesis is to investigate the effects of estrogens in an ER 
positive non-tumourigenic mammary epithelial cell line, as shown here, MCF-12A cells are the best 
candidates for this purpose as the gene and protein analysis clearly demonstrates that these cells 
express a functional ER. 
GPER-1 was also found to be present at both the gene and protein level in both MCF-10A and 
MCF-12A cell lines.  GPER-1 gene expression decreased upon E2 treatment in the ER negative MCF-10A 
cell line and ER competent MCF-12A cell line.  This E2-induced down-regulation of GPER-1 gene 
expression was however only statistically significant in MCF-12A cells (P < 0.05). 
ERα gene expression was down-regulated upon E2 treatment in MCF-7 cells as, at the gene 
level, suggesting that the down-regulation of the ER in response to estrogen occurs at the transcriptional 
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level.  This agrees with previous reports, where estrogen down-regulated ERα expression, not only at 
the gene level, but also at the protein level (Jenesen et al, 1999; Marsaud et al, 2003; Kocanova et al, 
2010).  In terms of the down-regulation of ERα gene expression, it has been proposed that activated ERα 
is able to bind to various regions located within the promoter region of the ER.  This negative feedback 
mechanism prevents any further transcription of the gene, but because the ER lacks an ERE, other co-
activators must be involved, such as AP-1 and SP-1 (Saceda et al, 1989; Kaneko et al, 1993; Santagati et 
al, 1997). 
In MDA-MB-231 cells, ERα gene expression was only detected upon E2 treatment.  Previous 
studies have shown that MDA-MB-231 cells are negative for ERα (Rai et al, 2005; Zhang et al, 2011).  An 
increase in ERα gene expression in response to E2 has been observed in other cell lines that express the 
gene at very low levels (Read et al, 1989).  Therefore, a similar effect may be occurring in MDA-MB-231 
cells following E2 treatment. 
2.7.2 Proliferation in Response to Estrogen 
It is well established that the development of the breast is influenced by estrogens (Russo et al, 1999) 
and that E2 can stimulate the proliferation of breast cancer cell lines and may influence breast cancer 
growth in vivo (Lippman et al, 1976; Russo et al, 2002).  To study this further, non-tumourigenic, and 
tumourigenic cell line proliferation studies were performed in the presence of E2, ICI 182,780 and a 
combination of the two.  Additionally the role of GPER-1 in mediating cellular proliferation was studied 
using an agonist and antagonist for this receptor and co-incubation of the GPER-1 antagonist, G-15 with 
E2. 
It was observed that in MCF-10A, MCF-12A and MCF-7 cells, the lack of EGF, resulted in a lack of 
proliferation.  A dependence on EGF has been noted previously in the MCF-10A and MCF-12A cell line 
(Soule et al, 1990; Paine et al, 1992; Wang et al, 1997), but not in MCF-7 cells.  This discrepancy may be 
due to the very low concentration of serum used and the phenol red-free media, rather than a necessity 
for EGF itself.   
E2 does not appear to greatly influence proliferation of the cell lines studied, although a small 
increase in cell number was observed in MCF-7 cells in response to E2 treatment.  This lack of 
proliferation in response to the steroid hormone would be expected in the ERα negative MCF-10A and 
MDA-MB-231 cell lines and has been observed previously (Spink et al, 2006), but it is also common for 
ER positive non-transformed mammary epithelial cells, such as MCF-12A to be non-proliferative in 
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response to stimulus (Clarke et al, 1997; Russo et al, 1999).  Additionally, it is important to remember 
that MCF-7 cells, although estrogen-responsive, do not always show significant proliferation in response 
to estrogens, and proliferation in response to these compounds, varies significantly between cell 
batches (Payne et al, 2000). 
The lack of proliferative effect of E2 in MCF-12A cells suggests that E2 does not induce 
proliferation in non-transformed cell lines, regardless of their ER status, and supports previous work 
demonstrating that non-transformed mammary epithelial cells do not increase DNA synthesis in 
response to E2 treatment (Haslam, 1986).  Alternatively, it has been hypothesised that in cell cultures, 
and even in in vivo models, two populations of epithelial cells exist; one which is ER positive and the 
other which is ER negative.  It is the ER negative cells that proliferate in response to paracrine signals 
from ER positive cells and cells in the surrounding stroma, after stimulation by E2 (Nandi et al, 1995; 
Clarke et al, 1997; Russo et al, 1999; Mallepell et al, 2006; Gupta et al, 2007).  This theory adds an 
additional level of complexity to the model of hormonal carcinogenesis, whereby the events leading to 
breast cancer are governed not just by the presence of E2, but also the interactions of the various cell 
types in the mammary gland and surrounding tissue. 
Another possibility is linked to the expression of ERβ. It has been demonstrated that increased 
expression of this receptor correlates with decreased cell proliferation (Sotoca et al, 2008).  
Furthermore, in breast tumours, the ratio of ERα to ERβ is higher than though of normal breast tissue 
(Lazennec et al, 2001).  These observations have led to the hypothesis that ERβ suppresses the 
proliferative effects of ERα, and would mean that reduced ERβ expression correlates with increased 
proliferation (Covaleda et al, 2008).  Indeed, Covaleda et al (2008) demonstrated this effect in breast 
cancer cell lines.  However, the exact mechanism for how ERβ mediates the actions of ERα, to our 
knowledge, remains elusive.  The small stimulatory effect of ICI 182, 780, either alone or in combination 
with E2, on MCF-12A proliferation could be explained by the confirmed presence of GPER-1 in MCF-12A 
cells, as both E2 and ICI 182,780 can act as agonists for this receptor (Kamanga-Sollo et al, 2008; Kuhn et 
al, 2008).  Indeed, when MCF-12A cells were treated with the GPER-1 agonist, G-1, increased 
proliferation was observed.  This means that, in MCF-12A cells at least, GPER-1 activation can induce 
proliferative effects.  In addition to this, when the GPER-1 antagonist, G-15 was added to E2 and ICI 
182,780 co-incubated MCF-12A cells, the proliferation curve resembled that of solvent controls. 
Our observations agree with previously published work showing that E2 has a mitogenic effect 
on the MCF-7 cell line (Lewis et al, 2005; Spink et al, 2006; Wang et al, 2008b).  In fact, out of all four cell 
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lines analysed, MCF-7 cells were the only cells to show increased proliferation in response to E2 
treatment.  The impact of estrogens on MCF-7 proliferation has been widely studied.  Several factors are 
believed to contribute to the mitogenic effect of E2 in this cell line.  Firstly, E2 is able to induce the 
transcription of the proto-oncogenic transcription factor, c-fos via genomic and non-genomic 
mechanisms (Prall et al, 1997; Sabbah et al, 1999; Duan et al, 2002).  C-fos proteins form dimers with 
members of the Jun transcription factor family to form the AP-1 transcription factor that consequently 
mediates the transcription of various genes involved in differentiation and proliferation.  Consequently, 
the expression of cyclin D1, a protein involved in cell cycle progression, is up-regulated in response to E2 
in the MCF-7 cell line and this correlates with increased proliferation (Prall et al, 1997; Planas-Silva et al, 
2001).  Estrogens also down-regulate the expression of the cyclin dependent kinase (CDK) inhibitor 
p27kip1 thus preventing the interactions of cyclins and CDKs which is necessary for cell cycle progression 
(Foster et al, 2003).  Finally, in terms of the cell cycle, E2 treatment induces the hyperphosphorylation of 
the Rb protein.  In its hyperphosphorylated state Rb becomes liberated from elongation actor-2 (EF2), 
allowing the transcription of genes required for passage through the G1/S phase checkpoint and 
consequently, increased proliferation (Foster & Wimalasena, 1996; Hurd et al, 1997; Dinda et al, 2002).  
These E2-induced alterations in gene expression or phosphorylation status present plausible 
mechanisms by which estrogens induce their proliferative effects.  As stated above, MCF-7 cells were 
the only cells to have a proliferative response to E2.  Co-incubation of E2 with ICI 182,780 or G-15 in this 
cell line, seemed to significantly reduce this effect.  It, therefore, would appear that both the ER and 
GPER-1 are capable of mediating the proliferative effects of estrogens in MCF-7 cells.  Strangely 
however, G-1, a GPER-1 agonist, appeared to have an anti-proliferative effect.  The reason for this 
remains unclear and warrants further investigation, although is not in the scope of this thesis. 
As described in the results section, ICI 182,780 treatment of MCF-7 cells, either alone or in 
combination with E2, prevented cell proliferation, which agrees with previous findings that ICI 182,780 
and other ER antagonists induce growth arrest in this cell line (Lippman et al, 1976; Carroll et al, 2000; 
Lewis et al, 2005; Martin et al, 2005; Wang et al, 2008b). 
The lack of response of ERα negative MDA-MB-231 to E2 and ICI 182,780 is not surprising, 
considering the absence of ERα in this cell line.  These cells do, however, express ERβ, and given the lack 
of response to E2, this may suggest that ERβ does not mediate the proliferative effects of estrogens.  
Similar observations with E2, ICI 182,780 and even tamoxifen have been demonstrated previously 
(Lippman et al, 1976; Rai et al, 2005; Wang et al, 2008b).  These cells were the only cell line that 
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proliferated in the absence of growth factors, which suggests that they have become self-sufficient in 
terms of growth signals, a common hallmark of cancer (Hanahan & Weinberg, 2000).  Indeed, Ras 
mutations, as displayed in MDA-MB-231 cells, results in increased production of TGFα (Ciardiello et al, 
1988; Cancer Genome Project).  This means that MDA-MB-231 are capable of producing growth factors, 
and may, therefore, mean that they are capable of surviving in an environment where growth factors 
are limited. 
Finally, the role of GPER-1 in proliferation was investigated.  All of the cell lines tested are 
competent for this receptor.  In MCF-7 cells, the only cell line in which E2 increased proliferation, GPER-
1 antagonism did not reverse this effect.  This suggests that, at least in the case of MCF-7 cells, GPER-1 
does not mediate the mitogenic influences of estrogens.  In MCF-12A cells however, ICI 182,780 and G-
1, both GPER-1 agonists, did increase proliferation.  This may implicate that GPER-1 in this cell line can 
mediate changes in proliferation, although E2 itself does not increase induce this effect.  It remains to be 
seen whether GPER-1 is implicated in the apoptotic process in the cell lines studied or indeed in three-
dimensional (3D) cultures of MCF-12A cells, which will consist of work in later chapters.  Nevertheless, it 
would appear that GPER-1 in the non-tumourigenic ER-competent MCF-12A cell line may be implicated 
in cellular proliferation. 
The data presented here suggests that estrogens may not impact greatly on cellular proliferation 
in these cell lines, and, therefore, may be exerting their effects via other mechanisms.  However, as 
discussed above, these studies were performed using individual cell lines.  In the human mammary 
gland, multiple cell types are present, and these signal to one another to induce alterations in cell 
growth and behaviour.  Therefore, it is plausible that the lack of significant proliferation in response to 
E2 is due to the absence of paracrine signalling mechanisms with other cell types.  Indeed, as mentioned 
earlier, there is evidence that suggests that responses of both normal and malignant mammary 
epithelium to estrogens is not as a result of estrogens directly, and that estrogens instead induce the 
release of growth factors, such as EGF and TGFα, which, in turn proceed to induce proliferation 
(Vonderhaar, 1987; Salomon et al, 1992).  Further experiments, such as the co-culture of ER positive and 
ER negative cells, or of epithelial cells with cells of the stroma, would shed further light on this, however 
for the purpose of the work to be described in later chapters this is not necessary at this stage. 
The work presented here has not conclusively shown that E2 acts as a mitogen in ER-competent 
cell lines or that the primary function of GPER-1 is associated with proliferation.  It has, however, 
established an understanding of how the cells lines tested respond to estrogens and will be important, 
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particularly in the case of the MCF-12A data, for future work.  The observations here will allow us to 
compare the differences between monolayer cultures of MCF-12A cells, and those grown in 3D.  This is 
important to investigate as we are aiming to utilise a 3D model of mammary epithelial MCF-12A cells, to 
more accurately characterise the impact of estrogens in a more physiologically relevant setting, and 
highlight the failings of only conducting experiments in traditional monolayer cultures. 
In the proceeding chapters we will investigate the impact of estrogenic compounds on 3D 
cultures of MCF-12A cells and try to elude the role of the ER and GPER-1 in mammary carcinogenesis 
and the mechanisms involved using a 3D model. 
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CHAPTER III: Establishing Three Dimensional Cultures of Non-
Tumourigenic Breast Cells 
3.1 Principles of Three Dimensional Culture 
Monolayer culture of normal and breast cancer cells has provided valuable knowledge regarding cancer, 
in respect to oncogenic events, molecular mechanisms of cancer progression and cancer therapy 
(Darbre et al, 1983; Santen et al, 1987).  Additionally, these monolayer cultures provide insight into the 
biological processes and responses to treatments, such as apoptosis, proliferation and drug resistance 
(Normanno et al, 2006).  However, the monolayer culture system has limitations.  Previous reports have 
shown that the effects of cytotoxic compounds, potential therapies, oncogenes and tumour suppressor 
genes in traditional monolayer cultures often do not translate to the same effects observed in three-
dimensional (3D) cultures, in in vivo models or in humans (Dhiman et al, 2005; Horning et al, 2008; Yang 
et al, 2009).  For example, in monolayer cultures of breast cancer cells, HER2 (a receptor that has 
implications for breast cancer treatment and prognosis) forms heterodimers with HER3 resulting in PI3K 
signalling, but, in 3D, HER2 forms homodimers and MAPK signalling is favoured (Pickl & Ries CH, 2009).  
Hence, monolayer cultures often give a poor representation of how possible carcinogens, genetic 
aberrations and treatments affect cancer initiation and progression in vivo.  Indeed, analysis has 
revealed that cells cultured in monolayer and 3D differ in their gene and protein expression patterns and 
in the integration of signalling pathways (Gaedtke et al, 2007; Kenny et al, 2007; Härmä et al, 2010; 
Weigelt et al, 2010).  For example, global gene expression analysis has revealed that in monolayer 
cultured hepatocytes, genes associated with the extracellular matrix (ECM), cytoskeleton and adhesion 
are up-regulated, whereas in 3D cultured cells, genes associated with metabolism are up-regulated 
instead (Chang & Hughes-Fulford, 2009).  At the protein level, 3D cultures, compared to monolayer 
cultures, have down-regulated levels of prohibitin and up-regulated levels of annexin 4, suggesting a 
decrease in proliferation and increased apoptosis, respectively (Grun et al, 2009).  These findings 
suggest that cells can have dramatic and fundamental functional differences, depending on the means 
of culture. 
 Also of extreme importance, is the inability of monolayer cultures to recapitulate the micro-
environment found in vivo.  In an in vivo setting, signals from the micro-environment exist, originating 
from the surrounding stroma, immune cells, endothelial cells and the ECM, and these impact upon the 
development of the mammary gland (Bissell & Radisky, 2001).  However, in monolayer cultures, these 
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external cues are not present.  Consequently, cellular organisation into functional structures and ECM 
interactions cannot be studied.  As mentioned previously, one way to overcome the limitations of 
monolayer cultures is by using 3D models of immortalised cell lines, where the signals from the ECM are 
restored, and in vivo architectural and physiological features recapitulated (Lawrenson et al, 2009).  As 
described in detail in Chapter I, 3D culture using reconstituted basement membrane matrix (Matrigel) 
allows the organisation of non-malignant epithelial cells, such as those of the breast, into structures that 
resemble the glandular architecture of the breast (Figure 3.1) (Debnath et al, 2002; 2003).  In Matrigel, 
non-tumourigenic breast cells form polarised, basement membrane encapsulated acini that undergo 
growth arrest and luminal hollowing.  The 3D cellular organisation also allows cells to form cell-cell 
attachments, such as gap junctions, and to communicate with one another, in a similar fashion to what 
occurs in the human breast tissue. 
 
Figure 3.1:  Comparison of acini in vitro and in histological samples from humans.  (A) An in vitro MCF-10A acinus.  
A single layer of cells surrounds a hollowing lumen and is surrounded by basement membrane (Debnath et al, 
2003) (B) Human mammary acini.  A bilayer of cells surrounds a hollow lumen and is encapsulated by a basement 
membrane (Duke University, 2011) 
 
In addition to allowing the study of normal features of the mammary gland, 3D cultures of breast cells 
can also be used to investigate the mechanisms implicated in the neoplastic transformation of the 
breast.  For instance, treatment of MCF-10A cells cultured in Matrigel, with the carcinogen, 2-amino-1-
methyl-6-phenylimidazol [4,5-b] pyridine (PhIP), results in increased proliferation and irregular acinar 
shape (Choudhary et al, 2012).  Furthermore, luminal filling and excess proliferation, common hallmarks 
of breast cancer, can be induced through the over-expression of oncogenes, such as cyclin D1 and Bcl-2, 
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or suppression of tumour suppressor genes (Muthuswamy et al, 2001; Debnath et al, 2002).  However, it 
is worth noting that the ectopic overexpression of cyclin D1 or Bcl-2 alone, results in delayed, rather 
than inhibited lumen formation.  Likewise, suppression of pro-apoptotic Bim expression delays lumen 
formation and this has been substantiated in in vivo models (Reginato et al, 2005; Mailleux et al, 2007).  
As described previously, and will be discussed in more detail in further chapters, profound and 
permanent dysregulation of acini morphogenesis requires the over-activation and inhibition of multiple 
pathways.  This can be exemplified by the formation of acini lacking hollow lumen if both cyclin D1 is up-
regulated and PI3K hyperactivated, or if BIM expression is reduced with simultaneous up-regulation of 
BCL-2 expression (Debnath et al, 2002; Mailleux et al, 2008). 
3D studies have also been conducted using tumourigenic cell lines in order to attempt to revert 
cancerous phenotypes.  Antibodies blocking β1 integrin or the EGFR, reverted some of the abnormal 
acini structures of malignant cells and resulting in organised acini similar to non-tumourigenic breast 
morphology (Weaver et al, 1997). 
Given the aforementioned observations, it is clear that 3D culture, provides an opportunity to 
investigate a more physiologically relevant context in which to study, not only functions involved in 
mammary gland formation and maintenance, such as signalling pathways, polarity, apoptosis and gene 
expression, but also the processes involved in the early stages of carcinogenesis and cancer progression.  
It should be noted, however, that the 3D culture system has limitations in itself.  For example, 
most simple 3D culture experiments reported in the literature do not recapitulate interactions with the 
stroma, as they are comprised of epithelial cells only.  To achieve this, it would be necessary to culture 
various cell types together, such as epithelial, myoepithelial, fibroblast and immune cells.  Techniques 
for the heterotypic 3D co-cultures of these various cell types of the breast have recently been 
developed, such as co-cultures of epithelial cells with fibroblasts, endothelial cells or adipocytes 
(reviewed in Wang & Kaplan, 2012).  At the beginning of this work, many of these techniques were in 
their infant stages and not widely used.  Also, some issues concerning variability had been reported with 
heterotypic 3D co-cultures due to the different scaffolds required for the different cell types and batch 
variation in creating these scaffolds (reviewed in Weigelt & Bissell, 2008), which led to some concerns 
about using this set-up for our work. Finally, from the perspectives of cost and complexity, it was not 
possible to implement these models in our laboratory within the time-frame of this PhD.  In spite of 
being unable to utilise heterotypic 3D cultures of mammary epithelial cells, it is our belief that the single 
cell type model we implemented to be sufficient to address the issue of whether estrogens have an 
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impact on acini formation, and to dissect the mechanisms behind these effects.  Furthermore, at this 
stage, little work has been performed using 3D cultures of MCF-12A cells, and, therefore, a more 
focused approach using one cell type was deemed more appropriate.  Obviously, however, in the future 
heterotypic cultures with these cells and other cell types (i.e. fibroblasts) would be needed to more 
entirely understand the full impact of estrogens on the formation of mammary acini. 
3.2 3D Culture of Non-Tumourigenic Breast Cell Lines 
As mentioned previously, non-malignant breast cells grown in Matrigel, such as MCF-10A mammary 
epithelial cells, form polarised spheroid acini consisting of a single layer of epithelial cells (outer cells) 
attached to a basement membrane surrounding a hollow lumen (Debnath et al, 2002; Debnath et al, 
2003; Underwood et al, 2006; Imbalzano et al, 2009).  This basement membrane consists of a sheet of 
ECM at the basal surface, is composed of laminin, type IV collagen, entactin, proteoglycans and heparin 
sulphate (Debnath et al, 2003) and functions to provide structural support and regulate the organisation 
and proliferation of acini. 
Previous work conducted in 3D models using MCF-10A cells has provided knowledge concerning 
some of the processes involved in mammary duct formation.  In this cell line, cells proliferated for 14 
days in Matrigel before undergoing growth-arrest.  During acini morphogenesis, initially structures 
consist of complete spheres of cells, but from day 8 apoptosis, as shown by activated caspase-3 staining, 
was observed, until complete formation of a hollow lumen after 25 days.  This hollowing achieved 
through a combination of apoptosis, autophagy and anoikis in cells that lack contact with the basement 
membrane (inner cells) (Debnath et al, 2002; Mills et al, 2004; Fung et al, 2008).  The deposition of the 
basement membrane, as indicated by laminin V and polarised organization of hDlg and the Golgi 
apparatus was observed from day 3 and maintained throughout acini morphogenesis (Figure 3.2) 
(Debnath et al, 2003).  The final structures have basal polarisation of α6 integrin, collagen IV, laminin V 
and Disks large and apical polarisation of the Golgi apparatus (Debnath et al, 2003).  E-cadherin and β-
catenin are also localised at cell-cell junction (Debnath et al, 2002).  In the following sections a brief 
overview of the different processes involved in the formation of acini will be presented. 
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Figure 3.2: Schematic representation of the morphological programme of MCF-10A cells grown in Matrigel 
(taken from Debnath et al, 2003). 
 
Despite extensive research into the morphological changes acini go through, the precise mechanisms 
and signalling pathways necessary for acini morphogenesis, remains elusive.  Although much work has 
been conducted to investigate the role of individual oncogenes upon acini formation, there is little 
research into the implications of the dysregulation of these processes and pathways by compounds, 
such as estrogens. 
This 3D culture of mammary epithelial cells provides a way to study glandular epithelium 
morphogenesis, as demonstrated by Debnath et al (2003).  Non-malignant mammary epithelial cells 
grown in 3D form acini-like hollow spheroids that recapitulate the in vivo features of the breast.  These 
acini display apico-basal polarization with basal deposition of collagen IV and laminin V.  This model has 
provided the opportunity to study both the structural and functional implication of cancer genes in a 
physiologically relevant model, in which control conditions can be regulated.  It also presents a model in 
which to study the early indications of carcinogenesis: loss of polarity, luminal filling and loss of 
proliferative control. 
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3.3 Luminal Clearing 
The exact mechanisms and signalling pathways involved in lumen formation remain unclear, and it is still 
unknown whether this is achieved through pro-survival signals to the outer cells or protection of these 
cells from apoptotic signals. 
As mentioned previously, the clearance of the central cells of acini, has been shown to occur by 
a combination of apoptosis, anoikis and autophagy (Debnath et al, 2002; Mills et al, 2004; Fung et al, 
2008).  Failure of one of these mechanisms delays lumen formation, rather than inhibiting it.  However, 
if both autophagy and apoptosis are inhibited simultaneously, the formation of the hollow lumen is 
impeded and luminal filling is observed (Mills et al, 2004).  Suppression of these pathways is a common 
event in cancer in vivo, and luminal filling is an early indication of carcinogenesis (Debnath et al, 2002; 
Russo et al, 2010. 
The apoptotic process can be extrinsically or intrinsically triggered.  Extrinsic apoptosis involves 
the activation of receptors within the cell membrane by pro-apoptotic ligands, such as Fas ligand (FasL), 
tumour necrosis factor (TNF) or TNF-related apoptosis-inducing ligand (TRAIL).  Various proteins are 
recruited which, ultimately, leads to the activation of caspase-8 and down-stream caspases, such as 
caspase-3 (Figure 3.3).   
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Figure 3.3: Extrinsic apoptosis pathways.  Death receptor-mediated signalling upon binding of death ligands such 
as FasL, TNF or TRAIL and recruitment of TNF receptor type 1-associated DEATH domain protein (TRADD) and Fas-
associated protein with death domain (FADD) results in the activation of caspases and subsequent apoptosis. 
 
Intrinsic apoptosis (Figure 3.4) occurs under conditions that induce cellular stress such as heat, 
radiation, deprivation of nutrients, hypoxia, increased Ca2+ concentration or viral infections.  The 
intrinsic apoptotic mechanism is executed by members of the B-cell lymphoma (Bcl-2) protein family 
and caspases.  Members of the bcl-2 family can be either pro-apoptotic or anti-apoptotic and whether a 
cell enters apoptosis or not is dependent on the ratio, localization and phosphorylation status of these 
factors.  For example, if there are more available pro-apoptotic factors than anti-apoptotic ones, cells 
are more likely to undergo apoptosis.  Transcriptional regulation can affect the amount of these factors 
present.  However, phosphorylation events, which can be mediated by AKT or MAPK signalling, can also 
impact on whether pro- or anti-apoptotic factors are able to exert their functions (Datta et al, 1997).  
Important anti-apoptotic factors include Bcl-2 homology (BH) domain containing: Bcl-2 and Bcl-xl, and 
important pro-apoptotic factors include Bcl-2 interacting protein (Bim), Bcl-2 associated X protein (Bax), 
p53 upregulated modulator of apoptosis (PUMA) and Bcl-2-antagonist of cell death (Bad).  These pro-
apoptotic factors can be divided into two categories: multi-domain Bax-like, or Bcl-2 homology 3 (BH3)-
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only.  Members of the first category include Bax and members of the latter include Bad, Bim and Puma.  
These BH3 domain containing factors bind to anti-apoptotic factors such as Bcl-2 and Bcl-xl, thus 
preventing their association with pro-apoptotic Bax.  This liberates Bax, enabling it to dimerise with 
other Bax proteins on the outer mitochondrial membrane. 
The role of Bax is to form oligomers on the outer mitochondrial membrane surface that 
promote the release of factors, such as cytochrome c and second mitochondria-derived activatator of 
caspases (SMAC’s) from the mitochondria, which in turn, promote the activation of executers of 
apoptosis.  In normal conditions, binding to Bcl-2 or Bcl-xl renders Bax inactive and, hence, apoptosis 
does not occur.  In the event of cellular stress, the pro-apoptotic factors such as, Bad bind to the anti-
apoptotic factors, preventing their binding to Bax and allowing the initiation of apoptosis.  Bax dimers 
interact with mitochondrial voltage-dependent anion channels (VDAC’s), causing the formation of a 
channel known as the mitochondrial apoptosis-induced channel (MAC), a decrease in mitochondrial 
membrane potential and triggering the release of cytochrome c, apoptosis-inducing factor (AIF) and 
SMAC’s (Candé et al, 2002; Saelens et al, 2004; Dejean et al, 2006).  These factors proceed to promote 
induce chromatin condensation, DNA fragmentation and activate the caspases (Susin et al, 1999; 
Loeffler et al, 2001).  Activated caspase 3 then proceeds to cleave and activate the effectors of apoptosis 
resulting in proteolysis of components of the cytoskeleton, degradation of the nuclear envelope, DNA 
fragmentation and nuclear shrinkage (Rao et al, 1996; Lee et al, 1997; Chan et al, 1999). 
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Figure 3.4: Intrinsic apoptosis pathways. Cellular stress results in the dimerization of pro-apoptotic Bax, which 
results in cytochrome c release from mitochondria and subsequent activation of caspases, leading to apoptotic 
onset. 
 
In the context of 3D cultures of mammary epithelial cells, activated caspase-3 is observed in the 
centrally located cells prior to luminal clearance, implicating apoptosis in this process.  Furthermore, 
activated AKT is only observed in the outer cells attached to the basement membrane (Debnath et al, 
2002; Debnath et al, 2003b).  Activation of this pathway inactivates Bad and the caspases, which results 
in decreased apoptosis and increased survival (Datta et al, 1997; Polo et al, 2010).  In 3D cultures, it 
would appear that detachment from the basement membrane determines the fate of the inner cells of 
acini, and this would imply that the intrinsic mechanism is more likely to be implicated in luminal 
clearing.   
As mentioned earlier, apoptosis alone is not solely responsible for hollow lumen formation 
(Debnath et al, 2005) and other mechanisms of cell death seem to play a role in this process.  Studies 
have shown that autophagic vesicles are present in centrally located acini cells (Mills et al, 2004; Fung et 
al, 2008), suggesting that autophagy is also involved in formation of the hollow lumen.  Autophagy is a 
catabolic process in which components of a cell are degraded by lysosomal action.  The process involves 
a membrane forming around cellular organelles to form a vesicle, referred to as an autophagosome.  
This fuses with a lysosome containing acidic lysosomal hydrolases that degrades the contents of the 
vesicle (Figure 3.5). 
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Figure 3.5: The autophagic process.  Target organelles are surrounded by a membrane, and this fuses with a 
lysosome, where the contents are degraded by lysosomal hydrolases. 
 
Luminal filling is a characteristic of the early stages of breast cancer, and this suggests that apoptosis is 
an important process involved in the development and maintenance of the mammary gland, and 
highlights that apoptotic onset is a very valuable step in acini morphogenesis.  Therefore, it is important 
to understand the mechanisms behind apoptotic onset and how these are disrupted. 
During tumourigenesis, cells evade the processes of apoptosis, anoikis (death as a result of 
detachment from the ECM) and autophagy, leading to an increase in cell number.  One way in which 
cancer cells acquire resistance to apoptosis and anoikis is through the constitutive activation of 
signalling pathways, due to oncogenic Ras and c-myc activation (Frisch & Francis, 1994; Rosen et al, 
2000).  This can result in the deactivation of pro-apoptotic factors and caspases, which prevents the 
apoptotic process.  Anti-apoptotic factors, such as Bcl-2 and Bcl-xl, are also commonly over-expressed or 
mutated in cancer, which results in increased sequestering of pro-apoptotic Bax and an inhibition of 
mitochondria-mediated apoptosis (Tsujimoto et al, 1985; Krajewska et al, 1996).  In the case of 
autophagy, this process can be inhibited through the actions of the PI3K pathway, which is often 
dysregulated in cancer (Bellacosa et al, 1995).  Often, dysregulation of the apoptotic and autophagic 
processes alone does not result in carcinogenesis, and other mutations in genes involved in processes, 
such as metabolism and proliferation, are required for a cancerous phenotype. 
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3.4 Proliferation 
The cell cycle is the process by which cells divide and is composed of two phases: interphase, where cells 
prepare to divide and mitosis, the production of two daughter cells.  Interphase itself is also composed 
of several phases: G1, S and G2.  Additionally, non-dividing cells remain in a state of rest denoted G0 
(Figure 3.6).  Normally, cells cannot just pass through the cell cycle and divide uncontrollably.  The 
process is regulated at three checkpoints by cyclins and cyclin dependent kinases (CDKs) to prevent 
mutated cells or cells lacking an adequately assemble mitotic spindle to divide. 
 
Figure 3.6: The cell cycle. Cells progress through the cycle passing through interphase (G1, S & G2), before 
undergoing division during mitosis to produce two daughter cells. 
 
The G1/S restriction point is regulated by cyclin D, which binds to and activates CDK4 and CDK6.  CDK4 
and CDK6 go on to phosphorylate the retinoblastoma (Rb) protein, liberating it from the transcription 
factor, E2F.  E2F can then activate the transcription of genes required for transition into S phase.  
Further regulation is applied to progression through the cell cycle by the presence of CDK inhibitors, 
such as p21CIP1/WAF1 and p16ink4, which function to inhibit progression through G1.  The dysregulation of 
the cyclins, CDKs and CDK inhibitors is common in cancer and results in uncontrolled progression 
through the cell cycle and increased proliferation (Tsihlias et al, 1999).   
Immunocytochemistry (ICC) of 3D cultures of mammary epithelial cells showed that the 
expression of CDK inhibitor, p27kip1 gradually increased throughout morphogenesis, implying that during 
acinar morphogenesis, proliferation is initially high, but with time cell cycle progression is inhibited, 
which results in decreased cellular proliferation and, hence, growth-arrest.  Simultaneously, Ki-67 (a 
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marker of proliferation) was expressed at high levels during acini formation, but following growth-arrest, 
its expression declined (Coppock et al, 2007).  In a different study it was reported that AKT was only 
present in the basement membrane-attached outer cells of acini (Debnath et al, 2002; Debnath et al, 
2003b).  Given the activation of this kinase is still maintained following a cessation of proliferation, this 
implies that during the later stages of acinar morphogenesis, AKT functions as a pro-survival mechanism, 
rather than an anti-apoptotic one (Hutchinson et al, 2001).   Previous work has also demonstrated that 
in 3D cultures, mammary epithelial cells proliferate excessively when cyclin D1 is over expressed, or Rb 
is inactivated and that increased proliferation is involved in loss of growth arrest and luminal filling 
(Muthuswamy et al, 2001; Debnath et al, 2003b).  Finally, it has also been shown that excessive 
proliferation, in itself, is not sufficient to induce luminal filling and that aberrations in other processes, 
such as apoptosis are required (Debnath et al, 2002). 
3.5 Polarity 
Cellular polarity is defined by the asymmetrical distribution of proteins in cellular domains.  The control 
of proliferation, survival, migration, asymmetric stem cell division and, ultimately, correct functioning of 
epithelial tissues is dependent on the establishment of baso-apical polarity, and abnormal cell polarity is 
the hallmark of many cancers.   
In the acini of the breast, as the hollow lumen forms, apical polarity is established, as seen by 
the apical formation of tight junctions markers, such as proteinase-activated receptor-3 (PAR3) and 
PALS1 (Plachot et al, 2009).  Hemidesmosome formation of α6β4 integrins at the basal surface 
(Koukoulis et al, 1991) and apical localization of Zonula Occludens-1 (ZO-1) (Fogg et al, 2005) is also 
established during acini formation.  Disruption of acinar apical polarity, such as the redistribution of 
tight junctions, can force cells into the cell cycle (Chandramouly et al, 2007) and, therefore, may have 
implications upon acini formation and correct mammary gland function (Itoh & Bissell, 2003). 
It would appear that the correct establishment and maintenance of polarity is essential for acini 
development and, thus, it is important to know the signalling pathways involved in establishing polarity.  
Src kinases are activated early in the AKT signalling cascade and these phosphorylate PAR-3 resulting in 
delayed tight junction formation (Wang et al, 2006).  Polarity proteins can also influence signalling 
pathways.  In Drosophila, PAR-3 recruits PTEN to developing junctions and promotes the formation of 
PIP2 from PIP3 (Pinal et al, 2006), which reduces Akt signalling. 
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3.6 Considerations for 3D Culture 
Matrigel is extracted from the Engelbreth-Holm-Swarm (EHS) mouse tumour and is essentially basement 
membrane in a solubilised form, with a composition of laminin, collagen and entactin (Kleinman et al, 
1986).  Although variation exists from batch to batch, the approximate composition consists of 60% 
laminin, 30% collagen IV and 8% entactin, with the remainder consisting of heparin sulphate 
proteoglycans, growth factors and matrix metalloproteinases (BD Biosciences, 2011).  It is the presence 
of these structural proteins that allow cells cultured in 3D matrices to form interactions with proteins 
which they would encounter in vivo, but are, otherwise, not present in traditional monolayer cultures 
(Streuli et al, 1995; Hughes et al, 2010).  These interactions then result in the activation of various 
signalling cascades and can regulate the transcription of various genes, in addition to providing 
structural support for 3D structures (Streuli et al, 1995; reviewed in El-Hamamsy & Yacoub, 2009). 
The use of 3D culture systems presents many considerations and requires optimisation of 
conditions for varying cell lines.  Firstly, the cells themselves can behave differently within Matrigel, 
depending on the number of times they have undergone trypsinisation and re-seeding after resurrection 
(passage number), morphology in monolayer culture prior to seeding onto Matrigel and seeding density.  
After resurrection from stocks stored in liquid nitrogen, mammary epithelial cells, such as MCF-10A and 
MCF-12A, require approximately 2 passages to fully recover and to adapt to the culturing conditions.  If 
cells have only undergone a single passage following resurrection, acini are usually smaller in size and 
lumen formation does not occur (Benton et al, 2009).  Similarly, MCF-10A and MCF-12A cells that are 
over-confluent or under stress have a spindle-like morphology in monolayer culture, and will not 
produce acini in 3D culture (Debnath et al, 2003).  Finally, regarding the seeding density, optimisation of 
the correct seeding density is essential for good acini formation.  If the number is too low, acini do not 
form or those formed are small in size and slow in growth.  On the other hand, if too many cells are 
seeded, as acini grow, they overlap with each other, and this affects proper acini formation and acini 
visualisation at the end of the experiment. 
The source, composition, and thickness of Matrigel, as well as whether it is combined with other 
3D matrices, also impacts upon successful 3D culture (Swamydas et al, 2010).  The presence of growth 
factors, such as fibroblast growth factor, transforming growth factor-β (TGFβ), EGF or insulin-like growth 
factor can impact upon epithelial growth in Matrigel (Vukicevic et al, 1992) and, therefore, growth 
factor-reduced versions are typically used for 3D studies.  Despite the manufacturer’s quality control 
measures, Matrigel composition varies from batch to batch and this lot variation can severely affect 
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acini morphogenesis.  It is, therefore, necessary to test different Matrigel lots to determine the best one 
for further experiments.  The most appropriate Matrigel batch will produce spherical acini of similar 
sizes that arrest in growth and produce hollow lumen.  Another consideration when working with 
Matrigel, is that it rapidly polymerizes at temperatures above 4oC.  For this reason, it must be handled 
and stored appropriately to avoid untimely polymerization, which may affect acini formation or hinder 
subsequent analysis by immunocytochemistry and microscopic visualisation. 
The way in which cells are seeded when using Matrigel also impacts upon acini formation.  In 
initial published studies using the 3D Matrigel matrix, cells were completely embedded in the Matrigel.  
However, a more recent method involving an overlay procedure (termed the “overlay method”) has 
been developed, whereby cells are seeded onto a layer of polymerised Matrigel and grown in media 
supplemented with 2% Matrigel (Debnath et al, 2003).  The latter method, not only has the benefit of 
using significantly less Matrigel, and, hence, being far more economical, but the resultant acini are larger 
in size.  This is advantageous as the lumen of these acini are easily identified. 
3.7 Materials and Methods 
All reagents were purchased from Sigma-Aldrich (Dorset, UK), unless otherwise stated. 
3.7.1 Cell Lines and Routine Culture 
MCF-12A cells were cultured as described in Chapter II, in the Materials and Methods section. 
3.7.2 3D Cultures of Immortalised Mammary Epithelial Cells: The Overlay Method 
45 µl growth factor reduced Matrigel® (BD Biosciences, Bedford, MA USA) was spread evenly over the 
surface of each well of an eight-well chamber slide (Lab-Tek® Chamberslide™ System Nalge Nunc 
International, Naperville, IL, USA) and incubated at 37oC for a minimum of 15 minutes, to allow the 
Matrigel to set.  Confluent cells were trypsinized as per routine culture, resuspended in a total of 7 ml 
re-suspension medium and centrifuged for 5 minutes at 150 g.  The re-suspension media was aspirated 
and cells were re-suspended in 2 ml assay media, before pipetting several times through a 1000 µl 
Gilson pipette (P1000) to obtain a single-cell suspension.  Additional assay media was added so that the 
final volume of cell suspension was approximately 8 ml.  Cells were counted and diluted in assay media 
(Table 3.1) in order to obtain a final concentration of 20,000 cells per ml.  The cell suspension was added 
in a 1:1 ratio to assay media containing 4% Matrigel and 10 ng/ml EGF.  400 µl of this cell suspension 
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was plated per well, on top of the Matrigel in the chamber slides.  This ensured that 8000 cells were 
seeded into each well.  Media changes consisting of 400 µl assay media containing 2% Matrigel and 5 
ng/ml EGF were carried out every four days.  Cells were maintained at 37oC in 5% CO2.  The morphology 
of the acini was assessed throughout the incubation period by light microscopy.  Following completion 
of 20 days, (although this was later reduced to 16 days), incubation in 3D culture, immunocytochemistry 
was performed and acini were imaged using the Zeiss LSM 510 META confocal microscope (Carl Zeiss 
Ltd, Hertfordshire, UK). 
 
Table 3.1: Assay media composition for MCF-12A cells (Debnath et al, 2003) 
Component Assay Medium 
DMEM/F12 (Invitrogen, Paisley, UK) 500 ml 
Horse Serum (Invitrogen, Paisley, UK) 
 
2% 
Epidermal Growth Factor  
 
- 
Cholera Toxin 
 
100 ng/ml 
Insulin 10 µg/ml 
Hydrocortisone 
 
0.5 µg/ml 
Pen/Strep 5000 µg/ml 
L-Glutamine (MCF-10A media only) 109.5 mg/2.8 ml 
 
3.7.3 Immunocytochemistry  
At the end of the incubation period, the media was aspirated from individual wells and cells were fixed 
with freshly prepared 2% paraformaldehyde (PFA) in phosphate buffered saline (PBS), pH 7.4 for 20 
minutes, at room temperature.  Cells were permeabilised to allow antibody entry across the plasma 
membrane, using 0.5% Triton-X, (to avoid disruption of the tertiary structure of proteins), in PBS for 10 
minutes, at 4oC.  Samples were then washed three times with 100 mM glycine solution (130 mM NaCl, 7 
mM Na2HPO4, 3.5 mM NAH2PO4, 100 mM glycine in PBS) for 10 minutes at room temperature, with 
gentle rocking, to quench the cross-linking induced by the fixation procedure.  Samples were incubated 
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with the primary blocking solution (130 mM NaCl, 7.7 mM NaN3, 0.1% BSA, 0.2% Triton X-100, 0.05% 
Tween-20, 10% goat serum) for 1 hour at room temperature, to prevent unspecific primary antibody 
binding.  The primary block solution was aspirated and the secondary block (130 mM NaCl, 7.7 mM 
NaN3, 0.1% BSA, 0.2% Triton X-100, 0.05% Tween-20, 10% goat serum, 20 µg/ml goat anti-mouse F(ab’)2 
fragment (Jackson Immuno Research, Suffolk, UK) was applied for 40 minutes at room temperature, 
prior to 18 h primary antibody incubation at 4oC, to prevent unspecific antibody binding through the Fc 
receptor and reduce background staining as a result.  Primary antibodies and concentrations are listed in 
Table 3.2 (antibodies were diluted in secondary block solution).  Antibodies were centrifuged at 5000 
rpm for 5 minutes, to prevent aggregate formation prior to dilutions being prepared in the secondary 
block solution.   
 
Table 3.2: Primary antibodies used for immunocytochemistry to investigate apoptosis and polarity in 3D culture 
of mammary epithelial cells 
Primary Antibody Species Source Purpose Dilution 
Cleaved caspases-3 Rabbit Cell Signalling, 
Hertfordshire,UK 
Apoptotic marker 1:200 
Laminin Mouse Abcam, 
Cambridge, UK 
Basement 
membrane 
1:200 
 
Samples were washed three times with immunofluorescence buffer (IF) (130 mM NaCL, 7 mM Na2HPO4, 
3.5 nM NaH2PO4, 7.7 NaN3, 0.1% BSA, 0.2% Triton X-1000, 0.05% Tween-20) at room temperature, with 
gentle rocking for 20 minutes.  Secondary antibodies (Table 3.3) were prepared in IF buffer with 10% 
goat serum and applied to samples for 50 minutes, at room temperature.  As with primary antibodies, 
secondary antibodies were centrifuged at 5000 rpm for 5 minutes, prior to dilutions preparation with IF 
buffer + 10% goat serum. 
 
 
 
 
 
 
124 
 
Table 3.3: Secondary antibodies used for immunocytochemistry to investigate apoptosis and polarity of 
mammary epithelial cells 
Secondary Antibody Species Source Dilution 
Alexa Fluor® 488 anti-rabbit IgG Goat Molecular Probes 
(Invitrogen, Paisley, UK) 
1:200 
Alexa Fluor® 555 anti-mouse IgG Goat Molecular Probes 
(Invitrogen, Paisley, UK) 
1:200 
 
After this, samples were washed three times with IF buffer at room temperature with gentle rocking for 
20 minutes and then counterstained with 5 µM TOPRO-3 (Molecular Probes, Invitrogen, Paisley, UK) in 
PBS for 15 minutes at room temperature.  Samples were rinsed with PBS for 5 minutes with gentle 
rocking and mounted with Prolong Antifade Reagent (Molecular Probes, Invitrogen, Paisley, UK).  
Samples were left to dry at room temperature overnight and image acquisition was conducted using the 
Carl Zeiss MicroImaging, Inc. LSM510 confocal microscopy system with LSM version 4.20 (Carl Zeiss Ltd, 
Hertfordshire, UK).  All images are representative of three independent experiments performed in 
duplicate. 
3.8 Results 
3.8.1 Acini Morphogenesis: Optimisation of the Overlay Method for 3D Cultures of 
MCF-12A Cells Matrigel Composition Impacts on Acini Formation 
Debnath et al (2003), describe in their protocol that better 3D of cultures MCF-10A were obtained from 
Matrigel lots where protein concentrations ranged between 10 and 12 mg/ml and where endotoxins 
levels did not exceed 2 EU/ml.  Because of this, various batches of Matrigel with varying protein 
concentrations and endotoxin levels were tested.  It was observed that these characteristics of Matrigel 
did, in fact, dramatically influence acini morphogenesis and morphology. 
Based on the literature, normal acini grown using the methodology described here and by 
Debnath et al, (2003), are spheroid and comprised of a single layer of cells, observed by staining with a 
nuclear counterstain (blue) surrounding a hollow, or hollowing lumen with the presence of apoptotic 
cells (green).  This structure is surrounded by a basement membrane (red) as shown in Figure 3.7. 
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Figure 3.7: Confocal image of acini from 3D cultures of MCF-10A cells.  Cells are shown in blue through the use of 
a nuclear counterstain.  Green staining shows activated caspase-3 as a marker for apoptosis and red staining shows 
laminin V as a marker for the basement membrane.  (Image from Debnath et al, 2003.) 
 
After 20 days in 3D culture, cells cultured in Matrigel batches that contained a protein concentration 
below 10 mg/ml and endotoxin level of 2.0 EU/ml, or above, formed acini of varying sizes.  The resultant 
acini were also not hollow and some cells in contact with the basement membrane were apoptotic, as 
indicated by the presence of activated caspase-3.  Laminin was also observed to be connecting adjacent 
acini (Figure 3.8).  The extent of luminal filling decreased as protein concentration increased, and at 10.4 
mg/ml protein, acini were almost hollow with continuing signs of apoptosis.  The laminin connections 
between acini were not observed in higher protein concentrations and, thus, the image quality in terms 
of background staining greatly improved upon seeding in higher protein concentrations.  Finally, cells 
cultured onto Matrigel where the protein composition was 10.3 mg/ml and the endotoxin level was less 
than 1.5 EU/ml formed spherical acini exhibiting hollow lumen after 20 days in culture.   
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Figure 3.8: Acini grown in Matrigel with different protein and endotoxin concentrations.  Acini were 
immunostained with antibodies against laminin V (red) and activated caspase-3 (green) to identify basement 
membrane and apoptotic cells, respectively.  Cells were counterstained with TOPRO-3 (blue) as a nuclear stain. 
 
In terms of seeding density, 20,000 cells per ml was sufficient to produce an adequate number of acini 
and seeding densities greater than 25,000 cells per ml resulted in overlapping and interconnecting 
structures that impeded analysis of LCM images.  Also, it was observed that using 45 µl as opposed to 
the 40 µl Matrigel suggested by Debnath (2003), made Matrigel spreading easier and produced a more 
even distribution of acini, less overlapping structures, and importantly, more acini that fit the 
characteristics described above (hollow lumen and intact basement membrane).  In initial experiments, 
monolayer growth of cells underneath the Matrigel proved to be an issue, as it obscured acini during 
analysis.  Modification of the amount of Matrigel used appeared to resolve this issue, as did ensuring 
that Matrigel was evenly spread across the whole surface of the chamber wells, with no bubbles. 
3.8.2 3D Culture: Time-Course 
To characterise the development of acini with ER, GPER-1 competent MCF-12A cells, a time-course was 
set up with 20,000 cells being seeded every four days, as described previously.  Following 4, 8, 12 and 16 
days in 3D culture, acini were fixed and immunocytochemistry was performed (Figure 3.9).  The aim of 
this was to establish the timing of key events during morphogenesis, such as the formation of the 
basement membrane, induction of apoptosis and growth arrest.  This provides the opportunity to study 
the impact of estrogens on these events, in future experiments.   
After 4 days in Matrigel, MCF-12A cells had formed small, spherical cellular clusters clearly 
surrounded by a basement membrane, as shown by the presence of laminin V around the spheroid 
structures.  At this point, there was little or no evidence of caspases-mediated apoptosis of the centrally 
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located cells and organisation of the cells was absent.  Between days 8 and 16, it became evident that 
acini consisted of two populations of cells: a single cell layer of cells attached to the basement 
membrane and a population of cells not in contact with the basement membrane.  This was inferred by 
the observation that only the cells lacking contact with the basement membrane showed evidence of 
caspase-mediated apoptosis. 
Between 8 and 12 days, the acini continued to grow in size and remained spherical.  The cells in 
contact with the basement membrane organised themselves into a uniform arrangement during this 
time and extensive apoptosis, as indicated by the presence of activated-caspase-3, was observed within 
the central cells of the acini.  At 16 days, complete or near complete, spherical acini with hollow lumen 
surrounded by a single layer of epithelial cells were observed with an approximate size of 120 ± 6.9 µm 
and the surviving outer layer of cells showed no signs of apoptosis.  In acini where the formation of the 
hollow lumen was not yet complete, signs of apoptosis were still present (Figure 3.9; 3.10). 
 
Figure 3.9: Time-course of MCF-12A acini over 16 days.  Acini were stained with antibodies against laminin V (red) 
and activated caspase-3 (green) to identify basement membrane and apoptotic cells respectively.  Cells were 
counterstained with TOPRO-3 (blue) as a nuclear stain. 
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Figure 3.10: Schematic of MCF-12A morphogenesis in 3D culture.  Basement membrane deposition (red) occurs as 
early as 4 days.  Proliferation and increase of acinar size terminates between days 12 and 16 and apoptosis (green) 
of the central cells occurs from day 8.  Finally at day 16 a hollow lumen is observed, surrounded by a layer of 
organised epithelial cells attached to a basement membrane. 
3.9 Discussion 
The composition of Matrigel clearly has an effect on acini formation.  Based on our observations, the 
factors that significantly impact on the development of these structures are protein and endotoxin 
concentrations. 
Among the various proteins present in Matrigel, collagen, laminin and fibronectin are key 
constituents (Kleinman et al, 1986), although the levels of these and other constituents vary from batch 
to batch. 
During breast development or carcinogenesis, in humans and in vivo, there are changes in the 
levels of collagen, laminin and fibronectin, and this aids breast morphogenesis (Woodward et al, 2001; 
Bissell et al, 2005; Wolf et al, 2009).  Fibronectin stimulates cellular proliferation and increased levels of 
fibronectin result in increased proliferation and increased acinar size (Williams et al, 2008).  Laminin also 
promotes proliferation, as well as cell adhesion and its absence in 3D matrices results in acini lacking 
lumen and displaying aberrant polarity (Gudjonsson et al, 2002).  Collagen facilitates cell growth, 
differentiation and attachment and regulates matrix modelling (Karamichos et al, 2006; Karamichos et 
al, 2007) and its presence stabilises the basement membrane during embryonic development (Pöschl et 
al, 2004). Increased collagen, however, increases cellular proliferation resulting in larger acini 
(Provenzano et al, 2009). 
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Although the supplier provides information regarding the approximate total protein 
concentration of each Matrigel batch, the precise concentration of individual components is not 
provided.  Under our experimental conditions, acini grown in Matrigel with lower protein concentrations 
had normal shape and size, but displayed filled lumen.  It has previously been reported that the absence 
of laminin or high concentrations of collagen, produce acini that lack hollow lumen (Gudjonsson et al, 
2002).  However, the exact reason for this, and indeed, for our observations presented above remains 
unclear. 
Endotoxins are lipopolysaccharides present in the membranes of gram-negative bacteria.  
Structurally, they are comprised of a hydrophobic lipid group and a polysaccharide tail.  It is the lipid 
group that is responsible for anchoring the endotoxin to the membranes of bacteria and mediating the 
effects of endotoxins.  Endotoxins are present in water, serum, resins and culture additives and, can be 
released upon the destruction of gram-negative bacteria.  Therefore, endotoxin contamination of 
Matrigel can potentially occur as a result of the use of detergents, or during the Matrigel extraction 
process. 
Endotoxins have previously been shown to interact with cell membranes resulting in surface 
ruffling and cell membrane disruption (Csaba et al, 1984).  This membrane disruption, however, was not 
the only effect observed in Matrigel with higher endotoxin levels, suggesting that endotoxins may 
interact with other cellular processes.  Indeed, it has been shown that endotoxins can influence the 
production of various cytokines, such as tumour necrosis factor alpha (TNFα) in various cell types 
including those of the breast (Adams & Czuprynski, 1990; Bienhoff et al, 1992; Safieh-Garabedian et al, 
2004) and other cellular products such as cyclooxygenase-2 (COX-2), collagenases and prostaglandins 
(Barker & Holt, 1983; Morales et al, 1984; Cury et al 1988; Huang et al, 2008).  TNF is usually associated 
with induction of apoptosis, however, it has also been reported to promote the growth of both normal 
and breast cancer cells via MAPK and Akt signalling pathways (Rivas et al, 2008).  This mitogenic action 
and dysregulation of cell signalling pathways could account for the lack of hollowing observed in acini 
grown in Matrigel containing larger amounts of endotoxins.   
Additionally, endotoxins can have mitogenic effects in some mammalian cell lines and have 
consequences for cell differentiation (Brunette, 1984; Meghji et al, 1996; Dawson, 1998; Putnins et al, 
2002).  It could, therefore, mean that increased endotoxin levels in Matrigel contribute to increased 
proliferation, as characterized by luminal filling. 
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Overall, in our work, it became clear that the Matrigel composition greatly affects acini 
formation and for this reason it was ensured all subsequent experiments were conducted using Matrigel 
with a protein concentration of 10 mg/ml or above and an endotoxin level not exceeding 1.5 EU/ml. 
Following optimisation of the 3D overlay method described by Debnath (2003) and selection of 
the appropriate Matrigel batch and seeding density, a time-course to investigate the formation of acini 
from 3D cultures of MCF-12A cells was performed.  This was necessary to identify when key events 
(deposition of the basement membrane, proliferative arrest and formation of the hollow lumen) 
occurred, so that in future work, we could assess the effects of estrogens upon 3D cultures of MCF-12A 
cells.  During these initial experiments, it was observed that MCF-12A cells grown in 3D formed acini 
with a hollow, or near hollow, lumen after 16 days, and following this observation, subsequent 
experiments were performed for 16 days.  This is a similar timeframe to what was observed with 3D 
cultures of MCF-10A cells (Debnath et al, 2003).  This may infer that the morphogenic programme of 
non-transformed mammary epithelial cells cultured in Matrigel occurs in the same manner across cell 
lines, although this would have to be studied further. 
Whilst establishing the time-course for acini morphogenesis in MCF-12A cells, it became evident 
that there are two cell populations within acini: cells at the periphery of the spheroid structures, 
attached to an underlying basement membrane, and those that are centrally located.  The two 
populations have very different properties (e.g. polarity and attachment to the basement membrane) 
and fates; the outer peripheral cells are attached to a basement and organise themselves into a single 
layer of organised cells, whereas the centrally located cells are initially disorganised and then undergo 
apoptosis and are cleared as acini formation progresses.  Given that this luminal clearance coincides 
with the expression of activated caspase-3, it can be inferred that mitochondria-meditated apoptosis 
plays a role in the formation of the hollow lumen.  This observation is in agreement with the data 
reported by Debnath and co-workers in ER negative MCF-10A cells grown in 3D culture (Debnath et al, 
2002; Debnath et al, 2003). 
Basement membrane formation appears to be an early occurrence in acini development and 
was clearly visible after 4 days in 3D culture.  The observation that basement membrane deposition 
occurs so early during acini morphogenesis suggests that this process is fundamental for subsequent 
stages in acini formation, such as the establishment of apico-basal polarity, proliferation and luminal 
clearing. 
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We observed that MCF-12A acini underwent growth arrest, as inferred by the cessation of 
increased acinar size, indicating decreased proliferation, at approximately 12 days, as acini did not grow 
greatly in size between days 12 and 16 days in 3D culture.  Studies with the proliferative marker, Ki-67, 
have shown that during MCF-10A acinar morphogenesis proliferation increases between day 1 and 12 
and then decreases again (Coppock et al, 2008). 
By establishing a time-course, the morphogenic process of single MCF-12A cells to hollow acinar 
structures can be modelled and is comparable to that described for MCF-10A cells (Figure 3.10) 
(Debnath et al, 2003; Coppock et al, 2007).  This, in addition to optimising the conditions for 3D culture 
of MCF-12A cells, will enable to study the impact of estrogens upon key stages in the morphogenic 
programme: deposition of the basement membrane, proliferation, apoptosis and hollow lumen 
formation.  The model, therefore, provides us with an opportunity to model the effects of estrogenic 
compounds on mammary gland formation, using an in vitro methodology. 
To conclude, in this chapter we describe the work carried out to establish a 3D model, in which 
to study the morphogenesis of non-transformed ERα, ERβ, GPER-1-competent MCF-12A cell acini.  The 
structures formed under these conditions present features resembling those found in the human 
mammary gland, such as a layer of epithelial cells encapsulating a hollow lumen, surrounded by 
basement membrane.  Once this preliminary work was carried out we could proceed to study the impact 
of estrogens on the formation and maintenance of the epithelial acini in our 3D Matrigel model. 
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Chapter IV: 3D Culture: The Effects of Endogenous and Exogenous 
Estrogens on Acini Formation 
 
In Chapter III, we studied and characterised the morphogenesis of MCF-12A in 3D culture.  Defining the 
normal behaviour of these cells when grown in Matrigel in vitro provides a baseline, control reference to 
which treated acini can be compared against.  As discussed previously, estrogen exposure has been 
associated with breast cancer risk and although the molecular mechanisms involved have been 
extensively studied, little work has been carried out on the impact of estrogen on the architecture and 
formation of the mammary gland.  The Matrigel 3D model provides an opportunity to study this in an in 
vitro setting. 
4.1 Involvement of the ER and GPER-1 in Breast Carcinogenesis 
Both clinical and epidemiological data have demonstrated that there is a link between exposure to 
female ovarian hormones, such as E2, and breast cancer risk (bPike et al, 1993).  These effects, as well as 
the normal physiological function of estrogens, are mediated by ERα and ERβ, although more recently, 
estrogens have been demonstrated to also activate growth factor signalling pathways and associate with 
GPER-1 (Filardo et al, 2002).  These effects are also responsible for some down-stream effects of E2 
(Migliaccio et al, 1996; Filardo et al, 2002).  The exact mechanism through which estrogens contribute to 
breast epithelium formation, breast carcinogenesis and cancer progression remains unclear, although 
various theories have been developed.   
Firstly, estrogens promote cellular proliferation (Russo et al, 1999).  In Chapter II, however, 
increased proliferation was not observed in ER competent MCF-12A cells.  Nevertheless, increases in 
proliferation, provides an increased chance for mutations to occur which may result in a cancerous 
phenotype.  Furthermore, it remains to be seen whether estrogen treatment of 3D cultures of MCF-12A 
cells results in increased proliferation. 
An alternative hypothesis is that, independently from the ER, genotoxicity induced by estrogens 
and their metabolites may lead to tumourigenesis.  In this model, the presence of estrogens and their 
metabolites increases the rate at which mutations occur due to the production of electrophiles capable 
of forming DNA adducts (Ashburn et al, 1993).  This carcinogenic effect has been demonstrated in the ER 
negative mammary epithelial, MCF-10F cell line, whereby treatment with E2 induced DNA adduct 
formation and caused loss of heterozygosity (LOH), the loss of normal function of one gene allele where 
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the second allele was previously inactivated, in chromosome 11 (Russo et al, 2002; Lu et al, 2007).  In 
their corresponding experiments, Russo et al (2002; 2003) also assessed the ductulogenic potential of 
MCF-10F cells treated with E2.  In these experiments, it was shown that in MCF-10F cells cultured in 3D 
collagen matrices and treated with E2, increased proliferation was observed and cells lost their 
capability to form hollow ductules, resulting in the formation of large solid masses.  These data may 
implicate ERβ in mediating some of E2’s effects in terms of increased proliferation, but the authors 
attributed these effects to genotoxic events, rather than ER-mediated actions.  These observations 
further demonstrate the importance of studying estrogens in a more physiologically relevant context, 
although it remains to be seen whether E2 impacts upon MCF-12A cells cultured in Matrigel in a similar 
fashion. 
As described in Chapter III, 3D cultures of breast epithelial cells, such as MCF-10A and MCF-12A 
have been utilized for their ability to recapitulate some of the characteristics of breast epithelium in 
vivo.  These features include the formation of highly organised, polarised, growth-arrested structures 
with hollow lumen and basal deposition of the basement membrane.  This 3D model has also been used 
to study the transformation of cells to a malignant state, by allowing the detection of changes, such as 
the disruption of polarity, increased proliferation and luminal filling (Debnath et al, 2003).  The work 
presented in this chapter aims to further investigate the impact of estrogens on acini formation using ER 
competent MCF-12A cells, in an in vitro Matrigel model.  Our work differs from that conducted and 
described by Russo and colleagues (2002; 2003) in that MCF-12A cells express both ERα and ERβ, 
whereas MCF-10F cells only express ERβ at low levels.  Our methodology allows us to investigate 
whether the ER mediates the actions of estrogens on the 3D epithelial architecture of acini. 
In Chapter II, we confirmed the expression of the estrogen-responsive receptor, GPER-1 in the 
MCF-12A cell line, in addition to ERα and ERβ.  As described previously, the precise function of GPER-1 in 
the mammary gland is unknown, but it may be associated with tamoxifen resistance in the MCF-7 cell 
line (Ignatov et al, 2010).  To date, there is little published data regarding the role of GPER-1 in acini 
morphogenesis.  Therefore, in addition to investigating the role of the classical ER, we will also assess 
whether this receptor is also involved in mediating the impact of estrogens upon MCF-12A acini 
morphogenesis in 3D culture. 
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4.2 Xenoestrogens 
As mentioned in Chapter I, xenoestrogens, such as o,p’-DDT, β-hexachlorocyclohexane (β-HCH), BPA and 
n-propylparaben can exert estrogenic actions via interactions with the ER. 
BPA is able to bind to ERα, ERβ, mER and GPER-1 (Matthews et al, 2001; Watson et al, 2005; 
Thomas & Dong, 2006).  Although its affinity for the ER is 10,000-fold less than that of E2 (Kuiper et al, 
1998), studies have shown that it may be just as efficacious as E2, in respect to the detrimental effects 
of E2 in vivo, and may also be equally potent in terms of non-genomic calcium ion secondary messenger 
generation (reviewed in Vanderberg et al, 2007).   
In vitro, BPA is able to stimulate the proliferation of MCF-7 breast cancer cells, although not to 
the same extent as E2 (Krishnan et al, 1993; Miyakoshi et al, 2009).  Perinatal exposure to BPA in rats 
has been shown to affect breast development and increase the risk of developing breast cancer later in 
life.  These effects are observed as undifferentiated structures, delayed hollow formation, increased 
sensitivity to estrogen and increased incidence of preneoplastic lesions after birth (Muñoz-de-Toro et al, 
2005; Vandenberg et al, 20072; Moral et al, 2008).  BPA also may reduce the sensitivity of some tumours 
to chemotherapy treatment (LaPensee et al, 2010). 
As with E2, BPA is able to elicit genomic effects.  Gene microarray PCR analysis has revealed that 
BPA appears to impact upon genes involved in differentiation, proliferation, cell death and immune 
responses (Moral et al, 2008).  The consequence of this change in genomic profile was undifferentiated 
structures and delayed lumen formation in vivo.  At the molecular level, BPA has been documented to 
decrease DNA methylation (Dolinoy et al, 2007), which suppresses the expression of certain genes, and 
induce DNA adduct formation (De Flora et al, 2011).  Additionally, BPA has been linked to aneuploidy in 
breast cancer cells, an effect believed to be mediated by extranuclear signalling cascades (Kabil et al, 
2008).  BPA can also generate non-genomic actions, such as the activation of MAPK signalling in rat 
sertoli cells, and more importantly, in human breast cancer cell lines (Dong et al, 2011; Pupo et al, 
2012).  The consequence of these non-genomic effects may present itself as increased cellular 
proliferation or survival, and these may, in turn, result in the morphological effects on breast epithelium 
described above. 
Compared to E2, the affinity of BPA to the ER is very low and so it has been classed as a weak 
estrogen, along with many other xenoestrogens.  However, the low estrogen activity elicited by these 
compounds individually is something that should not be ignored, as low levels of individual 
xenoestrogens can have an additive effect with other xenoestrogens and endogenous estrogens (Silva et 
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al, 2002).  This leads to a stronger response to estrogenic compounds in combination, than observed 
individually. 
Although naturally occurring, propylparabens, are also synthetically manufactured and used in 
cosmetics as preservatives and in food products as additives.  Upon absorption into the body, parabens 
are metabolized and excreted rapidly.  They are weakly estrogenic and the presence of parabens has 
been found in breast cancer tumours at low concentrations and exhibit weak estrogenic activity (Darbre 
et al, 2004; Harvey & Everett, 2004).  These observations led to suggestions that parabens may be 
associated with breast cancer risk.  Although this correlation remains to be proven, treatment with 
parabens has been demonstrated to increase proliferation of MCF-7 cells in an ER-dependent fashion 
(Byford et al, 2002). 
o,p’-DDT and β-HCH, were used as pesticides worldwide until being banned by much of the 
developed world.  As they are highly lipophillic, resist degradation and have a very high half-life, they 
accumulate in the environment and the food chain, and are present in human samples many years after 
a ban in its use (Ahlborg et al, 1995; Rivas et al, 2001).  β-HCH has been detected in breast cancer 
samples at higher levels than in normal tissue samples, suggesting that there may be a correlation 
between β-HCH levels and breast cancer incidence (Mussalo-Rauhamaa et al, 1990; Ahlborg et al, 1995).  
β-HCH treatment of mammary epithelial cells causes changes in the gene expression of various 
oncogenes, including cyclin D1 and it enhances tumour development in vivo (Mussalo-Rauhamaa et al, 
1990; Wong & Matsumura, 2007).  Similarly, o,p’-DDT, is capable of inducing the transcription of the 
progesterone receptor, TFF1 and various E2-responsive genes (Soto et al, 1995; Dees et al, 1997).  
Additionally, both β-HCH and o,p’-DDT have been reported to stimulate the proliferation of ER 
competent mammary epithelial cell lines (Steinmetz et al, 1996) and to activate growth factor signalling 
cascades in human cancer cells (Silva et al, 2010). 
Given that the xenoestrogens described above exert similar actions to E2 and have long been 
hypothesised to contribute to breast cancer risk, we considered it important to study the impact of 
xenoestrogens on 3D cultures of MCF-12A cells with the aim of elucidating if and how these compounds 
affect acini morphogenesis. 
4.3 The Effect of Receptor Antagonists 
As mentioned previously, the endogenous hormone, E2 is involved in both normal physiological 
processes and disease, and this effect is primarily mediated by the ER.  Approximately two thirds of 
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breast cancers are dependent on E2 at some point during cancer progression (Musgrove & Sutherland, 
2009) and thus antagonists that target the ER, such as the SERM, tamoxifen and pure antagonist, 
fulvestrant (ICI 182,780), have been used in the treatment of the disease (Katzenellenbogen et al, 2000; 
Jordan, 2009).  ICI 182,780 is an analogue of E2 and its structure differs from that of other ER 
antagonists, such as tamoxifen and raloxifene, in that it possesses a steroidal-like structure (Figure 4.1).   
ICI 182,780 acts as a competitive inhibitor of the ER and has a binding activity of 89% of E2, compared to 
2.5% of tamoxifen (Wakeling & Bowler, 1988; Wakeling et al, 1991).  ICI 182,780 acts by binding to the 
ER and thus impairing ER dimerisation and translocation to the nucleus.  Moreover, it also promotes ER 
protein degradation (Fawell et al, 1990; Nicholson et al, 1995; Salazar et al, 2011).  Consequently, ICI 
182,780 not only inhibits the activity of the ER but also down-regulates ER at the protein level. 
 G-15, as discussed in Chapter II, is a GPER-1 antagonist, that selectively binds to GPER-1 and 
exhibits little affinity towards ERα and ERβ.  G-15 binds to GPER-1 with an affinity of approximately 20 
nM, whereas, the affinity of E2 for this receptor is between 3-6 nM, thus E2 displays a higher affinity for 
GPER-1 (Thomas et al, 2005; Dennis et al, 2009). 
 
 
 
Figure 4.1: The chemical structures of E2, ICI 182,780, tamoxifen and G-15.  ICI 182,780 is structurally more 
similar to E2 that selective estrogen receptor modulators (SERM's), such as tamoxifen (Adapted from Osborne et 
al, 2004 and www.sigmaaldrich.com). 
The co-incubation of estrogens with the ER antagonist ICI 182,780 or the GPER-1 antagonist, G-15, or 
indeed a combination of the two, will help to evaluate whether the malformations induced by estrogens 
are mediated by the ER, GPER-1 or both.  Additionally, the 3D cultures of MCF-10A cells in the presence 
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of the estrogenic test compounds will provide us with an example of an ER negative non-tumourigenic 
cell line. 
In this chapter, we study the impact of estrogens upon the morphogenesis of ERα, ERβ, GPER-1 
competent MCF-12A acini in a 3D model.  The use of this model offers an opportunity to study the 
involvement of these receptors in breast morphogenesis, as well as the impact of ER agonists, such as 
estrogens and estrogen-like chemicals, on mammary gland formation, disruption and, potentially, 
carcinogenesis. 
In order to achieve this, MCF-12A acini were first treated with a range of E2 concentrations to 
ensure that any observed effects in response to E2 were due to the presence of estrogens.  We then 
progressed to investigate the role impact of E2 and xenoestrogens upon acini morphogenesis and the 
role of the ER and GPER-1 through co-incubation studies with ICI 182,780 and G-15.  Finally, the ER 
negative, but GPER-1 competent MCF-10A cell line was cultured in 3D in the presence of E2 and select 
xenoestrogens to further investigate and confirm the role of the ER in mediating the effects of E2 in our 
3D model. 
4.4 Materials and Methods 
4.4.1 Dose Responses Studies with E2 
Varying concentrations of the natural hormone, E2, were tested on MCF-12A acini grown in Matrigel for 
16 days.  Cells were seeded onto Matrigel as described previously and samples were treated with 
increasing concentrations (1 pM, 10 pM, 100 pM 1 nM and 10 nM) of E2.  Media changes were carried 
out as described before and after 16 days, acini were fixed and immunocytochemistry performed.  
Controls consisted of 0.5% ethanol.  All estrogen concentrations were prepared using absolute ethanol 
and final ethanol concentration did not exceed 0.5% as this concentration was shown in previous work 
to not cause observable cytotoxicity (data not shown).  Experiments were performed in duplicate twice. 
4.4.2 Effect of Estrogenic Compounds on Acini Formation 
MCF-10A and MCF-12A cells were seeded onto Matrigel, as described previously, and samples were 
treated with 0.5% etOH (solvent control), 1 nM E2, 10 µM BPA (>99% Sigma-Aldrich, Dorset, UK), 10 µM 
n-propylparaben (>99%, Sigma-Aldrich, Dorset, UK), 10 µM β-HCH (>99% Sigma-Aldrich, Dorset, UK) or 
10 µM o,p’-DDT (>99% Sigma-Aldrich, Dorset, UK).  The only exception was in the case of the assay 
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media for MCF-10A cells, which contained L-glutamine (Chapter II, Table 2.1).  Media changes, 
consisting of 400 µl assay media with 2% Matrigel, 5 ng/ml EGF with the above treatments, were carried 
out every four days.  Cells were maintained at 37oC in 5% CO2.  Experiments were performed in 
duplicate three times and were double-blinded. 
4.4.3 Effects of E2 and Estrogen-Like Compounds on Acini Formation: Time-Course 
Analysis 
Time-course experiments were performed for E2, BPA and n-propylparaben-treated acini at 4, 8, 12 and 
16 days, as described previously.  Experiments were performed in duplicate three independent times 
and were double-blinded.  Acini size was measured using the LSM 5 Image Browser (Zeiss) and mean 
and standard error calculated from 6 randomly selected acini for each treatment. 
4.4.4 The Effect of Receptor Antagonists 
Cells were seeded as before with or without a 1h pre-incubation with 1 µM ICI 182,780 (a kind gift from 
Dr. Ian White at the MRC Molecular Endocrinology Group, Leicester, UK), 10 nM G-15 (Sigma-Aldrich, 
Dorset, UK) or a combination of ICI 182,780 and G-15 for 12 and 16 days.  Cells were treated as 
described before, with 1 nM E2, 10 µM BPA or 10 µM n-propylparaben, following pre-incubation with 
the receptor antagonists.  Solvent controls consisted of 0.5% ethanol with 0.2% DMSO.  Experiments 
were performed in duplicate, three independent times. 
4.4.5 Acici Quantification and Statistical Analysis 
Acini formation and disruption by the test compounds were quantified by analysing confocal images of 
acini and measuring the size, in addition to enumeration of the total number of cells and number of 
apoptotic cells within representative acini.  Additionally, the percentage of apoptotic cells were 
calculated as the number of activated (cleaved) caspase-3 positive cells (shown in green) over the total 
number of cells in each acini.  A minimum of 10 randomly selected acini were analysed for each 
independent experiment for each treatment. 
For experiments involving co-incubation with ICI 182,780 or G-15, the ratio of cell number to acini size 
was also calculated to allow for the differentiation between reduction in cell number due to lumen 
formation (i.e. increased apoptosis) or decreased acini size (i.e. proliferative arrest).  If the presence of 
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either inhibitor leads to a reduction in cell number as a consequence of lumen formation, then the ratio 
of cell number to acini size would decrease.  If, however, the number of cells decreased solely due to 
smaller acini size, then this ratio would be unaffected. 
Data analysis was performed using the Prism Software (GraphPad Software, version 5.04, La Jolla, CA, 
USA).  ANOVA followed by Dunnett’s post-hoc test was applied in order to compare treatments against 
controls, whilst ANOVA and Bonferroni’s post-hoc test was used to compare paired samples (treatment 
with inhibitors). 
4.5 Results 
4.5.1 Effects of E2 on Acini Formation in MCF-12A Cells: Dose Response 
MCF-12A acini under control conditions produced spherical acini that underwent growth arrest at 16 
days.  These acini consisted of a single layer of cells attached to a basement membrane, surrounding a 
near-hollow central lumen and were on average 121 µm in diameter.  Upon treatment with E2, 
however, acini became progressively larger, misshapen and disorganised (the outer cells of acini did not 
form a uniform single layer), and presented filled lumen in a concentration-dependent manner (Figure 
4.2). 
Even at concentrations as low as 1 pM, the effects of E2 on acini formation were observed and 
as the concentration of the hormone was increased, these effects become more pronounced.  At 1 pM 
E2, MCF-12 acini were generally similar to controls, both in morphology and size (average diameter 128 
µm ± 7.9), but some structures displayed less luminal clearing.  At 10 pm E2, however, acini were slightly 
larger than those formed under control conditions, measuring on average 136 µm ± 6.7.  Here, the acini 
possessed completely filled lumens with little or no sign of apoptosis, as indicated by the reduction in 
activated caspase-3 expression (shown throughout in green).   
As the E2 concentration was increased to 1 nM and 10 nM, MCF-12A acini become considerably 
larger, being 182 ± 12.6µm and 217 ± 15.6 µm in diameter on average, respectively.  At these higher 
concentrations, the acini were clearly misshapen and disorganised with completely filled lumen.  The 
increased acinar size and irregular shape are both indicators of uncontrolled proliferation (Debnath et al, 
2002).   
As the concentration of E2 increased, however, the abundance of malformed acini increased.  
For example: at E2 concentrations of 1 nM, over 70% of acini were misshapen and at 10 nM, acini were 
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no longer spherical and are greatly increased in diameter (Figure 4.2).  This data suggests that estrogens 
induce acini malformations and do so in a dose-dependent manner.  It should be noted at this point, 
that E2 treatment resulted in acini of varying size and shape and the images presented are 
representative of the majority of acini presented in each sample.   
 
 
Figure 4.2: Dose response analysis of MCF-12A cells in 3D culture with increasing E2 concentration after 16 days 
incubation.  Cells were either treated with solvent (0.5% ethanol) as a negative control, or increasing 
concentrations of E2 ranging from 1 pM to 10 nM.  Acini were stained with antibodies against laminin V (red) and 
activated caspase-3 (green) to identify basement membrane and apoptotic cells, respectively.  Cells were 
counterstained with TOPRO-3 (blue) as a nuclear stain.  As E2 concentration increases the extent of acini disruption 
also increases in respect to luminal filling and acini size and shape.  Experiments are representative of duplicate 
experiments performed twice. 
4.5.2 Impact of E2 and Other Estrogenic Chemicals on MCF-12A Acini Formation 
After 16 days incubation, acini treated with the test compounds were larger in diameter, exhibited filled 
lumen and were of an irregular shape.  Basement membrane deposition was observed in all treatments, 
as this did not seem to be disrupted, even in the most affected structures.  The malformations induced 
by n-propylparaben were similar to those seen with 1 nM E2 in respect to shape, luminal filling and size.  
Treatment with BPA, however, resulted in acini that were more spherical than E2 or n-propylparaben-
treated samples.  Treatment with o,p’-DDT or β-HCH resulted in acini that were malformed in a similar 
fashion to acini treated with n-propylparaben.  (Figure 4.3).   
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Figure 4.3: MCF-12A cells grown in 3D culture for 16 days incubation with estrogenic compounds.  Cells were 
treated with solvent (0.5% ethanol) as a negative control, 1 nM E2, 10 µM BPA, 10 µM n-propylparaben 10 µM 
o,p’-DDT, or 10 µM β-HCH and acini stained with antibodies against laminin V (red) and activated caspase-3 (green) 
to identify basement membrane and apoptotic cells, respectively.  Cells were counterstained with TOPRO-3 (blue) 
as a nuclear stain.  Experiments are representative of duplicate experiments performed three times. 
4.5.3 Effects of E2 and Estrogen-Like Compounds on Acini Formation – Time-
Course Analysis 
A time-course was conducted for MCF-12A cells grown in 3D culture treated with the test compounds: 
E2, BPA and n-propylparaben.  This would allow comparison between controls and treated acini to be 
investigated in terms of key events and stages in MCF-12A acini morphogenesis, such as the formation 
of the basement membrane, apoptotic onset, growth arrest and luminal clearance (Figure 4.4). 
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Figure 4.4: Schematic of MCF-12A morphogenesis in 3D culture.  Basement membrane deposition (red) occurs as 
early as 4 days.  Proliferation and increase of acinar size terminates between days 12 and 16 and apoptosis (green) 
of the central cells occurs from day 8.  Finally at day 16 a hollow lumen is observed, surrounded by a layer of 
organised epithelial cells attached to a basement membrane. 
 
Additionally, it was of interest to see if all test compounds exerted their actions on MCF-12A acini at the 
same time points, in the same manner and to the same extent.  The apoptotic marker, activated 
(cleaved) caspase-3 was used to investigate the impact of the test estrogenic compounds upon 
apoptotic onset, which was evident from day 8 in control 3D cultures, as demonstrated in Chapter III.  
Antibodies against laminin V were used to investigate whether estrogens affected basement membrane 
deposition, which under control conditions in Chapter III, was observed as early as day 4 in 3D culture. 
 E2, BPA and n-propylparaben were carried forward to perform a 16 day time-course and o,p’ 
DDT and β-HCH were omitted.  Although it would have been ideal to investigate all five test compounds 
from the initial 16 day incubation experiments, time and financial constraints limited the amount of 
estrogenic compounds that could be tested.  E2 was selected, as it is the most relevant endogenous 
estrogen and is known to be implicated in hormonal carcinogenesis of the breast.  In terms of 
xenoestrogens, BPA and n-propylparaben were selected, because, as mentioned in the introduction, 
they are currently of great public, scientific and regulatory interest, whereas o,p’ DDT and β-HCH have 
been already banned from use in agriculture, making them less interesting and relevant chemicals to 
study. 
As with E2, BPA and n-propylparaben treatments resulted in large, deformed, non-spherical 
acini with filled lumens after 16 days in 3D culture (Figure 4.5).  The increase in acini size compared to 
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controls was evident as early as 4 days incubation, with etOH controls measuring 61 ± 4.2 µm in 
diameter on average, as opposed to 72 ± 5.2 µm in the case of estrogen-treated acini, meaning that 
treated acini were approximately 18% larger than controls.  At the 4-day time point, the various 
estrogenic treatments induced similar responses in respect to increased acinar size.  After 8 days 
incubation, etOH controls measured 99 ± 6.2 µm in diameter on average and, as before, estrogenic 
treatment resulted in larger acini, although there was no great variation between the treatments.  On 
average, following 8 days incubation with E2, BPA or n-propylparaben, acini were 111 ± 7.2, 128 ± 8.9 
and 109 ± 10.2 µM in diameter, respectively.  This made E2 and n-propylparaben treated acini 
approximately 12% larger than controls, and BPA-treated acini almost 30% larger on average than 
controls.  At this time point, it should also be noted that there was variability in the size of acini treated 
with BPA, with some acini reaching 141 µM in diameter.  Estrogen-treated acini continued to increase in 
diameter, unlike untreated acini which underwent growth arrest after approximately 12 days.  At this 
time point, solvent controls were, on average, 110 µM in diameter and estrogen-treated acini were on 
average 17% larger than controls.  For the treated acini, size was variable with E2, BPA and n-
propylparaben treated acini measuring 129 ± 8.8, 134 ± 9.4 and 130 ± 12.4 µm in diameter on average, 
respectively.  At 16 days, solvent control acini were on average 112 µm ± 6.9 in diameter whereas 1 nM 
E2, BPA and n-propylparaben-treated acini were 159 ± 14.9, 186 ± 12.2 and 244 ± 14.6 µm in diameter 
respectively (45%, 69% and 121% larger than controls respectively).   
As well as luminal filling, decreased apoptosis was also observed with all treatments, most 
notably through days 12-16.  This was inferred through the reduction in activated caspase-3 detection 
following estrogen treatment, in comparison to solvent controls.  The reduction in apoptosis was more 
pronounced upon treatment with BPA or n-propylparaben, which displayed fewer apoptotic cells, 
despite containing a greater number cells where the lumen would form, throughout the entirety of 
incubation in 3D culture.  None of the treated acini showed any signs of cellular organisation, in respect 
to the uniform arrangement of the cells in contact with the basement membrane, which was observed 
in the solvent controls. 
Basement membrane formation, as shown by the deposition of laminin, appeared to be 
unaffected by treatment with E2, BPA or n-propylparaben.  Of all the treatments, the most deformed 
acini resulted from n-propylparaben and BPA treatments following 16 days incubation in Matrigel.  
These acini showed increased indications of disruption in comparison to solvent controls and 1 nM E2-
treated acini.  Most notably, acini treated with BPA or n-propylparaben showed no organisation of the 
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outer layer of cells in contact with the basement membrane and there appeared to be more cells 
present in the luminal space.  They were also, on average, larger in diameter than both their etOH and 
E2-treated counterparts (Figure 4.5). 
 
Figure 4.5: Confocal images for time-course of MCF-12A estrogen-treated acini in 3D culture.  Samples were 
incubated with solvent (0.5% ethanol) as a control, 1 nM E2, 10 µM BPA or 10 µM n-propylparaben for 4, 8, 12 and 
16 days.  Acini were stained with antibodies against laminin V (red) to identify the basement membrane.  Anti-
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bodies against activated caspase-3 (green) were used a marker of apoptosis.  Cells were counterstained with 
TOPRO-3 (blue) as a nuclear stain.  Images are representative of duplicate experiments performed three 
independent times. 
 
An interesting observation made with the samples treated with E2, was that in some acini, cells 
appeared to be moving out of the acini structure, through the basement membrane (Figure 4.6).  This 
seems to indicate that the cells acquired some invasive potential, being able to disrupt the basement 
membrane and migrate into the environment outside the acini.  The development of invasive 
characteristics is an indication of neoplastic transformation (Hanahan & Weinberg, 2000), and the 
implications of this will be discussed further in the discussion section. 
 
     
Figure 4.6: Confocal image of 1 nM E2-treated MCF-12A acini after 12 and 16 days in 3D culture.  Acini stained 
with antibodies against laminin V (red) and activated caspase-3 (green) to identify basement membrane and 
apoptotic cells respectively.  Nuclear staining was achieved by counterstaining with TOPRO-3 (blue).  The arrows 
indicate cells migrating through the basement membrane and invading the extra-acinar environment. 
 
Finally, in addition to the observations described before, it was also observed that a small proportion of 
treated MCF-12A cells grown in Matrigel formed multi-acinar structures.  This was more evident in 
samples treated with n-propylparaben (Figure 4.7).  These multi-acinar structures were comprised of a 
larger, filled acini with smaller filled acini “budding off” from the central mass.  These have also been 
observed in 3D cultures of MCF-10AT cells, a breast cell line that has been transformed by induced 
expression of oncogenic Ha-Ras (Imbalzano et al, 2009).  The entire structure was surrounded by 
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basement membrane, although there were indications of laminin expression within the structure itself.  
This may, however, be due to the acini being comprised of a 3D structure and so some of the buds from 
the main structure may be in a different plane, resulting in the surface of this bud being imaged inside 
the main structure. 
 
 
Figure 4.7: Confocal image of n-propylparaben MCF-12A acini after 16 days in incubation.  Laminin V, an indicator 
for basement membrane deposition, is shown in red.  Activated caspase-3, a marker for apoptosis is shown in 
green, although was not detected in the sample shown.  Nuclear counterstaining (TOPRO-3) is shown in blue. 
4.5.4 The Impact of ER & GPER-1 Antagonists on Estrogen-Induced Acini 
Disruption 
One of the main characteristic of most estrogenic compounds, including E2, BPA and n-propylparaben, is 
their ability to bind to and activate the ER and GPER-1.  We, therefore, were interested in investigating 
whether receptor antagonists for the ER or GPER-1 would prevent the acini disruption induced by 
estrogenic treatment, revealing a potential involvement of these receptors in estrogen-induced acini 
malformation.  3D cultures of MCF-12A cells were treated with the test compounds E2, BPA or n-
propylparaben in combination with the ERα antagonist ICI 182,780, GPER-1 antagonist G-15 or a 
combination of both antagonists, for 16 days.  The inhibitors were also tested in the absence of 
estrogens.  From this work, it became apparent that the antagonists alone exerted a small impact upon 
MCF-12A acini morphology and induced a small degree of luminal filling.  Nevertheless, we observed 
that the presence of both antagonists reverted the extent of acini disruption caused by the three test 
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compounds and, when used in combination, the extent of reversion was greater than with either 
antagonist alone. 
As shown in Figure 4.8, co-incubation with ICI 182 780 allowed E2-treated acini to recuperate 
some of the features displayed by solvent control acini. This is exemplified by partial luminal clearance, 
in addition to an overall increase in acini organisation.  This increased organisation was inferred by the 
presence of a uniform layer of outer cells in contact with the basement membrane surrounding a nearly 
hollow lumen.  Although at 16 days activated caspase-3 was absent in E2 samples pre-treated with ICI 
182,780, the resulting acini were smaller, more spherical and displayed less luminal filling than samples 
treated with E2 alone.  Similar effects were observed upon co-incubation with the GPER-1 antagonist, G-
15, although G-15 also resulted in acini of a much smaller size compared to those treated with E2 + ICI 
182, 780.  Co-incubation with both antagonist simultaneously had a greater impact on the reversion of 
E2-induced malformations and produced organised, spherical, growth-arrested acini with partial luminal 
filling.  This strongly suggests that both the ER and GPER-1 are involved in mediating the effects of E2 on 
3D MCF-12A structures. 
Both antagonists also reverted some of the BPA and n-propylparaben-induced acinar 
malformations.  However, this reversion was more notable with BPA-treated samples than with n-
propylparaben.  Co-incubation of BPA with ICI 182, 780 or G-15 resulted in a reduction in acini size.  
These acini were also more spherical and organised, and presented partially cleared lumen, features 
that were absent when acini were treated with BPA alone.  Upon co-incubation of both antagonists with 
BPA, the acini were even smaller and the extent of luminal clearing was greater than that observed upon 
co-incubation of the estrogen with ICI 182, 780 or G-15 individually. 
On the other hand, when used alone, neither antagonist, greatly reverted the effects of n-
propylparaben in terms of luminal filling or overall organisation.   Acini were, however, smaller in size 
and spherical.  Interestingly, G-15 co-incubation with n-propylparaben resulted in larger nuclei, as 
indicated by TOPRO-3 staining.  This was not observed when the antagonists were used in combination, 
however co-incubation with both ICI 182, 780 and G-15 did appear to increase the extent of luminal 
clearance compared to n-propylparaben treatment alone. 
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Figure 4.8: The role of ER and GPER-1 in estrogen-induced MCF-12A acini disruption.  Samples were treated with 
1 nM E2, 10 µM BPA or 10 µM n-propylparaben, alone, or in combination with 1 µM ICI 82, 780, 10 nM G-15 or 1 
µM ICI 82, 780 + 10 nM G-15, for 16 days.  Acini were then stained with antibodies against laminin V (red) and 
activated caspase-3 (green) to identify basement membrane and apoptotic cells, respectively.  Cells were 
counterstained with TOPRO-3 (blue) as a nuclear marker.  Experiments are representative of duplicate experiments 
performed two independent times. 
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4.5.5 The Effect of Estrogens on ERα-Negative MCF-10A Cells in 3D Culture 
We then proceeded to investigate the impact of E2, BPA and n-propylparaben in MCF-10A cells, which in 
Chapter II were shown to be negative for ERα and ERβ.  This was performed to ascertain whether the ER 
is required for estrogens to induce acini disruption, as the previous results in the ER positive MCF-
12Acell line seem to indicate.  MCF-10A cells do, however, express GPER-1, as demonstrated in Chapter 
II and, as this receptor has been shown to influence the effects of estrogens in MCF-12A cells, it is 
possible that the same may be true in MCF-10A cells.  The MCF-10A cell line has been commonly used in 
3D culture investigations (Debnath et al, 2002: Debnath et al, 2003) to characterize acini formation in 
Matrigel. 
Under solvent control conditions, we observed that following 16 days in Matrigel, MCF-10A cells 
formed growth-arrested, spherical acini with hollow lumen.  Here, acini were round and well organised, 
with a single layer of cells surrounded by a basement membrane.  The lumen was completely formed 
with no residual apoptotic cells.  However, in contrast to untreated cells, a small proportion of acini 
presented some slight filling of the lumen (Figure 4.9), evident by the presence of a second layer of cells 
attached to the outer cells, which seems to indicate a mild disruption of acini formation or maintenance.  
The MCF-10A acini were characteristically similar to those reported previously (Debnath et al, 2003) and 
also bore resemblance to the etOH control acini of MCF-12A cells. 
Treatment with E2, BPA or n-propylparaben did not greatly impact upon acini formation. 
Additionally, n-propylparaben-treated samples did not have a smooth basement membrane structure 
that was observed with controls and other treatments (Figure 4.9). 
 
 
Figure 4.9: LCM images of normal epithelial breast MCF-10A cells cultured in Matrigel for 16 days.  Samples were 
treated with solvent controls (0.5% ethanol), 10 nM E2, 10 µM BPA or 10µM n-propylparaben.  Acini Anti-bodies 
against laminin V (red) and activated caspase-3 (green) were used to identify the basement membrane and 
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apoptotic cells respectively.  Cells were counterstained with TOPRO-3 (blue) as a marker for the nucleus.  
Experiments are representative of experiments performed in duplicate on three independent times. 
4.5.6 Acini Quantification and Statistical Analysis 
After acini size was measured using the Carl Zeiss MicroImaging, Inc. LSM510 confocal microscopy 
system with LSM version 4.20 (Carl Zeiss Ltd, Hertfordshire, UK), ANOVA was performed to compare 
treatments against controls and treatments against treatment + inhibitor. 
Although estrogen-treated MCF-12A acini were larger throughout, at 8 days, only acini incubated with n-
proplparaben were significantly larger in size.  After 12 days incubation, acini treated with BPA or n-
propylparaben were significantly larger than solvent controls.  Finally, after 16 days, treatment with all 
compounds (E2, BPA or n-propylparbaben) resulted in acini that were significantly larger in diameter in 
comparison to controls (Figure 4.10). 
 
Figure 4.10: Quantification of acini size.  Acini size was determined by analysing confocal images following 4, 8, 12 
and 16 days incubation.  Data corresponds to mean ± SEM and results from three independent experiments, where 
a minimum of 10 representative acini were analysed per experiment. * (p<0.05), ** (p<0.01) and *** (p<0.001) 
indicate significant differences between treatments and controls. 
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When the percentage of apoptotic cells per acini was calculated we found that this was significantly 
decreased in all treatments and at all time points, indicating that these estrogenic compunds have an 
anti-apoptotic impact on MCF-12A acini (Figure 4.11). 
 
Figure 4.11: Quantification of percentage of apoptotic cells per acini.  The percentage of apoptotic cells (those 
positive for activated caspase-3 staining) was calculated for 8, 12 and 16 days incubation in Matrigel.  Data 
corresponds to mean ± SEM and results from three independent experiments, where a minimum of 10 
representative acini were analysed per experiment. * (p<0.05), ** (p<0.01) and *** (p<0.001) indicate significant 
differences between treatments and controls. 
We next sought to investigate whether the reversion of estrogen-induced malforamtions by ER or GPER-
1 antagonists were statistically significant following 16 days incubation.  The reduction in acini diameter 
in E2-treated sample was only significant upon co-incubation with ICI 182,780.  In BPA-treated samples, 
either antagonist, or a combination of the two, significantly reduced acinar size.  In n-propylparben-
treated samples, a significant reduction in MCF-12A acini size was observed only when ICI 182,780 was 
present.  Neither inhibitor had a significant impact on the average number of cells per acini in n-
propylparaben-treated samples, however the dat here was most variable for controls and this may 
account for the lack of significant decreases in cell number.  In E2-treated samples, ICI 182,780 or G-15 
alone reduced the average number of cells, however in combination this reduction was no longer 
significant.  Only when BPA-treated samples were co-incubated with ICI 182,780, either alone, or in 
combination with G-15, did cell number significantly reduce (Figure 4.12).  Taking these observations 
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into account along with the LCM images, suggests that the various estrogenic test compounds utilse the 
ER and GPER-1 differently in the MCF-12A cell line. 
 
Figure 4.12: Acini Size after 16 days upon co-incubation with ER and GPER-1 antagonists.  Data corresponds to 
mean ± SEM and results from three independent experiments, where a minimum of 10 representative acini were 
analysed per experiment. * (p<0.05), ** (p<0.01) and *** (p<0.001) indicate significant differences between 
treatments and controls. 
4.6 Discussion 
Following on from the results presented in Chapter III, where we established a time-course for the 
formation of acini by MCF-12A cells, in this chapter, we proceeded to establish a time-course for MCF-
12A acini formation in the presence of both endogenous and exogenous estrogens, namely: E2, BPA and 
n-propylparaben. 
The data presented in this chapter shows that under control conditions (0.5% ethanol), MCF-
12A cells cultured in Matrigel form growth arrested, spherical, hollow acini after 16 days incubation.  In 
comparison, MCF-12A cells treated with estrogens form malformed acini.  The malformations observed, 
such as loss of the single layer of cells in contact with the basement membrane, luminal filling, 
misshapen acini, over-proliferation and invasion through the basement membrane resemble those 
observed in early breast cancer lesions (Debnath et al, 2003; Hebner et al, 2008).  Furthermore, the 
estrogen-treated malformed acini also resemble those produced by malignant cells cultured in 3D 
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(Petersen et al, 1992).  It is important to note at this point, however, that whilst these estrogen-treated 
acini resemble breast cancer lesions, they have not necessarily undergone neoplastic transformation.  
This would have to be confirmed by genotyping of estrogen-treated acini.   
4.6.1 Proliferation of MCF-12A Acini in Response to Endogenous Estrogen and 
Xenoestrogens 
The test compounds led to increased acinar size and this effect could be seen as early as 4 days in 3D 
culture.  This suggests that the presence of estrogenic compounds increases cellular proliferation.  As 
noted previously, estrogen-treated were misshapen and in some cases multi-acinar structures were 
present, characterised by what appeared to be multiple acini that were encapsulated by a single 
surrounding basement membrane.  These multi-acinar filled structures have been observed previously 
in 3D cultures of MCF-10A cells with ectopic expression of HER-2, a receptor associated with increased 
responses to growth factors, and hence, increased proliferation (Muthuswamy et al, 2001; Debnath et 
al, 2002) (Figure 4.13).  These observations also suggest that estrogens induced an increase in the 
proliferation of MCF-12A cells cultured in Matrigel.  It is clear that in this 3D model, estrogens have an 
impact upon acini size and shape, thus indicating uncontrolled cellular proliferation, although this was 
not the only estrogen-induced effect observed.  These observations are supported by other studies that 
report cellular proliferation in response to estrogens in rats (Holland & Roy, 1995).  Holland & Roy 
(1995) observed that in female rats, proliferation of mammary epithelial cells was increased following 
treatment with estrone. 
 
Figure 4.13: Comparison of multi-acinar structures grown in Matrigel. (A) Phase contrast image of a MCF-10A 
multi-acinar structure where HER-2 was ectopically expressed.  Staining for DAPI is shown (Taken from Debnath et 
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al, 2002).  (B) Confocal image of a n-propylparaben treated MCF-12A multi-acinar structure.  Basement membrane 
was visualised by staining with antibodies against laminin V (red).  Anti-bodies against activated caspase-3 were 
used as an indicator of apoptosis (green) but were not observed in this sample.  Nuclear counterstaining was 
performed using TOPRO-3 (blue). 
Previously published data has demonstrated that E2-treated MCF-10F acini formed in 3D collagen 
matrices, have increased Ki-67, a marker of proliferation (Kocdor et al, 2009).  This supports the idea 
that the estrogen-induced increased acinar size and irregularity of shape were, to some extent, due to 
increased cellular proliferation. 
The disruption of acini formation at 16 days shown in the 3D model has also been replicated in 
vivo in mouse and rat models and this both supports our results and adds validation to the model used 
(Hilakivi-Clarke et al, 2006).  In the aforementioned study, in utero estrogen treatment resulted in lack of 
apoptotic cells in the TEBs of rat mammary glands compared to in untreated animals where apoptotic 
cells were present.  Additionally, E2 can induce hyperplasia, demonstrated by increased number of ducts 
and alveoli size, and irregular shaping of the lumen and luminal filling of the mammary gland in rats 
(Kovalchuk et al, 2007; Starlard-Davenport et al, 2010).  In other in vivo studies, animals underwent 
perinatal exposure to BPA and the results were alterations in mammary gland organization during 
puberty and adulthood, reduced levels of apoptosis and increased number of proliferative cells (Markey 
et al, 2001; Munoz de Toro et al, 2005; Murray et al, 2007).  Interestingly, some of these alterations 
mirrored known risk factors associated with breast cancer risk in humans, such as increased responses 
to estrogen, increased epithelial density and carcinomas (Vandenberg et al, 2009). 
It has been reported that when proliferation becomes unregulated in 3D cultures, the cause of 
this may be that signalling pathways influencing survival become over-activated, or that signals that 
would normally induce cell death are blocked.  Indeed, ectopic expression of HER2, an oncogenic 
receptor involved in growth factor signalling, results in large, malformed multi-acinar structures 
(Debnath et al, 2002).  Furthermore, activated AKT is localised to the outer cells of acini that possess 
contact with the basement membrane.  Cells destined for apoptosis, i.e. the central cells, do not express 
activated AKT and disruption of this dichotomy disrupts proliferation and the apoptotic process 
(Debnath et al, 2003b; reviewed in Debnath & Brugge, 2005).  This supports the idea that acinar 
disruption occurs as a result of disruption of key signalling pathways and this will be studied further in 
relation to estrogens in later chapters. 
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4.6.2 Apoptosis and Lumen Formation Following Estrogen-Treatment of   MCF-12A 
Acini 
In addition to increasing proliferation, estrogens appear to have an inhibitory impact upon apoptosis, 
and indeed, it has been demonstrated that E2 is able to suppress apoptosis (Murdoch & Kirk, 2002).  The 
exact mechanism for this is unclear, however, it has been demonstrated that E2 increases Mdm2 
expression (Brekman et al, 2011).  This would ultimately lead to the inhibition of p53, thus preventing 
p53-mediated apoptosis.  In addition to this, E2 treatment of synovial fibroblasts has been shown to 
have a suppressive effect upon apoptosis and this was mediated by the MAPK pathway (Yamaguchi et 
al, 2012).   
Under control conditions, activated caspase-3 was observed after 8 days in 3D culture and was 
still evident at 12 days.  Upon formation of the hollow lumen after 16 days, activated caspase-3 was no 
longer observed as no, or very few, cells were left to be cleared.  As activated caspase-3 is an indicator 
of apoptosis, it can be assumed that through days 8 to 16, apoptosis occurs, leading to the formation of 
the hollow lumen.  When cells were treated with the test compounds, less activated caspase-3, and 
hence less apoptosis, was observed throughout, and there was little evidence of luminal clearance.  
Further to this, the presence of apoptotic cells in some of the estrogen-treated samples was not specific 
to the inner cell population within acini.  This would suggest that despite signs of apoptosis in estrogen-
treated samples, as indicated by the presence of activated caspase-3, apoptosis is dysregulated and is 
not sufficient to induce luminal clearance.  This may be due to reduced apoptosis, but the increased 
proliferation discussed previously may also contribute to this observation.  The estrogen-induced 
reduction in apoptosis indicates that the central cells of the acini, which lack direct contact with the 
basement membrane, had acquired the ability to survive without signals from the ECM.  It is already 
known that these signals can be transmitted from the surrounding environment via cell surface 
receptors, such as integrins and the EGFR, and promote survival and proliferation (reviewed in Shaw et 
al, 2004).  In order to proliferate, normal cells require growth signals, such as activation of receptors by 
growth factors or components of the ECM.  It is known that some oncogenes exert their pro-survival 
influence by mimicking these normal growth signals or enhancing them.  In this way, cancer cells 
become self-sufficient from growth signals, and hence, do not rely on an external cue to enter into a 
proliferative state.  A plausible explanation for estrogen-treated cells forming malformed acini may be 
that these cells have become self-sufficient, and thus do not require external growth cues in order to 
proliferate or survive, or that estrogens are able to activate the pathways involved in survival.  
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Nevertheless, the acquisition of self-sufficiency for growth signals remains a hallmark of cancer 
(Hanahan & Weinberg, 2000) and is involved in the initiation and progression of cancer in vivo.   
In normal tissues, homeostasis is achieved not only by the stimulatory effect of growth signals, 
but also through anti-growth signals.  These anti-growth signals can induce their anti-proliferative 
effects by forcing cells into a quiescent state.  It may therefore be that estrogen-induced acinar 
malformations were also as a result of an acquired insensitivity to anti-proliferative signals.  Indeed, it 
has been shown that estrogens are able to suppress the transcription of the anti-growth factor, TGFβ, in 
MCF-7 cells (Matsuda et al, 2001). 
A role for estrogens in suppressing apoptosis, and thus impacting upon acini formation is 
supported by the observation that E2 and BPA can increased the expression of anti-apoptotic Bcl-2 and 
Bcl-xl via both genomic and non-genomic mechanisms of action (Perillo et al, 2000; Gompel et al, 2004; 
Bratton et al, 2010; LaPensee et al, 2010).  In the aforementioned studies, the disruption of single genes 
associated with apoptosis did not induce luminal filling.  When, however, apoptosis was suppressed and 
proliferation enhanced simultaneously, luminal filling was observed (Debnath et al, 2002; Reginato et al, 
2005).  This would suggest that the disruption of acini requires a combination of uncontrolled hyper-
proliferation and apoptotic suppression, both of which were observed in the estrogen treated 3D 
cultures of MCF-12A cells described in this chapter.   
Similar aberrations with E2 transformed MCF-10F cells grown in 3D collagen matrices have also 
been previously reported (Russo et al, 2002; Russo et al, 2006; Tiezzi et al, 2007; Russo et al, 2010).  In 
these 3D studies, treatment of MCF-10F cells with E2 induced neoplastic phenotypes.  Normally, these 
immortalised breast cells form duct-like structures in collagen gels, similar to the acini formed in 
Matrigel.  However, in the presence of E2, these cells experience a decrease in ductulogenic potential 
and an increase in invasive potential.  Additionally, when injected into immunodeficient mice, these cells 
are capable of forming tumours, which is indicative of neoplastic transformation.  The xenoestrogens, 
BPA and BBP resulted in similar effects to those induced by E2, in a similar way to the data presented in 
this chapter.  Russo and colleagues argue that these E2-induced effects are as a result of genotoxicity of 
estrogens and their metabolites, and are independent of the ER (Russo et al, 2002; Russo et al, 2010).  
The E2-transformed MCF-10F acini in these studies were found to have undergone various genetic 
alterations and epigenetic modifications, such as the loss or amplification of chromosomes and DNA 
methylation (Russo et al, 2010).  Contrary to the published data by Russo et al, only minimal 
malformations were observed in Matrigel cultures of ER negative MCF-10A cells treated with estrogens.  
157 
 
This suggests that genotoxicity may not be the determining factor in E2-induced acini malformations and 
the ER does, in fact, play a role in mediating the effects of estrogens. 
It remains unclear whether the acinar malformations observed in response to estrogen 
treatment were a consequence of increased proliferation, decreased apoptosis, or indeed, a 
combination of both.  Given that estrogen-treated acini were larger in size and possessed filled lumens 
with reduced levels of apoptosis, it would suggest that increased proliferation and decreased apoptosis 
are both implicated, respectively.  Several mechanisms are involved in the development and 
maintenance of mammary acini for proliferation and apoptosis.  It is thought that RTKs, such as the EGF 
receptor, mediate signalling pathways, such as PI3K and MAPK.  Additionally, there also appears to be a 
key role in genes involved in the cell cycle and apoptosis, including cyclin D1 and Bcl-xl (Debnath et al, 
2002; Reginato et al, 2005; Yanochko & Eckart, 2006).  In the event that signalling pathways become 
over-activated, the resultant acini become malformed.  This has been shown in the MCF-10A cell line, 
where hyper-activation of the PI3K pathway disrupted acini polarity and led to increased proliferation 
and consequently increased acini size (Liu et al, 2004). 
4.6.3 The Basement Membrane of MCF-12A Acini and the Impact of Estrogens 
Despite the apparent impact of estrogens upon proliferation and apoptosis during the morphogenesis of 
MCF-12A acini, estrogen treatment did not appear to impact upon the deposition of basement 
membrane.  The basement membrane forms a separation between acini and the stroma of the breast 
and provides a physical barrier for tumours that arise within these structures.  However, a characteristic 
of cancer progression is the migration and invasion of cancer cells across this boundary (Hanahan & 
Weinberg, 2000).  The observation that estrogenic treatment resulted in cells invading through the 
basement membrane suggests that the invasive potential of the cells had been increased.  Indeed, 
Matrigel invasion studies with non-tumourigenic MCF-10F cells and the breast cancer cell line, T47-D 
have demonstrated that E2 treatment results in a higher potential for migration and invasion (Huang et 
al, 2007; Zheng et al, 2011).  It is worthy to note that normal cells do not have the capability to invade, 
and thus, the data presented here and by Huang et al (2007) suggests that estrogenic treatment of 
normal breast cells seems to result in the acquisition of invasive potential.  The exact mechanism for 
invasion appears to be highly complex and is not completely understood.  Various changes in expression 
or activation status of proteins have been found to be associated with increased invasive potential.  For 
example, estrogens have been reported to down-regulate E-cadherin expression (Oesterreich et al, 
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2003), increase matrix-degrading protease production and secretion (Briozzo et al, 1988), induce the 
phosphorylation of ezrin, impact upon cytoskeleton remodelling (Giretti et al, 2008; Zheng et al, 2011) 
and alter the expression of various integrins (Li et al, 2000; Kimmins et al, 2003).  Given that estrogens 
can impact on so many of the mechanisms involved with invasion, it is plausible that the observed 
invasion of cells across the basement membrane was as a result of estrogen treatment. 
4.6.4 Both the ER and GPER-1 are Implicated in Estrogen-Induced Acini Disruption 
Both ICI 182, 780 and G-15 induced a small degree of acini disruption.  ICI 182,780 is an agonist for 
GPER-1 (Filardo et al, 2000) and this could imply that its effects were a result of GPER-1 activation.  
Activation of GPER-1 can interfere with EGF-mediated signalling and this could account for the 
disruption.  In this model, GPER-1 ligands, such as E2 or ICI 182,780, activate GPER-1 and cause the 
subsequent activation of the Gβγ subunit.  This activates Src and Src consequently activates 
metalloproteinase (MMP) which cleaves heparin-bound EGF from pro-heparin-bound EGF complexes 
and thus liberates it to activate the EGF receptor.  The result is the activation of EGFR-mediated 
signalling pathways, such as the MAPK cascade (Figure 4.14) (Filardo et al, 2002). 
 
 
Figure 4.14: Cross-talk between GPER-1 and MAPK pathways.  Ligand binding to GPER-1 activates the Gβγ subunit 
which activates Src.  Src mediates the activation of metalloproteinase (MMP) which releases heparin-bound EGF.  
The heparin-bound EGF can then activate the EGFR causing MAPK signalling. 
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Further to the model above (Figure 4.14), GPER-1 agonists, such as ICI 182,780, can mobilise 
intracellular calcium and induce rapid PI3K signalling (Stenoien et al, 2001; Wei et al, 2012).  Thus, ICI 
182,780 potentially disrupts key signalling pathways involved in acini formation.  It may, therefore, be 
the case that when acini were treated with ICI 182,780, the aberrations to acinar structure were due to 
ICI 182,780 induced activation of GPER-1. 
Interestingly, treatment with G-15 alone, but not ICI 182,780 alone resulted in smaller acini, an 
effect that was reversed with the etOH controls were treated with both ICI 182, 780 and G-15.  This 
suggests that G-15 may have an impact upon acini, and it has recently been demonstrated that G-15 is 
capable of inducing effects through the ER (Dennis et al, 2011).  One important point to consider is that 
in controls co-incubated with both ICI 182, 780 and G-15, acini were more similar to controls than 
samples treated with each of the antagonists individually.  This suggests that if it is the case that G-15 is 
activating the ER, and ICI 182,780 is activating GPER-1, the combination of the two prevents the 
activation induced by either G-15 or ICI 182,780.  Although from the results, the reason for ICI 182, 780 
or G-15’s small effects on acini formation cannot be completely determined, toxicity can be ruled out as 
neither antagonist induced toxic effects in the monolayer MCF-12A cultures described in Chapter II. 
Acinar malformations induced by estrogenic treatment were partially reverted upon co-
incubation with ICI 182, 780 or G-15.  Most notably, co-incubation of the estrogenic test compounds 
with ICI 182,780 or G-15 resulted in acini that were similar in size to ethanol controls, or smaller in the 
case of E2 co-incubation with G-15.  The presence of the antagonists also reverted the irregular acinar 
shape induced by the test compounds, although in the case of n-propylparaben, ICI 182,780 only 
partially reverted the impact of n-propylparaben upon acinar shape.  The observation that ICI 182,780 
and G-15 were capable of reverting some of the effects of the test compounds upon MCF-12A acini 
suggests that the activation of the ER and GPER-1 resulted in increased proliferation.  This further 
supports previous observations, showing that in a 3D model, estrogens induce acinar malformations by 
increasing cellular proliferation. 
In terms of apoptosis and luminal clearance, no significant increase in activated caspase-3 was 
observed upon co-incubation of the test compounds with either ICI 182,780 or G-15.  Increased luminal 
clearance was however observed when the test compounds were co-incubated with ICI 182,780 or G-15.  
The exception to this was following n-propylparaben treatment of acini, where neither ICI 182,780 nor 
G-15 increased the expression of activated caspase-3 or the extent of luminal clearance.  This suggests 
that the ER and GPER-1 may be implicated in the estrogen-induced luminal filling of MCF-12A acini, but a 
160 
 
mechanism other than apoptosis may be responsible for the formation of the hollow lumen.  
Autophagy, the process by which cells break down their own organelles has been proposed to be at 
least partially responsible for luminal clearance in acini.  The presence of autophagic vesicles in the 
central cells of MCF-10A acini has been demonstrated (Debnath et al, 2002; Underwood et al, 2006).  
Furthermore, TRAIL is involved in the initiation of the autophagic process during the morphogenesis of 
MCF-10A acini and combined inhibition of autophagy and apoptosis results in luminal filling (Debnath et 
al, 2002; Mills et al, 2004).  This data supports the idea that perhaps apoptosis was not solely 
responsible for the luminal clearance of MCF-12A acini upon co-incubation of the estrogen test 
compounds with ICI 182,780 or G-15.  It does, however, raise the question as to why antagonism of ERα 
and GPER-1 did not result in the same levels of activated caspase-3 observed in etOH controls. A role for 
GPER-1 in mediating the E2-induced acinar malformations observed in MCF-12A acini is also suggested 
by the observation that ICI 182, 780 and G-15, when used in combination, reverted more of the 
estrogen-induced malformations than with either antagonist alone.  Indeed it has been demonstrated 
that E2 and BPA can bind to GPER-1 and activate various signalling cascades resulting in increased 
proliferation that is ER-independent (Razandi et al, 1999; Bouskine et al, 2009; Sheng & Zhu, 2011).  The 
observation that ER antagonism with ICI 182,780 did not fully revert the treatment-induced 
malformations suggests the involvement of ER-independent mechanisms of action, and is supported by 
findings that E2 and BPA are able to mediate non-genomic signalling via a membrane-associated 
receptor not related to ERα or ERβ (Nadal et al, 2000; Ropero et al, 2002).   
When estrogen-treated MCF-12A acini were co-incubated with a combination of ICI 182,780 and 
G-15, the reversion of estrogen-induced malformations was greater.  In particular, estrogen treatment 
combined ICI 182,780 + G-15 treatment resulted in acini that were very similar to controls.  These were 
the same size as control structures, were spherical in shape and the outer cells in contact with the 
basement membrane were organised into a single uniform layer.  The lumen was not, however, 
completely hollow, suggesting that not all of the effects of E2 had been prevented by ERα and GPER-1 
antagonism.   
One possible receptor present in our cell line is a 36 kDa isoform of ERα that resides in the 
plasma membrane.  This receptor is able to mediate the non-genomic effects of estrogens and its 
activity is not prevented by either tamoxifen or ICI 182,780 (Wang et al, 2006).  It is currently not known 
whether MCF-12A cells express this receptor, and it would be of interest, in the future, to investigate 
the presence and role of this receptor in this cell line.  Moreover, the bi-phasic activation of the PI3K 
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pathway is not completely abrogated by ICI 182,780 co-incubation with estrogens and it is proposed 
that an estrogen-response membrane receptor could be responsible for this effect (Marino et al, 2003).  
It is, therefore, feasible that some of the effects elicited by the estrogens in the MCF-12A cells are 
mediated through this receptor although further experiments are required to confirm this. 
Unlike MCF-12A cells, estrogen-treated MCF-10A acini, on the whole, formed growth-arrested, 
spherical, well organised acini with a small increase in cell numbers within the lumen.  The primary 
difference between MCF-10A and MCF-12A cells is that the latter express ERα and ERβ.  This, in addition 
with the partial reversion of E2-induced acinar malformations upon ICI 182,780 co-incubation, suggests 
that the disruption elicited by E2 is strongly dependent of the expression of the ER.  Other estrogen-
responsive receptors, such as GPER-1, which both cell lines express, may, however, play a role in the E2-
induced acinar malformations and this might be behind the slight acinar disruption seem with E2-
treated MCF-10A cells.  In vivo, ovariectomy, which would prevent the presence of endogenous 
estrogen, not only prevents the development of ER positive tumours, but also that of ER negative 
tumours (Early Breast Cancer Trialists’ Collaborative Group, 1992).  This, and giving that E2 can induce 
PI3K signalling in ER negative breast cancer cells (Friedl & Jordan, 1994; Tsai et al, 2001), does indeed 
support the hypothesis that estrogen may induce effects independently of the ER, via estrogen-
responsive receptors, such as GPER-1, truncated ERα isoforms or even a receptor with the 
pharmacological profile of γ-adrenergic receptor (Nadal et al, 2000).  In contrast to the data shown, 
other groups have shown that the ER negative MCF-10F cell line form acini comparable to benzoapyrene 
(BP)-treated acini in response to E2 (Soule et al, 1990; Russo et al, 2002; Russo et al, 2002b; Mello et al, 
2007).  This was not observed in the MCF-10A cell line and may be due to differences in receptor 
expression or culture conditions. 
4.6.5 Xenoestrogens Appear to Induce Greater MCF-12A Acinar Malformations 
than Endogenous E2 
Although all of the compounds tested induced larger mis-shapened acini possessing filled lumens, the 
malformations induced by BPA and n-propylparaben were greater than those induced by E2.  The 
affinities of these compounds to the ER are between 1000 and 2000 times less than that of E2 (Bouskine 
et al, 2009), which suggests that the affinity of these estrogenic compound for the ER does not 
necessarily correlate with biological response.  It has been demonstrated that different ER ligands 
induce different conformation of ER-ligand complexes and hence the recruitment of co-factors and 
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subsequent gene transcription could differ between different estrogens.  Additionally, different ER 
ligands impact upon the stability of ERα in different ways.  This indicates that different estrogens may 
have varying effects upon ER degradation and could therefore induce increased responses to E2 through 
decreasing the level of activated ER degradation (Wijayaratne & McDonnell, 2001).  It is also noteworthy 
that xenoestrogens, such as BPA, may exert actions via pathways independent of the ER that E2 does 
not itself utilize.  For example, it has already been shown that BPA is capable of binding to the thyroid 
hormone receptor (Zoeller, 2007).  Therefore, some of the effects induced by BPA or n-propylparaben 
may have been mediated by another receptor.  Interestingly, different ER ligands have been shown to 
induce different transcriptional responses.  For example, although the transcriptional response for BCL-2 
was the same for E2 and BPA-treated MCF-7 cells, BPA induced a greater up-regulation of JUN and FOS, 
which are involved in proliferation and apoptosis, (Tilghman et al, 2012.  The differences in the extent of 
acinar malformations observed in response to the different compounds tested may, therefore, be due to 
differences in the transcriptional responses that each of these compounds elicits.  BPA, like E2, has also 
been shown to form adducts with DNA and this may lead to mutations (Atkinson & Roy, 1995; Izzotti et 
al, 2009).  It may, therefore, also be plausible that the genotoxicity induced by endogenous estrogens 
and xenoestrogens differs and this may account for the differences in acinar malformations.   
The malformations induced by n-propylparaben treatment of acini were not reverted to the 
same extent, in terms of luminal clearing and organisation, as E2 or BPA treated samples, following co-
incubation with either antagonist.  This could suggest that the mode of action of n-propylparaben is 
different from the other tested estrogens.  Indeed, it has been demonstrated that n-propylparaben can 
induce chromosome aberrations and sister-chromatid exchange, whereas E2 only induced chromosomal 
aberrations in the Chinese hamster ovarian cell line, CHO-K1 (Tayama et al, 2008).  It has also been 
demonstrated that the regulation of genes induced by parabens differs from the transcriptional 
responses induced by E2 (Das et al, 1998; Ghosh et al, 1999; Pugazhendhi et al, 2007).  Whether these 
are mediated through ERα, ERβ, GPER-1, or indeed by another mechanism, remains unresolved, 
although it has been demonstrated that environmental estrogens, such as chlordecone, induce gene 
expression changes through a mechanism that is independent of ERα (Das et al, 1997).   
Interestingly, mammary epithelial cells treated with parabens or other xenoestrogens are able 
to evade the effects or the tamoxifen and ICI 182,780 (Das et al, 1998; Ghosh et al, 1999; Goodson et al, 
2011).  This is similar to what we observed upon co-incubation of n-propylparaben treated MCF-12 acini 
with ICI 182,780 and G-15 and suggests that the effects of parabens, such as n-propylparaben, are at 
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least in part mediated by receptors other than the ER or GPER-1.  The hypothesis that the ER is not 
solely responsible for the impact of estrogenic compounds upon acini morphogenesis is further 
supported by the observations that estrogen treatment induced mild malformations of MCF-10A acini 
and this was most notable upon treatment with n-propylparaben.  In this instance however, a role of 
GPER-1 in mediating the effects of n-propylparaben is a possibility, as MCF-10A cells are GPER-1 
competent as shown in Chapter II. 
4.6.6 MCF-12A Cells Cultured in 3D Respond Differently to Estrogens than Cells 
Grown in Monolayer  
Strangely, in Chapter II, increased proliferation was not observed in the MCF-12A cell line in response to 
E2 treatment, suggesting that cells respond differently to estrogens and other extracellular signals under 
more physiologically relevant 3D conditions than in monolayer (Dhiman et al, 2005; Horning et al, 2008; 
Yang et al, 2009).  The response of breast cancer cells to the HER-2 antibody, trastuzumab, exemplifies 
the culture-dependent proliferative changes associated with monolayer and 3D cultures.  In one study, 
2D cultures of SKBR-3 cells showed only a limited decrease in proliferation following incubation with 
trastuzumab.  However, following 3D culture, trastuzumab treatment decreased proliferation by 48% 
(Pickl & Ries, 2009).  Another study using primary cultures of mammary epithelial cells has 
demonstrated that the functionality of the ER, and, hence, a cell’s ability to respond to estrogen, is 
compromised in monolayer cultures.  When these cells were cultured in 3D, however, they regained 
their responsiveness to estrogenic treatment (Novaro et al, 2003).  Additionally it has also been shown 
that cells cultured in 3D express higher levels of ERα in comparison to the same cells cultured in 
monolayer, which may result in increased estrogen responsiveness (Yang et al, 2000).  In monolayer 
cultures of MCF-12A cells, described in Chapter II, E2 induced no change in proliferation, however, upon 
3D culture, estrogen-treated acini were larger than controls and misshapen, both indicators of 
uncontrolled, increased proliferation.  These observations, taken together with the reported literature, 
suggest that the regulation of cellular proliferation of mammary epithelial cells extends beyond the 
presence of growth factors or hormones and that the micro-environment (monolayer or 3D culture) 
governs the responses to these mitogens.  It remains unclear, however, at this point if this was due to 
increased ERα expression in 3D cultures or increased functionality of the ER in response to estrogens.   
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4.6.7 Conclusions 
In conclusion, estrogens are able to induce luminal filling and disruption of acinar growth in ERα-
competent MCF-12A cells and this effect is not observed to the same extent in ERα negative MCF-10A 
cells, although mild effects are observed.  This alone suggests that the ER is involved in mediating some 
of the effects elicited by estrogens on acini formation.  We conducted further experiments using ER and 
GPER-1 antagonists to elucidate the role of estrogen-responsive receptors, and found that both ICI 
182,780 and G-15 alone were able to revert some of the induced malformations.  Furthermore, this 
reversion was greater when the antagonists were used in combination.  This further supports the 
hypothesis that estrogens are able to disrupt acini formation and do so via the ER, and to some extent 
through GPER-1 and emphasises a role for these receptors in mediating the actions of estrogens during 
glandular morphogenesis and maintenance of breast tissue. 
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Chapter V: Signalling Pathways Implicated in Acini Formation 
 
In Chapter IV, we observed that estrogens were capable of disrupting the formation of MCF-12A acini, 
and to a much smaller extent, MCF-10A acini.  As discussed in Chapter I, estrogens are capable of 
eliciting both genomic and non-genomic responses.  In this chapter we will try to dissect the 
mechanisms through which estrogens disrupt acini morphogenesis, by focusing on the potential role of 
extracellular signalling cascades, more specifically, the PI3K and MAPK signalling pathways on these 
effects. 
The work described in Chapters III and IV, and in studies conducted with MCF-10A, cells has 
demonstrated the importance of proliferation and apoptosis for the correct organisation of 3D acinar 
structures (Debnath et al, 2002; Debnath et al, 2003; Mills et al, 2004; Murtagh et al, 2004; Debnath et 
al, 2005; Fung et al, 2008).  Several reports have demonstrated that correct acini formation in 3D 
cultures requires a fine balance between cellular proliferation and cell death.  If these processes are 
dysregulated, acini become deformed and display luminal filling, irregular shapes and loss of apico-basal 
polarity (Debnath et al 2003b; Reginato et al, 2005; Haenssen et al, 2010).   
To date, a number of mechanisms responsible for cell proliferation and apoptosis have been 
identified as playing an important role in the development and maintenance of mammary acini.  These 
include signal transduction pathways associated with the EGFR, such as the PI3K and MAPK cascades,   
as well as proliferation and apoptosis-regulating genes such as CCND1 and BCL-XL (Debnath et al, 2002; 
Liu et al, 2004; Yanochko & Echhart, 2006).  Often, dysregulation of acinar structures arises when one or 
more of these pathways are activated or blocked.  For example, in 3D cultures of MCF-10A cells, 
hyperactivation of the PI3K cascade disrupts acinar polarity, acinar size and proliferation, resulting in 
deformed acini of increased size (Irie et al, 2005).  When hyperactivation of the PI3K cascade or EGF 
signalling is combined with ectopic up-regulation of the oncogene, cyclin D1, MCF-10A acini escape 
proliferative arrest and present with filled lumen (Debnath et al, 2003).  Transfection of oncogenes 
involved in signalling pathways, such as B-Raf of the MAPK cascade, into MCF-10A cells, which are then 
grown in 3D results in the loss of acinar organisation and an invasive cell phenotype (Herr et al, 2011).  
Furthermore, 3D cultures of the malignant breast cell line, HMT-3522, have revealed that increased 
MAPK pathway activity results in the development of abnormal acinar structures (Beliveau et al, 2010). 
In this chapter, we will explore the role of the PI3K and MAPK pathways in MCF-12A acini 
formation, using inhibitors specific for these pathways.  Estrogens have been demonstrated to activate 
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these pathways and it would, therefore, be of interest to investigate whether the estrogen-induced 
acinar malformations seen in Chapter IV are a consequence of hyperactivation of these signalling 
cascades (Wozniak et al, 2005; Tong et al, 2010). 
5.1 The PI3K Signalling Pathway 
As mentioned previously, the PI3K and MAPK pathways are involved in proliferation, survival, apoptosis, 
motility, differentiation, tumour invasion and angiogenesis.  The activation of the PI3K signalling 
pathway occurs in the cytoplasm, in response to the stimulation of RTKs, such as the IGF-1 receptor or 
G-protein-coupled receptors.  Following PI3K activation, the secondary messenger, PIP3 is generated 
from the phosphorylation of PIP2 (Vanhaesebroeck et al, 2001).  Targets of PIP3 include AKT, which, in 
turn, phosphorylates various target proteins.  PI3K signalling has implications for cyclin D1, cyclin D2, 
mdm2-p53 axis, Bcl-2 phosphorylation, Bad, caspase-9, Myc, and the regulation of p27kip1, amongst 
many others (Figure 5.1) (Datta et al, 1997; Mayo et al, 2002; Wanzel et al, 2005). 
The cyclins, on the other hand, are required for progression through the cell cycle; cyclin D1 and 
D2 aid progression through the G1/S checkpoint following binding with CDK2 and CDK4.  Thus, increased 
expression of these proteins by PI3K action can result in increased cell cycle progression and increased 
proliferation (Bouchard et al, 2004).  Cip and kip proteins, such as p27kip1, are CDK inhibitors that 
function to regulate the formation of cyclin-CDK complexes and, thus, modulate progression through 
the cell cycle.  Mutations or activation by AKT prevent their inhibitory effect upon cyclin-CDK complex 
formation and, hence, result in increased progression through the cell cycle and increased proliferation 
(Banerji et al, 2001; Yuan et al, 2007).   
Apoptotic proteins are also targeted by activated AKT: the pro-apoptotic factor Bad is 
phosphorylated by this kinase, causing it to dissociate from anti-apoptotic Bcl-2 and Bcl-xl.  These in 
turn, are liberated and bind to pro-apoptotic Bax, preventing its action (Datta et al, 1997; Cardone et al, 
1998). 
p53, a tumour suppressor gene that functions to initiate DNA repair, regulate the cell cycle and 
induce apoptosis, is another target of AKT.  Specifically, AKT inhibits transcription and apoptosis 
mediated by p53 and promotes its degradation, at least in part through Mdm2 protein (Ogawara et al, 
2002).  Mdm2 is an ubiquitin ligase, that upon phosphorylation and activation by AKT, ubiguinates p53, 
thus targeting it for proteasome degradation, and inhibiting its pro-apoptotic function.  Ultimately, 
activation of AKT effectors results in increased cell cycle progression, cellular proliferation, survival and 
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decreased apoptosis (Figure 5.1) (Tokunaga et al, 2008).  We showed that AKT can become activated in 
response to estrogens in ER competent MCF-12A and MCF-7 cells, and given that its activation promotes 
cell survival and suppresses apoptosis, estrogen-induced activation of this kinase may contribute to the 
malformations observed in estrogen-treated MCF-12A acini. 
 
 
Figure 5.1: Targets of activated PI3K/AKT signalling.  AKT activation leads to increased survival, cell cycle 
progression, cell growth and decreased apoptosis via the activation or inhibition of various proteins (Figure 
adapted from Tokunaga et al, 2008). 
5.2 The MAPK Signalling Pathway 
Activation of RTKs or G-protein-coupled receptors in the cell membrane initiates the MAPK signalling 
cascade.  Receptor activation leads to the recruitment of the GRB2-SOS complex and activation of Ras 
upon the binding of GTP.  Ras-GTP then proceeds to phosphorylate and activates Raf kinase which, in 
turn, phosphorylates and activates the serine/threonine protein kinases MEK1/2.  Phosphorylated MEK1 
and MEK2 phosphorylate tyrosine residues within ERK1/2 regulatory sites and activate them, permitting 
them to activate or inhibit their target proteins.  The MAPK pathway shares some common effectors 
with the PI3K pathway such as p27kip1 and c-Myc.  In addition to these, the MAPK cascade also has 
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implications for Bim, ZO-1 and β-catenin (Figure 5.2), among many others (Pinkas & Leder, 2002; Ewings 
et al, 2007). 
 
 
Figure 5.2: Implications of activated ERK1/2 as a result of MAPK signalling.  ERK1/2 activation leads to increased 
survival, cell cycle progression and cell growth and decreased apoptosis via activation or inhibition of various 
proteins and transcription factors (Pinkas & Leder, 2002; Davis, 2003; Ewings et al, 2007). 
The dysregulation of MAPK and PI3K signalling pathways is a recurring hallmark of cancers (Bellacosa et 
al, 1995; Hilger et al, 2002; Di Cosimo et al, 2007).  Both these pathways frequently undergo genetic 
alterations during cancer initiation and progression through all tiers of the signal transduction pathway, 
from the receptor level to the effectors.   
Because of the over-activation of signalling pathways in tumours, inhibitors of PI3K and MAPK 
signalling are being investigated for their use in cancer therapy.  Such drugs used or in development for 
therapy include gefitinib, trastuzumab, wortmannin derivatives and LY 294002 conjugates (Tokunaga et 
al, 2008; Maria et al, 2009).  To date, the wortmannin derivative, PX-866 (ProlX Pharmaceuticals) and 
the LY 294002 Arg-Gly-Asp-Ser-conjugated pro-drug, SF1126 (Semafore Pharmaceuticals) have shown 
promising results in early studies in ovarian, colon, lung, prostate and breast cancer and are in the 
process of undergoing phase 1 clinical trials (Ihle et al, 2004, 2005; Garlich et al, 2008). 
Estrogens are able to induce rapid non-genomic effects, such as the activation of the PI3K and 
MAPK pathways via the ER and GPER-1 (Improta-Brears et al, 1999; Wozniak et al, 2005; Tong et al, 
2010).  Consequently, this has implications for proliferation, apoptosis and treatment response.  We 
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hypothesised, therefore, that the MAPK and PI3K cascades may be implicated in the malformations 
induced in MCF-12A acini by estrogens.  In order to test this, the role of PI3K and MAPK signalling during 
acini morphogenesis was investigated using specific inhibitors for the ERK1/2 or PI3K/AKT cascades.  LY 
294002 is a commonly-used, potent, specific inhibitor of PI3-kinase that is derived from quercetin, a 
plant-derived flavanoid.  It functions in a reversible, competitive fashion to inhibit the binding of ATP to 
the catalytic subunit of PI3K and, thus, prevents PI3K activation, but does not affect the activities of 
other signalling proteins including EGFR, Src tyrosine kinases, protein kinase A (PKA), protein kinase C 
(PKC) or MAPK (Vlahos et al, 1994).  There are reports, however, that LY 294002 can interact with mTOR, 
casein kinase 2 (CK2), glycogen synthase kinase 3β (GSK3β), Hsp90 and Ca2+-mediated signalling (Brunn 
et al, 1996; Davies et al, 2000; Tolloczko et al, 2004; Gharbi et al, 2007).  For the purpose of the data 
presented here, however, this is not an issue as the aim of using LY 294002 was to abrogate PI3K 
signalling, and many of these proteins are components of this pathway.  PD 184352 is a commonly used 
specific MAPK pathway inhibitor that acts by preventing the activation of MEK1 (the kinase responsible 
for phosphorylating ERK 1/2), and, consequently preventing the activation of both ERKs (Davies et al, 
2000).  We proceeded to co-incubate the previously tested compounds with the MAPK and PI3K 
pathway inhibitors to selectively block each cascade individually.  The main aims of this were to 
investigate the impact of these signalling pathways on the formation of MCF-12A acini and whether they 
are involved in the estrogen-induced disruption of these acinar structures. 
5.3 Materials and Methods 
LY 294002 (Promega, Southampton, UK) and PD 184352 (Promega, Southampton, UK) were 
resuspended in DMSO to produce 50 mM stock solutions.  Subsequent dilutions to make working stock 
concentrations of 10 µM and 25 µM, respectively, were also prepared using DMSO.  Dilutions were 
stored at -20oC and allowed to reach room temperature prior to use. 
For incubation with the inhibitors, cells were pre-treated for 1 hour with 10 µM PI3K inhibitor, 
LY 294002 or 25 µM MEK inhibitor, PD 184352 and seeded onto Matrigel with 0.5% etOH, 1 nM E2, 10 
µM BPA or 10 µM n-propylparaben for 8 and 12 days, as described previously, as these were the time-
points where activated caspase-3 was observed most strongly (See Materials and Methods in Chapter 
III and IV).  Controls consisted of 0.5% etOH + 0.2% DMSO.  Inhibitor-free samples were also prepared, 
containing the test estrogenic compound at the same concentration as before in combination with 0.2% 
DMSO. 
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In order to confirm that the changes observed were due to interaction of estrogens with the 
studied cascades, cells were seeded and maintained as described previously for 16 days and treated 
with PD 184352 or LY 294002 in combination with varying concentrations of E2 (1 pM, 10pM, 1 nM).  
Controls consisted of 0.5% etOH or E2 + 0.2% DMSO. 
5.4 Results 
5.4.1 The Effect of MAPK and PI3K Pathway Inhibitors on Acini Disruption by 
Estrogenic Compounds 
One of the first observations made in our experiments was that the presence of the inhibitors affected 
the formation of acini, not only in estrogen-treated samples, but also in controls.  Most notable, was the 
observation that both inhibitors seemed to have a weak effect on proliferative control, as they reduced 
the overall number of acini formed in controls with inhibitor by approximately 50%, relative to controls 
without inhibitor.  A similar decrease in acini abundance was also observed in samples treated with 
treatment + inhibitor in comparison to treatment alone.  
More importantly, however, were the differences between MCF-12A acini treated with the 
selected estrogenic test compounds and the test compounds in combination with a MAPK or PI3K 
pathway inhibitor, which were observed after 8 days incubation in 3D culture (Figure 5.3).  The impact 
of the inhibitors was seen, primarily, in the size and shape of acini.  As can be seen in Figure 5.3 & 5.4, 
the presence of the PI3K inhibitor, LY 294002, resulted in acini that were spherical and notably smaller in 
diameter in relation to samples treated with the test compounds alone.  Interestingly, this effect, 
although observed with all the estrogenic compounds tested, was more marked in samples co-incubated 
with E2.  This could be because BPA and n-propylparaben exert greater malformation than E2, and 
hence, not all of their effects could be reverted to the same extent as the endogenous hormone.  
Alternatively, it could be that the effects of BPA and n-propylparaben are mediated by other pathways, 
which are not blocked by LY 294002.  Similarly, when estrogen-treated MCF-12A acini were co-
incubated with the MAPK pathway inhibitor, PD 184352, acini were again spherical and smaller in size, 
although larger than those observed upon co-incubation with LY 294002. 
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Figure 5.3: Confocal images of MCF-12A acini after 8 days in 3D culture with MAPK and PI3K pathway inhibitors: 
Samples were treated with 1 nM E2, 10 µM BPA or 10 µM n-propylparaben, alone or in combination with 10 µM LY 
294002 or 25 µM PD 184352, for 8 days.  Acini were then stained with antibodies against laminin V (red) and 
activated caspase-3 (green) to identify basement membrane and apoptotic cells, respectively.  Cells were 
counterstained with TOPRO-3 (blue) as a nuclear stain.  Controls consisted of 0.5% ethanol with 0.2% DMSO, 10 
µM LY 294002 or 25 µM PD 184352.  
12 day co-incubation of treated samples with LY 294002 resulted in spherical acini that were slightly 
smaller in diameter than those observed in solvent controls (Figure 5.4).  Notable luminal clearing was 
also observed in E2-treated samples co-incubated with LY 294002 at the same time-point.  However, this 
effect was not observed with BPA or n-propylparaben, highlighting the possibility that these compounds 
may act through pathways distinct from those of E2. 
After 12 days in 3D culture, treatment with PD 184352 alone, had an impact on acini formation, 
as these exhibited some luminal filling (Figure 5.4).  Given that PI3K and MAPK signalling pathways are 
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implicated in cell survival, proliferation and apoptosis, it is hardly surprising that the inhibition of these 
pathways affected acini. 
 
 
Figure 5.4: Confocal images of MCF-12A acini after 12 days in 3D culture with MAPK and PI3K pathway 
inhibitors. Samples were treated with 1 nM E2, 10 µM BPA or 10 µM n-propylparaben, alone or in combination 
with 10 µM LY 294002 or 25 µM PD 184352, for 12 days.  Acini were then stained with antibodies against laminin V 
(red) and activated caspase-3 (green) to identify basement membrane and apoptotic cells, respectively.  Cells were 
counterstained with TOPRO-3 (blue) as a nuclear stain.  Controls consisted of 0.5% ethanol + 0.2% DMSO, 10 µM LY 
294002 or 25 µM PD 184352. 
The results presented above suggest that in this 3D model, the PI3K and MAPK pathways are involved in 
proliferation, and to a smaller extent, luminal clearance.  Furthermore, the estrogenic test compounds 
may be eliciting their effects via these pathways, particularly in the case of overcoming growth arrest to 
induce malformations of MCF-12A acini, characterised by increased acinar size, irregular shape and 
luminal filling.  It would also appear that the effects of LY 294002 and PD 184352 differ suggesting that 
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the PI3K and MAPK pathways and individual specific roles in acini formation.  Co-incubation of 
treatments with LY 294002 gives rise to acini that are smaller in size and may indicate the main role of 
the PI3K pathway is concerned with proliferation.  On the other hand, co-incubation with PD 184352 
appeared to have more of an impact on lumen formation, suggesting that the MAPK pathway is more 
involved in apoptosis. 
5.4.2 Acini Quantification and Statistical Analysis 
MCF-12A acini cultured for 8 and 12 days in Matrigel were quantified as described previously. 
After 8 days incubation, LY 294002 with 0.5% ethanol resulted in acini that were smaller in diameter and 
contained less cells per acini.  PD 184352 did not have a significant impact on acini size or number of 
cells per acini in rthanol controls.  Although not statistically significant, a small reduction in acini size of 
E2-treated acini was observed when cells were co-incubated with LY 294002.  However, this observation 
was not made when cells were co-incubated with PD 184352.  The average number of cells was reduced 
upon co-incubation of E2 with LY 294002 or PD 184352 and strangely, the number of apoptotic cells was 
also reduced upon co-incubation with both pathway inhibitors.  Neither LY 294002 or PD 184352 were 
able to reverse the impact of BPA on acini size, or have a significant impact upon the average number of 
cells per acini or percentage of apoptotic cells.  LY 294002 and PD 184352 both significantly reduced 
acinar size and the number of cells per acini in n-propylparaben-treated samples, and this reversal of 
these characteristics was more pronounced than those observed with E2, suggesting that n-
proplyparaben may utilise the MAPK and PI3K pathways to a greater extent than endogenous E2 when 
eliciting its effects in these cells.  There was, however, no change in the number of apoptotic cells at this 
timepoint. 
Following 12 days incubation, ethanol control acini were of a similar size, and contained a similar 
number of cells, to those treated with LY 294002 or PD 184352.  The presence of PD 184352 did 
however result in a reduced percentage of apoptotic cells per acini.  In the case of BPA and n-
propylparaben, co-incubation with LY 294002 or PD 184352 resulted in reduced acini size and a decrease 
in the average number of cells per acini.  An increase in the percentage of apoptotic cells was also 
observed relative to cells treated with BPA or n-propylparaben alone.  LY 294002 or PD 184352 did not 
have a great impact on acini size of E2-treated acini, however, they did result in less cells present per 
acini.  This supports the findings from the LCM images where partial luminal clearing was observed with 
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the presence of pathway inhibitors in estrogen-treated samples (Figure 5.4).  As with BPA and n-
propylparaben, co-incubation of E2-treated acini with LY 294002 or PD 184352 significantly increased 
the percentage of apoptotic cells, and thus would indicate that inhibition of apoptosis through 
activation of the MAPK and PI3K pathways is one mechanism through which the test compounds were 
able to induce luminal filling (Figure 5.5). 
 
Figure 5.5: Quantification of acini size, number of cells per acini and percentage of apoptotic cells.  The size of 
acini (µm) and the number of cells per acini were determined by analyzing confocal images of the incubation 
periods of 8 and 12 days.  Data corresponds to mean ± SEM and results from three independent experiments, 
where a minimum of 10 representative acini were analysed per experiment. * (p<0.05), ** (p<0.01) and *** 
(p<0.001) indicate significant differences between treatments and controls. 
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5.5 Discussion 
In Chapter IV, the estrogenic test compounds disrupted the architecture of MCF-12A acini and this was 
mediated by both the ER and GPER-1.  Perturbations in the structure of the mammary gland in vivo, such 
as luminal filling and loss of organisation are indicative of a cancerous phenotype.   
Using a previously established 3D model, our results in this chapter indicate that the E2-induced 
malformations of MCF-12A acini involve, at least to some extent, the PI3K and MAPK signalling 
pathways.  This was concluded, as inhibition of these pathways partially reverted some of the 
malformations induced by the estrogenic test compounds, such as the loss of proliferative control and 
luminal filling.   PI3K and MAPK signalling are often hyper-activated in cancer (Bellacosa et al, 1995; 
Hilger et al, 2002; Di Cosimo et al, 2007) and are often associated with resistance to anti-hormone 
therapy (McGlynn et al, 2009).  Previous work has shown that in 3D cultures of mammary epithelial 
cells, the increased expression of activated AKT is associated with mis-shapened acini and increased 
proliferation (Debnath et al, 2003b; Isakoff et al, 2005).  In addition to these 3D culture observations, 
monolayer culture has provided insights into the consequences of hyper-activation of the PI3K pathway, 
such as anchorage-independent growth, independence from growth factors and evasion from anoikis 
(Isakoff et al, 2005).  All of these characteristics could have implications for 3D cultures in terms of 
acinar size and shape as well as the formation of the hollow lumen. 
As a large number of studies have now demonstrated that extranuclear signalling cascades, in 
particular the PI3K and Erk pathways, are targets for estrogenic action, it is plausible that some of the 
effects induced by estrogens on acini formation involve interactions with these secondary messenger 
cascades.  The results presented in this chapter indicate that, in fact, PI3K and MAPK signalling are 
involved in MCF-12A acini formation and that estrogens interact with these pathways to exert their 
effect on these spheroid structures.   
5.5.1 The PI3K Signalling Pathway is Involved in Estrogen-Induced Acinar 
Malformations 
Treatment with the PI3K inhibitor, LY 294002, in combination with the test compounds, resulted in a 
decrease in the number of acini formed and acini size at all time points, and thus reverted some of the 
effects induced by the estrogenic compounds.  In, E2, but not BPA or n-propylparaben-treated samples, 
there was also increased luminal clearing and activation of caspase-3, when samples were co-incubated 
with this inhibitor. 
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The PI3K pathway, and in particular the activation state of AKT, is already known to be 
important for the morphogenesis of MCF-10A acini.  AKT in its active form is present only in the outer 
cells of MCF-10A acini under normal conditions (Debnath et al, 2003b).  This could explain why, normally, 
outer cells in contact with the basement membrane survive, whereas the central cells undergo 
apoptosis and are cleared to form the hollow lumen.  Aberrations in PI3K signalling have, however, been 
shown to impact upon the formation of growth-arrested, spherical acini.  The effect of LY 294002 on 
acini size in 3D cultures has also been observed in cell derived from hamster mammary tumours and 
cultured in Matrigel (Polo et al, 2010).  This suggests that during acini formation, the PI3K pathway plays 
a role in the control of cellular proliferation.  These findings are further supported by other groups that 
have observed decreased proliferation, decreased EGFR, cyclin D1 and β1 integrin, increased PTEN and 
reversion of some malignant phenotypes in response to PI3K inhibition in 3D culture (Wang et al, 2002; 
Isakoff et al, 2005; Provenzano et al, 2009; Eritja et al, 2010).  Furthermore, it has been demonstrated 
that PI3K signalling is a target for estrogenic action (Watson et al, 2007; Yin et al, 2007) and is implicated 
in the E2-induced proliferation of various cell types.  PI3K pathway inhibitors, such as LY 294002 have 
been shown to inhibit E2-mediated transcription and progression into the S phase of the cell cycle 
(Lobenhofer et al, 2000; Marino et al, 2003; Gao et al, 2004). 
Overall, our data is in agreement with previous publications by suggesting that the PI3K 
signalling pathway is involved in MCF-12A acini morphogenesis, especially by controlling cellular 
proliferation.    
It was clear, from our results that the effect of PI3K pathway inhibition was more marked with 
E2 treatment than BPA or n-propylparaben. This suggests that the mechanism of action of the 
xenoestrogens differs from that of E2.  Similar observations were also made upon MAPK inhibition of E2, 
BPA and n-propylparaben treated MCF-12A acini.  Indeed, it has been shown that ERK signalling 
activation patterns, i.e. the time points at which ERK is phosphorylated and de-phosphorylated following 
treatment of E2, differ from BPA (Wang et al, 2005).  At this point is noteworthy to discuss briefly the 
interactions of xenoestrogens, such as BPA, with estrogen-responsive receptors in terms of their elicited 
genomic and non-genomic responses.  Many studies have shown that xenoestrogens exert very weak 
genomic responses, and only at concentrations that are at least 1000 times that observed with E2 
(reviewed in Bulayeva & Watson, 2004).  It is generally accepted that these genomic response are 
mediated by the classical ER receptors: ERα and ERβ.  However, as described in Chapter I, estrogens are 
capable of non-genomic events, which is what we aimed to study in this chapter.  Unlike genomic 
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responses, the exact mechanism underlying the non-genomic effects of estrogens remains of much 
debate, although it is commonly accepted that a membrane-associated estrogen-responsive receptor is 
probably involved.  When Bulayeva & Watson (2004) investigated the patterns of ERK phosphorylation 
of pituitary tumour cells in response to 1 nM E2 they observed a bi-modal ERK activation pattern that 
occurred three times after treatment application.  When, however, xenoestrogens at a concentration of 
1 nM were applied, the patterns of ERK activation differed depending on the xenoestrogen tested.  
These responses ranged from no response at all, in the case of BPA, to single sustained ERK activation, in 
the case of the coumestrol.  Although in this instance, BPA did not induce activation of the ERK pathway, 
the data clearly shows that E2 and xenoestrogens induce different patterns of non-genomic responses.  
Other data has shown that even at 1 nM concentrations, BPA is capable of stimulating the release of 
intracellular calcium, a key secondary messenger implicated in the PI3K pathway (Wozniak et al, 2005).  
Although our data demonstrated that endogenous estrogens and xenoestrogens are capable of inducing 
distinctly different non-genomic responses, it has not yet shed light on as to whether the mechanism of 
action is different, or how.   
A possibility that remains is that the difference in responses to the cascade inhibitors is not 
associated with a different mechanism of action, but due to a potency or concentration issue.  As shown 
in previous chapters, we have shown that in 3D cultures of MCF-12A cells, the effects of the exogenous 
estrogens are more marked than those of the endogenous E2. Although the concentrations selected for 
these studies were chosen based on previous publications, showing a similar level of effect for all 
chemicals in cells such as MCF-7 (Kabil et al, 2008; Silva et al, 2011), it is possible that, in this 
experimental setting, chemicals have different potencies, and BPA and n-propylparaben are more 
potent than E2.  In this case, the same concentration of LY 294002 would have potentially a weaker 
impact on a xenoestrogens’ effects than on E2, even if all chemicals acted via the same mechanisms.  In 
the future, it would therefore be of interest to perform the experiments described here with lower 
concentrations of both BPA and n-propylparaben to ascertain whether their effects could be reverted 
further by LY 294002. 
Taken together with the reported literature, the data presented in this chapter and in Chapter 
IV, implies that estrogens promote cellular proliferation in 3D cultures of MCF-12A cells.   It would also 
appear that the activation of the PI3K pathway by estrogens is, in part, responsible for the MCF-12A 
malformations associated with increased and dysregulated proliferation.  As described previously, 
hyperactivation of the PI3K pathway in 3D culture models results in large misshapen acini with increased 
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cellular proliferation (Liu et al, 2004; Brummer et al, 2006; Schweppe et al, 2009), similar to those 
observed upon E2 treatment.  This observation is comparable to the process of tumourigenesis in which, 
PI3K signalling is often hyper-activated.  This has consequences for proliferation, apoptosis, adhesion, 
migration, metastasis, angiogenesis and the correct arrangement of the cytoskeleton (Levine et al, 2005; 
Yin et al, 2007; Liu et al, 2010).  It is therefore plausible that the estrogen-induced activation of the PI3K 
pathway, as inferred by the reversal of estrogen’s effects upon co-incubation with LY 294002, may have 
implications for tumourigenesis and cancer progression in vivo. 
5.5.2 The MAPK Signalling Pathways are Involved in E2-Induced Acinar 
Malformations 
Acini treated with the test compounds in combination with the MAPK pathway inhibitor, PD 184352, 
became spherical in shape and formed growth-arrested structures with some evidence of luminal 
clearing.  This suggests that the actions of estrogens are not solely mediated by the PI3K pathway, but 
also by the MAPK cascade.  The MAPK pathway involves a kinase cascade and is involved in proliferation, 
apoptosis, survival, differentiation and motility in response to mitogens and growth factors in normal 
cells.  However during carcinogenesis, overexpression, amplification or mutations in the various 
components of the pathway result in the dysregulation of these processes, leading to hyper-activation 
of the pathway.   
 Inhibition of the MAPK pathway by PD 184352 initially produced acini that were smaller in size 
when compared to etOH controls.  This decrease in acinar size, however, was not observed after 12 days 
incubation.  This suggests that inhibition of the MAPK pathway delays acinar proliferation, thus the 
smaller acinar size, however, other mechanisms may overcome this proliferative suppression.  This 
could, for example, be achieved by activation of the PI3K pathway, which as described above, estrogens 
are capable of achieving in our 3D model. 
In addition to a reverting the estrogen-induced increased acinar size, MAPK pathway inhibition 
also resulted in spherical acini.  This suggests that proliferation in the presence of the MAPK inhibitor, 
PD 184352, acini were able to recuperate the proliferative control that was lost in response to estrogen 
treatment.  These observations indicate that estrogens seem to illicit their proliferative effects on 3D 
cultures of MCF-12A cells, at least in part, via activation of the MAPK pathway.  A plausible mechanism 
for this may be increased progression through the cell cycle in response to estrogens.  Indeed, one of 
the effectors of the MAPK pathway is cyclin D1 (Lobenhofer et al, 2000; Marino et al, 2002), a key 
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regulator of cell cycle progression and importantly, cyclin D1 expression can also be induced by E2 
(Planas-Silva et al, 2001).  The role of this protein is to facilitate the passage of cells through the G1/S 
boundary of the cell cycle, and thus an increase in cyclin D1 expression correlates with increased 
proliferation.  Importantly E2-induced progression through G1 to S phase of the cell cycle in response to 
E2 is inhibited by MAPK inhibition (Lobenhofer et al, 2000).  The results presented above do not elude to 
whether the levels of cyclin D1 were affected by estrogen or pathway inhibitor treatment, although the 
possibility of a role for this key regulator of cell cycle progression remains plausible and warrants further 
investigation. 
After 12 day co-incubation with PD 184352, increased luminal clearance and activated caspase-3 
expression was observed, suggesting reduced cell survival and increased apoptosis in response to MAPK 
signalling inhibition, in addition to the decreased proliferation described previously.  In Chapter III, we 
defined a time-course for the morphogenesis of MCF-12A acini .  In this time-course, the onset of 
apoptosis, as inferred by the expression of activated caspase-3, occurred after 8 days incubation.  This 
suggests that the MAPK cascades are not solely responsible for the reduction in apoptosis in response to 
the test compounds but that other, earlier signalling pathways may be involved.  Nevertheless, 
estrogens appear to reduce apoptosis and inhibit lumen formation, in part via activation of the MAPK 
pathway.  Indeed, it has previously been shown that activation of MEK protects cells from apoptosis and 
autophagy by inhibiting the expression and activation of pro-apoptotic Bim (Thaker et al, 2001; Reginato 
et al, 2005; Wickenden et al, 2010).  Bim phosphorylation by ERK1/2 prevents its association with Bcl-2 
and Bcl-xl, which enables these anti-apoptotic factors to bind to pro-apoptotic Bax and prevent 
apoptosis (Ewings et al, 2007; bEwings et al, 2007). Furthermore, Bim’s phosphorylation promotes its 
degradation (Ley et al, 2003).  This presents one mechanism through which estrogen-activated MAPK 
signalling could induce luminal filling, although this malformation was not completely reverted by MEK 
or PI3K inhibition, implying that a combination of signalling cascades are involved or that other 
estrogen-activated pathways or compensating upon inhibition of one pathway, as demonstrated by 
Pearson & Hunter (2009). 
 The data presented in this chapter adds to the existing body of evidence that shows that E2, and 
xenoestrogens, such as BPA and n-propylparaben are capable of eliciting non-genomic effects such as 
activation of the MAPK pathway (Migliaccio et al, 1996).  This ultimately leads to increased cellular 
proliferation and decreased apoptosis (Chen et al, 2004; Watson et al, 2007; Sheng & Zhu, 2011).   
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5.5.3 Conclusions 
Over-activation of signalling pathways is one mechanism in which breast tumours acquire resistance to 
anti-hormone therapy (Isakoff et al, 2005; Liu et al, 2007; McGlynn et al, 2009; Musgrove & Sutherland, 
2009).  The results above indicate that estrogens act through both PI3K and MAPK signalling to increase 
cellular proliferation and cell survival, resulting in deformed, filled acini that evade growth-arrest.  It was 
observed before, that the effects of n-propylparaben were not reverted by treatment with ER or GPER-1 
antagonists.  Interestingly, the results presented in this chapter show that PI3K and MAPK signalling 
mediate, to some extent, the effects of n-propylparaben, particularly in relation to proliferation.  This 
was inferred from the decrease in acinar size and reversion to a more spherical shape when n-
propylparaben-treated MCF-12A acini were co-incubated with the PI3K pathway inhibitor, LY 294002. 
Further to this, the MAPK pathway inhibitor, PD 184352 also resulted in smaller, more spherical acini 
with increased signs of apoptosis and luminal clearing.  Consistent with these results, increased AKT 
activity in tumourigenic MCF-7 cells has been shown to result in ICI 182780 resistance and incubation of 
3D cultures of MCF-7 cells with LY 294002 result in spherical acini displaying hollow lumen (Beeram et al, 
2007; Vahidnezhad et al, 2009).  This highlights that the non-genomic mechanisms of estrogens, such as 
increased proliferation due to the activation of the PI3K or MAPK pathways, may play a role in breast 
carcinogenesis and resistance to anti-hormone therapy.  Although not conclusive, (and more work is 
required) this could indicate that complete reversion of a cancer-like phenotype both in vitro and in vivo 
requires therapy involving a combination of anti-hormone treatment and MAPK and PI3K signalling 
inhibition. 
Finally, the data presented here supports the hypothesis that endogenous estrogens and 
xenoestrogens are capable of inducing non-genomic responses.  Through the activation of signalling 
pathways, such as that of the PI3K and MAPK cascades, estrogenic compounds may in vivo, interfere 
with the normal actions of endogenous estrogen.  Activation of these pathways may lead to cross-talk 
between estrogen and growth factor signalling, as described in Chapter I and this may have implications 
for physiological signalling pathways, causing them to become hyper-activated.  In this way therefore, 
estrogens are capable of inducing rapid cellular responses, such as increasing cellular proliferation, that 
are normally performed in response to growth factor stimulation. 
It cannot be determined whether the mediator of the non-genomic actions of estrogens is a 
membrane bound form of ER, GPER-1 or perhaps another undefined receptor.  However, given that 
both ER and GPER-1 antagonists were able to revert some of the effects induced by estrogens, both may 
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be implicated in the progression to a cancer-like phenotype.  In any case, the data presented in this 
chapter and in Chapter IV, clearly shows that estrogens are capable of disrupting MCF-12A acini 
morphogenesis to some extent via the ER and GPER-1, and possibly other receptors.  Furthermore, the 
disruption of acini by estrogens also appears to involve the PI3K and MAPK pathways, implying that the 
mode of action of the disruptive effects of estrogens is at least in part non-genomic.  These findings may 
have implications for how breast cancer is treated, as common ER antagonists, such as Fulvestrant and 
Tamoxifen do not target GPER-1.  This would allow GPER-1 competent cells to continue to respond to 
estrogens through activation of signalling pathways, such as PI3K and MAPK.  It would therefore be of 
interest to investigate whether a combination of receptor and pathway antagonism is capable of further 
reverting the estrogen-induced MCF-12A acinar malformations in our 3D culture model. 
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Chapter VI: The Role of Estrogen-Receptive Receptors in Mediating the 
Effects of Estrogens 
 
From the data presented in Chapter IV and V, it became apparent that both endogenous and exogenous 
estrogens have the ability to disrupt the morphogenesis of MCF-12A acini in 3D culture.  The described 
structural changes in acini, i.e. luminal filling; increased size; and irregular shape, have been previously 
associated with a dysregulation of apoptosis and proliferation processes (Debnath et al, 2002; Shaw et 
al, 2004).  In addition, the data presented in Chapter V, shows that by blocking pathways known to 
mediate such processes (such as PI3K and ERK), some of the detrimental effects of the test compounds 
can be reverted.  These observations provide indirect evidence that estrogens interact with cell growth 
and death to induce MCF-12A acini malformations. However, direct evidence of the impact of estrogens 
on these cellular functions in MCF-12A acini is still missing. 
 To date, the vast majority of evidence gathered concerning the intracellular targets of estrogens 
in vitro has been obtained from breast cancer cells, such as the MCF-7 cell line (Lucas et al, 2010).  The 
same wealth of knowledge, however, is lacking for the non-tumourigenic MCF-12A cell line that has 
been utilised in this study.  In Chapter II, we showed that estrogen treatment of MCF-12A cells had no 
significant impact upon cell number.  This indicated that estrogens, in monolayer cultures of this cell 
line, neither increased proliferation nor suppressed apoptosis.  However, in 3D cultures, estrogens 
clearly promoted MCF-12A cell proliferation and had an inhibitory effect upon apoptosis (See Chapter 
IV), as indicated by the increased acinar size and irregular shape of estrogen-treated acini with filled 
lumens. 
These conflicting observations between monolayer and 3D cultures of breast cells have been 
described before (Horning et al, 2008; Pickl & Ries CH, 2009).  Several reports have demonstrated that 
cells behave differently depending on whether they are cultured in monolayer or 3D, and that the latter 
has the closest resemblance to the arrangement of cells in vivo and, therefore, provides information 
that is more representative of what actually occurs in the human breast.  The differences between the 
behaviour of cells cultured in monolayer and in 3D models are exemplified by observations that cells 
cultured in 3D are more resistant to chemotherapy than monolayer-cultured cells; and the gene 
expression profiles of these cells differ depending on culture methodology (Horning et al, 2008).  
Furthermore, the organisation of the membrane receptor, HER2 differs depending on culture conditions 
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and this has an impact the activation of various signalling pathways, most notably, an increase in MAPK 
signalling in 3D cultures (Pickl & Ries CH, 2009). 
In order to compare the outcomes from monolayer and 3D cultures, and further understand the 
interaction of estrogens with the mechanisms involved in glandular architecture formation, we selected 
a number of well characterised apoptotic genes, as well as a few cytoplasmic kinases for both cellular 
death and survival, for the studies described in this chapter.  
6.1 Apoptosis: The Apoptotic Factors 
As discussed previously, apoptosis is the biological process by which a cell undergoes programmed cell 
death, and, along with proliferation, regulates tissue homeostasis.  In the context of breast 
development, the formation of the hollow mammary ducts and TDLUs is dependent on the fine balance 
between proliferation and apoptosis.  If apoptosis is dysregulated, such as during cancer, cells become 
resistant to apoptosis, which then results in the accumulation of cells.  The dysregulation of apoptosis in 
cancer cells can occur as a result of inhibition of tumour suppressor genes, the activation of oncogenes, 
impaired function of the apoptotic executioners or over-activation of pro-survival signalling pathways.  
This apoptotic resistance, in addition to contributing to tumour formation, can also impact upon a 
patient’s response to therapeutic strategies.  The data shown in chapters II, III and IV clearly 
demonstrates that estrogens impact upon mammary gland formation in a 3D model.  The estrogen-
treated acini in these experiments exhibited decreased levels of activated caspase-3 and filled lumens.  
This is indicative of a reduction in apoptosis, a process that, in part, is regulated by the ratio of pro-
apoptotic factors to anti-apoptotic factors. 
The interaction between pro- and anti-apoptotic factors can determine whether a cell enters 
apoptosis or not and has implications for prognosis (Figure 6.1).  This ratio between intracellular Bax and 
Bcl-2 has a significant impact upon a cell’s ability to respond to apoptotic stimuli, such as the detection 
of irreparable genetic aberrations: cells with a high Bax/Bcl-2 ratio are more sensitive to an apoptotic 
stimulus than cells with a lower Bax/Bcl- ratio.  For example, breast cancer patients with higher ratios of 
Bax/Bcl-2 respond better to chemotherapy.  On the other hand, in patients where this ratio is lower, Bcl-
2 is able to suppress therapy-induced apoptosis (Orlandi et al, 1999; Zhang et al, 1999).  If the 
expression of only a single apoptotic gene is dysregulated, the effect upon apoptosis may be negligible.  
However, the cumulative dysregulation of multiple apoptotic factors could impact upon the apoptotic 
process. 
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Pro-apoptotic factors include Bax and Bad, and members of the anti-apoptotic factor family 
include Bcl-2 and Bcl-xl.  The pro-apoptotic factors can be classified as Bax-like or BH3-only.  Bax-like 
apoptotic factors, such as Bax, contain the Bcl-2 homology domains BH1, BH2 and BH3.  Members of the 
BH3-only family contain just the BH3 domain and members include Bad, Bim and PUMA (reviewed in 
Adams & Cory, 2007).  The anti-apoptotic factors Bcl-2 and Bcl-xl are members of the Bcl-2 subfamily of 
anti-apoptotic factors and contain BH1, BH2, BH3 and BH4.  It is the presence of the BH3 domain that 
promotes the formation of homodimers and heterodimers of the apoptotic factors.  Specifically, it is 
thought that the C-terminal membrane anchor domains located in the BH3 binding pocket permits the 
dimerization process via the two terminal charged residues (Suzuki et al, 2000; Jeong et al, 2004).  The 
dimerization of the apoptotic factors can either promote apoptosis or have an inhibitory effect upon it, 
depending on the apoptotic factors involved.  For example, homodimerization of Bax promotes 
apoptosis; whereas, dimerization of Bcl-2 or Bcl-xl with Bax, inhibits apoptosis.  Both the levels and the 
activation status of these apoptotic factors are regulated by transcription, protein modification and 
degradation. 
 
 
Figure 6.1: Apoptotic Factors.  The interaction of pro- (green) and anti- (red) apoptotic factors and the impact 
upon apoptotic onset.  Bax dimerization induces apoptosis by promoting cytochrome c release from mitochondria.  
Bcl-2 or Bcl-xl binding to Bax inhibits the pro-apoptotic actions of Bax.  On the other hand, pro-apoptotic factors, 
such as Bad, PUMA and Bim, can bind to, and inhibit the actions of Bcl-2 and Bcl-xl. 
 
6.1.1 Bcl-2  
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The function of the anti-apoptotic factor, Bcl-2, is to sequester Bax, and inhibit apoptosis.  In normal 
breast tissue, Bcl-2 expression varies depending on the development stage of the mammary gland.  For 
example, in the developing breast tissue of the foetus, Bcl-2 expression is observed in the basal cell layer 
of the budding mammary gland (Nathan et al, 1994).  Furthermore, Bcl-2 expression shows cyclic 
variation through the menstrual cycle (Sabourin et al, 1994).  These observations have led to the idea 
that Bcl-2 is necessary for the growth and morphogenesis of the breast. 
Cell line studies have demonstrated that the basal expression of BCL-2 is higher in tumourigenic 
cells, such as in the MCF-7 and MDA-MB-231 cell lines, in comparison to non-tumourigenic cell lines, 
such as MCF-10A and MCF-12A (Zapata et al, 1998; Amundson et al, 2000).  Given that Bcl-2 is also 
commonly over-expressed in breast cancer, this may suggest that Bcl-2 is implicated in malignant 
progression (Nahta & Esteva, 2003).  This idea is further supported by observations that in breast 
cancer, Bcl-2 is expressed in 80% of tumours and this is associated with decreased levels of apoptosis, 
resistance to chemotherapy , increased tumour size and ER expression (Orlandi et al, 1999; Zhang et al, 
1999; Kymionis et al, 2001).  In 3D cultures, caspase-mediated apoptosis is associated with the 
formation of the hollow lumen of acini.  In a similar fashion to what occurs in vivo and in the human 
mammary gland, ectopic expression of Bcl-2, or indeed Bcl-xl, in 3D cultures of mammary epithelial cells 
results in the delayed formation of the hollow lumen (Debnath et al, 2002; Humphreys et al, 2006; 
Underwood et al, 2006).  This seems to indicate that Bcl-2 plays an important role in lumen formation 
during acini morphogenesis, but, given that its overexpression in vitro delays lumen formation, rather 
than inhibit it, suggests that other factors are also involved. 
In terms of its mode-of-action, Bcl-2 binds to Bax, localises to the outer mitochondrial 
membrane, nuclear membrane and endoplasmic reticulum, and functions to prevent Bax from forming 
homodimers and initiating mitochondria-mediated apoptosis (Krajewska et al, 1993; Jeong et al, 2004).  
The expression and activity of Bcl-2 can be regulated through transcription, microRNA (miRNA) binding 
and phosphorylation events (Cheema et al, 2003; Deng et al, 2004; Cimmino et al, 2005).  The activation 
of signalling pathways by growth factors, such as vascular endothelial growth factor (VEGF), increases 
the expression of Bcl-2 at the protein level (Pidgeon et al, 2001) and Bcl-2 transcription can be induced 
by the signal transducers and activation of transcription (STAT) transcription factor family (Lord et al, 
2000).  In the case of post-transcriptional gene regulation by miRNA, these single-stranded moieties bind 
to target sequences in mRNA, preventing mRNA translation and decreasing the corresponding protein 
level.  Hence, the presence of miRNAs that target Bcl-2 mRNA results in less Bcl-2 protein, which, 
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consequently, results in the promotion of apoptosis.  From the perspective of estrogen-mediated 
regulation of the Bcl-2 gene, miRNAs may also play a role.  Indeed, it has been demonstrated that E2 
induced a down-regulation in the expression of the miRNA, mi-R21, which targets BCL-2 
(Wickramasinghe et al, 2009).    Also important, for the scope of this thesis, is the fact that it has been 
established that E2 is capable of up-regulating BCL-2 expression in breast cancer cell lines (Wang & 
Phang, 1995; Lucas et al, 2010).  This up-regulation of BCL-2 expression potentially increases the ratio of 
pro- to anti-apoptotic factors and in particular the Bax/Bcl-2 ratio, favouring an anti-apoptotic effect.  
Indeed, Wang & Phang (1995) demonstrated that E2 increased Bcl-2 expression in MCF-7 cells, thus 
decreasing the Bax/Bcl-2 ratio, and this in turn resulted in decreased cell death.   
6.1.2 Bcl-xl 
Bcl-xl, an anti-apoptotic factor, localises to the cytosol or outer mitochondrial membrane.  If present in 
the form of homodimers, Bcl-xl resides in the cytosol, however, following the formation of heterodimers 
with Bad or Bax, it localises to the outer mitochondrial membrane (Jeong et al, 2004).  Bcl-xl exerts its 
anti-apoptotic function through the formation of heterodimers with Bax and, thus, preventing the 
homodimerisation of this factor and the apoptotic process that follows it (Billen et al, 2008).  It has been 
proposed that Bcl-xl binds to proteins involved in Bax activation, and this prevents the activation of Bax 
(bKim et al, 2006).   
 The activities of Bcl-xl can be regulated at both the transcriptional and post-translational level.  
At the transcriptional level, BCL-XL transcription is activated by extracellular growth factors, such as EGF 
or VEGF.  These growth factors activate the AKT and MAPK signalling pathways, which, in turn, induce 
the expression of c-Fos and c-Jun, transcription factors involved in the transcription of BCL-XL (Pidgeon 
et al, 2001; Takeuchi et al, 2006).  Post-translational events, such as the phosphorylation of Bcl-xl results 
in its inactivation and permits Bax dimerization with other Bax proteins (Scatena et al, 1998).   
 The over-expression of Bcl-xl in cancer is associated with resistance to p53-mediated apoptosis, 
increased metastasis and resistance to chemotherapy (Schott et al, 1995; Amundson et al, 2000; 
Fernández et al, 2000).  Although there is limited data available concerning the correlation between the 
ER and Bcl-xl expression, or the correlation between tumourigenic state and Bcl-xl, the basal expression 
of BCL-XL is up-regulated the MDA-MB-231 cell line, compared to non-tumourigenic cell lines 
(Amundson et al, 2000). 
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Based upon what is known about Bcl-2 and Bcl-xl, and their role in apoptosis, it is plausible that 
in our MCF-12A 3D model, the expression of these anti-apoptotic factors will be up-regulated in 
response to E2 treatment.  This could explain some of the anti-apoptotic effects (luminal filling and 
reduced activated-caspase-3) induced by estrogen treatment described in Chapter IV.  As mentioned 
above, it has already been documented that E2 is capable of up-regulating BCL-XL expression in MCF-7 
cells (Gadd et al, 2002).  There is, however, little reported data on the MCF-12A cell line.  For these 
reasons, it is important to investigate whether E2 can impact on BCL-2 and BCL-XL expression in the non-
tumourigenic MCF-10A and MCF-12A cell lines, in a similar fashion to those described in cancer cell 
lines. 
It is important to note that a splice variant of Bcl-xl exists, known as Bcl-xs.  This apoptotic factor 
is pro-apoptotic and its presence would therefore favour the initiation of the apoptotic process.  It is 
known to contain a transmembrane region in addition to BH3 and a BH4 domain (Boise et al, 1993).  Bcl-
xl on the otherhand contains the BH1, BH2, BH3 and BH4 domains.  Bcl-xs is hypothesised to be 
implicated in cancer cell apoptosis, based upon the observation that loss of Bcl-xs expression correlates 
with decreased survival in patients with myelogenous leukemia (Yamaguchi et al, 2002).  Bcl-xs localises 
to the mitochondria and is implicated in caspase-dependent and caspase-independent cytochrome c 
release and its activity is inhibited by the presence of Bcl-xl and Bcl-2, although its exact mechanism of 
action remains elusive (Chang et al, 1999; Lindenboim et al, 2001).   
6.1.3 Bax 
The pro-apoptotic factor, Bax is cytosolic and bound to anti-apoptotic factors, such as Bcl-xl.  However, 
upon its activation, Bax localizes to the outer mitochondrial membrane where it signals to the 
mitochondria to release cytochrome c and activate the effectors (the caspases) of apoptosis (Wolter et 
al, 1997; Suzuki et al, 2000).  Bax activation and its translocation to the mitochondrial membrane can 
occur as a result of phosphorylation via AKT or MAPK signalling pathways, however, depending on the 
site, phosphorylation can have the opposite effect and inactivate Bax (Gardai et al, 2004; Kim et al, 
2006).  In addition to phosphorylation events, the activity of Bax can be regulated at the level of 
transcription: wild type p53 (but not mutant p53) and c-Myc are able to initiate the transcription of the 
Bax gene (Miyashita & Reed, 1995; Mitchell et al, 2000).   
It has been demonstrated that the protein levels of Bax are reduced in invasive tumours of the 
breast (Krajewski et al, 1995; Baccouche et al, 2003).  Similar findings have also been identified in cell 
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lines: normal mammary cell lines have a higher basal expression of BAX in comparison to breast cancer 
cell lines (Bargou et al, 1995; Amundson et al, 2000).  This lower level of BAX expression reduces the 
ratio of pro-apoptotic to anti-apoptotic factors and is associated with increased metastasis and 
resistance to chemotherapy (Krajewski et al, 1995).  However, in cases of breast cancer where BAX 
expression is not decreased, patients tend to have a good prognosis and respond well to chemotherapy 
(Kapranos et al, 1997).  Literature concerning the influence of E2 upon BAX expression has 
demonstrated that in MCF-7 cells, E2 does not impact upon BAX expression, but may instead disrupt the 
apoptotic factor ratio by increasing BCL-2 expression (Wang & Phang, 1995).  It remains to be seen if this 
is also the case in the MCF-12A cell line and whether if, in a 3D culture system estrogens have a similar 
impact upon the expression of apoptotic factors such as BAX. 
6.1.4 Bad 
Bad is a cytosolic, pro-apoptotic factor, which in its inactive state is hyperphosphorylated.  However, in 
the presence of an apoptotic stimulus, Bad is dephosphorylated, migrates to the mitochondria and 
forms heterodimers with Bcl-2 and Bcl-xl.  Transcriptionally, BAD expression is controlled by p53, which 
acts to initiate transcription.  Bad, when in excess, then acts to negatively regulate the entry of p53 to 
the nucleus through the formation of Bad/p53 complexes and, thus, prevents further Bad transcription 
(Jiang et al, 2006).  At the post-translational level, Bad is inactivated by phosphorylation at specific 
serine residues: Ser112, Ser136 and Ser 155, via the AKT pathway and this can be induced by EGF 
(Chattopadhyay et al, 2001; Ezzoukhry et al, 2011).  This phosphorylation results in the formation of a 
complex comprised of Bad and 14-3-3 proteins in the cytosol and prevents Bad’s interaction with Bcl-2 
or Bcl-xl (Zha et al, 1996), which leaves these anti-apoptotic factors free to form heterodimers with Bax 
and prevent apoptosis.   
In non-malignant breast tissue, the basal levels of Bad are higher than those present in other 
tissues and this implies that Bad may have a specialized function in the breast (Kitada et al, 1998).  BAD 
expression is documented to be unaffected by E2 treatment in neuronal cells (Dubal et al, 1999), but 
there is little literature available concerning the effects of estrogens on Bad expression in breast cells or 
if GPER-1 has any potential role in the regulation of BAD.  However, it has been shown that the 
expression of Bad in patients with breast carcinoma is reduced, compared to normal mammary tissue, 
suggesting that the suppression of Bad could be involved in the progression to a malignant phenotype in 
the breast (Yu et al, 2010). 
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6.2 Impact of Estrogens on the Expression Profile of Apoptotic Genes: Evaluating 
the Mechanisms Behind Estrogen Disruption During Acini Morphogenesis 
It is clear that the literature concerning the impact of estrogens upon apoptotic gene expression and the 
role of GPER-1 in these transcriptional responses, is limited.  This lack of data is particularly notable for 
the MCF-12A cell line.  However, with an important role for apoptosis in the formation of lumen in acini 
(Chapter IV), the observed impact of estrogens on MCF-12A acini morphogenesis and the indication 
from other cell lines that gene expression of apoptotic genes can be modulated by estrogens, it is likely 
our test chemicals also influence expression of these genes in MCF-12A cells, and this is an issue that 
requires further investigation.  In Chapter IV, the co-incubation of E2 with either ER or GPER-1 
antagonists partially reverted some of the estrogen-induced MCF-12A acini malformations, in terms of 
luminal clearance, suggesting an anti-apoptotic role for estrogens, mediated by both the ER and GPER-1.  
In order to take this work further and develop an understanding of the mechanisms and genes involved 
in such effects, we decided to follow a similar approach to investigate whether the ER or GPER-1 were 
involved in the regulation of expression of apoptosis-related genes following E2 treatment.  For that, 
MCF-12A cells were treated with both ER and GPER-1 agonists alone and in combination with specific 
receptor inhibitors, prior to gene expression analysis. 
Ideally, the gene expression analysis experiments would have been conducted in 3D cultures of 
MCF-12A cells, as these are believed to be more physiologically relevant, as discussed previously.  
However, financial, time and technical constraints hindered this.  It was decided, instead, to optimise 
primers and perform initial experiments in monolayer cultures of MCF-12A and other cell lines.  
Following these preliminary experiments, where primer pairs would be optimised and initial expression 
profiles obtained, experiments were to be repeated with 3D cultures of MCF-12A cells.  
In the interest of investigating whether the tumourigenic status, or indeed the ER status, of a 
cell line had an impact on changes in gene expression in response to E2, the same four cell lines in 
Chapter II were treated, and real-time PCR was used to analyse gene expression.  The data obtained for 
monolayer cultures of MCF-12A cells following the various treatments will be valuable for comparison 
with 3D cultures of estrogen-treated MCF-12A cells in future gene analysis experiments.  Primarily, this 
will enable us to determine whether the genomic responses to estrogen in monolayer are an accurate 
representation of what occurs in a more physiologically-relevant 3D setting. 
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6.3 Non-Genomic Effects of Estrogens in MCF-12A cells: An Alternative 
Mechanisms for Acini Disruption 
Estrogens do not just impact upon transcription, and, as discussed in previous chapters, the non-
genomic responses to estrogen have been explored in detail (Improta-Brears et al, 1999; Sun et al, 
2001).  As described in Chapter I and Chapter V, estrogens can exert their effects via non-genomic 
mechanisms.  This is exemplified by the activation of the PI3K and MAPK cascades and has been 
reported in various cell lines (Castoria et al, 1999; Improta-Brears et al, 1999; Sun et al, 2001).  However, 
similarly to the expression profiles of apoptosis-related genes, there is little data available concerning 
the non-genomic actions of estrogens in the MCF-12A cell line.  As observed in Chapter V, in 3D cultures 
of estrogen-treated MCF-12A cells co-incubated with PI3K or ERK1/2 inhibitors, the malformations 
induced by estrogens were partially reverted.  Similar observations have been made in previous 
publications, where the PI3K and MAPK pathways appeared to be implicated in acini formation of 
mouse mammary tumour cells and in 3D cultures of MCF-10A cells (Debnath et al, 2002; Yanochko & 
Eckhart, 2006; Polo et al, 2010).  Similarly, work by Schedin and colleagues (Schedin et al, 2004) has 
shown that 3D cultures of MCF-12A cells, which have been transformed through ectopic expression of 
Ras, present filled lumens, suggesting that over-activation of Ras signalling (a component of the MAPK 
pathway) impacts upon apoptosis and proliferation (Figure 6.2).   
 
Figure 6.2: Ras mutations induce luminal filling in 3D cultures of MCF-12A cells.  Wild-type MCF-12A cells form 
spherical hollow acini in 3D culture whereas Ras-transformed MCF-12A cells form solid masses.  Size bars equal 25 
µm (Image from Schedin et al, 2004). 
The data presented in Chapter V adds to this knowledge and indicates that the MAPK and PI3K 
pathways seem to mediate the effects of estrogens in 3D cultures of MCF-12A cells.  This could 
potentially mean that estrogens exert non-genomic effects via activation of signalling cascades in 3D 
191 
 
cultures of non-transformed breast epithelial cells, to induce a phenotype that resembles that of breast 
cancer.  To date, there is no direct evidence that estrogens activate PI3K or MAPK signalling cascades in 
monolayer, or indeed 3D cultures, of MCF-12A cells.  As discussed previously, responses to treatments 
can differ depending on whether cells are cultured in monolayer or in 3D.  In order to investigate if 
estrogens activate MAPK and PI3K signalling in a 3D setting, it was first necessary to establish whether 
this occurred in MCF-12A monolayer cultures and optimise antibodies for future work.  Unfortunately, 
due to time and technical constraints, it was not possible to progress and investigate the impact of E2 on 
MAPK and PI3K signalling by protein analysis in 3D cultures.  Nevertheless, the monolayer culture of 
estrogen-treated MCF-12A cells has still provided us with some knowledge regarding the non-genomic 
responses to estrogens in this cell line. 
 As discussed previously, GPER-1 is capable of mediating some of the non-genomic effects of 
estrogens, and its activation can have implications for PI3K and MAPK signalling (Figure 6.3). 
 
 
Figure 6.3: GPCR-mediated signalling.  Activation of G proteins following ligand binding to the GPCR induces the 
MAPK and PI3K signalling pathways through the formation of secondary messengers. 
 
As for its role in cancer, GPER-1 gene expression has found to be decreased in breast cancer samples 
and its expression correlates with ERα expression (Kuo et al, 2007).  In breast cancer GPER-1 is reported 
to stimulate the proliferation, migration, metastatic potential and drug resistance cumulating in a 
poorer prognosis (Maggiolini et al, 2004; Filardo et al, 2006/2008; Pandey et al, 2009).  Previous work 
has demonstrated that E2 and BPA, are able to induce ERK1 and ERK2 activation in various human 
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breast cancer cell lines via the activation of GPER-1, including the ER negative, but GPER-1 positive cell 
line, SKBR3 (Dong et al, 2011).  This observation is contrary to the hypothesis that GPER-1 requires the 
ER to mediate the actions of E2. 
The role of GPER-1 in the regulation of apoptotic genes remains poorly understood, as is the role 
of this receptor in mediating in the non-genomic actions of estrogens in the MCF-12A cell line.  Gene 
analysis by real-time PCR following treatment with E2 in combination with G-15 was performed to 
investigate the impact of E2 upon the expression of key apoptotic factors.  Further to this protein 
analysis was also performed to study the activation of key proteins involved in PI3K and ERK signalling. 
6.4 Materials and Methods 
6.4.1 Preparation of Cultures for Apoptotic Gene Expression Studies 
The MCF-10A, MCF-12A, MCF-7 and MDA-MB-231 cell lines were seeded into 6-well plates at a density 
of 25,000 cells per ml in full media and allowed to reach 70% confluency.  The media was then replaced 
with phenol red-free assay media containing 0.5% CDS serum.  After 24 h of growth factor and estrogen 
depletion, cells were treated with E2 (1 nM) with or without 30 min pre-incubation with 100 nM ICI 
182,780 or 10 nM G-15, for 12 hours.  In addition, cells were also treated with 100 nM G-1 with or 
without 30 min pre-incubation with 100 nM ICI 182,780 or 10 nM G-15 for 12 hours.  RNA extraction and 
RT real-time PCR were performed, as described previously.  Solvent controls consisted of 0.5% ethanol + 
0.2% DMSO.   
6.4.2 Primer Design 
Primers for the apoptotic factors: BCL-2, BCL-XL, BAX, and BAD were designed based on their mRNA 
sequence (Genebank), using Beacon Designer 5TM.  To ensure good quality primers for real-time PCR, 
these were designed with a GC content higher than 50%, a Tm of 50-65
oC, no repeating sequences longer 
than 3 bases, and no complimentary pairing of primers (Bustin, 2002). 
To optimise the designed primer pairs, a 10-fold cDNA dilution series (5 concentrations) was 
prepared and amplified in the presence of several concentrations of each specific primer pair.  The 
concentrations of primers tested were (forward:reverse): 100:100, 150:150, 200:200, 250:250 and 
300:300 nM.  A standard curve was constructed plotting the threshold cycle against cDNA dilution for 
each primer set concentration (Figure 6.4). 
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Figure 6.4: Example of a standard curve obtained during primer optimisation (BioRad, iCycler).  Threshold cycle is 
plotted against cDNA dilution (-1 corresponds to neat cDNA, -2 to 1:10 etc).  From the calculated standard curve, 
the correlation coefficient and PCR efficiency are automatically calculated. 
The calculated standard curve allows the correlation coefficient and PCR efficiency to be determined 
and, hence, allows the appropriate primer concentration to be selected.  In a perfect reaction, the total 
amount of target cDNA should double following each PCR cycle.  To assess this, various characteristics of 
the standard curve provide information regarding to how efficient the amplification reaction was.  The 
slope of a PCR standard curve is an indicator of PCR efficiency.  A slope of -3.3 for a 10-fold cDNA 
dilution series correlates to sample detection 3.3 cycles apart and corresponds to an approximate PCR 
efficiency of almost 100%.  This is an accepted parameter for optimised primers following real-time PCR 
of a 10-fold cDNA dilution and would indicate that each cycle of amplification resulted in the doubling of 
the amount of cDNA.  In addition to this, correlation coefficients greater than 0.99 indicate an optimised 
reaction, again, where cDNA content doubled during each PCR cycle for each cDNA dilution. 
For all reactions, a total volume of 20 µl reaction volume consisting of primer pairs at the 
concentrations listed in Table 6.1, 0.8 µl cDNA and 10 µl SYBR Green (Bio-Rad, Herts, UK) was added to 
each well of a 96-well PCR plate (Bio-Rad).  Amplification was performed using the iCycler (Biorad) and a 
2-step PCR protocol as described in Chapter II.   Briefly, cDNA was denatured at 95oC for 3 minutes and 
then cooled to 55oC to allow primer binding.  40 subsequent cycles of heating to 95oC for 1 minute and 
cooling to 55oC for 1 minute were performed to allow denaturing of the newly produced strands, further 
annealing and cDNA amplification.  Amplification curves were generated to calculate Ct values.  Melt 
curves were also generated upon real-time PCR protocol completion to ensure that there was a single 
amplification product.  Experiments were performed in duplicate three independent times.  As before, 
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β-ACTIN was used as a reference gene, as it is unaffected by estrogen treatment in the cell lines of 
choice. 
 
6.4.3 Real-Time Polymerase Chain Reaction (Real-Time PCR) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.4.4 Data and Statistical Analysis 
As described previously, the relative expression of the target genes were calculated using the Pfaffl 
equation (Chapter II, Equation 2.1).  Gene expression in treated and control samples was normalised 
against the reference gene, β-ACTIN.  Results were expressed as fold increase over controls (ethanol + 
DMSO) with the values for controls being set to 1.  In this case, an up-regulation in gene expression 
would show as a value greater than 1, and a down-regulation in gene expression would correspond to a 
decreased deviation from control conditions. 
Quantification of gene expression and REST were performed on the data obtained from the real-
time PCR.  The Pfaffl equation, as described previously, standardises the expression of target genes to 
the reference gene.  The mathematical model utilises PCR efficiencies for individual primer pairs and the 
mean Ct deviations between controls and sample groups.  The average expression ratio ± standard error 
Table 6.1: Primers for real-time PCR.  All primer pairs were ordered from Eurogentec. 
cDNA  Genebank 
Ascension 
Number 
Primer 
Sense 
Primer Sequence (5’-3’) Concentration 
(nM) 
Target 
Size 
(bp) 
β-
ACTIN 
X00351 Forward TGCTATCCAGGCTGTGCTAT 300 97 
Reverse GATGGAGTTGAAGGTAGGTT 300 
BCL-2 EU287875 Forward CCTGGTGGACAACATC 100 160 
  Reverse GAGCAGAGTCTTCAGAG 100  
BCL-XL BT007208 Forward TGAACAGGTAGTGAATGAAC 100 105 
  Reverse TCCTTGTCTACGCTTTCC 100  
BAX BC014175 Forward CCTCCTCTCCTACTTTGG 150 103 
  Reverse GCCTCAGCCCATCTTC 150  
BAD BT006678 Forward GATGAGTGACGAGTTTGTG 150 133 
  Reverse GCCCAAGTTCCGATCC 150  
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of the mean (SEM) was calculated for each gene and tested for statistical significance by a Pair Wise 
Fixed Reallocation Randomisation Test (REST© Relative Expression Software Tool) (Pfaffl et al, 2002).  
With this, comparisons were made between both controls and treatments; and between treatments and 
treatments with inhibitors.  P-values were also calculated using the REST© tool and a value of 0.05, or 
less, was considered statistically significant. 
Finally, to ascertain whether changes in BCL-2 and BAX expression would convey a pro- or anti-
apoptotic influence, the relative gene regulation values were used to calculate the Bax/Bcl-2 ratio 
relative to β-ACTIN.  This was calculated by dividing the relative gene regulation values (normalised to β-
ACTIN) of BAX by that of BCL-2.  A value of 1 was set for controls (solvent-treated samples).  Anything 
above this value indicates an increase in the Bax/Bcl-2 ratio which would favour apoptosis.  A value 
lower than 1 would indicate a decrease in the Bax/Bcl-2 ratio, and this would favour survival.  Statistical 
analysis was performed using the unpaired t-test and a value of < 0.05 was considered statistically 
significant. 
6.4.5 Activation of MAPK and PI3K Signalling Pathways 
For the MCF-10A, MCF-12A, MCF-7 and MDA-MB-231 cell lines, 1 million cells per ml were seeded in full 
media into 65 mm petri dishes and maintained at 37oC in 5% CO2.  Upon 80% confluency, the media was 
removed and replaced with phenol red-free media containing 0.5% CDS serum for 24 h.  Cells were 
treated with 20 ng/ml EGF, 1 nM E2 or 100 nM G-1 for 20 minutes with or without a 20 min pre-
incubation with 10 nM G-15.  Controls consisted of 0.5% etOH with 0.2% DMSO in phenol red-free 
media containing 0.5% CDS serum.  In these initial experiments, the ER antagonist, ICI 182,780 was not 
included as our aim was to investigate whether GPER-1 was capable of mediating the non-genomic 
responses to E2, in respect to PI3K and MAPK activation. 
Lysate preparation and western analysis were performed as described previously using the 
antibodies in Table 6.2.  Following image acquisition, membranes were stripped of the phosphorylation-
specific antibodies and re-probed with the corresponding total-protein antibody. 
To strip membranes after probing with phosphorylated antibodies, membranes were incubated 
at 50oC for 45 minutes with 4 ml 10% SDS, 2.5 ml 0.5 M Tris HCl pH 6.8, 13.5 ml water and 160 µl β-
mercaptoethanol.  The membranes were then washed three times for 10 minutes with TBS-Tween and 
blocked using 5% milk before probing with total AKT or total ERK antibodies (Table 6.2).  Detection was 
performed by ECL as described in Chapter II. 
196 
 
 
Table 6.2: Primary antibodies used for western blot analysis of AKT and MAPK signalling. 
Antibody Source Dilution 
P-AKT (Cell Signalling) Rabbit 1:1000 in 5% BSA 
Total AKT (Cell Signalling) Rabbit 1:1000 in 5% BSA 
P-ERK 1/2 (Cell Signalling Rabbit 1:3000 in 5% BSA 
Total ERK 1/2 (Cell Signalling) Rabbit 1:3000 in 5% BSA 
 
6.5 Results 
6.5.1 The Effects of E2 on Apoptotic Factor Expression 
In the MCF-12A cell line, E2 treatment significantly up-regulated BCL-2, BCL-XL and BAX expression 
relative to controls.  G-15 alone also induced an up-regulation in BCL-XL expression.  Co-incubation of E2 
with G-15 significantly reversed the E2-induced up-regulation of BAX, but failed to impact upon the 
effect of E2 on the remaining genes.  Treatment with G-1 led to an up-regulation of BCL-2 expression 
and this was strongly reverted upon co-incubation with G-15.  Strangely, ICI 182,780 also inhibited the 
effect of G-1 upon BCL-2 expression (Figure 6.5).   
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Figure 6.5: Fold changes in gene expression of apoptotic genes in MCF-12A cells.  Negative controls (etOH/DMSO) 
have been set to 1 and are shown as a horizontal dashed line.  A significant changes in expression in treatment 
relative to controls are referred to as (a).  Significant changes in gene expression relative to E2 (b) and G-1 (c) are 
also indicated.  P-values of 0.001 (***). 0.01 (**) and 0.05 (*) are indicated.  Error bars represent +/- standard 
error or the mean.  Data is representative of three experiments performed in duplicate. 
 
In MCF-10A cells, E2 only significantly decreased the expression of BAD.  Both combinations of E2 with 
ICI 182,780 and ICI 182,780 + G-15 led to a down-regulation of BAD expression relative to samples 
treated with the steroid alone.  An up-regulation of BCL-2 in response to G-15 and a down-regulation in 
BAX expression following ICI 182,780 treatment was also shown to be statistically significant. 
The up-regulation of BCL-2 expression in response to G-1 or G-1 with ICI 182,780 relative to 
etOH controls was deemed statistically significant.  G-1 treatment also significantly up-regulated BAX 
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expression relative to controls and the down-regulation in BAX expression upon co-incubation with G-15 
was deemed statistically significant relative to G-1 treated cells (Figure 6.6). 
 
Figure 6.6: Fold changes in gene expression of apoptotic genes in MCF-10A cells.  Negative controls (etOH/DMSO) 
have been set to 1 and are shown as a horizontal dashed line.  A significant changes in expression in treatment 
relative to controls are referred to as (a).  Significant changes in gene expression relative to E2 (b) and G-1 (c) are 
also indicated.  P-values of 0.001 (***). 0.01 (**) and 0.05 (*) are indicated.  Error bars represent +/- standard 
error or the mean.  Data is representative of three experiments performed in duplicate. 
 
In MCF-7 cells, E2 treatment significantly down-regulated the gene expression of BAX (p < 0.001) and 
BAD and up-regulated BCL-2 expression.  G-15 alone also appeared to down-regulate the expression of 
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BAX.  Co-incubation of E2 with ICI 182,780 or with both ICI 182,780 and G-15 significantly reverted the 
E2-induced up-regulation of BCL-2 expression.  This was despite the E2-induced BCL-2 up-regulation 
being considered statistically insignificant.  Although the up-regulation of BCL-XL expression in response 
to E2 was also considered insignificant, co-incubation with G-15 significantly increased gene expression 
relative to controls and E2-treated samples. G-15 and ICI 182,780 together caused a significant decrease 
in gene expression relative to controls and E2-treated samples.    Co-incubation of E2 with G-15 also 
increased BAX expression significantly, completely reversing the down-regulation induced by E2. 
G-1 treatment induced a down-regulation in the expression of BAX and neither ICI 182,780 or G-
15 had a significant impact upon this.  Strangely, G-1 in combination with either ICI 182,780 or G-15 
caused a significant up-regulation in BAD expression relative to controls (Figure 6.7). 
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Figure 6.7: Fold changes in gene expression of apoptotic genes in MCF-7 cells.  Negative controls (etOH/DMSO) 
have been set to 1 and are shown as a horizontal dashed line.  A significant changes in expression in treatment 
relative to controls are referred to as (a).  Significant changes in gene expression relative to E2 (b) and G-1 (c) are 
also indicated.  P-values of 0.001 (***). 0.01 (**) and 0.05 (*) are indicated.  Error bars represent +/- standard 
error or the mean.  Data is representative of three experiments performed in duplicate. 
 
In MDA-MB-231 cells, ICI 182,780 alone induced a significant down-regulation in BAX expression.  The 
increase in expression of BCL-2 induced by E2 was insignificant.  The E2-induced down-regulation of BCL-
XL expression was, likewise, insignificant.  It remains to be seen, whether these seemingly insignificant 
changes in gene expression impact upon the Bax/Bcl-2 ratio, or indeed, if the cumulative effect of E2 on 
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apoptotic factor expression is more important than the impact of E2 on an individual gene’s level of 
expression.  E2 also caused an insignificant down-regulation in the expression of BAX.  This was reversed 
upon co-incubation with G-15.  Only BCL-2 expression was significantly influenced by treatment with G-
1.  In this case, an up-regulation in gene expression was observed that was unaffected by co-incubation 
with either G-15 or ICI 182,780 (Figure 6.8). 
 
 
Figure 6.8: Fold changes in gene expression of apoptotic genes in MDA-MB-231 cells.  Negative controls 
(etOH/DMSO) have been set to 1 and are shown as a horizontal dashed line.  Significant changes in expression in 
treatment relative to controls are referred to as (a).   A significant changes in gene expression relative to E2 (b) and 
G-1 (c) are also indicated.  P-values of 0.001 (***). 0.01 (**) and 0.05 (*) are indicated.  Error bars represent +/- 
standard error or the mean.  Data is representative of three experiments performed in duplicate. 
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Table 6.3: Summary of gene expression in response to E2 and antagonists to the ER and GPER-1. ↑ indicates an 
up-regulation in gene expression and ↓indicates a down-regulation. a denotes relative to controls, b and c denote 
relative to E2 and G-1 treated cells, respectively 
Treatment Bcl-2 Bcl-xl Bax Bad 
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ICI 182,780    ↓a      ↓a  ↓a     
G-15 ↑a ↑a         ↓a      
E2 ↑a  ↑a  ↑a    ↑a  ↓a    ↓a ↓a 
E2 + ICI 182,780   ↓b ↓a          ↑b   
E2 + G-15 ↑a  ↓b  ↑a  ↑a 
↑b 
↓a 
↓b 
  ↑b ↑a 
↑b 
 ↑a 
↓b 
↑b  
E2 + ICI 182,780 + 
G-15 
  ↓b    ↓a 
↓b 
   ↑b   ↓a   
G-1 ↑a ↑a  ↑a    ↓a  ↑a ↓a   ↓a ↑a ↑a 
G-1 + ICI 182,780 ↓c ↑a 
↑c 
  ↓c ↓c ↑a   ↓a 
↓c 
↓a ↓a ↓c ↑c ↑a ↑a 
G-1 + G-15 ↓a ↑a        ↓c     ↑a 
↑c 
 
 
6.5.2 Bax/Bcl-2 Ratio 
The Bax/Bcl-2 ratio was calculated by dividing the relative gene regulation values obtained from the 
gene analysis data of BAX by that of BCL-2 for each treatment.  A value of 1 was set for etOH controls to 
enable comparison of Bax/Bcl-2 ratios following the treatments. 
In MCF-12A cells, treatment with E2 caused a decrease in the Bax/Bcl-2 ratio, which remained 
the same in the presence of ICI 182,780.  On the other hand, E2 in combination with G-15, decreased 
the Bax/Bcl-2 ratio further than observed with E2 or E2 with ICI 182,780.  Co-incubation of MCF-12A 
cells with both ICI 182,780 and G-15 seems to have slightly reverted the effects of E2 upon the Bax/Bcl-2 
ratio (Figure 6.9).  In all cases, this decrease in this Bax/Bcl-2 ratio in response to E2 would have an anti-
apoptotic influence upon MCF-12A cells, which does not appear to be antagonised by either of the 
tested inhibitors. 
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Figure 6.9: Relative Bax/Bcl-2 ratio for MCF-12A cells following incubation with E2 and ER or GPER-1 antagonists.    
A value of 1 was set as the Bax/Bcl-2 ratio for etOH controls and treatment ratios are relative to this.  Data is 
normalised to β-ACTIN.  Error bars represent standard error of the mean. D A P-value of < 0.05 was considered 
statistically significant and is denoted by *.  Data is from three experiments performed in duplicate. 
 
Conversely to what was observed in MCF-12A cells, in MCF-10A cells, E2 treatment increased the 
Bax/Bcl-2 ratio.  Co-incubation of E2 with ICI 182,780 or G-15 decreased the effect of the hormone, 
reducing the Bax/Bcl-2 ratio below control levels.  However, when E2 was combined with both ICI 
182,780 and G-15 an increase in the Bax/Bcl-2 ratio was observed (Figure 6.10).  The increase in Bax/Bcl-
2 ratio in response to E2 or E2 in combination with both ICI 182,780 and G-15 potentially signifies a pro-
apoptotic influence.  However, the decreased Bax/Bcl-2 ratio seen with the other treatments would 
favour an anti-apoptotic effect. 
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Figure 6.10: Relative Bax/Bcl-2 ratio for MCF-10A cells following incubation with E2 and ER or GPER-1 
antagonists.    A value of 1 was set as the Bax/Bcl-2 ratio for etOH controls and treatment ratios are relative to this.  
Data is normalised to β-ACTIN.  Error bars represent standard error of the mean.  A P-value of < 0.05 was 
considered statistically significant and is denoted by *.  Data is from three experiments performed in duplicate. 
 
E2 treatment of MCF-7 cells decreased the Bax/Bcl-2 ratio relative to etOH controls, which would 
suggest an anti-apoptotic influence of E2.  Co-incubations of E2 with ICI 182,780 or G-15 strongly 
reversed this effect, even if not to control levels.  When cells were treated with E2 in combination with 
ICI 182,780 and G-15 simultaneously, an increase in the Bax/Bcl-2 ratio was observed which may 
contribute to a pro-apoptotic influence, and revert the anti-apoptotic effect of E2 (Figure 6.11). 
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Figure 6.11: Relative Bax/Bcl-2 ratio for MCF-7 cells following incubation with E2 and ER or GPER-1 antagonists.    
A value of 1 was set as the Bax/Bcl-2 ratio for etOH controls and treatment ratios are relative to this.  Data is 
normalised to β-ACTIN.  Error bars represent standard error of the mean.  A P-value of < 0.05 was considered 
statistically significant and is denoted by *.  Data is from three experiments performed in duplicate. 
 
In MDA-MB-231 cells, E2 treatment only slightly decreased the Bax/Bcl-2 ratio and probably therefore 
had little impact upon apoptosis.  Interestingly, ICI 182,780 slightly reduced the effect of the hormone 
by inducing a small increase in the Bax/Bcl-2 ratio.  E2 in combination with G-15 or ICI 182,780 and G-15, 
caused a more marked increase in the Bax/Bcl-2 ratio (Figure 6.12).  This would suggest that antagonism 
of GPER-1 following E2 treatment has a pro-apoptotic influence relative to solvent controls. 
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Figure 6.12: Relative Bax/Bcl-2 ratio for MDA-MB-231 cells following incubation with E2 and ER or GPER-1 
antagonists.    A value of 1 was set as the Bax/Bcl-2 ratio for etOH controls and treatment ratios are relative to this.  
Data is normalised to β-ACTIN.  Error bars represent standard error of the mean.  A P-value of < 0.05 was 
considered statistically significant and is denoted by *.  Data is from three experiments performed in duplicate. 
6.5.3 Signalling Pathway Activation 
Activation of the PI3K and MAPK signalling pathways by estrogens is well documented (Tsai et al, 2001; 
Song et al, 2002; Lee et al, 2005).  Following the identification of GPER-1, it has also been demonstrated 
that E2 can induce the activation of these pathways through this receptor (Filardo et al, 2002; Dong et 
al, 2011).  To investigate the putative role of GPER-1 in mediating the non-genomic effects of E2 in the 
MCF-10A, MCF-12A, MCF-7 and MDA-MB-231 cell lines, cells were treated with E2 or G-1, either alone 
or in combination with the GPER-1 antagonist, G-15.  The primary aim of this was to investigate the non-
genomic responses to estrogens in the MCF-12A cell line, which to date, has not been characterized.  
The remaining cell lines served as a means of comparison of ER competent and ER negative, 
tumourigenic and non-tumourigenic cell lines. 
In the MCF-12A cell line, a basal level of P-AKT is present in controls and G-15 treated samples.  
However, it is worth noting that the level of total-AKT is also higher than the other samples for the G-15 
well.  The growth factor, EGF (used here as a positive control for comparison with estrogen treatment), 
causes the phosphorylation of AKT and this is not inhibited by co-incubation of EGF with G-15.  
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Treatment with E2 or G-1 individually, also increased the amount of P-AKT detected relative to controls 
and this was not inhibited by co-incubation with G-15 in either E2 or G-1 treated samples (Figure 6.13).   
 
 
Figure 6.13: Activation of AKT by phosphorylation in MCF-12A cells in response to E2 and G-1.  Immunoblot 
results for MCF-12A cells treated with E2 or G-1 with or without co-incubation with G-15.  Blots were probed with 
antibodies against P-AKT, stripped and probed again for antibodies against Total-AKT. 
 
Control and G-15 treated MCF-12A cells have a basal level of ERK1/2 phosphorylation.  Treatment with 
EGF, E2 or G-1 induced the phosphorylation of ERK1/2.  The phosphorylation of ERK1/2 induced by EGF 
was not inhibited upon co-incubation with G-15.  Co-incubation of E2 with G-15, however, did slightly 
decrease the level of P-ERK1/2 detected.  Finally, co-incubation of G-15 with G-1 completely abrogated 
P-ERK1/2 (Figure 6.14). 
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Figure 6.14: Activation of ERK1/2 by phosphorylation in MCF-12A cells in response to E2 and G-1.  Immunoblot 
results for MCF-12A cells treated with E2 or G-1 with or without co-incubation with G-15.  Blots were probed with 
antibodies against P-ERK1/2, stripped and probed again for antibodies against Total-ERK1/2. 
 
In the ER negative, GPER-1 competent MCF-10A cell line, EGF induced the activation of the PI3K 
pathway, as indicated by the increase of P-AKT levels, which results from AKT activation by PI3K.  This 
was inhibited upon co-incubation with G-15.  E2 treatment did not, however, induce measurable AKT 
activation.  Treatment with G-1 induced AKT activation, although not to the extent observed with EGF.  
As with EGF treatment, co-incubation of G-1 with G-15 prevented the activation of AKT (Figure 6.15). 
 
 
Figure 6.15: Activation of AKT by phosphorylation in MCF-10A cells in response to E2 and G-1.  Immunoblot 
results for MCF-10A cells treated with E2 or G-1 with or without co-incubation with G-15.  Blots were probed with 
antibodies against P-AKT, stripped and probed again for antibodies against Total-AKT. 
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A basal level of MAPK pathway activation was observed in untreated MCF-10A controls (no EGF) as 
shown by the detection of P-ERK1/2.  EGF treatment caused a pronounced activation of ERK1/2 and this 
was not abrogated upon co-incubation with G-15, although the effect was clearly reduced.  E2 
treatment resulted in a level of P-ERK1/2 that was similar to that observed in controls and upon co-
incubation with G-15, the level of P-ERK1/2 was reduced even further.  It is important to note, however, 
that the total level of ERK1/2 (T-ERK1/2) in G-15 treated samples is lower than seen in controls.  As a 
decrease in both total and phosphorylated forms of ERK1/2 were observed, it is not possible to make 
conclusions in relation to the phosphorylation status of ERK1/2 in this sample.  It is likely that the 
decrease in both forms of ERK1/2 was due to a lower protein loading onto the gel during western blot 
analysis. 
Activation of GPER-1 using G-1 resulted in increased P-ERK1/2 relative to controls.  Contrary to 
what was expected, this was not reversed upon co-incubation with G-15.  G-15 alone resulted in a level 
of P-ERK1/2 similar to that observed in control cells (Figure 6.16). 
 
 
Figure 6.16: Activation of ERK1/2 by phosphorylation in MCF-10A cells in response to E2 and G-1.  Immunoblot 
results for MCF-10A cells treated with E2 or G-1 with or without co-incubation with G-15.  Blots were probed with 
antibodies against P-ERK1/2, stripped and probed again for antibodies against Total-ERK1/2. 
 
In the MCF-7 cell line, a basal level of P-AKT was present in untreated controls and G-15 treated cells.  
EGF and E2 treatment resulted in activation of AKT and in neither case did co-incubation with G-15 
inhibit this effect.  G-1 treatment, on the other hand, did not appear to activate the kinase.  Strangely, 
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G-1 in combination with G-15 induced a slight increase in the intensity of the P-AKT band, but this could 
be attributable to a small increase in the total-AKT loaded protein (Figure 6.17). 
 
 
Figure 6.17:  Activation of AKT by phosphorylation in MCF-7 cells in response to E2 and G-1.  Immunoblot results 
for MCF-7 cells treated with E2 or G-1 with or without co-incubation with G-15.  Blots were probed with antibodies 
against P-AKT, stripped and probed again for antibodies against Total-AKT. 
 
MCF-7 cells had a basal level of P-ERK1/2 in controls.  G-15 treatment of these cells inhibited this 
background level of P-ERK1/2.  As expected, EGF treatment induced significant activation of P-ERK1/2 
and this was inhibited in the presence of G-15.  In E2 treated cells, there was a small detection of P-
ERK1/2, however, this was lower than in control samples.  This very weak activation of the MAPK 
signalling pathway was, however, abrogated upon co-incubation of E2 with G-15.  Finally, G-1 treatment 
induced the activation of P-ERK1/2 and this was completely inhibited by co-incubation of G-1 with G-15 
(Figure 6.18). 
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Figure 6.18: Activation of ERK1/2 by phosphorylation in MCF-7 cells in response to E2 and G-1.  Immunoblot 
results for MCF-7 cells treated with E2 or G-1 with or without co-incubation with G-15.  Blots were probed with 
antibodies against P-ERK1/2, stripped and probed again for antibodies against Total-ERK1/2. 
 
In the MDA-MB-231 cell line, P-AKT was only detected in cells treated with EGF, either alone or in 
combination with G-15.  No activation of the PI3K pathway was observed in controls or following G-15, 
E2 or G-1 treatment, in any combination (Figure 6.19). 
 
Figure 6.19: Activation of AKT by phosphorylation in MDA-MB-231 cells in response to E2 and G-1.  Immunoblot 
results for MDA-MB-231 cells treated with E2 or G-1 with or without co-incubation with G-15.  Blots were probed 
with antibodies against P-AKT, stripped and probed again for antibodies against Total-AKT. 
 
In the MDA-MB-231 cell line, both in control conditions and G-15 treatment P-ERK1/2 was still detected.  
EGF treatment caused the levels of ERK1/2 activation to increase compared to controls and this was not 
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inhibited upon co-incubation with G-15.   The level of P-ERK1/2 detected in response to E2 treatment 
was similar to that observed in controls, suggesting that E2 does not cause activation of the MAPK 
signalling cascade in this cell line.  Co-incubation of E2 with G-15, however, appeared to increase the 
level of P-ERK1/2 relative to controls.  As with E2, G-1 treatment did not elevate the level of P-ERK1/2 
beyond the levels observed in controls, but co-incubation of G-1 and G-15 did (Figure 6.20). 
 
 
Figure 6.20: Activation of ERK1/2 by phosphorylation in MDA-MB-231 cells in response to E2 and G-1.  
Immunoblot results for MDA-MB-231 cells treated with E2 or G-1 with or without co-incubation with G-15.  Blots 
were probed with antibodies against P-ERK1/2, stripped and probed again for antibodies against Total-ERK1/2. 
6.6 Discussion 
In Chapters IV and V, we showed that estrogens disrupt MCF-12A acini formation.  As described 
previously, estrogens bind to estrogen receptors in order to regulate the transcription of estrogen-
responsive genes.  In the context of the breast, this regulation is required for the growth and 
differentiation of TDLUs during breast development (Bocchinfuso et al, 2000; Feng et al, 2007).  We 
aimed to investigate the effects of E2 on the ERα, ERβ and GPER-1 competent MCF-12A cell line in terms 
of apoptotic factor expression and the activation of signalling cascades in monolayer.  The data 
presented in this chapter not only provides novel information on the responses of this non-tumourigenic 
cell line to estrogen treatment, but will also allow us to compare the effects of estrogens in monolayer 
and 3D cultures of MCF-12A cells, and, therefore, assess whether outcomes observed in monolayer are 
predicative of those observed in 3D cultures.  We achieved our aims to characterise the genomic and 
non-genomic responses to estrogens in MCF-12A cells.  Furthermore, by testing an agonist and 
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antagonist of GPER-1, we have developed some understanding of this receptor, and its actions,  in MCF-
12A cells.  We also repeated the experiments with three further cell lines for means of comparison with 
tumourigenic and ER negative cell lines.  
6.6.1 Genomic Responses to the Antagonists, ICI 182,780 and G-15 
Contrary to expectations, the ER antagonist, ICI 182,780, significantly down-regulated BAX expression in 
both ER negative cell lines: MCF-10A and MDA-MB-231.  Further to this, ICI 182,780 also down-
regulated BCL-2 and BCL-XL expression in MDA-MB-231 cells.  If these observations were due to the 
presence of residual estrogens in the CDS serum, the addition of ICI 182,780, would counteract the 
effects of any residual estrogens, resulting in the down-regulation of the aforementioned genes (Rea & 
Parker, 1996; Silva et al, 2010).  The problem with this theory, is that these cells are ERα negative.  
Furthermore, if this were the case, the effects of ICI 182,780 would oppose those observed with E2 and 
this was not seen in MDA-MB-231 cells.  It is therefore unlikely, that residual estrogens were 
accountable for the effects of ICI 182,780 alone. 
Another possible explanation for these effects is linked to the presence of GPER-1 in these cell 
lines.  It has previously been demonstrated that ER antagonists, such as ICI 182,780, can act as agonists 
for GPER-1, causing up-regulations in the expression of target genes such, as BCL-2 (Filardo et al, 2000; 
Somaï et al, 2003; Thomas et al, 2005).  This may account for why ICI 182,780 alone, in some instances, 
induced small changes in gene expression.  It may also account for why, in some cases, G-1 + ICI 182,780 
(both agonists for GPER-1), caused a greater change in gene regulation than G-1 alone.  In addition to 
having agonistic activities towards GPER-1, ICI 182,780 can also activate signalling pathways via the ER 
splice variant, ERα36 (Wang et al, 2006).  It is, therefore, plausible that some of the effects of ICI 
182,780 resulted from non-genomic signalling following the activation of ERα36.  It is, however, 
important to note here that the lack of AF-1 and AF-2 in ERα36 has been demonstrated to render ERα36 
incapable of inducing transcriptional responses directly and, therefore, any changes in gene expression 
would be as a consequence of signalling pathway activation (Wang et al, 2006; Chaudhri et al, 2012).  
The reported presence of ERα36 has been shown in MCF-7 and MDA-MB-231 cells, but it is unknown 
whether MCF-10A or MCF-12A cells express this receptor (Zhang et al, 2012).  Therefore, we cannot 
conclusively attribute the observations described above to ERα36 without further experiments. 
In the case of the treatment with the GPER-1 antagonist, G-15, an up-regulation of BCL-2 
expression was observed in MCF-10A and MCF-12A cells, and a down-regulation of BAX expression was 
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seen in MCF-7 cells following treatment.  This could mean that residual estrogens are still interacting 
with GPER-1 to induce changes in the transcription of apoptotic genes.  This idea remains unlikely, as if 
this were the case, the effects of G-15 would be the opposite to those observed with E2, and in the 
instance of MCF-7 cells, both G-15 and E2 induced a down-regulation in BAX gene expression.  Recently, 
it has been demonstrated that antagonists of GPER-1 are capable of inducing ER-dependent 
transcriptional responses (Dennis et al, 2011).  This could account for the up-regulation of genes in 
response to G-15 treatment or following co-incubation of E2 with G-15. 
6.6.2 Effects of E2 on Apoptotic Factor Expression in MCF-12A Cells and A 
Comparison with Other Cell Lines 
The effects of estrogens on the expression profiles of apoptotic genes were studied in three other cell 
lines (MCF-7, MDA-MB-231 and MCF-10A), in addition to the cell line of interest: MCF-12A.  These cell 
lines, which vary in terms of their ER and tumourigenic status, were used primarily for comparison with 
MCF-12A cells and to help draw conclusions, where possible, as to the role of the ER and GPER-1, and 
the impact of E2 on apoptotic events.  
In the ERα, ERβ and GPER-1 competent MCF-12A cell line, E2 induced a significant up-regulation 
in the expression of BCL-2, BCL-XL and BAX.  Although the up-regulation of BCL-2 and BCL-XL in response 
to E2 would make sense, as E2 promotes cell survival, the up-regulation of BAX expression was 
unexpected.  Despite this, E2 decreased the Bax/Bcl-2 ratio, which would, overall, promote survival, 
rather than cell death. 
The up-regulation of BCL-2 expression in MCF-12A cells following E2 treatment was not 
observed in ERα negative MCF-10A cells or MDA-MB-231 cells, but was seen in ER-competent MCF-7 
cells, and has been reported previously in the same cell line (Wang & Phang, 1995).   
 In MCF-12A cells, ICI 182,780 reverted the E2-induced up-regulation of BCL-2 and BCL-XL 
expression, even though this was not statistically significant.  On the other hand, it appears that GPER-1 
does not mediate the genomic responses of the BCL-2 and BCL-XL genes, as G-15 failed to decrease the 
actions of E2.  These observations suggest that, although weakly, the nuclear ER, and not GPER-1, is 
involved in regulating the expression of the apoptotic genes in this cell line.  It is worth noting, however, 
that there was a degree of variability in the results obtained for the BCL-2 data set.  Therefore, a role for 
GPER-1 in mediating BCL-2 transcription in response to E2 cannot be conclusively ruled out.  
Interestingly, in addition to ICI 182,780, G-15 also inhibited the E2-induced up-regulation of BCL-2 
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expression in MCF-7 cells, which was not observed in MCF-12A cells, and this could mean, that in some 
instances, GPER-1 is involved in the transcriptional response of BCL-2 to estrogens. 
To date, a correlation between GPER-1 expression and BCL-2 expression has not been 
documented in breast cancer patients, whilst a positive correlation between Bcl-2 and ER expression has 
(Rehman et al, 2000; Sjöström et al, 2002).  This, in combination with the data presented here, suggests 
that the ER is involved in the transcriptional regulation of the proto-oncogene, BCL-2.  Given its 
overexpression in 40-80% of breast cancer samples, and an involvement of the ER in its expression, it 
may mean that one of the contributing factors of ER involvement in breast cancer progression, is 
increased BCL-2 expression (Nahta & Esteva, 2003; Planas-Silva et al, 2007).  It is worth noting that the 
BCL-2 gene does not contain a perfect ERE within its promoter region, which raises the question as to 
how the ER may control BCL-2 expression.  There are two possibilities that may answer this: the first is 
the presence of imperfect ERE sequences in the coding region of BCL-2; the second is the presence of 
potential Sp-1 binding sites in the promoter region (Seto et al, 1988; Dong et al, 1999; Perillo et al, 
2000).  More recently, it has been shown that E2 mediates a decrease in the expression of mi-R21, a 
miRNA which targets BCL-2 (Wickramasinghe et al, 2009).  This down-regulation could, therefore, result 
in less BCL-2 degradation and increased BCL-2 transcript level, hence increased anti-apoptotic Bcl-2. 
The E2 induced up-regulation of BCL-XL expression seen in the MCF-12A cell line was not 
observed in MCF-10A, MCF-7 or MDA-MB-231 cells.  This raises the question to whether BCL-XL 
expression is affected by E2 in cell lines other than MCF-12A, although the gene does contain a putative 
ERE (Gollapudi & Oblinger, 1999; Koski et al, 2004).  Indeed, immunohistological studies have 
demonstrated that unlike Bcl-2 expression, Bcl-xl expression does not correlate with ER expression in 
breast cancer and in MCF-12A cells ICI 182,780 did not inhibit the E2-indced up-regulation of BCL-XL 
expression (Sjöström et al, 2002).  Unexpectedly, co-incubation of E2 with G-15 and ICI 182,780 together 
caused a significant down-regulation in BCL-XL expression in the tumourigenic MCF-7 and MDA-MB-231 
cell lines.  An up-regulation in BCL-XL expression was also observed in the MCF-7 cell line upon co-
incubation of E2 with G-15.  These observations may be due to off-target effects of G-15 or ICI 182,780 
with ERα or GPER-1, respectively.  In addition to these off-target interactions, it has also recently been 
demonstrated that ICI 182,780 can activate signalling pathways via ERα36 and activation of this pathway 
may have later consequences for gene transcription (Zhang et al, 2012).  This ER isoform has been 
confirmed in MCF-7 and MDA-MB-231 cells and therefore the changes in BCL-XL expression may be due 
to interactions of ICI 182,780 with ERα36.  This would, however, be counterintuitive as a decrease in Bcl-
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xl would confer a pro-apoptotic influence.  The exact reason for the down-regulation of BCL-XL in 
response to E2 and ICI 182,780 in MCF-7 and MDA-MB-231 cells, therefore, remains unknown. 
The E2-induced up-regulation of BAX expression was significantly reduced upon co-incubation 
with G-15, relative to BAX expression in E2-treated MCF-12A cells.  This seems to indicate GPER-1 is 
involved in mediating the transcriptional regulation of BAX in response to E2 treatment in this cell line.  
In addition to this, ICI 182,780 also negated the effect of E2 on BAX expression (although this effect was 
not significant), and therefore it appears that the transcriptional regulation of BAX, by estrogens, can be 
mediated by either of these receptors.  Given that in patients with ductal adenocarcinoma of the breast, 
the level of BAX expression does not correlate with ER status, it may mean that GPER-1 is involved in the 
transcriptional regulation of BAX (Yang et al, 1999; Rehman et al, 2000; Sjöström et al, 2002). 
The GPER-1 and ER-mediated up-regulation of BAX expression that was observed in response to 
E2 in MCF-12A cells was not observed in MCF-10A cells or MDA-MB-231 cells.  A change in expression 
was observed in MCF-7 cells, but this was a down-regulation in gene expression, which has previously 
been documented (Teixeira et al, 1995; Lucas et al, 2010).  It is worth noting at this point that E2, in 
MCF-7 cells, has also been shown to have no impact upon BAX expression or even elevate it (Wang & 
Phang, 1995; Gadd et al, 2002; Lewis et al, 2005).  Given that only MCF-12A and MCF-7 cells express 
ERα, the data would suggest that, in the case of BAX, ERα is necessary for the transcriptional response to 
estrogens.  However, given that ICI 182,780 was unable to inhibit the effect in MCF-7 cells, but G-15 
was, GPER-1 also plays a role.  This supports some previous findings where the ER was required for 
GPER-1 mediated responses to estrogens in ER negative SKBR-3 cells (Pedram et al, 2006).  As to how 
estrogens may illicit their effects through the ER, no ERE has been identified within the BAX gene, thus 
far.  The BAX gene does, however, contain Sp-1 sites and therefore E2 may regulate BAX expression 
through interactions with Sp-1 (Thornborrow & Manfredi, 2001). 
E2 did not impact upon BAD gene expression in MCF-12A cells.  However, in the MCF-10A and 
MCF-7 cell lines, E2 down-regulated BAD expression.  A down regulation in BAD following E2 treatment 
has previously been documented in neuronal cells, which, supports these findings (Gollapudi & Oblinger, 
1999).  In the case of MCF-10A cells, this down-regulation was reversed by both ICI 182,780 and G-15.  
This was not anticipated, as MCF-10A cells lack the ER and, hence, ICI 182,780 should not have been able 
to reverse this effect.  A possible explanation, other than experimental error, is the off-target effects of 
ICI 182,780 (Filardo et al, 2002).  As G-1 did not induce an up-regulation in BAD expression, it is unlikely 
that the effects of ICI 182,780 were mediated by GPER-1.  It, therefore, remains unclear as to why and 
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how ICI 182,780 was able to reverse the effect of E2.  Regardless, it would appear that GPER-1 is 
implicated in the E2-induced BAD transcriptional response.  This idea is supported by the data for the 
MCF-7 cells, where only G-15, and not ICI 182,780 was able to abrogate some of the effects of E2 upon 
BAD expression.  To date, no ERE, Ap-1 or Sp-1 sites have been identified within the BAD gene 
suggesting that the genomic responses observed are not mediated by the ER and this supports the data 
presented above concerning a role for GPER-1 in regulating BAD expression in response to E2.  Indeed, it 
has previously been reported that the level of BAD expression does not correlate with ER expression (Yu 
et al, 2010).  Estrogens can induce CREB phosphorylation in an ERα dependent fashion via activation of 
the MAPK pathway (Szego et al, 2006).  The transcription factor, CREB can then regulate the 
transcription of genes such as Bad (Finegan et al, 2009)  This could mean that estrogens are capable of 
inducing transcriptional responses in cells following the induction of non-genomic signalling pathways 
such, as the MAPK or PI3K pathways. 
Perhaps more importantly than the gene analysis results for the effect of E2 upon the 
expression of individual apoptotic genes, is the impact of E2 upon the Bax/Bcl-2 ratio.  We found that E2 
treatment in the ERα positive MCF-12A and MCF-7 cells decreased the Bax/Bcl-2 ratio.  A similar, but 
much smaller, decrease in the Bax/Bcl-2 ratio was also observed in ERα negative, but ERβ competent 
MDA-MB-231 cells.  This may mean that in ER competent cell lines, E2 has an inhibitory effect upon 
apoptosis.  In Chapter II, however, we observed no significant change in cell number following E2 
treatment in these cell lines which may mean that other mechanisms are in place in monolayer cultures 
of mammary epithelial cells that circumvent the anti-apoptotic effect of E2. 
The E2-induced decrease in the Bax/Bcl-2 ratio was not greatly reversed by co-incubation with 
ICI 182,780 or G-15, either alone or combination, in the MCF-12A cell line.  This was unexpected, as in 
this cell line, ICI 182,780 abrogated the E2-induced up-regulation of BCL-2.  However, ICI 182,780 also 
inhibited the E2-induced up-regulation of BAX.  This observation could therefore be due to ICI 182,780 
reversing both effects of E2, resulting in a lack of change in the overall Bax/Bcl-2 ratio.  In MCF-10A cells, 
E2 increased the Bax/Bcl-2 ratio, which is probably due to the E2-induced increase in BAX expression, 
and this was reversed by co-incubation with ICI 182,780 or G-15, suggesting that both of the receptors 
are responsible for this overall pro-apoptotic effect.  In the case of ICI 182,780, this reversal is probably 
due to the up-regulation of BCL-2 in response to E2 + ICI 182,780.  However, in the case of co-incubation 
with G-15, the effect may be attributable to the down-regulation of BAX expression in response to E2 + 
G-15.  A more marked reversion of the E2-induced reduced Bax/Bcl-2 ratio by ICI 182,780 or G-15 was 
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observed in the MCF-7 cell line, and this was more pronounced when the antagonists were used in 
combination.  This, like the relative expression data, suggests that both the ER and GPER-1 are 
implicated in apoptotic responses to estrogens, in respect to gene expression.  In MDA-MB-231 cells, the 
Bax/Bcl-2 ratio was slightly reduced by E2 treatment, and the presence of G-15, reversed this, implying 
that in MDA-MB-231 cells GPER-1 may be implicated in regulating the anti-apoptotic response to E2, in 
terms of gene expression.  Taken together, the data suggests that both the ER and GPER-1 may be 
involved in the anti-apoptotic effect that estrogens can exert on cells, in respect to gene expression. 
6.6.3 The Non-Genomic Effects of E2 
The protein analysis data showed that, in control conditions lacking EGF, activation of the MAPK and 
AKT pathways still occurred, as inferred by the detection of P-ERK1/2 and P-AKT.  This could be due to 
the presence of residual growth factors or estrogens in the assay media or CDS serum that were able to 
induce MAPK signalling (Rea & Parker, 1996; Silva et al, 2010).  It has been demonstrated that in the 
MCF-7 cell line, the PI3K pathway is constitutively activated (Sivko & DeWille, 2004).   However, in the 
MCF-10A and MCF-12A cell lines, this does not occur (Vasudevan et al, 2010).  The constitutive 
activation of components of the MAPK pathway have also been reported in MCF-10A, MCF-7 and MDA-
MB-231 cells (Krueger et al, 2001; Yue et al, 2002; Normanno et al, 2006).  In spite of the observed 
residual activation of the PI3K and MAPK signalling cascades, these effects were very small, and 
probably are not significant. 
In MCF-12A cells, E2 caused the phosphorylation, and, hence, activation of AKT and ERK1/2.  
This suggests that estrogens are capable of activating PI3K and MAPK signalling in this cell line.  GPER-1 
does not appear to play a role in mediating the induction of the PI3K pathway following E2 treatment, 
suggesting that other estrogen-responsive receptors may mediate this non-genomic effect of estrogens.  
Conversely, GPER-1 does appear to, at least partially, mediate the activation of the MAPK pathway in 
this cell line. 
We described above how the presence of E2 resulted in the phosphorylation of both AKT and 
ERK1/2, which is indicative of the activation of the PI3K and MAPK signalling cascades, and these effects 
were mediated partially by GPER-1.  As the effects were only partially inhibited by GPER-1 antagonism, 
another receptor is probably involved, potentially the ER, or a truncated form of it.  In MCF-7 cells, E2 
treatment resulted in the activation of AKT, but not ERK1/2, although previous work has shown that 
estrogens induce both PI3K and MAPK signalling (Improta-Brears et al, 1999; Pedram et al, 2006).  The 
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data also indicates that this was mediated by another factor, rather than GPER-1, although other groups 
have demonstrated that GPER-1 mediates the activation of MAPK signalling in response to E2 (Filardo et 
al, 2000).  However, these pathways did not appear to be activated by E2 treatment in ER negative MCF-
10A or MDA-MB-231 cells.  This may indicate that the presence of the ER is required for E2 to activate 
the PI3K and MAPK signalling pathways.  Indeed, it has been demonstrated that the presence of the ER 
is a requisite for E2-induced activation of signalling pathways, via GPER-1 in SKBR-3 cells (Pedram et al, 
2006).  Contradictory evidence, however, has also been documented in the SKBR3 breast cancer cell line 
where estrogens activated MAPK signalling via the GPER-1 independently of ER expression (Filardo et al, 
2000). 
G-15 did not always abrogate the effects of E2 and this indicates other estrogen-responsive 
receptors may be involved in mediating the non-genomic effects of estrogens.  These non-genomic 
effects may be mediated by the classical ER, although there are also membrane-associated ER’s that 
have been hypothesised to mediate these effects, such as ERα36 and ERα46 (Flouriot et al, 2000; Wang 
et al, 2006). 
6.6.4 A Function for GPER-1 
To ascertain the effect of GPER-1 activation upon apoptotic gene expression, cells were treated with the 
GPER-1 agonist, G-1.  We observed that G-1 up-regulated the expression of BCL-2 in MCF-10A, MCF-12A 
cells and MDA-MB-231 cells significantly and induced a small increase in expression in MCF-7 cells.  G-15 
was not always able, however, of inhibiting this effect, suggesting off-target effects of G-1 or G-15 (Kang 
et al, 2010; Dennis et al, 2011).  A down-regulation in BCL-XL expression following G-1 treatment was 
observed in MDA-MB-231 cells, and this was inhibited by G-15, suggesting that GPER-1 may mediate the 
transcription of BCL-XL.  G-1 also affected BAX expression, although the observed effect was not the 
same in each cell line: in MCF-10A cells, G-1 up-regulated BAX, whereas, in MCF-12A and MCF-7 cells, 
BAX was down-regulated.  Given that in MCF-7 cells the E2-induced down-regulation of BAX expression 
was inhibited by G-15 and that treatment with G-1 produced similar effects to that seen with E2, it is 
plausible that GPER-1 may be mediating the effects of E2 upon BAX.  Similar observations have also 
been made in sertoli cells and this supports the findings presented above (Lucas et al, 2010).  In MCF-
10A cells, he G-1 induced up-regulation of BAX expression and subsequent down-regulation following 
co-incubation with G-15 suggests that GPER-1 is capable of regulating the transcription of BAX, but, E2 
does not utilise this pathway in this ER negative cell line.  Strangely, in MCF-10A cells, G-1 in 
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combination with ICI 82,780 also caused a down-regulation in BAX expression relative to controls and E2 
treated samples.  As ICI 182,780 alone also induced a down-regulation of BAX expression in this cell line, 
this observation may be attributable to the presence of ICI 182,780.  In a similar fashion to BAX, BAD 
expression was also affected by G-1 differently in the four cell lines (down-regulated in MCF-10A cells 
and up-regulated in MCF-7 and MDA-MB-231 cells).  The reason for these observations remains unclear 
as it does not appear that a cells tumourigenic state or ER status corresponds to genomic response to G-
1.  In MCF-10A cells, co-incubation of G-1 with G-15 inhibited the effect of G-1 confirming the effect 
seen was due to GPER-1.  ICI 182,780 in combination with G-1 however further decreased Bad 
expression which may be due to the agonistic properties of ICI 182,780 towards GPER-1 (Filardo et al, 
2000).  In the case of MDA-MB-231 cells, E2 treatment did not induce the same effect as with G-1.  This 
suggests that although GPER-1 activation can impact upon BAD expression, E2, although a ligand for 
GPER-1, cannot induce this effect.  Furthermore, in the MCF-7 cell line, the effect induced by G-1 was 
the opposite of that induced by E2 which raises the question as to whether the effects induced by E2 
were mediated by GPER-1.  It has been demonstrated by some that activation of GPER-1 can have 
opposing effects to ERα (Oprea et al, 2010).  Although GPER-1 activation did have an impact apoptotic 
factor expression, it is important to note that the response of an individual gene may not alone have an 
impact on a cell’s apoptotic potential.  It is more likely that the cumulative effect of changes in the 
expression multiple genes has a greater impact upon whether a cell enters apoptosis, or not. 
In respect to the non-genomic response to GPER-1 activation, G-1 resulted in the increased 
presence of P-AKT in MCF-10A cells and P-ERK in MCF-10A and MCF-7 cells.  As with the real-time PCR 
data, G-15 was not always capable of inhibiting the effects of G-1 upon the phosphorylation status of 
AKT or ERK1/2.  Nevertheless, AKT activation appeared to be mediated by GPER-1 to some extent at 
least, suggesting that the activation of GPER-1 can result in MAPK or PI3K signalling.  These results, when 
compared to the activation status of AKT and ERK1/2 following E2 treatment, did not always correlate.  
This suggests that although E2 is capable of activating signalling pathways via GPER-1, it does not always 
do so, and therefore other factors may be implicated.  
Although the reason why G-15 did not always inhibit the effects of G-1, it possible to suggest 
that GPER-1 activation can induce transcriptional responses and activation of the PI3K and MAPK 
signalling pathways.  Hence, the activation this receptor may have an impact on apoptosis through the 
transcriptional regulation of key apoptotic genes, and proliferation through the activation of the PI3K 
pathway.  Furthermore, the presence of GPER-1, regardless of ER expression, did not always result in 
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AKT or ERK1/2 activation following treatment with G-1.  This further implies that the response of GPER-1 
to stimulation involves factors other than whether cells express GPER-1, or indeed the ER. 
6.6.5 Possible Off-Target Effects 
We observed that the data for G-1 and E2 + G-15 did not always agree, or that in some instances ICI 
182,780 was able to inhibit the effects of G-1.  A plausible explanation could be off-target interactions of 
ICI 182,780, G-1 or G-15.  Indeed, it has been demonstrated recently that G-1 can bind to and activate 
ERα36 (Filardo et al, 2002; Kang et al, 2010).  The ERα36 status of the MCF-12A cell line is not currently 
reported in the literature, and therefore, G-1 interactions with this receptor cannot be ruled out and this 
could present a reason for the gene analysis discrepancies.  At high enough concentrations, G-15 can 
cause activation of ERα, although the concentrations used in this work were not high enough to produce 
this effect (Dennis et al, 2011).  
  As detailed above, G-15 did not always abrogate the effects of G-1.  Recently G-15 has been 
shown to possess a low affinity for ERα.   Hence a second GPER-1 antagonist with improved selectivity 
has recently been synthesised.  This new GPER-1 antagonist has been called G-36 and displays a lower 
degree of ERα binding and activation (Dennis et al, 2011).  As this data was not available at the time 
when experiments were being conducted, it would be of significance to repeat the G-15 co-incubations 
with G-36 and investigate whether the effects elicited by G-1 or indeed E2 can be abrogated with this 
new GPER-1 antagonist.  Even more recently, the compound, ethyl 3-[5-(2-ethoxycarbonyl-1-
methylvinyloxy)-1-methyl-1Hindol-3-yl] but-2-enoate (MIBE), that has the ability to bind to and inhibit 
both ERα and GPER-1 in breast cancer cells has been identified (Lappano et al, 2012).  This dual 
antagonist could provide a promising treatment for breast cancer patients as it would ablate the effects 
of E2 mediated by both the ER and GPER-1 simultaneously.  MIBE has another advantage in relation to 
other ER antagonists as it does not display agonistic properties towards GPER-1, which both tamoxifen 
and ICI 182,780 do (Filardo et al, 2000; Filardo et al, 2002).  MIBE’s antagonistic properties for GPER-1, 
are also greater than those of G-15, making it the better choice for antagonism of this receptor in 
particular (Lappano et al, 2012).  Given the dual-agonistic properties towards both ERα and GPER-1, it 
would be of future interest to investigate whether MIBE was capable of completely reverting the effect 
of E2 and G-1 upon gene expression in the cell lines studied. 
We also observed that ICI 182,780, when in combination with E2, was able to reverse the effects 
of E2 in ER negative cell lines.  It is worth considering that ICI 182,780, although an ER antagonists, has 
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agonistic properties towards other receptors.  Indeed, it has been demonstrated that ICI 182,780 acts as 
an agonist for GPER-1 (Filardo et al, 2000; Filardo et al, 2002; Thomas et al, 2005). 
6.6.6 Conclusions 
In this chapter, we have shown for the first time, that in ER, GPER-1 competent non-tumourigenic MCF-
12A cells, E2’s intracellular effects promote proliferation, through activation of signalling pathways and 
suppression of apoptosis, by lowering of the Bax/Bcl-2 ratio.  However, as shown in Chapter II, E2 
treatment had very little impact upon cell number, and if apoptosis were being inhibited, even in the 
lack of increased proliferation, an increase in cell number would be expected.  Therefore, other 
mechanisms may be in place in this cell line that control the overall cell number.  One possibility is that 
other factors, not included in this study, such as MDM2, Bim or PUMA, were regulated by estrogens, and 
these counteracted the decreased Bax/Bcl-2 ratio or activation of MAPK and PI3K signalling.  Also, it is 
worth noting that an increase in the expression of a gene does not always correspond to an increase in 
protein or activity levels, due to post-translational modifications of various apoptotic factors.  For 
instance, Bcl-2, Bcl-xl and Bad can all be phosphorylated, and this impacts upon their ability to form 
dimers, and hence their activity: phosphorylation of Bcl-2, Bcl-xl or Bad has an inhibitory effect on their 
activity (Munger & Roizman, 2001; Delivora-Papadopoulos & Mishra, 2010).  The phosphorylation of 
Bad, in particular, can be achieved through activated AKT (Lewis-Wambi & Jordan, 2009).  Given that 
activated AKT (P-AKT) was detected, in response to E2, in MCF-12A and MCF-7 cells, this may further 
impact on the overall apoptotic status of these cells.  Furthermore, ubiquitylation of Bax targets it for 
degradation and hence lowers the protein level of this pro-apoptotic factor (Amsel et al, 2008).  In the 
future, it would be of interest to extend the panel of apoptotic genes studied and to perform protein 
analysis in addition to gene analysis. 
 The next step in our work is to perform gene and pathway activation analysis in 3D cultures of 
MCF-12A cells treated with E2.  As discussed in the next chapter, we assessed the impact of E2 upon 
apoptotic gene expression in these 3D cultures.  Unfortunately, due to time and technical limitations, 
the signalling cascades following E2 treatment of MCF-12A cells grown in 3D could not be investigated.  
Obviously, in the future, this would be of interest to study. 
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Chapter VII: Separating the Two Cell Populations in Acini 
 
In Chapter III, IV and V, we showed that in 3D in vitro cultures of MCF-12A cells, the seeded cells 
organise themselves into acini, comprising of two populations: the inner and outer cells.  We observed 
that it was the inner cells that underwent apoptosis, as inferred by the expression of activated caspase-
3, and were then cleared.  The outer cells, on the other hand, were in contact with the basement 
membrane and did not undergo apoptosis.  Other differences between these populations have been 
described in the literature.  For example, in 3D cultures of MCF-10A cells, the outer cells are polarised, 
whereas inner cells do not display this level of polarisation (Debnath et al, 2002).  Furthermore, 
activated AKT is mainly expressed by the outer cells and only during the later stages of MCF-10A acini 
morphogenesis (Debnath et al, 2002b), when the inner cells are undergoing clearance.  3D cultures of 
cell lines derived from other tissues have also shown that the inner and outer cells of 3D structures have 
different characteristics.  For example, in 3D cultures of colonic HCT116 cells, following 4 days 
incubation, the proliferative marker, ki-67, is only detected in the outer cell population (Tsunoda et al, 
2010). 
 Given that the two populations within acini display distinct characteristics, it may be the case 
that these cells respond differently to treatments or stimuli.  However, currently, it is not fully 
understood what factors determine which cells are to survive and which are to be cleared by apoptosis.  
It is unclear whether the central cells of acini receive, and respond to, death signals; or whether the 
outer cells receive, and respond, to proliferative stimuli.  Given that it is the cells lacking contact with 
the basement membrane that undergo cell death, it is plausible that these cells die through the lack of 
signalling pathway activation, which is achieved through basement membrane interaction.  Indeed, 
evidence for this specialised form of apoptosis, termed anoikis, has been documented.  For example, in 
3D cultures of MCF-10A cells, the pro-apoptotic factor Bim, is induced in cells following detachment 
from the basement membrane (Reginato et al, 2003; 2005).  Furthermore, when ECM-derived signalling 
is disrupted in CID-9 mammary epithelial cells, increased indicators of cell death are observed in cells in 
contact with the basement membrane (Boudreau et al, 1995).  This observation suggests that apoptotic 
suppression is one way in which cells in contact with the basement membrane escape clearance.  
Regardless of this, the precise reasons for the final fate of the two acini cell populations remains unclear. 
It is important to better understand the processes involved in acini formation, i.e. apoptosis and 
proliferation, and how these processes differ between the outer and central cells of acini.  This would be 
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likely to provide valuable information on how the disruption of these normally highly regulated 
processes can result in cancers. 
In vivo, homeostasis of mammary tissue is achieved through a controlled balance between 
proliferation and apoptosis.  Whilst proliferation is necessary for the growth of the breast, the apoptotic 
process is equally important for the normal development of the mammary gland.  This is because the 
process of apoptosis leads to hollow duct formation and involution, the process by which the lobules of 
the breast reduce in size, once they are no longer functionally necessary.  The importance of apoptotic 
and proliferative control is exemplified by luminal filling, which appears to occur when both processes 
are dysregulated, and is often observed in vivo and in breast cancer patients (Harris et al, 1995; 
Humphreys et al, 1996). 
One way in which these processes can be studied is by assessing the expression profile of genes 
involved in apoptosis and proliferation, such as BCL-2, BAX and CCND1 (the gene encoding cyclin D1).  
The development of the mammary gland in vivo, involves extensive changes in gene and protein 
expression levels of various apoptotic factors.  The expression of BAX and BCL-XL appears to remain 
relatively constant during mammary gland development, but both are down-regulated during lactation 
and then up-regulated during the onset of mammary gland involution.  BAD expression, however, 
increases significantly during the late pregnancy and lactation phases of breast maturation, until 
involution has been achieved (Heermeier et al, 1996; Schorr et al, 1999).  The anti-apoptotic factor, Bcl-
2, also undergoes dynamic changes in expression during the morphogenic process.  In non-pregnant 
females and during the early stages of pregnancy, BCL-2 is expressed, but during lactation, or in the 
early stages of mammary gland involution, its levels become undetectable.  CCND1 expression, on the 
other hand, is associated with cell cycle progression and thus, proliferation.  Cyclin D1 is involved in the 
regulation of cell cycle progression during the G1 phase.  The overexpression of CCND1 is a commonality 
in malignancies of the breast and is amplified in approximately 20% of mammary tumours (Zhou et al, 
2009; Lari & Kuerer, 2011).  The correlation between ER and CCND1 expression in breast cancer patients 
remains unclear, with some studies reporting a positive correlation (Oh et al,2001) and other studies 
finding no association between the two (Lebeau et al, 2003; Millar et al, 2007). 
By conducting gene analysis of key apoptotic genes and CCND1 in the inner and outer cells of 
MCF-12A acini, we may shed some more light onto the differences between the two cell populations.  
These genes have already been demonstrated to be involved in the formation of the hollow lumen 
during acini morphogenesis, as demonstrated by delayed lumen formation following ectopic expression 
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of Bcl-2, Bcl-xl or cyclin D1 (Debnath et al, 2002; 2003).  As it is more likely that a combination of factors 
contribute to the dysregulation of acini formation, rather than a single factor, it was decided to see if 
estrogens affected the gene expression of these factors.  Additionally, Bax, a key factor in the apoptotic 
process, and Bad, an inhibitor of Bcl-2 and Bcl-xl function, were also investigated.  This investigation can 
also provide some information on whether these populations respond differently to external signals, in 
this instance, the hormone E2.  Given that it is the inner cells that undergo apoptosis and are cleared, 
one would expect that this population of cells expressed higher levels of BAX and BAD, and lower levels 
of BCL-2, BCL-XL and CCND1, relative to the outer cells.  This would favour apoptosis.  However, 
following E2 treatment, we would expect the inner cells of E2-treated acini to express higher levels of 
BCL-2, BCL-XL and CCND1, and lower levels of BAX and BAD, in comparison to the inner cells of control 
acini.  This would, instead, favour survival of the inner cells of acini, and would correspond to the 
increased luminal filling observed in 3D cultures of MCF-12A cells described as in previous chapters. 
The overall increased proliferation, as inferred by increased acinar size and irregular shape, in 
response to estrogens, did not appear to be restricted to the inner cells exclusively, indicating that the 
outer cells are also affected.  In this instance, it would be expected that CCND1 expression, an indicator 
of proliferation, would increase in both populations following treatment with estrogen.  By defining the 
impact of estrogenic action on target genes, we could further clarify the processes involved in hormone-
mediated acinar malformations, and potentially speculate how each population impacts on hormonal 
carcinogenesis. 
7.1 Studying Gene Expression Profiles in Cells from 3D Cultures 
The study of gene expression profiles in 3D cultures has been met with difficulty in the past: firstly, the 
low number of cells present in cultures, although this can be counteracted through increasing the 
seeding density and pooling of wells, has proven to be a limitation.  Secondly, cells grown in a 3D matrix 
are embedded within the Matrigel that must be removed prior to analysis, which can now be achieved 
using cell recovery solutions, but was not always a straightforward task.  More recent solutions permit 
the depolymerisation of Matrigel without enzyme action and high temperatures, processes that can 
cause biochemical changes, and, thus, maintain the integrity of RNA. 
Studying gene expression in monolayer may obviate some of these problems, but, monolayer 
cultures themselves present their own problems, when used to study gene expression in response to a 
stimulus, such as E2.  This can be demonstrated by the work conducted in Chapter VI, where E2 did not 
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show a great impact upon the expression of apoptotic genes in the MCF-12A cell line.  However, it was 
clearly demonstrated in previous chapters that in 3D cultures, apoptosis is suppressed by estrogens, as 
inferred by the reduction in the levels of activated caspase-3 in acini, following E2 treatment.  Given that 
cells in vivo or cultured in 3D matrices behave differently from those grown in monolayer, it is plausible 
that E2 also impacts on apoptotic gene expression differently in different settings (Horning et al, 2008; 
Pickl & Ries CH, 2009; Yang et al, 2009).  There are limited publications regarding the gene expression 
profiling of 3D cultures of mammary epithelial cells.  The most thorough work has focused on comparing 
the gene expression profiles of different breast cell lines cultured in 3D to identify differences in their 
gene expression signatures, using Affymetrix high-density oligonucleotide arrays.  It was observed that 
the gene expression profile of mammary epithelial cells cultured in 3D reflects the morphology they 
adopt in a 3D matrix (Kenny et al, 2007).  However, to our knowledge, there has been no work 
conducted on comparing the gene expression of the inner cells with the outer cells, within acini. 
In our work, initially, whole acini were extracted from Matrigel for gene expression analysis.  
However, as mentioned before in this chapter and presented in Chapters III, IV and V, as well as in the 
reported literature (Debnath et al, 2002; 2003), two populations of cells exist within acini cultured in 
Matrigel: the outer cells attached to the basement membrane and the inner cells that undergo 
apoptosis and are progressively cleared, leaving a hollow lumen.  As these two distinct populations of 
cells within the acini of 3D cultures seem to have specific functions and fates, it is likely that the gene 
expression profile of these cells will also differ, as described previously.  Based on this, another potential 
limitation associated with studying the expression of genes in whole acini becomes clear, as it is possible 
that the differences in gene expression in one population might mask the changes in gene expression of 
the other, and lead to results that are not representative of what actually occurs in the acini.  In order to 
evaluate the differences between the two populations and study how gene expression profiles change in 
each one, in response to E2, it would be necessary to first separate the two populations of acini.  This, 
however, is no easy task and, to our knowledge, has not been carried out previously.  Consequently, we 
devised, developed and tested a novel method by which the inner and outer cells of acini can be 
separated. 
One way in which cells of a mixed population can be separated into their component 
populations is by fluorescence activated cell sorting (FACS).  FACS works by separating cells by 
fluorescent markers that are uniquely present in the desired population that you wish to separate.  
Through the use of lasers, these fluorophores can be excited, the emitted light detected and the cells 
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separated into a population of cells expressing the marker and a second population of cells lacking the 
marker. 
7.2 The Principles of FACS 
FACS is a form of flow cytometry that enables a heterogeneous mixture of cells to be separated into 
distinct cell populations based on fluorescent and light scattering properties of individual cells.  
Antibodies against specific markers and bound to specific fluorophores are used to label individual cell 
populations within this mixture.  These markers are used to distinguish the different populations during 
the FACS procedure.  Different fluorophores have characteristic excitation and emission wavelength 
spectra.  This means that multiple fluorophores can be used within one session and that multiple 
populations within a mixture can be obtained, providing the emission wavelengths of the fluorophores 
do not overlap.   
In terms of the sorting methodology, the cell mixture passes through a vibrating pressurized 
liquid stream whereby clumps of cells are separated into single droplets.  Next, the single-file cell stream 
passes through a series of lasers and detectors.  The various laser wavelengths excite the fluorescent 
molecules and these, in return, emit light of a particular wavelength, which is detected by a 
photomultiplier tube.  Depending on the fluorescence emission wavelength, cells are differentially 
charged.  The charged cells can then be separated according to this charge by electrodes resulting in the 
separation of a cell mixture into its component populations (Figure 7.1).  As all these procedures can be 
done under sterile conditions, cells can then be re-cultured or undergo further analysis via 
methodologies, such as real-time PCR. 
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Figure 7.1: The Process of FACS.  Fluorescently labelled cells (red) become charged upon excitation by lasers and 
are separated according to this positive charge.  Non-labelled cells (green) are not excited by the laser and hence 
produce no emission spectra.  These cells remain uncharged and are separated from the mixed population 
accordingly. 
 
The data from FACS can provide information on the total number of cells present within each population 
and their characteristics, in various formats.  Firstly, an intensity plot depicting fluorescence (x-axis) 
against frequency (y-axis) depicts the number of cells present with each emission wavelength (Figure 
7.2A).  Alternatively, a dot plot depicting the fluorescence of one dye (y-axis) against another (x-axis) can 
show the number of cells with no staining, staining with one fluorophores, or both fluorophores (Figure 
7.2B). 
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Figure 7.2: Schematic Representations of Data Following FACS Analysis.  A) Cell number is plotted against 
fluorescence wavelength.  Three populations are shown: Grey = unstained cells, Green = Fluorophore 1, Red = 
Fluorophore 2 B) Non-labelled cells are shown in the bottom left quadrant.  Red and green labelled cells are shown 
in the upper left and bottom right quadrants respectively.  Cells with both markers would be shown in the upper 
right quadrant.  Each dot represents a single event, i.e. a single cell. 
 
In order to perform FACS and obtain two separate populations of cells from acini, it is first necessary to 
find a specific marker for one, or both cell populations.  From our work with 3D cultures, and published 
literature, laminin, which composes the basement membrane, was observed to be localised to the outer 
edge of acini and in contact with the outer cells (Debath et al, 2002; 2003).  Moreover, this protein binds 
to transmembrane receptors, namely, integrins which, in turn, have been shown to locate specifically to 
the outer cells of the spheroid structures (Debnath et al, 2003).  For this reason, integrin β4 was 
considered a possible good candidate for using in the separation of the two populations within acini, as 
it would act as a marker for the outer cells. 
7.3 Integrin 
In the context of the breast, interactions between cells and the ECM in vivo are involved in the 
branching of the mammary ducts at the embryonic stage (Silberstein et al, 1992) and during mammary 
gland proliferation, differentiation, lactation and involution (Talhouk et al, 1992; Sympson et al, 1994).  
This is achieved through signalling from the ECM, via receptors, such as the integrins.  Reciprocally, 
cellular aspects, such as shape, internal cell architecture and expression of particular genes can impact 
upon the integration of the signals originating from the ECM and even impact upon the architecture of 
the ECM itself (Roskelley et al, 1994; Ingber et al, 1995). 
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Integrins comprise a large family of transmembrane proteins that are involved in cellular 
adhesion to the ECM and link the components of the extracellular environment, such as laminin, 
collagen, fibronectin and vitronectin, to the intracellular actin cytoskeleton.  Upon integrin binding to 
the ECM, integrin clustering occurs.  This adhesion can, in turn, engage various signalling pathways, such 
as the MAPK and PI3K cascades, that mediate survival, proliferation, migration and invasion of cells 
(Chen et al, 1994) (Fig 7.3)  
 
 
Figure 7.3: Integrin signalling. Activation of the AKT and MAPK signalling pathways cumulating in increased 
proliferation and survival in response to the binding of integrins to components of the ECM.  The antibody against 
integrin β4 (green) binding to integrin β4 (blue) is also shown. 
 
Previous work has identified integrins, such as integrin α6, as markers of basal polarity in 3D cultures of 
MCF-10A cells, and this localization has been implicated in mediating particular functions, such as 
establishment of polarity and activation of survival pathways (Debnath et al, 2003; Liu et al, 2004).  
Integrin β4 forms complexes with integrin α6 in epithelial cells and acts as a receptor for laminin, making 
it an ideal candidate marker for future work.  An antibody against this specific integrin was selected due 
to its availability and compatibility with our previously established protocols. 
7.4 Other Considerations 
When developing this new approach, another important point to consider was the selection of an 
appropriate time point at which to extract acini from Matrigel and separate the two populations.  The 
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ideal time point to do this would be just before cells undergo clearance from the centre of the acini, but 
while these are entering the apoptotic programme.  This is because we want to analyse the gene 
expression of the inner cells before they are cleared from the lumen, so that they are viable for RNA 
extraction and gene analysis.  However, we also had to ensure that the fates of the two cell populations 
had been determined and that the acini were comprised of two distinct cell populations.  The time-
course analysis in Chapter III, showed that following approximately 8 days incubation, the central cells 
of MCF-12A acini were starting to express activated-caspase 3, an indicator of apoptosis, but had not yet 
been cleared.  It was therefore decided to perform experiments following 7 days incubation in Matrigel 
to ensure that cells would be present in each population, but would still be preparing for their 
determined fate. 
7.5 Materials and Methods 
The same protocol was used to grow MCF-12A acini for whole and separated acini in preparation for 
extraction and gene analysis.  MCF-12A cells were seeded onto Matrigel, as previously described, at a 
seeding density of 100,000 cells per ml to ensure a significant number of cells would be recovered for 
FACS analysis and subsequent real-time PCR.  Cells were treated with either 0.5% ethanol or 1 nM E2 in 
0.5% ethanol for 7 days with media changes performed every 3 days.  At the end of the incubation 
period, cells were pooled from 8 chambers of an 8 chamber slide to ensure an adequate cell number 
was obtained for further analysis. 
7.5.1 Cell Recovery 
After maintenance in 3D culture for 7 days, cells were recovered from the Matrigel using MatriSperse 
Cell Recovery solution (BD Biosciences, Bedford, MA USA).  For that, medium was removed and wells 
washed 3 times with cold PBS.  200 µl Matrisperse cell recovery solution (BD Biosciences, Bedford, MA 
USA) was added to each well and a P1000 pipette tip was used to gently dislodge the Matrigel and 
transfer it to 1.5 ml centrifuge tubes that were kept on ice.  Wells were washed twice with 100 µl cell 
recovery solution and samples left on ice for 90 minutes with gentle mixing at 30 minute intervals.  
Samples were centrifuged at 6000 rpm for 3 minutes at 4oC and washed twice with cold PBS.  They were 
centrifuged again at 6000 rpm for 3 minutes at 4oC and the PBS aspirated, so only the pellet remained. 
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7.5.2 FACS Staining and FACS 
Cells were fixed by re-suspension in freshly prepared 4% PFA for 20 minutes at room temperature, 
centrifuged at 4000 rpm for 5 minutes and washed with PBS.  Cells were then permeabilised with 0.5% 
Triton-X for 10 minutes at 4oC, centrifuged at 4000 rpm for 5 minutes and washed with PBS.  Buffer (130 
mM NaCl, 7.7 mM NaN3, 0.1% BSA, 0.2% Triton X-100, 0.05% Tween-20) containing 10% goat serum was 
applied to the pellet to prevent unspecific antibody binding and cells were centrifuged for 10 minutes at 
4000 rpm.  Cells were then re-suspended in 100 µl antibody against human integrin β4 (mouse 
monoclonal antibody) at a 1:100 dilution in buffer containing 10% goat serum and incubated at 4oC 
overnight.  1 ml PBS was added and the cells were centrifuged for 10 minutes at 4000 rpm, then washed 
in PBS, before being re-suspended in 100 µl anti-mouse Alexafluor 555 (secondary antibody comprised 
of an anti-mouse antibody conjugated to a fluorophore with a similar excitation and emission spectra to 
Cy3, but with increased photostability and brighter resultant protein staining) at a 1:100 dilution and 
incubated at 4oC for 45 minutes.  1 ml PBS was added and the cells were centrifuged for 10 minutes at 
4000 rpm, then washed in PBS three times.  The final pellet was re-suspended in 1 ml PBS and 
transferred into 12 x 75 mm microtubes (BD Biosciences, Bedford, MA USA).   FACS was performed using 
the BD FACS Aria II cytometer (BD Biosciences, Bedford, MA USA) to separate integrin and non-integrin 
labelled cells. 
Cells were separated into three populations: integrin-labelled, non-integrin-labelled and a mixed 
population. The mixed population was discarded, as it was only necessary to ensure thorough sorting of 
the labelled and non-labelled cells.  Data analysis was performed using BD FACS Diva (Biosciences, 
Bedford, MA USA). 
7.5.3 Confirmation that Integrin β4 is Unique to One Population 
Prior to FACS, it was necessary to confirm that integrin β4 was differentially expressed by the two cell 
populations of acini, and that cell liberation from Matrigel did not affect integrin β4 detection (for 
example, loss of integrin β4 due to internalisation and degradation).  In order to do this, firstly, cells 
were grown in 3D culture for 8 days, as at this point acini remain whole with no luminal clearing evident, 
and whole acini were stained with antibodies against integrin β4 and TOPRO-3 used as a nuclear 
counterstain, as described previously. 
In a second experiment, following 8 days incubation, MCF-12A acini were extracted from the 
Matrigel, as described above, and a sample of cell suspension prior to FACS was dropped onto glass 
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slides into a defined area.  After drying, cells were fixed and stained using antibodies against integrin β4 
and the nuclear counterstain, 4’, 6-diamidino-2-phenylindole (DAPI) (Sigma-Aldrich) as described in the 
immunocytochemistry protocol detailed in previous chapters, with a few adjustments to the protocol.  
As the desired areas to be stained were marked by a PAP pen, a volume of 500 µl of 2% PFA, 0.5% Triton 
X and primary and secondary antibody dilutions were required to sufficiently cover the desired area. 
Washing steps were performed in petri dishes with gentle rocking in volumes of 5 ml to sufficiently wash 
away excess antibodies.  In order to counterstain the nucleus using DAPI, the immunocytochemistry was 
followed until the washing steps following incubation with the secondary antibodies. After this, 500 µl 
DAPI (300 nM) prepared in dH20 was applied to the marked areas and samples were incubated for 5 min 
at room temperature.  Samples were then washed in PBS for 5 min with gentle rocking.  The PAP pen 
was removed and the samples mounted as described previously. 
Both samples were analysed using the Zeiss LSM 710 confocal microscope (Carl Zeiss Ltd).  
7.5.4 Gene Analysis Procedures 
RT real-time PCR was used to analyse the difference in gene expression between inner and outer cell 
populations in EtOH controls and 1 nM E2-treated samples.  As before, β-ACTIN was used as the 
reference gene. 
7.5.5 RNA Extraction 
RNA extraction was performed on separated samples using the Nucleospin® RNA XS kit (Machery-Nagel, 
Düren, Germany), which is specifically designed for RNA extraction from small cell numbers.  Samples 
were lysed using 100 µl RA1 lysis buffer and 2µl tris 2-carboxyethylphosphine (TCEP) and vortexing 
vigorously.  5 µl 4ng/µl carrier RNA solution was added and samples were again vortexed and spun 
down.  100 µl 70% ethanol was added to optimise binding conditions and samples were mixed by 
pipetting up and down before being loaded onto NucleoSpin® XS columns.  Samples were centrifuged 
for 30 seconds at 11,000 x g.  Desalting of the silica membrane was achieved by the addition of 100 µl 
membrane desalting buffer (MDB) and centrifugation at 11,000 x g for 30 seconds.  25 µl rDNase was 
applied directly to the membrane of the columns and samples were incubated at room temperature for 
15 minutes.  100 µl RA2 buffer was added to the columns and samples were incubated for 2 minutes at 
room temperature before centrifugation for 30 seconds at 11,000 x g.  400 µ RA3 buffer was then added 
and samples were centrifuged at 11,000 x g for 30 seconds.  A final wash with 200 µl RA3 buffer and 
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centrifugation for 2 minutes at 11,000 x g was performed before RNA was eluted in 10 µl RNase-free 
water at 11,000 x g, for 1 minute. 
7.5.6 Reverse Transcription Real-Time PCR 
Reverse transcription was performed as described previously.  Real-Time PCR was performed as 
described previously, using primers for BAX, BAD, BCL-2, BCL-XL and CCND1 (Table 7.1).  β-ACTIN was 
used as a reference gene.  Finally, gene expression analysis and determination of the Bax/Bcl-2 ratio was 
performed as described previously.  Statistics was performed using the pair wise fixed reallocation 
randomisation test (REST, Pfaffl et al, 2002) and the unpaired t-test for gene expression and Bax/Bcl-2 
ratios, respectively.  A p-value of 0.05 was considered statistically significant. 
 
Table 7.1: Primers used for real-time PCR analysis of 3D cultures of MCF-12A cells.  Primers were designed using 
Beacon Designer 5 and purchased from Eurogentec.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
cDNA  Genebank 
Ascension 
Number 
Primer 
Sense 
Primer Sequence (5’-3’) Concentration 
(nM) 
Target 
Size (bp) 
β-
ACTIN 
X00351 Forward TGCTATCCAGGCTGTGCTAT 300 97 
Reverse GATGGAGTTGAAGGTAGGTT 300 
BCL-2 EU287875 Forward CCTGGTGGACAACATC 100 160 
  Reverse GAGCAGAGTCTTCAGAG 100  
BCL-XL BT007208 Forward TGAACAGGTAGTGAATGAAC 100 105 
  Reverse TCCTTGTCTACGCTTTCC 100  
BAX BC014175 Forward CCTCCTCTCCTACTTTGG 150 103 
  Reverse GCCTCAGCCCATCTTC 150  
BAD BT006678 Forward GATGAGTGACGAGTTTGTG 150 133 
  Reverse GCCCAAGTTCCGATCC 150  
CCND1 AF212040 Forward TGGAATGGTTTGGGAATAT 200 146 
Reverse CCTGGCAATGTGAGAATG 200 
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7.6 Results 
7.6.1 Gene Expression of Whole Acini 
Firstly, we investigated the expression of key apoptotic and proliferative genes in whole acini following 7 
days incubation in Matrigel.  Following gene expression analysis by real-time PCR, the relative 
expression ratio, as calculated using the Pfaffl equation (Pfaffl et al, 2002), were plotted for each gene.  
We observed that the only significant changes in gene expression in response to E2 were an up-
regulation of CCND1 and a down-regulation of BAX (P < 0.05) (Figure 7.4). 
 
Figure 7.4: Effect of E2 on gene expression in MCF-12A acini.  Negative controls (etOH) are set to 0.  Bars show 
relative changes in gene expression following 1 nM E2 stimulation during the incubation period in 3D culture.  
Positive values indicate a gene up-regulation and negative values indicate gene down-regulation.  Error bars 
represent +/- standard error of the mean (n = 6).  P-values are shown for each data set.  A P-value of 0.05 was 
considered statistically significant and is donated by a *. 
7.6.2 Bax/Bcl-2 Ratio of Whole Acini 
The Bax/Bcl-2 ratio was calculated as previously described.  Although the up-regulation in BCL-2 
expression in response to E2 treatment was not statistically significant (Figure 7.4), E2 treatment did 
decrease the Bax/Bcl-2 ratio relative to etOH controls (Figure 7.5).  This potentially means that E2 can 
have a negative impact upon apoptosis and, thus, promote cellular survival in 3D cultures of MCF-12A 
cells. 
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Figure 7.5: Relative Bax/Bcl-2 ratio for MCF-12A cells cultured in Matrigel for 7 days and treated with 1 nM E2.    
A value of 1 was set for the Bax/Bcl-2 ratio for etOH controls and treatment ratios are relative to this.  Data is 
normalised to β-actin.  Error bars represent standard error of the mean (n = 6).  P-values < 0.05 were considered 
statistically significant and are denoted by an *. 
 
As can be seen in Figure 7.4, the expression of pro-apoptotic BAD, as well as the anti-apoptotic factors, 
BCL-2 and BCL-XL, was not significant.  This observation partially contradicts the observations in 
monolayer, where cultures of MCF-12A cells showed an increase in BCL-2 expression following E2 
treatment (Figure 6.5).  Although this may have been due to differences in cell responses determined by 
whether they were cultured in monolayer or 3D, another reason may be that the outer and inner cell 
populations of E2 respond differently to E2, in terms of gene expression.  If this is the case, it is plausible 
that the response to E2 in one population may mask that of the other.  The need to test this hypothesis 
emphasises the need to separate the two populations of cells (which has been discussed previously), 
and analyse gene expression in both of them, in response to E2 treatment.  This requirement led to the 
development FACS separation of MCF-12A acini into inner and outer cell populations for gene 
expression analysis. 
7.6.3 Confirmation of Integrin β4-Specific Localisation to Outer Acinar Cells 
In order to ensure the correct separation of both inner and outer cell populations from acini, it was 
necessary to confirm that only one cell population expressed integrin β4, so that cell sorting could be 
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performed reliably.  Following immunocytochemistry and microscopic analysis of MCF-12A cells grown 
in 3D cultures with an antibody against integrin β4 and TOPRO-3 nuclear counterstain, integrin β4 was 
seen to localise to the basal side of the outer acinar cells.  There was no staining for integrin in the inner 
cells of acini (Figure 7.6).  This observation indicates that integrin β4 can potentially be used as a marker 
to separate the outer from the inner populations of MCF-12A acini by FACS, as its expression is limited 
to the outer cells of the spheroid structures. 
 
 
Figure 7.6: LCM image of MCF-12A acinus after 8 days incubation in Matrigel.  Acini were fixed and stained with 
antibodies against integrin β4 (red) and then counterstained with TOPRO-3 (blue) as a nuclear marker.   
7.6.4 Proof That Integrin β4 is not Lost During Sample Preparation 
To confirm that acini recovery from Matrigel did not result in the loss of integrin β4 (as a result of 
receptor internalisation, ubiquitylation or degradation), the expression of this marker was analysed by 
immunocytochemistry and LCM, following liberation from the Matrigel.  We observed that there 
appeared to be two different populations: one positive for DAPI only, and another that expressed both 
DAPI and integrin β4 (Figure 7.7).  Assumedly, these populations correlate with the inner and the outer 
cells of MCF-12A acini, respectively.  Taking this together with the staining of whole acini, these 
observations seem to imply that the expression of integrin β4 is exclusive to cells of acini that are in 
contact with the basement membrane.  Furthermore, we can now be confident that the process of acini 
extraction from Matrigel does not result in the loss of integrin β4 and consequently, integrin β4 can be 
used as a marker to separate the inner cells of acini from the outer. 
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Figure 7.7: DAPI and integrin β4 staining of cells after acini extraction from Matrigel.  Following acini isolation 
from Matrigel after 8 days incubation, cells were stained for integrin β4 (red) and counterstained with DAPI (blue).  
Despite all cells being positive for the nuclear counterstain DAPI (blue), only some cells expressed integrin β4 (red) 
which confirmed that not all cells expressed integrin β4.  Arrow indicates cell where only nuclear staining is 
present as inferred by positive DAPI staining but lack of integrin β4.  Circle indicates where cell would be if it had 
stained positive for integrin β4. 
7.6.5 Selection of a Time-Point for Acini Separation 
The final step in optimisation of conditions for the separation of the inner and outer cell populations of 
MCF-12A acini was to select an appropriate time point at which to perform FACS.  In Chapter III, we 
performed a time-course analysis for the morphogenesis of MCF-12A acini (Figure 7.8). 
 
Figure 7.8: Time-course of MCF-12A acini over 16 days.  Acini were stained with antibodies against integrin β4 
(red) and activated caspase-3 (green) to identify basement membrane and apoptotic cells, respectively.  Cells were 
counterstained with TOPRO-3 (blue) as a nuclear stain. 
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At 4 days, acini were small in size and because we required the maximum cell number possible, this time 
point was not optimum for future gene analysis.  Also, at this point, the staining for integrin β4 was 
diffuse and disperse throughout the acini structure, probably indicating that, at this early time-point, the 
two distinct populations of cells were not yet completely differentiated and expression of integrin β4 
was not significant.  Following 8 days incubation in Matrigel, MCF-12A acini were larger and showed no 
sign of apoptosis, as indicated by the lack of activated caspase-3.  However, at 12 days, luminal clearing 
and extensive activated caspase-3 was evident.  This means that time-points after 12 days are not 
candidates for the comparison of outer and inner cells, as some cells had already cleared from the 
central area.  Furthermore, as the remaining inner cells were clearly marked an on the path to cell 
death, it is likely they would not be functionally active anymore and the expression of apoptotic genes 
no longer observable.  Therefore, a time-point at around 8 days, where two clear populations of viable, 
live cells were obtained, would be the optimum time-point.  7 days was selected to perform FACS, as 
this time-point was adequate for our needs and was convenient for the collaborative effort with the 
FACS operator. 
7.6.6 FACS 
Following staining of the extracted acini with antibodies against integrin β4, cells were separated into 
three populations: P1 (integrin β4 labelled), P2 (a mixed population) and P3 (unlabelled).  The P2 cells 
were disregarded as contained a small fraction of both tagged and untagged cells.  The P1 and P3 
populations, however, were prepared for gene analysis by real-time PCR.  The majority of cells were 
untagged, which is probably due to more cells being contained within the volume of a sphere than those 
present on the surface (Figure 7.9; 7.10; 7.11).  
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Figure 7.9: FACS Raw Data: The number of events, or cells, in each population.  FACS was performed until a total 
of 10,000 events had occurred. Red (P1) = Integrin β4-labelled cells, Pink (P2) = mixed population of labelled and 
unlabelled cells, and Blue = unlabelled cells. 
 
 
Figure 7.10: Intensity plot for FACS-separated cells for etOH controls and E2-treated samples.  Fluorescence is 
plotted along the x axis against frequency (y-axis).  The three populations are shown: Red (P1) = Integrin β4-
labelled cells, Pink (P2) = mixed population of labelled and unlabelled cells, and Blue = unlabelled cells. 
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Figure 7.11: Dot plot diagrams for FACS-separated etOH and E2-treated samples.  Fluorescence in the range of 
Texas Red is plotted against side scatter (SSC-A).  Each dot corresponds to a single event.  Red (P1) = Integrin β4-
labelled cells, Pink (P2) = mixed population of labelled and unlabelled cells, and Blue = unlabelled cells. 
7.6.7 The Two Populations of Acini Have Different Expression Profiles 
After the inner and outer populations of etOH control and E2 treated acini were separated by FACS and 
real-time PCR was performed, changes in gene expression were observed in apoptotic genes that were 
not previously observed, following gene expression analysis of whole acini.  As can be seen in Figure 
7.12, in etOH controls BCL-XL expression was lower in the inner than the outer cells of acini (outer cell 
expression is set to 0, so positive values indicate an up-regulation of a gene in the inner cells relative to 
the outer cells, and a negative expression value indicates a down-regulation in the inner cells).  
Following E2 treatment, however, BCL-XL expression increased in inner cells relative to the outer cells (p 
< 0.05).  It is likely that this E2-induced up-regulation of an anti-apoptotic factor would contribute 
towards an anti-apoptotic influence and, hence, promote the survival of the inner population of cells.  
Although not statistically significant, the inner cells of etOH controls expressed higher levels of BAX and 
BAD compared to the outer population.  This may have a pro-apoptotic influence on these inner cells.  
When acini were treated with E2, however, the inner cells expressed less BAX (p < 0.05) and BAD than 
the outer cells and, thus, would be more likely to survive and evade apoptosis. 
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Figure 7.12: Relative gene expression of inner cells compared to outer cells.  Red bars are controls and blue bars 
are E2-treated cells.  A positive value is indicative of an up-regulation in gene expression and a negative value is 
indicative of a gene down-regulation.  Data is normalised to β-actin.  Error bars represent the standard error of the 
mean (n = 6).  A p-value of 0.05 was considered statistically significant and is donated by an *. 
7.6.8 Gene Expression of FACS-Separated Acini in Response to E2 
We then sought to see if E2 treatment caused changes in gene expression in both inner and outer 
populations, relative to controls (controls are set to 0).  BCL-2 expression was up-regulated by E2 in the 
both the inner and outer cells of MCF-12A acini, but was only significant in the outer cells (p < 0.05).  
Interestingly, E2 significantly down-regulated the expression of BCL-XL which was unexpected as this 
would contribute to a pro-apoptotic effect.   As expected, BAX expression was down-regulated by E2 in 
both the inner and outer cell populations (P < 0.05), and this was more marked in the inner cells.  This 
may present one part of the mechanism by which estrogens act to induce luminal filling in MCF-12A 
acini, as decreased BAX would have an anti-apoptotic effect.  In addition to this, E2 also down-regulated 
BAD expression relative to controls in the inner cells of acini (P < 0.05).  However, unexpectedly, BAD 
expression was up-regulated in the outer cells of acini following E2 treatment (P < 0.05).  Although not 
statistically significant, E2 induced a small up-regulation in CCND1 expression in the outer and inner cells 
(Figure 7.13).  This may contribute to an increase in proliferative ability of both populations, and may 
account for the increased acinar size that was observed when 3D cultures of MCF-12A cells were treated 
with estrogens. 
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Figure 7.13: Relative gene regulation of E2-treated inner and outer cells compared to controls (x-axis).  Red bars 
are from inner cells and blue bars are from outer cells.  A positive value is indicative of an up-regulation in gene 
expression and a negative value is indicative of a gene down-regulation relative to controls.  Data is normalised to 
β-actin.  Error bars represent the standard error of the mean (n = 6).  A p-value of 0.05 was considered statistically 
significant and is donated by an *. 
7.6.9 Bax/Bcl-2 Ratio 
The Bax/Bcl-2 ratio was calculated by dividing the relative expression ratio of BAX by that of BCL-2 
obtained from the Pfaffl equation (Pfaffl et al, 2002).  The lower the Bax/Bcl-2 ratio, the more likely a 
cell is to undergo apoptosis.  The Bax/Bcl-2 ratio for solvent controls was lower in the inner population 
of MCF-12A acini compared to outer cells, which would indicate that the inner cells are more likely to 
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undergo apoptosis.  In both the inner and outer populations, E2 treatment reduced the Bax/Bcl-2 ratio 
(Figure 7.14).  This would likely contribute to an anti-apoptotic effect and hence may explain why E2-
treated acini underwent less apoptosis, and displayed luminal filling, as observed by marked reductions 
in activated caspase-3 expression in Chapter IV. 
 
Figure 7.14: Bax/Bcl-2 ratio for FACS-separated MCF-12A cells cultured in Matrigel and treated with 1 nM E2.    
Lower Bax/Bcl-2 ratios correlate with an increased pro-apoptotic influence.  Error bars represent standard error of 
the mean (n = 6).  Data is normalised to β-actin.  A p-value < 0.05 was considered statistically significant and is 
denoted by an *. 
7.7 Discussion 
7.7.1 Analysis of Whole MCF-12A Acini Cultured in Matrigel 
In Chapter VI, it was demonstrated that E2 induced up-regulation of BCL-2, BCL-XL and BAX expression 
in monolayer cultures of MCF-12A cells.  Given that cells behave differently in monolayer from in vivo or 
in 3D, it was important to investigate if the same gene regulation was seen in our 3D cultures (Horning 
et al, 2008; Pickl & Ries CH, 2009; Yang et al, 2009).  By studying the expression profile of genes involved 
in cell proliferation and apoptosis in 3D cultures, we hoped to provide a further understanding of the 
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mechanisms that regulate acini formation, as well as those involved in estrogen-induced acini 
disruption. 
Firstly, gene expression analysis of specific apoptotic and proliferative genes was carried out in 
whole acini, recovered from 7 days Matrigel cell cultures.  As described in the results section, when real-
time PCR was performed on E2-treated whole acini extracts, BAX expression was down-regulated and no 
significant changes were seen in the expression of BCL-2 and BCL-XL.  The effect on these apoptotic 
genes was accompanied by an increase in CCND1 levels.  In contrast to this, E2-treated monolayer 
cultures of MCF-12A cells resulted in the up-regulation of BCL-2 and BCL-XL, in addition to BAX (Chapter 
VI).  The differences in gene expression of cells cultured in 3D and in monolayer have been described 
previously.  For example: following gene analysis of prostate cells, cultured in monolayer and in 
Matrigel, approximately 3400 mRNA’s were expressed differently (Härmä et al, 2010).  This study 
identified that prostate cells cultured in Matrigel, without treatments, differed from monolayer cultures, 
in terms of the expression of genes associated with metabolism, proliferation and epigenetic 
modifications.  The differences in gene expression were hypothesised to account for further 
observations that prostate cultures grown in Matrigel displayed reduced growth and proliferation than 
monolayer cultures.  If the same pattern holds true for mammary epithelial cells, in particular for MCF-
12A cells, the difference in gene expression profiles may account for why MCF-12A cells grown in 
monolayer or Matrigel responded differently to E2, in respect to apoptotic factor expression.  Indeed, it 
has been shown that the gene expression profile of bovine mammary epithelial cells cultured in Matrigel 
differs from that of cells grown in monolayer (Kozlowski et al, 2009).  These changes in expression 
between monolayer and 3D cultures involved genes associated with cell signalling, apoptosis and 
proliferation.   
An overall increase in the expression of CCND1 of E2-treated MCF-12A acini may account for the 
increased proliferation, as inferred by the increased acinar size and deviation from a uniform spherical 
shape, and the ability of estrogen-treated acini to escape proliferative suppression, observed in 3D 
cultures of these cells in Chapter IV.  Likewise, the down-regulation in BAX expression may be a 
contributing factor to the decreased levels of apoptosis in E2-treated acini.  These observations are 
supported, at least in respect to the role of cyclin D1, by previous findings in which ectopic expression of 
CCND1 caused cells to evade proliferative suppression (Debnath et al, 2002).  Following gene expression 
analysis, the Bax/Bcl-2 ratio was also calculated.  We did not observe a significant change in expression 
of BCL-2 following E2 treatment.  However, the Bax/Bcl-2 was reduced, and this would favour survival, 
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rather than apoptosis.  This change in the Bax/Bcl-2 ratio may therefore account for the reduction in 
apoptosis observed in estrogen-treated acini in Chapter IV. 
7.7.2 Optimisation of Separation of Acini Cell Populations by FACS 
As mentioned earlier, it is worth noting that there are two cell populations present within the acini (the 
inner and the outer cells).  It is likely, given that these two populations undergo different fates, that the 
gene expression profile of the inner and outer cells differs.  We observed an overall increase in CCND1 
and a decrease in BAX expression following gene analysis of whole MCF-12A acini.  However, the 
methodology did not allow us to ascertain the specific impact of E2 upon each individual population 
found in acini.  For this reason, we then proceeded to separate the inner cells from the outer cells of 
acini by FACS.  In order to achieve this, a protocol for the fluorescent tagging of the two populations had 
to first be developed and optimised, as, to our knowledge; there are no published reports of the use of 
FACS technique to separate cells within 3D cultures of immortalised cells.  We utilised this technique to 
develop a novel way to investigate the difference between the two populations of MCF-12A acini, and 
the impact of E2 upon each.  For the first time, we achieved the separation of MCF-12A cells cultured in 
Matrigel into the inner and outer populations for gene analysis investigation. 
In this chapter, integrin β4 was identified as a suitable marker to separate acinar cells, as our 
work demonstrated that this receptor is only expressed by the outer cells of acini in contact with the 
basement membrane, in a similar fashion to integrin α6 (Debnath et al, 2003; Liu et al, 2004).  Following 
the successful separation of the cells of acini by FACS, the RNA from these samples had to be extracted 
and real-time PCR conducted.  These processes had to be adapted from our standard protocols to 
accommodate for the fact that the cell number available was markedly lower.  Nevertheless, using RNA 
extraction kits designed for small quantities of cells and careful adaptation of the protocol, sufficient 
RNA was extracted in order for real-time PCR to be conducted.  Despite the good quality data obtained 
for the separated acinar cells, it should be noted that the protocol is in its infant stages and still requires 
optimization, which will be discussed briefly in the following paragraphs.  Having said this, we have, 
nevertheless, demonstrated for the first time that cells grown in 3D culture can be separated based on 
integrin β4 expression and used for further analysis by techniques, such as real-time PCR. 
Following the separation of MCF-12A cells grown in 3D culture for 7 days, the data from the 
FACS software was analysed for both etOH controls and E2 treated samples.  It was observed that only a 
small proportion of the cell visualised were labelled for Integrin β4.  One possible explanation for this 
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was that the labelling of integrin β4 was insufficient.  Various factors can contribute to this, such as 
insufficient antibody concentration and incubation periods, or the use of an inappropriate buffer.  
Furthermore, loss of integrin β4 expression, through internalisation and degradation, could contribute 
to the low abundance of cells in the labelled population (Kelly & Owen, 2011).  We demonstrated by 
immunocytochemistry, that some cells still retained their integrin β4 expression following extraction 
from Matrigel.  However, this approach yielded only qualitative data, and it is possible that some level of 
integrin expression was lost.  An alternative possibility for these results could be due to a larger quantity 
of cells occupying the volume of a sphere compared to that present on the surface.  This means that the 
majority of cells would not be labelled (as they would be inner cells) and would account for the lower 
proportion of integrin β4 labelled cells.  Given the confirmation of integrin β4 presence following acini 
extraction from Matrigel and various optimisation steps to ensure sufficient labelling of integrin β4, one 
of the most likely possibilities for the low number of cells was the difference in cell number between the 
two populations. 
Although our data still demonstrated clearly that there are differences in the gene expression of 
cells obtained from each population, more work will have to be performed in the future to further 
improve and validate this novel technique.  In future, it may be of interest to attempt the procedure 
with a higher concentration of integrin β4 antibody, or to try and increase overall cell number, possibly 
through the pooling of additional wells. 
Cell sorting with other markers for each population may also further validate our findings.  Such 
markers include antibodies against tight junctions, for example, zonula occludens protein 1 (ZO-1) 
antibodies.  This would allow separation as ZO-1 is reported to be expressed exclusively by the outer 
cells of mammary epithelial cells cultured in Matrigel (Plachot et al, 2009). 
7.7.3 Effects of Estrogen Treatment on Inner and Outer Cells of MCF-12A Acini 
Firstly, one of the important points for discussion is the differences in gene expression between the 
outer and inner cell populations of control acini.  In control acini, the expression of BCL-XL and CCND1 
was lower in the inner population of cells compared to the outer population.  In addition to this, the 
expression of BAX and BAD was higher in the inner population.  A decrease in the expression of BCL-XL 
and CCND1 and an increased expression of BAX and BAD in the inner population would have a pro-
apoptotic and anti-proliferative influence.  This observation was expected, as this inner population is 
composed of cells that are destined to be cleared during the formation of the hollow lumen.  Having 
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analysed the difference in gene expression between the inner and outer cells within MCF-12A acini 
under control conditions, we can now potentially further understand the mechanisms behind acini 
morphogenesis.  Our data appear to indicate that the inner cells of acini, under control conditions, 
express lower levels of anti-apoptotic factors (BCL-XL) and a higher abundance of pro-apoptotic factors 
(BAX and BAD), suggesting that the regulation of the balance of apoptotic factors in implicated in the 
hollowing of the central lumen by apoptosis.  Furthermore, decreased CCND1 in the inner cells, would 
imply that these inner cells have a lower proliferative ability than the outer cells, and this may account 
for why they undergo proliferative suppression. 
Having classified the differences in gene expression between the inner and outer populations 
found within acini under control acini, we could then investigate the impact of estrogens upon this, in 
the hope that it may provide us with some information on the mechanisms involved in the estrogen-
induced acinar malformations. 
E2 induced an increase in BCL-2 expression in the outer population of cells (and a small increase 
in the inner cells) within MCF-12A acini.  In vivo, Bcl-2 overexpression has been found to partially 
suppress apoptosis during the formation of the TEBs of the breast, however, this induced over-
expression of BCL-2 does not prevent the mammary gland from developing in vivo and does not result in 
luminal filling in vitro (Humphreys et al, 1996; Debnath et al, 2002; Underwood et al, 2006).  Despite 
this, a role for Bcl-2 in the initiation and progression of breast cancer is suggested as the anti-apoptotic 
factor is overexpressed in approximately 80% of breast tumours (Zhang et al, 1999).  We observed that 
E2 did not greatly impact upon the expression of BCL-2 in the inner cells of MCF-12A acini, suggesting 
that luminal filling was not due to increased BCL-2.  This observation is supported by previous studies 
whereby ectopic BCL-2 expression in 3D cultures of MCF-10A cells resulted in larger acini with delayed 
onset on hollow lumen formation, but where complete luminal filling did not occur (Debnath et al, 2003; 
Karantza-Wadsworth et al, 2007).   
E2 induced a down-regulation of BCL-XL expression in comparison to untreated controls in both 
the inner and outer cell populations, but this was only statistically significant in the outer population.  As 
Bcl-xl is an anti-apoptotic factor, its down-regulation would contribute to a pro-apoptotic influence.  Our 
observations were therefore, unexpected, as in Chapter IV, we demonstrated that estrogens induced 
acinar malformations that appeared to be associated with an increase in cell proliferation and a 
decrease in cell death.  Furthermore, gene expression analysis of whole acini showed that E2 up-
regulated BCL-XL expression.  The reason for the discrepancies in the data may be down to experimental 
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error or it could be that E2 did in fact down-regulate BCL-XL expression.  In this instance, given the 
reduced levels of apoptosis observed in estrogen-treated acini, it would appear that Bcl-xl alone does 
not play a major role in the formation and maintenance of the hollow lumen.  Indeed, it has been shown 
that ectopic expression of BCL-XL did not inhibit lumen formation, but did delay its formation (Debnath 
et al, 2002; Mills et al, 2004).  However, a down-regulation in BCL-XL expression in response to 
estrogens has not previously been reported in the literature and in the future will have to be confirmed.  
The gene expression data from FACS-separated acini agrees with previous observations that E2, in 
monolayer cultures of MCF-12A cells, up-regulated BCL-2.  However, the remaining gene data is not in 
agreement with the monolayer data, and although this may be due to experimental error, it is well 
known that cells cultured in 3D behave differently to those cultured in monolayer in response to a 
stimulus (Horning et al, 2008; Pickl & Ries CH, 2009; Yang et al, 2009). 
E2 treatment of MCF-12A acini induced a significant down-regulation of BAX expression in both 
the inner and outer cell populations within MCF-12A acini.  This effect seemed to indicate that E2 
treatment has an anti-apoptotic influence in both populations, which was corroborated by the dramatic 
decrease in the Bax/Bcl-2 ratio induced by E2 in both inner and outer cells.  Decreased Bax expression 
and a role for Bax in tumour progression have been postulated in patients with breast cancer (Krajewski 
et al, 1995; Sturm et al, 2000).  In combination with the data presented here, this may mean that Bax is 
involved in the estrogen-induced acinar malformations, in regards to luminal filling, and that this may be 
one contributing factor that leads to a cancerous phenotype.  To date, there is little literature 
concerning Bax expression in 3D cultures of mammary epithelial cells.  In one of the few reports 
concerning this gene, acini formed from primary breast cancer cells treated with PI3K pathway 
inhibitors, displayed increased Bax at the protein level.  The authors concluded that activation of the 
PI3K pathway was necessary for tumour growth in a 3D setting, and acted in a way that suppressed the 
apoptotic process (Polo et al, 2010).  In Chapter VI, we demonstrated that in monolayer cultures of 
MCF-12A cells, E2 was capable of inducing PI3K, as inferred by the increased detection of activated AKT.  
Furthermore, in Chapter V, we observed that inhibition of PI3K signalling by the AKT inhibitor, LY 
294002, resulted in increased signs of apoptosis.  Although the activation of AKT in 3D cultures of MCF-
12A cells is yet to be investigated, it may be plausible that through the activation of PI3K signalling, BAX 
expression is decreased, and, hence, less caspase-mediated apoptosis is observed. 
To date, no ERE has been confirmed in the promoter region of the BAX gene, which raises the 
question as to how E2 was able to impact upon its gene expression.  The presence of Sp-1 or Ap-1 
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binding sites in the BAX gene have not yet been disproved and, therefore, the ER may be co-operating 
with Sp-1 or Ap-1 in order to induce transcriptional responses.  Alternatively, it is possible that the E2-
induced activation of the MAPK and PI3K signalling cascades, culminating in a transcriptional response.  
Indeed, as mentioned above, E2 resulted in the activation of both PI3K and MAPK signalling in MCF-12A 
cells, and in other cell lines.  Given that c-Myc activity is increased upon MAPK pathway activation and 
p53 activity is repressed upon PI3K pathway activation; and that p53 and c-Myc regulate BAX 
transcription, it is plausible that estrogens impact upon the expression of BAX via this mechanism 
(Miyashita & Reed, 1995; Mitchell et al, 2000). 
In Chapter VI, no significant changes were observed in BAD expression in response to E2 in the 
monolayer cultures of MCF-12A cells.  When gene expression analysis for whole MCF-12A acini was 
performed, again, no significant changes in BAD expression were observed in response to E2 either.  
However, when E2-treated FACS-separated acini were analysed, it was observed that E2 induced a 
down-regulation of BAD expression in the inner cell population in relation to control samples.  However, 
an up-regulation of the gene was observed in the outer cells.  Given that E2 had opposing effects on BAD 
expression in each population, this may explain why, in whole acini, no effect was observed.  As 
described previously, Bad is a pro-apoptotic factor; consequently, a down-regulation of this gene would 
result in an anti-apoptotic influence over the central cells of MCF-12A acini promoting increased cell 
survival, which would not occur under control conditions.  Taken together with the E2-induced 
reduction in Bax/Bcl-2 ratio, our data suggests that E2 has an anti-apoptotic effect upon both 
populations of acini, although compared to etOH controls, this is more pronounced in the inner 
population.  Interestingly, this observation is in agreement with the observations presented in Chapter 
IV, where estrogens disrupted acini formation.  Although BPA and n-propylparaben appeared to impact 
on acini as a whole (i.e. both the inner and outer populations), the disruption induced by E2 appeared to 
concentrate on the inner cells within acini.  This was inferred from the observations that BPA and n-
propylparaben resulted in much larger acinar with greater malformation in regards to their shape, in 
comparison with E2-treated acini.  We speculate that, if the endogenous hormone, had a strong impact 
upon the proliferation of the outer cells, the resultant acini would be more deformed and larger (as seen 
with the other treatments).  Taking into account the gene expression data presented in this chapter, it is 
possible that E2 targets the inner cells more than outer cells, and therefore has a greater impact on 
lumen formation, as opposed to acini size and morphology. 
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In addition to investigating the effects of E2 upon the expression of key apoptotic factors during 
acini formation, the expression of the cell cycle progression marker, CCND1, was also studied.  Cyclin D1 
has previously been suggested to mediate the proliferation of cells treated with steroids, such as 
estrogen, and studies have shown that increased ER expression in breast cancer cells correlates with 
increased levels of the CCND1 gene (Buckley et al, 1993; Sicinski et al, 1995).  Under control and E2 
conditions, the inner cells of acini expressed less CCND1 compared to the outer cells, although this was 
not statistically significant.  This would appear to suggest that the outer population of cells within MCF-
12A acini have a greater level of proliferative ability.  It is important to note at this point, that the 
proliferative ability of cells within acini differs depending on incubation time in Matrigel.  We 
demonstrated in Chapter III, when we defined the morphogenesis of MCF-12A acini, that cells undergo 
proliferative arrest, as inferred by a cessation in the increase of acinar size, following approximately 16 
days in 3D culture.  Similar findings have been reported in the literature (Debnath et al, 2003).  At 7 
days, acini are still growing, whilst hollow lumen formation simultaneously occurs, and therefore it 
would be expected to observe active proliferative genes in the outer cells.  However, if cells were 
recovered following 20 days incubation in Matrigel, when growth-arrest of acini has occurred, it is likely 
that genes associated with proliferation would not be expressed at such levels.  It may be of interest in 
the future, to perform gene analysis on FACS-separated acini at various time-points in the morphogenic 
process to identify how the expression profile of both the inner and outer populations changes over 
time. 
Following whole extraction of E2-treated acini from Matrigel and gene analysis on the whole 
acini population, CCND1 was significantly up-regulated.  In the FACS-separated MCF-12A 3D cultures, E2 
treatment increased the expression of CCND1 in both the inner and outer cell populations.  However, 
this was only a small effect and was not significant.  Regardless, it would appear E2 up-regulates the 
expression of CCND1 in MCF-12A cells grown in 3D, and this may confer a stimulatory effect on 
proliferation, and account for the lack of proliferative suppression in E2-treated samples.  A role for 
cyclin D1 in mediating acinar malformations in 3D cultures of MCF-10A, as discussed previously, has 
already been alluded to, and our data supports these findings as increased CCND1 expression correlated 
with distortion of MCF-12A acini (Debnath et al, 2003).   
In this chapter we have demonstrated for the first time that estrogen treatment of ERα, ERβ, 
GPER-1 competent non-tumourigenic MCF-12A cells cultured in 3D impacts upon the gene expression of 
apoptotic factors.  These changes in gene expression impact upon the Bax/Bcl-2 ratio and may be 
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involved in the malformations induced by estrogens, described in Chapter IV.  Previous studies utilising 
3D cultures to study the impact of apoptotic factors upon acini formation concentrate on knock-out or 
ectopic expression of single genes, and has shown that although implicated in luminal clearing, many 
factors are not solely responsible for the correct formation of acini.  For example, the disruption of BAD 
or CCND1 expression alone in 3D culture has previously been found not to induce luminal filling, but did 
correlate with increased levels of DNA fragmentation and partial apoptotic resistance after apoptotic 
stimulus, or delayed luminal clearance (Debnath et al, 2003; Schmelzle et al, 2007).  These previous 
observations have led to the hypothesis that in order to induce luminal filling, there must be increased 
proliferative signalling in addition to decreased apoptosis (Humphreys et al, 1996; Debnath et al 2002; 
Shaw et al, 2004).  The data presented in this chapter partially supports this theory, in that changes in 
BCL-XL, BAX, BAD and CCND1 expression were observed in E2-treated samples, rather than a change in 
the expression of a single gene.  Thus, our data appears to indicate that changes in the expression of 
multiple genes are responsible for the malformed MCF-12A acini observed, when these cells are treated 
with estrogens, and the impact of estrogens on gene expression differs between the inner and outer 
populations of MCF-12A acini.  It should be noted, though, that apoptotic genes may undergo post-
transcriptional modifications which affect their ability to perform their functions, as described 
previously.  It may, therefore, be of interest in the future to study the presence of activated protein 
forms by immunocytochemistry of acini, as performed in Chapter III, IV and V, or protein analysis of 
FACS-separated acini. 
In conclusion, we have developed a technique by which acini can be separated into the inner 
and outer populations and have shown that these two populations differ in their gene expression 
profiles.  The protocol is, however, in its infant stages and requires further optimisation and validation.  
Following this, we would be able to investigate of a wider selection of genes which would enable us to 
further understand the mechanism by which estrogens impact upon acini formation.  Furthermore, it 
would also be of interest to conduct protein analysis of the two populations within acini, with targets 
such as P-AKT and P-ERK1/2, as was performed in monolayer cultures.  Nevertheless, it appears that E2 
does impact upon gene expression in a way that would contribute to an inhibitory effect upon apoptosis 
and this may, therefore, account for the E2-induced acinar malformations.  Given that attachment of 
normal mammary epithelial cells to the basement membrane is essential for cell growth and survival, 
the reduction in the Bax/Bcl-2 ratio and Bad expression within the inner cell population may play a role 
in enabling these cells to evade apoptosis (Weaver et al, 1997). 
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Chapter VIII: Final Discussion and Conclusions 
 
As detailed in Chapter I, estrogens are essential for the normal development of the mammary gland 
(Korach et al, 1996).  Traditionally, it was thought that the actions of these endogenous hormones were 
mediated solely by a nuclear ER, in the form of ERα and ERβ.  More recently, it has been proposed that 
estrogens are capable inducing extra-nuclear effects by interacting with estrogen responsive receptors 
associated with the cell membrane.  One such transmembrane receptor is the G-protein-coupled 
receptor: GPER-1 (Filardo et al, 2002), and hence, we also investigated the role of this receptor in 
cellular responses to endogenous estrogens and xenoestrogens, in addition to the traditional ER. 
Despite the essential role of estrogens in breast development, they are, paradoxically, also 
linked to the development and progression of breast cancer.  It is now widely accepted that some of the 
most important risks factors for breast cancer are, in fact, linked to the cumulative lifetime exposure to 
estrogens.  Although the intracellular mechanisms of estrogenic action and the role of estrogens in 
neoplastic transformation have been extensively studied, little is known about how estrogenic effects 
lead to changes in the structure of the mammary epithelium, which are characteristic of breast cancer.  
In addition to this, even though a large number of environmental contaminants have been shown to 
have estrogenic activity at different physiological levels, evidence that these might also be responsible 
for cancer development is still missing.  We, therefore, selected the endogenous estrogen, and a small 
panel of xenoestrogens, to investigate the impact of estrogenic compounds on acini development in an 
in vitro model. 
8.1 Evaluating the Effects of Estrogens in Monolayer 
The aim of the work conducted in this thesis was to utilise a 3D model to investigate the impact of 
estrogens on acini morphogenesis, using an ER competent non-tumourigenic mammary cell line.  
Therefore, our first task was, to identify a cell line in which the ER was expressed.  We identified the 
MCF-12A cell line expressed ERα and ERβ, and, for the first time, showed that this cell line was also 
GPER-1 competent.  Based on this, MCF-12A cells were selected as an example of an ER positive non-
tumourigenic cell line for future 3D studies.  In conjunction with this, the ERα, ERβ and GPER-1 status of 
the MCF-10A, MCF-7 and MDA-MB-231 cell lines was also confirmed.  This was particularly necessary for 
the MCF-10A cell line, which was to be used as an example of an ER negative non-tumourigenic 
mammary cell line for comparison with MCF-12A cells grown in Matrigel. 
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We next sought to investigate whether E2 stimulated cellular proliferation of normal MCF-12A 
cells, and whether this was mediated by the ER or GPER-1.  Unsurprisingly, E2 did not impact upon the 
proliferation of the ERα negative MCF-10A and MDA-MB-231 cell lines.  However, due the presence of 
ERα, we expected that E2 treatment would increase the proliferation of MCF-12A and MCF-7 cells.  This 
was only observed in MCF-7 cells, where E2 induced a small increase in proliferation, agreeing with 
previously published data (Spink et al, 2006; Wang et al, 2008b).  As discussed previously, there were a 
few reasons why we did not observe a proliferative response to E2 in MCF-12A cells, and such a small 
increase in MCF-7 proliferation.  Briefly, it may be that ER-competent cells do not proliferate in response 
to estrogens and instead secrete growth factors via a paracrine fashion to ER negative cells in close 
proximity and it is these ER negative cells that then proliferate (Russo et al, 1999; Mallepell et al, 2006; 
Gupta et al, 2007).  Another possibility is that the expression of ERβ, negated the proliferative effect of 
E2 mediated by ERα (Sotoca et al, 2008).  However. it may be that non-tumourigenic cell lines do not 
proliferate in response to E2 (Haslam, 1986).  Regardless of the reason, we observed that monolayer 
cultures of MCF-12A cells do not proliferate in response to E2 and these unexpected observations led us 
to wonder if the effects of estrogen treatment in a 3D culture model would substantiate those observed 
in monolayer culture. 
8.2 The Complexities of 3D Culture 
Prior to studying the impact of estrogens in a 3D culture model of MCF-12A cells, it was first necessary 
to adapt the methodology used by Debnath et al (2002), for use with this cell line.  In Chapter III, we 
successfully adapted the 3D methodology (Debnath et al, 2002) to the MCF-12A cell line.  The most 
challenging aspect of this was selecting the correct composition of Matrigel.  As Matrigel is produced in 
batches, the availability of a particular specification is not always a possibility, which forced us to screen 
several batches of Matrigel with different endotoxin and protein concentrations to identify the most 
appropriate compositions available to us.  We found that MCF-12A cells grown in Matrigel only formed 
spherical acini with hollow lumen in one batch of Matrigel tested.  This batch had a protein composition 
of 10.3 mg/ml and an endotoxin level of less than 1.5 EU/ml.  In batches where the protein composition 
was less than 9.5 mg/ml, or the endotoxin level greater than 2 EU/ml, MCF-12A, acini did form, but 
lacked completely hollow lumen.  It remains unclear whether the determining factor concerning the 
suitability of a Matrigel batch was the protein concentration or the endotoxin level, although it is known 
that endotoxins can impact upon cellular and physiological responses, both in vitro and in vivo (Kendrick 
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et al, 2008).  Regardless, these observations highlight the importance of selecting the appropriate 
Matrigel for individual cell lines, prior to commencing experiments.  Importantly, it appears that a low 
endotoxin level and high protein concentration is necessary for the formation of acini, and this was also 
reported with 3D cultures of MCF-10A cells (Debnath et al, 2003). 
 Using our optimised 3D methodology, we proceeded to establish a time-course for the 
morphogenesis of MCF-12A acini, in order to understand when some of the key events in the 
morphogenic programme occurred.  Basement membrane deposition was an early event in the 
morphological programme and is present following just four days incubation.  Acini increased in 
diameter up until approximately day 12 and then underwent growth arrest.  Apoptotic onset, as 
indicated by the presence of activated caspase-3 and luminal clearing, was evident following 12 days 
incubation and after 16 days, the lumen were near hollow.  The final acini consisted of a spherical single 
layer of cells, in contact with a basement membrane, surrounding a hollow, or near-hollow, lumen.  
These MCF-12A acini were very similar to those formed in the 3D culture of MCF-10A cells, both in ours 
and in other laboratories, in respect to their morphological programme and final structure (Debnath et 
al, 2002; 2003).  This similarity acted as validation to our 3D model of ER competent mammary epithelial 
cells, which allowed us to proceed to the next stage of investigating the impact of estrogenic 
compounds upon MCF-12A acini formation with confidence in the reliability of the chosen assay. 
8.3 Estrogens in a 3D Culture Model Disrupt Acini Formation 
In Chapter IV, we began to investigate the impact of estrogens on the formation of MCF-12A acini.  
Firstly, we conducted a dose response for MCF-12A acini with E2 concentrations ranging from 1 pM to 
10 nM.  We observed that disruption of the MCF-12A acini structures occurred in a dose-dependent 
fashion.  This disruption presented as increased acinar size, luminal filling, and, at concentrations 
exceeding 1 nM, loss of spherical shape.  From these results, it was decided to use 1 nM E2 in 
subsequent experiments, as it physiologically relevant, commonly used in the literature to study 
estrogenic effects in in vitro studies and induced clearly identifiable disruption in 3D cultures of MCF-
12A acini. 
Four estrogenic compounds were then selected, in addition to the endogenous hormone, to 
investigate the impact of estrogenic compounds on MCF-12A acini, following 16 days incubation: o,p’-
DDT, β-HCH, BPA and n-propylparaben.  All of the test compounds induced acinar malformations to 
some extent, such as luminal filling, irregular shape, increased acinar size and decreased apoptosis.  BPA 
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and n-propylparaben were selected, in addition to E2, to be used in further experiments, due to their 
current interest in the literature and the media (in regards to their endocrine disrupting properties and 
everyday exposure), their estrogenic qualities and their clear effects on MCF-12A acini. 
 In time-course analysis experiments, basement membrane deposition was not affected by the 
test compounds.  However, increased size of treated samples, compared to controls, was observed 
following just four days and continued throughout the incubation period.  An additional indicator of 
uncontrolled proliferation presented as misshapen acini, as opposed to the spherical acini observed in 
controls throughout the time-course. 
In addition to allowing acini to escape proliferative control, estrogen treatment also had a 
suppressive impact on apoptosis, as shown by the reduction in activated caspase-3.  Furthermore, there 
was no evidence of hollow lumen formation with samples treated with the test compounds.  This adds 
to the evidence presented in this thesis, that estrogens induce luminal filling of MCF-12A acini and do 
so, at least to some extent, through suppression of caspase-mediated apoptotic pathways.  One 
interesting observation was that acini aberrations were more pronounced upon treatment with BPA and 
n-propylparaben than with the endogenous hormone, E2.  This suggests that although these 
xenoestrogens are considered less potent than E2, they cause greater acinar deformations in a 3D 
culture model.  This raises the question as to whether the effects of these xenoestrogens are mediated 
by the same receptors or pathways as endogenous E2, or whether they target additional processes, that 
have not been covered in this thesis.  Indeed, the metabolites of BPA, have been shown as having the 
ability to form DNA adducts, a process which may lead to genotoxicity (Atkinson & Roy, 1995).  It is 
worth noting at this point that the BPA, in addition to the metabolites of E2, are also capable of 
transforming MCF-10F cells, a normal breast epithelial cell line that is ERα negative but ERβ competent 
(Russo et al, 2002; Fernandez & Russo, 2010) and that these effects have been attributed to 
genotoxicity.   Another hypothesis is linked to the genomic effects of BPA, as the gene expression profile 
of cells, both in vitro and in vivo, is affected differently by E2 and BPA, and this may account for some of 
the differences in the acinar malformations between the two estrogenic compounds (Shioda et al, 2006; 
Natsoulis et al, 2008). 
On the other hand, it has been shown, that BPA, even at low doses, is capable of activating non-
genomic signalling pathways, mediated by a membrane-associated estrogen receptor, in a different 
manner to E2 (Bouskine et al, 2009).  Similar observations, relating to different activation of pathways 
have been made with other environmental estrogens, such as endosulfan, nonylphenol and β-HCH, 
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(Bulayeva and Watson, 2004; Silva et al, 2010).  Overall, this may mean that xenoestrogen evaluation 
needs to be based, not only on the affinity to the nuclear ER, but also on the affinity to other 
membrane-associated receptors, as well as activation of extranuclear cascades.  It is important that the 
non-genomic effects are taken into consideration when studying the full estrogenic profile of 
xenoestrogens, as these may have physiological effects in vivo and in humans that are not directly linked 
to the ER.   
If the perturbations in MCF-12A acini in response to estrogens are indicative of neoplastic 
transformation, the question arises as to whether BPA and n-propylparaben are more carcinogenic than 
endogenous E2.  The question to whether BPA does act as a carcinogen remains of some debate.  A 
study in rats and mice showed that BPA had carcinogenic properties in rats, but not in mice, and 
concluded from this that BPA was not considered a carcinogen (NTP, 1982).  However, more recently, a 
link between neonatal exposure to BPA and breast cancer in rats has been demonstrated (Durando et al, 
2007).  Furthermore, it is proposed that increased exposure of developing foetuses to endogenous and 
exogenous estrogens (including BPA and n-propylparaben) sensitize tissues, such as the prostate or the 
breast, via epigenetic mechanisms (i.e. methylation).  With exposure in later life, estrogens act upon 
these “sensitized” tissues to promote cancer initiation and progression (McLachlan et al, 2001).  
However, it remains to be seen whether the carcinogenic properties of BPA, n-propylparaben, or indeed 
other xenoestrogens are stronger than endogenous E2 in humans, and although our 3D model clearly 
shows that the effects elicited by BPA and n-propylparaben were greater than those induced by E2, this 
in vitro assay does not provide us with the full picture as to the mechanisms and carcinogenic properties 
of the test compounds. 
Regardless as to the mechanism through which xenoestrogens appeared to induce greater 
acinar malformations that endogenous E2, it is clear that these compounds induce perturbations in 
MCF-12A acini.  Both BPA and parabens have been identified in human breast tissue samples, suggesting 
that they may accumulate in the body, leading to continuous long-term exposure (Darbre et al, 2004; 
Fernandez et al, 2007).  These compounds are also widely used: BPA in food packaging and parabens in 
cosmetics and as food preservatives, and hence, exposure to them occurs on a daily basis.  Therefore, if 
these compounds, were indeed found to induce neoplastic lesion formation, it could have dramatic 
consequences for an individual’s cancer risk. 
 In Chapter IV, we observed that both the ER and GPER-1 are involved in estrogen-induced 
disruption of MCF-12A acini.  The antagonists of these receptors did not, however, completely revert all 
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of the effects of the estrogens tested and this may suggest that other receptors or factors are involved.  
Alternatively, it may be that the estrogens or their metabolites are exerting genotoxic effects, 
independently of any receptor.  Indeed, it has been demonstrated that estrogen metabolites are 
capable of forming DNA adducts, and this can lead to mutations (Ashburn et al, 1993).  We also 
observed that small perturbations in MCF-10A acini (ER negative, GPER-1 positive) were present 
following treatment with the test compounds.  It is unclear at this point whether this effect was 
mediated by GPER-1, or indeed another receptor, or was due to genotoxicity, which has been 
demonstrated in 3D cultures of MCF-10F cells in response to E2 (Russo et al, 2002; Lu et al, 2007). 
 In Chapter V, we demonstrated that both the PI3K and MAPK pathways are involved in the 
estrogen-induced disruption of MCF-12A acini.  Inhibition of these pathways resulted in smaller 
spherical acini, indicating that these pathways may be disrupted by estrogens, resulting in the loss of 
proliferative control.  The impact of pathway inhibition upon estrogen-induced apoptotic suppression 
and luminal filling was less significant, although there was a small increase in luminal clearing and 
activated caspase-3 following incubation with PI3K or MAPK inhibitors, in combination with the test 
compounds. 
 The data presented in Chapters IV and V supports previous in vivo evidence that estrogens can 
disrupt the processes involved in mammary gland development.  For example: in utero, estrogen 
exposure results in less apoptosis in the TEBs of rat mammary glands; and E2 causes over-proliferation 
in rat mammary glands (Hilakivi-Clarke et al, 2006; Murray et al, 2007; Starlard-Davenport et al, 2010). 
 Although it is clear that estrogens induce acinar disruptions in 3D cultures of MCF-12A cells and 
that these perturbations resemble those seen in the early stages of breast cancer in vivo and in humans, 
it cannot be claimed that the structures are of a malignant phenotype.  Genotyping of acini would allow 
us to see if genes involved in cancer progression, such as TP53 (the gene that encodes p53), have been 
affected by estrogen treatments.  Furthermore, and more importantly, these findings would need to be 
reproduced in vivo, to validate the hypothesis that estrogens impact on the architecture of the breast.  
One such way in which a transformed phenotype of estrogen-treated acini could be confirmed, is 
through the implantation of treated acini into mice, and seeing if tumour formation occurs. 
Regardless of whether estrogens elicit their effects via genomic, non-genomic mechanisms or 
through genotoxicity, it is apparent that the test compounds impact on both proliferation and apoptosis.  
Previous studies have shown that ectopic expression of single genes does not impact upon lumen 
formation.  However, when apoptosis is suppressed and proliferation stimulated simultaneously, 
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luminal filling is observed (Debnath et al, 2002; Reginato et al, 2005).  This would suggest that the 
disruption of acini requires a combination of uncontrolled hyper-proliferation and apoptotic 
suppression, both of which were observed in the estrogen-treated 3D cultures of MCF-12A cells.  In light 
of work carried out by Russo and colleagues (2002; 2003; 2006), a possible role for estrogen-induced 
genotoxicity may also contribute to the malformations of MCF-12A acini in response to the presence of 
estrogenic compounds.  Importantly, the work presented in this thesis, has demonstrated that estrogens 
and xenoestrogens impact on the formation of mammary acini in a 3D in vitro model.  If the same is true 
in vivo, or in humans, these estrogenic compounds, particularly BPA and n-propylparaben, may have 
serious detrimental consequences for the formation and maintenance of the mammary gland in humans 
and, hence, exposure to them may contribute to an individual’s risk of developing breast cancer.  Given 
that many xenoestrogens are highly lipophilic and are consequently stored in breast and adipose tissues, 
and the prevalence of BPA and parabens in everyday products, exposure is common place and the effect 
of these compounds, and their impact on human health, needs to be better understood. 
8.4 The Effects of Estrogens on in Monolayer and a Role for GPER-1 
In Chapter VI, we investigated the impact of E2 on the gene expression of key apoptotic factors in 
monolayer cultures, with the aim to extend this to 3D cultures of MCF-12A cells.  We observed that 
estrogens did impact on apoptotic factor gene expression in monolayer cultures of breast cells.  ER 
antagonism did not always abrogate the genomic effects of E2, implying that although the ER does have 
a role in the transcriptional responses of apoptotic genes to estrogens, another estrogen-responsive 
receptor is also implicated.  We identified a potential role for GPER-1 in mediating some of the genomic 
responses to endogenous E2, in both ER negative and ER positive mammary epithelial cell lines.  
Correlations between ER and Bcl-2 expression have been reported in breast cancer patients, thus 
supporting a role for this receptor in regulating the expression of BCL-2 (Rehman et al, 2000; Sjöström et 
al, 2002).  However, to our knowledge, there is no data concerning the correlation between GPER-1 and 
apoptotic factor expression.  It remains to be seen if these observations in monolayer are replicated in 
3D models, or indeed in vivo.  However, it is clear that E2 can impact upon the expression of genes 
involved in apoptosis and, thus, act to suppress cell death. 
 The Bax/Bcl-2 ratio was calculated to see if the changes in gene expression would result in an 
overall apoptotic or anti-apoptotic influence.  We observed that in ERα cells, the Bax/Bcl-2 ratio was 
decreased by E2, which would contribute towards an anti-apoptotic effect.  This may imply that the 
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presence of ERα has an impact on responses of cells following estrogen treatment, regardless of the 
expression of other estrogen-responsive receptors, such as GPER-1.  In the future, investigating the 
effects of E2 on a wider panel of breast cell lines or isogenic cell line studies (for example, where the 
genomic effects of E2 are analysed in two MCF-12A populations: one expressing ERα, and the other 
where ERα expression has been abrogated) may shed some further light onto this hypothesis. 
 In Chapter VI, we also investigated the impact of E2 upon PI3K and MAPK signalling, 
concentrating on whether this was mediated by GPER-1.  It was our hope to continue this investigation 
with 3D cultures of MCF-12A cells; however, time, technical and financial constraints ultimately 
prevented this.  We found that E2 activated MAPK signalling in MCF-10A and MCF-12A cells, via GPER-1.  
This supports previous findings that E2 is capable of inducing non-genomic responses in the ER negative 
SK-BR-3 breast cancer cell line, possibly through activation of GPER-1 (Filardo et al, 2000).  E2-induced 
activation of the PI3K was also observed in MCF-12A, MCF-7 and MDA-MB-231 cells, although this was 
not GPER-1 mediated.  This may implicate the ER, as opposed to GPER-1, in mediating these effects, as 
has been demonstrated in MCF-7 cells (Lee et al, 2005; Pedram et al, 2006).  In combination, this protein 
analysis data suggests that E2 can activate the PI3K and MAPK signalling cascades, and that GPER-1 
mediates some of these non-genomic responses, even though it is clearly not the sole player in these 
events.  It is unclear whether the ER is mediates these responses in the cells studied, but given that 
MDA-MB-231 cells do not express ERα, it may be that ERβ or another estrogen-responsive receptor is 
responsible.  Indeed, it has been demonstrated that in non-small cell lung cancer (NSCLC) cells, ERβ can 
mediate the activation of the MAPK and PI3K signalling pathways (Zhang et al, 2009).  Unfortunately, 
there is not a wealth of data concerning the non-genomic responses to estrogens in the cell lines studied 
(with the exception of the MCF-7 cell line).  This prevents us from comparing some of the results with 
pre-existing data.  It does however for the first time demonstrate that in ER negative MCF-10A, as well 
as ER positive MCF-12A cells, estrogens are capable of inducing non-genomic responses. 
Given that both in monolayer and in 3D, estrogens exerted some of their effects via GPER-1, it 
may be that GPER-1 is a potential target for breast cancer therapy and that, to negate the effects of 
estrogens on breast cancer cells in humans, both the ER and GPER-1 need to be targeted.  This theory 
will need further investigation in animal models, but may be a possibility in overcoming some of the 
effects of endocrine-therapy resistant tumours or targeting ER negative breast cancers. 
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8.5 Acini can be Separated into Inner and Outer Cell Populations 
From the LCM images in Chapter III, IV and V, it was clear that within MCF-12A acini, two cell 
populations exist: an inner and an outer population.  The outer cells organise themselves into a single 
layer surrounding a hollow lumen, do not undergo apoptosis and have contact with the basement 
membrane.  The inner cell population, on the other hand, are the centrally located cells that undergo 
apoptosis and are cleared, resulting in the formation of a hollow lumen.  Given that these two 
populations have two very different fates, it was hypothesised that their gene expression profiles would 
be different.  In order to investigate this, however, it was first necessary to find a method that was 
capable of separating the two populations.  In Chapter VII, we developed a method through which we 
could separate the inner from the outer cells of MCF-12A acini for gene analysis studies, which to our 
knowledge, has not been previously reported.  The yields were low, but sufficient sample was obtained 
to proceed with RNA extraction and real-time PCR analysis of the expression of the selected target 
genes.  This technique provides us the opportunity to further understand the molecular mechanisms 
involved in the morphological programme of acini, and how compounds, such as estrogens, can act on 
these structures to cause a phenotype that resemble breast cancer in vivo and in humans. 
 Analysis of whole MCF-12A acini showed that E2 increased the expression of CCND1.  This would 
aide in cell cycle progression and, therefore, may also be one of the mechanisms through which the 
estrogens in Chapter IV increased cellular proliferation, and consequently led to the formation of larger, 
disorganised acini.  We then proceeded to investigate the differences in gene expression between the 
inner and outer cell populations in solvent control acini.  We observed that the inner cells expressed less 
BCL-XL compared to the outer cells and increased levels of BAD and BAX.  This means that the inner cells 
of acini are more likely to undergo apoptosis compared to the outer cells under normal conditions. 
 We next compared the gene expression of target genes in the outer and inner populations in E2-
treated samples, relative to controls.  CCND1 expression was up-regulated in response to E2 in both 
populations, indicating increased proliferative ability or the ability to overcome proliferative 
suppression.  We also found that E2 increased the expression of the anti-apoptotic factor, BCL-2 in both 
populations.  Unexpectedly, E2 also down-regulated the expression of BCL-XL in both populations, and 
the exact reason for this remains unclear.  The most pronounced observation was that E2 down-
regulated BAX expression in both inner and outer cells, which would confer an anti-apoptotic influence.  
BAD was down-regulated in the inner population also, although was up-regulated in outer cells.  When 
the Bax/Bcl-2 ratio was calculated, E2 decreased the Bax/Bcl-2 ratio in both the inner and outer cell 
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populations, which implies an anti-apoptotic effect.  Overall the data appears to suggest that E2 impacts 
upon the gene expression of the inner and outer populations differently.  The data appears to indicate 
that E2 has a more profound effect upon apoptotic genes in the inner cells, which is hardly surprising 
considering that these cells undergo apoptosis normally, and that the outer cells are already primed to 
survive. 
8.6 Estrogens Induce Different Effects Depending on Culture Conditions 
In Chapter II, we observed that E2 does not increase the proliferation of MCF-12A cells in monolayer 
culture.  Conversely, when the same cell line was cultured in 3D and treated with estrogenic 
compounds, including the endogenous hormone, the resulting acini were larger than control structures 
(Chapter IV), an indication of increased proliferation and uncontrolled growth.  On the other hand, the 
work conducted in Chapter VI showed that E2 treatment of monolayer MCF-12A cultures resulted in a 
significant increase in the gene expression of BCL-2, BCL-XL and BAX, whereas in 3D cultures, BAX and 
BAD expression were down-regulated in the inner cell population and BCL-XL expression was down-
regulated in the outer population after estrogen treatment. 
 The discrepancies between monolayer and 3D culture of MCF-12A cell line is supported by 
previous studies in which cells grown in monolayer respond differently to cells cultured in 3D or in vivo 
(Horning et al, 2008; Pickl & Ries CH, 2009; Yang et al, 2009).  Importantly, primary cultures of mammary 
epithelial cells have shown that in monolayer, ER’s functionality is compromised, whereas it is regained 
in 3D cultures of the same cells, allowing estrogens to elicit their effects (Novaro et al, 2003).  
Furthermore, cells cultured in 3D systems express higher levels of ERα compared to those cultured in 
monolayer (Yang et al, 2000).  Combined with the literature findings, our observations demonstrate the 
limitations of monolayer cultures, particularly in relation to the effects of estrogens upon proliferation.  
It also highlights the necessity to use more physiologically relevant in vitro models to investigate the 
impact of estrogenic compounds, or indeed any compound, upon cells behaviour and function.  
Unmistakeably, it cannot be denied that monolayer cultures have their benefits: they are cost-effective, 
easy to set-up and maintain, and are extensively used.  They do, however, lack stroma and structural 
architecture, hindering the study of physiological processes.  3D cultures overcome some of these 
problems and have the advantage of being more physiologically relevant than traditional monolayer 
cultures.  These 3D cultures permit a further understanding of cell organisation, cell-ECM interactions 
and function, and the effect of treatments on these processes.  They are more complex and costly than 
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monolayer cultures and still not perfectly recapitulate the microenvironment of tissues, such as the 
breast, or take into account interactions between different cell and tissue types, or indeed, the 
interaction of different organ systems.  More recently, 3D platforms that allow multiple cell types to be 
co-cultured have been developed, although in vivo models still provide the most physiologically relevant 
model we have available to us.  In vivo models are however, more expensive, require special expertise 
and approval, and are subject to variability.  Furthermore, there is now general pressure to encourage 
scientist to adopt experimental designs that move away from animal testing in a bid to reduce the 
amount of in vivo work (http://www.nc3rs.org.uk/landing.asp?id=2).  For these reasons, developments 
in in vitro techniques, such as 3D cultures, are needed to replace or reduce the number of animals used 
in experimental research, whilst still maintaining a higher level of physiological relevance in comparison 
with traditional monolayer methodologies.  Although work is still ongoing to improve 3D methodologies, 
these advances are a step in the right direction and present us with the most relevant way of studying 
physiological events, such as breast morphogenesis and the impact of estrogens on this process, without 
the need of in vivo studies. 
8.7 Future Work 
Although we observed various perturbations of MCF-12A acini following estrogen treatment, similar to 
those observed in the early stages of breast cancer in vivo (i.e. luminal filling and increased 
proliferation), the results do not yet tell us whether estrogens induced a neoplastic phenotype.  Genetic 
analysis for markers of carcinogenesis, such as LOH and chromosome amplifications would need to be 
performed to confirm this.  Furthermore, it would be interesting to extend this study into in vivo 
investigations and see if acini grown in the presence of E2 and implanted into the mammary fat pads of 
mice or rats, go on to form tumours. 
 Although more physiologically relevant than traditional monolayer cultures, 3D Matrigel still 
does not fully recapitulate the environment of the mammary gland.  For instance, the mammary gland is 
not just comprised of epithelial cells; adipocytes, myoepithelial and fibroblasts are also present.  As 
Matrigel cultures do not allow the interactions between the epithelia and stroma to be investigated, we 
are left with a lack of data concerning how these factors contribute to acini morphogenesis under 
normal and test conditions.  This leads to failing in understanding the origin of tumour formation.  Co-
cultures of mammary epithelial cells with fibroblasts, a cellular component within the breast stroma, 
may have recently been developed in a bid to further understand how the interactions with the 
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epithelial cells and stroma impact upon mammary gland development (Sadlonova et al, 2005).   More 
recently, co-cultures of epithelial cells with adipocytes has been achieved.  This has involved culturing 
pre-adipocytes in a collagen system, to form a synthetic fat pad that recapitulates the mammary stroma, 
and then seeding epithelial cells on top of it.  The result is the formation of branched structures with 
hollow lumen, similar to the ducts of the breast (Campbell et al, 2011).  This may shed even further light 
into how the interactions between the various cell types that compose the breast stroma and epithelial 
cells converge to result in the development of the mammary gland.  This co-culture methodology is not 
without its drawbacks, as different cell types require different growth conditions, leading to technical 
complexity.  Nevertheless, developing such a system to test estrogen treatments, would allow us to 
more thoroughly investigate the effects of estrogens on the environment of the mammary gland and the 
consequences for the formation of the mammary ducts. 
As stated in Chapter VII, time, financial and technical constraints, meant that we were unable to 
study the impact of estrogens on MAPK and PI3K signalling in 3D cultures of MCF-12A cells.  It would be 
of great interest in the future to investigate whether these pathways are activated differently in the 
inner and outer populations of MCF-12A acini.  This may provide further information relating to the 
reasons why only the inner cells undergo apoptosis and clearing, whereas, the outer cells survive.  
Further to this, it would be interesting to see if E2 impacts upon the activation of signalling pathways in 
each population, as this may allow us to understand more fully why estrogen treatment induced luminal 
filling and increased proliferation.  As activation of the MAPK and PI3K signalling cascades are implicated 
in proliferation and survival, E2 is capable of activating these pathways in monolayer cultures of MCF-
12A cells, and specific inhibitors reverted some of the effects of estrogens on 3D acini, it is plausible that 
some of the estrogen-induced acinar malformations are, in fact, attributable to the activation of these 
pathways.  Further, direct confirmation of this possibility is required which could be achieved by 
experiments involving the study of activated AKT and ERK1/2, by immunoblotting, in separated MCF-12A 
acini. 
 Although we observed changes in gene expression in FACS-separated MCF-12A acini, following 
treatment with E2, it would be interesting to see if the same changes are observed in response to BPA 
and n-propylparaben.  As these estrogenic compounds induced greater malformations of MCF-12A acini 
than E2, it may be that these have a greater impact on apoptotic factors or CCND1 expression in a 3D 
setting.  Until we further understand how xenoestrogens, such as these, impact upon gene expression or 
signalling pathways in a more physiologically relevant 3D setting, it remains hard to evaluate the impact 
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these compounds potentially have for the mammary gland development, breast carcinogenesis and 
cancer progression. 
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